Stock Code: 688271 Stock Abbreviation: United Imaging Healthcare

Summary of Shanghai United Imaging Healthcare Co., Ltd. 2025 Annual Report

Important Notice

I The Company's Board of Directors, directors, and senior management guarantee the truthfulness, accuracy, and completeness of the content of the annual report, and affirm that there are no false records, misleading statements, or material omissions, and they bear individual and joint legal liabilities.

II The company was not profitable at the time of listing and has not yet achieved profitability

□Yes√No

III Major Risk Warning

The company has detailed the potential related risks in this report. Please refer to Section IV, "Risk Factors," in Part Three, Management Discussion and Analysis.

IV All directors of the company attended the board meeting.

V Ernst & Young Hua Ming LLP (Special General Partnership) issued an unqualified audit report for the company.

VI Zhang Qiang, the company's legal representative, Wang Jianbao, the person in charge of accounting work, and Zhang Hui, the head of the accounting department (chief accounting officer), declare: They guarantee the truthfulness, accuracy, and completeness of the financial report in the annual report.

VII Profit distribution plan or capital reserve conversion plan for the reporting period approved by the board resolution

The company plans to use the total number of shares registered on the equity distribution record date, minus the total number of shares in the special securities account for repurchase, as the base. A cash dividend of RMB 1.80 per 10 shares (tax inclusive) will be distributed. This profit distribution does not include bonus shares or capital reserve conversion into share capital. As of March 31, 2026, the company's total share capital is 824,157,988 shares. After deducting 4,134,116 shares in the special securities account for repurchase, the total cash dividend to be distributed is RMB 147,604,296.96 (tax inclusive). If the company's total share capital or the total number of shares participating in the profit distribution changes before the record date for the equity distribution, the company intends to maintain the distribution ratio per share unchanged and adjust the total distribution amount accordingly.

The above profit distribution plan has been reviewed and approved at the 30th meeting of the company's second board of directors and is subject to approval by the shareholders' meeting.

If the company continues to be profitable in the first half of 2026 and meets the conditions for cash dividends, the company plans to add an interim dividend. The interim dividend for 2026 is expected to be no less than 10% and no more than 100% of the net profit attributable to the listed company's shareholders for the corresponding period.

The parent company has uncovered losses
□Applicable√Not applicable

VIII Whether there are important matters such as special corporate governance arrangements

□Applicable√Not applicable

IX Risk Statement for Forward-Looking Statements

√Applicable□Not applicable

The forward-looking statements in this report regarding the company's future plans, development strategies, etc., do not constitute substantial commitments to investors. Investors are advised to be aware of investment risks.

X Whether there is non-operational fund occupation by the controlling shareholder and other related parties

No

XI Whether there is provision of external guarantees in violation of decision-making procedures

No

XII Whether more than half of the directors are unable to guarantee the truthfulness, accuracy, and completeness of the annual report disclosed by the company

No

XIII Disclaimer on Language and Translation: this English document is a summary translation of the Company's official 2025 Annual Report, which was originally prepared and published in the Chinese language. While every effort has been made to ensure the accuracy of this translation, it is provided solely for reference and the convenience of English-speaking readers. Should there be any conflict, inconsistency, or discrepancy between this English summary and the Chinese original, the complete Chinese version shall govern and prevail for all legal and interpretation purposes.

Table of Contents

List of Documents for Reference	Financial report signed and sealed by the company's legal representative, the person in charge of accounting work, and the head of the accounting department.
	Original audit report with the seal of the accounting firm and the signatures and seals of the certified public accountants.
	The full text of all company documents and the original announcements publicly disclosed during the reporting period.

Section I Definitions

1. Definitions

In this report, unless the context otherwise requires, the following terms have the meanings set forth below:

Common Terms Definitions		
United Imaging Healthcare, the Company, the Group	refers to	Shanghai United Imaging Healthcare Co., Ltd.
United Imaging Limited	refers to	Shanghai United Imaging Healthcare Co., Ltd., the predecessor of the Company
Wuhan United Imaging	refers to	Wuhan United Imaging Healthcare Co., Ltd., a controlled subsidiary of the Company
Changzhou United Imaging	refers to	United Imaging (Changzhou) Healthcare Co., Ltd., a controlled subsidiary of the Company
Shanghai Xinman	refers to	Shanghai Xinman Crystal Materials Technology Co., Ltd., a controlled subsidiary of the Company
Guizhou United Imaging	refers to	United Imaging (Guizhou) Healthcare Co., Ltd., a controlled subsidiary of the Company
Shenzhen United Imaging	refers to	Shenzhen United Imaging Healthcare Co., Ltd., a controlled subsidiary of the Company
Beijing United Imaging	refers to	Beijing United Imaging Healthcare Co., Ltd., a controlled subsidiary of the Company
Beijing Technology	refers to	Beijing United Imaging Medical Technology Development Co., Ltd., a controlled subsidiary of the Company
Shanghai Yixintong	refers to	Shanghai United Imaging Yixintong Technology Co., Ltd., a controlled subsidiary of the Company
Xinjingnan	refers to	Shanghai Xinjingnan Metal Products Co., Ltd., a controlled subsidiary of the Company
Shanghai Zhiyu	refers to	Shanghai United Imaging Zhiyu Technology Co., Ltd., a controlled subsidiary of the Company
Shenzhen United Imaging Data	refers to	Shenzhen United Imaging Medical Data Service Co., Ltd., a controlled subsidiary of the Company
United Imaging UK	refers to	United Imaging Healthcare UK Ltd., a controlled subsidiary of the Company
United Imaging Hong Kong	refers to	United Imaging Healthcare Hong Kong Limited, a controlled subsidiary of the Company
United Imaging UAE	refers to	United Imaging Healthcare MENA FZCO, a controlled subsidiary of the Company
Korea United Imaging	refers to	United Imaging Healthcare Korea Co., Ltd., a controlled subsidiary of the company
Wuhan Scientific Instruments	refers to	Wuhan United Imaging Life Science Instruments Co., Ltd., a controlled subsidiary of the company
Wuhan Liantuo	refers to	Wuhan Liantuo New Materials Co., Ltd., a controlled subsidiary of the company
United States United Imaging	refers to	United Imaging Healthcare North America Inc., a controlled subsidiary of the company

Australia-New Zealand United Imaging	refers to	United Imaging Healthcare (Australia & New Zealand) Pty Ltd, a controlled subsidiary of the company
Poland United Imaging	refers to	UNITED IMAGING HEALTHCARE POLAND SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ, a controlled subsidiary of the company
Japan United Imaging	refers to	United Imaging Healthcare Japan Co., Ltd., a controlled subsidiary of the company
Malaysia United Imaging	refers to	United Imaging Healthcare (Malaysia) Sdn. Bhd., a controlled subsidiary of the company
South Africa United Imaging	refers to	United Imaging Healthcare Southern Africa (PTY) LTD., a controlled subsidiary of the company
Morocco United Imaging	refers to	United Imaging Healthcare North Africa SARLAU, a controlled subsidiary of the company
Kazakhstan United Imaging	refers to	United Imaging Healthcare Kazakhstan Limited Liability Partnership, a controlled subsidiary of the company
Singapore United Imaging	refers to	UNITED IMAGING HEALTHCARE PTE. LTD., a controlled subsidiary of the company
Colombia United Imaging	refers to	UNITED IMAGING HEALTHCARE COLOMBIA S.A.S, a controlled subsidiary of the company
Indonesia United Imaging	refers to	PT UIH Indonesia Solution, a controlled subsidiary of the company
Thailand United Imaging	refers to	United Imaging Healthcare (Thailand) Co., Ltd., a controlled subsidiary of the company
Europe United Imaging	refers to	United Imaging Healthcare Europe B.V., a controlled subsidiary of the company
Vietnam United Imaging	refers to	UNITED IMAGING HEALTHCARE VIETNAM CO., LTD., a controlled subsidiary of the company
Spain United Imaging	refers to	UNITED IMAGING HEALTHCARE ESPAÑA, S.L.U., a controlled subsidiary of the company
Italy United Imaging	refers to	UNITED IMAGING HEALTHCARE ITALY S.R.L., a controlled subsidiary of the company
France United Imaging	refers to	United Imaging Healthcare France SARL, a controlled subsidiary of the company
Germany United Imaging	refers to	United Imaging Healthcare Germany GmbH, a controlled subsidiary of the company
Mexico United Imaging	refers to	UNITED IMAGING HEALTHCARE MEXICO, S. DE R.L. DE C.V., a controlled subsidiary of the company
Brazil United Imaging	refers to	UNITED IMAGING HEALTHCARE DO BRASIL LTDDA, a controlled subsidiary of the company
Philippines United Imaging	refers to	United Imaging Healthcare Philippines, Inc., a controlled subsidiary of the company
UIHT	refers to	UIH Technologies LLC, a controlled subsidiary of the company
UIHS	refers to	United Imaging Healthcare North America LLC, a controlled subsidiary of the company
Shenzhen High Performance	refers to	Shenzhen High-Performance Medical Device National Research Institute Co., Ltd., an equity investment company
Wuhan Medical	refers	Wuhan Zhongke Medical Technology Industrial

Engineering Institute	to	Technology Research Institute Co., Ltd., an equity investment company
Wuhan Zhongke Polarization	refers to	Wuhan Zhongke Polarization Medical Technology Co., Ltd., an equity investment company
United Health	refers to	United Health Medical Big Data Technology Co., Ltd., an equity investment company
Aipu Qiang	refers to	Shanghai Aipu Qiang Particle Equipment Co., Ltd., an equity investment company
Yimai Sunshine	refers to	Jiangxi Rimag Group Co., Ltd., an equity investment company
Jiuyiyuan	refers to	Sichuan Longevous Beamtech Co., Ltd., an equity investment company
United Imaging Group	refers to	United Imaging Healthcare Technology Group Co., Ltd., a shareholder of the company
Shanghai Yingsheng	refers to	Shanghai Yingsheng Investment Partnership (Limited Partnership), a shareholder of the company
Botico	refers to	Shanghai Botico Investment Partnership (Limited Partnership), an enterprise controlled by the ultimate controlling person
Shanghai Yingchen	refers to	Shanghai Yingchen Investment Management Firm, an enterprise controlled by the ultimate controlling person
Macheng Yingyuan	refers to	Macheng Yingyuan Enterprise Management Center, an enterprise controlled by the ultimate controlling person
Ningbo Yingju	refers to	Ningbo Meishan Free Trade Port Zone Yingju Investment Management Partnership (Limited Partnership), the company's employee stock ownership platform
Ningbo Yingli	refers to	Ningbo Meishan Free Trade Port Zone Yingli Investment Management Partnership (Limited Partnership), the company's employee stock ownership platform
Ningbo Yingjian	refers to	Ningbo Meishan Free Trade Port Zone Yingjian Investment Management Partnership (Limited Partnership), the company's employee stock ownership platform
Ningbo Yingkang	refers to	Ningbo Meishan Free Trade Port Zone Yingkang Investment Management Partnership (Limited Partnership), the company's employee stock ownership platform
Shanghai Yingdong	refers to	Shanghai Yingdong Enterprise Management Partnership (Limited Partnership), the company's employee stock ownership platform
Shanghai Lianhe	refers to	Shanghai Alliance Investment Co., Ltd., a shareholder of the company
Zhongke Daofu	refers to	Shanghai Zhongke Daofu Investment Partnership (Limited Partnership), a shareholder of the company
Shanghai Beiyuan	refers to	Shanghai Beiyuan Investment Partnership (Limited Partnership), a shareholder of the company
Shanghai Yiduan	refers to	Shanghai Yiduan Investment Co., Ltd., a shareholder of the company
Shanghai Yingzhi	refers to	Shanghai Yingzhi Investment Partnership (Limited Partnership), a shareholder of the company

Shanghai Intelligent	refers to	Shanghai United Imaging Intelligence Co., Ltd., an enterprise controlled by the ultimate controlling person, formerly known as: Shanghai United Imaging Intelligent Medical Technology Co., Ltd.
Shanghai Wisdom	refers to	Shanghai United Imaging iHealthcare Investment Management Co., Ltd., an enterprise controlled by the ultimate controlling person
Shanghai Microelectronics	refers to	Shanghai United Imaging Microelectronics Technology Co., Ltd., an enterprise controlled by the ultimate controlling person
Wuhan Zhirong	refers to	Wuhan United Imaging Surgical Co., Ltd., an enterprise controlled by the ultimate controlling person
Shanghai Zhiyuan	refers to	Shanghai United Imaging MetaHealthcare Co., Ltd., an enterprise controlled by the ultimate controlling person
Shanghai Research Institute	refers to	Shanghai United Imaging Healthcare Advanced Technology Research Institute Co., Ltd., an enterprise controlled by the ultimate controlling person
GE HealthCare	refers to	GE HealthCare, core businesses include providing medical technology, pharmaceutical diagnostics, and digital solutions
Siemens Healthineers	refers to	Siemens Healthineers, core businesses include imaging diagnostics, clinical diagnosis and treatment, laboratory diagnostics, and supporting service business systems for molecular medicine
Philips Healthcare	refers to	Koninklijke Philips, committed to providing solutions in disease prevention, radiological diagnosis and treatment, health management, and monitoring
Elekta	refers to	Elekta was founded in 1972, headquartered in Sweden. Its main products include linear accelerators, Gamma Knife, high-field magnetic resonance radiotherapy systems, stereotactic head frame systems, oncology information systems, afterloading therapy machines, and source applicators
Varian	refers to	Varian was founded in 1948, headquartered in the United States, dedicated to providing radiotherapy, radiosurgery, proton therapy, and brachytherapy equipment and related software for cancer and other diseases. Its main products include linear accelerators, Edge Radiosurgery System, afterloading brachytherapy machines, and source applicators. It was acquired by Siemens Healthineers in 2021
Mindray	refers to	Shenzhen Mindray Bio-Medical Electronics Co., Ltd., primarily engaged in the R&D, manufacturing, marketing, and service of medical devices. Its main products cover three major areas: Patient Monitoring & Life Support, In-Vitro Diagnostics, and Medical Imaging. Medical imaging products include ultrasound diagnostic systems, digital X-ray imaging systems, and PACS
Wandong Medical	refers	Beijing Wandong Medical Technology Co., Ltd.,

	to	specializing in the R&D, manufacturing, production, and imaging diagnostic services of imaging medical devices. Products include DR product lines, MR product lines, DSA product lines, digital gastrointestinal product lines, CT product lines, and providing medical imaging diagnostic services
Neusoft Medical	refers to	Neusoft Medical Systems Co., Ltd., primarily engaged in the R&D, production, sales, and related solutions and services of large medical diagnostic and therapeutic equipment. Product lines cover CT, MR, DSA, XR, US, PET/CT, RT, as well as in-vitro diagnostic (IVD) equipment and reagents
CIC Consulting	refers to	CIC Investment Consulting (Shanghai) Co., Ltd., established in 2013, is an independent third-party professional industry research and analysis institution. Its business areas mainly include strategic consulting, commercial due diligence, and feasibility study report services for fundraising and investment
National Health Commission	refers to	National Health Commission of the People's Republic of China
CSRC	refers to	China Securities Regulatory Commission
National Development and Reform Commission	refers to	National Development and Reform Commission of the People's Republic of China
Sponsor	refers to	CITIC Securities Company Limited, China International Capital Corporation Limited
CITIC Securities	refers to	CITIC Securities Company Limited
CICC	refers to	China International Capital Corporation Limited
Accountant, Ernst & Young Hua Ming	refers to	Ernst & Young Hua Ming LLP (Special General Partnership)
FDA	refers to	The process by which the U.S. Food and Drug Administration (FDA) evaluates the safety and effectiveness of food, cosmetics, drugs, biological products, medical devices, and radiation products that need to be marketed in the United States according to relevant laws, regulations, standards, and procedures, and approves them for market sale
CE Certification	refers to	The European Union's certification for products, indicating that the product meets the requirements stipulated by relevant EU directives, and confirming that the product has passed the corresponding conformity assessment procedures and the manufacturer's declaration of conformity, and is affixed with the CE mark, which is a prerequisite for the product to enter the EU market for sale
NMPA Registration	refers to	The process by which the National Medical Products Administration, in accordance with relevant registration

		management systems, reviews and approves drugs, medical devices, and cosmetics that need to be marketed in China, and permits their market sale
Medical Imaging Diagnosis	refers to	Using various medical imaging techniques (such as X-rays, magnetic resonance, gamma rays, etc.) to obtain anatomical structure or organ function images of the human body, assisting doctors in disease assessment and judgment, and evaluating human health status
Radiation Therapy (RT)	refers to	Radiation Therapy (RT) refers to a local treatment method for tumors using radiation, including α, β, γ rays produced by radioactive isotopes, and X-rays, electron beams, proton beams, and other particle beams produced by various X-ray therapy machines or accelerators. Currently, mainstream RT products domestically and internationally include medical linear accelerators, cobalt-based Gamma Knife, and a small number of proton and heavy ion equipment
Life Science Instruments	refers to	Refers to instruments provided for all needs in related fields such as biomedical scientific research, population health management, diagnosis and treatment of various diseases, drug research and development and production, and biosecurity
Magnetic Resonance Imaging (MR or MRI)	refers to	Magnetic Resonance Imaging (MRI) involves applying a specific frequency of radiofrequency pulse to the human body in a static magnetic field, causing the atomic nuclei (mainly hydrogen protons) in the body to be excited and produce a magnetic resonance phenomenon. After the pulse stops, the atomic nuclei generate MR signals during the relaxation process. Through processes such as receiving MR signals, spatial encoding, and image reconstruction, the signals are ultimately processed into image information
X-ray Computed Tomography (CT)	refers to	X-ray Computed Tomography (CT) refers to a technology that uses a precise X-ray beam, together with a high-sensitivity detector, to perform cross-sectional scans around a specific part of the human body. By utilizing the different absorption and transmission rates of rays by different human tissues, the measured data is processed to generate images
X-ray Imaging (XR)	refers to	X-ray imaging equipment refers to a type of equipment that can emit X-rays and penetrate different human tissues, and after imaging processing, obtain different medical images. According to usage characteristics, it is generally divided into General X-ray (GXR) and Interventional X-ray (IXR). GXR includes conventional DR, mobile DR, mammography machines, and gastrointestinal machines, all of which use X-ray radiography for diagnostic examination of diseases; IXR mainly includes C-arm X-ray machines, primarily used for monitoring X-ray fluoroscopy and radiography during surgical procedures
Angiography X-ray	refers	Angiography X-ray Imaging System (DSA) is an X-ray

Imaging System (DSA)	to	imaging device used to provide image guidance for interventional procedures
Digital Medical X-ray Imaging (DR)	refers to	Digital Radiography (DR) is a medical radiological imaging device that directly or indirectly converts X-ray photon signals into digital images through a digital detector. It generally consists of an X-ray tube, digital detector, high-voltage generator, image acquisition and processing system, and image output system
Digital Mammography (Mammo, Mammography Machine)	refers to	Digital Mammography (Mammo) is a low-dose X-ray imaging device specifically used for the early diagnosis of breast cancer
C-arm X-ray Imaging	refers to	C-arm X-ray imaging is a device mainly used for monitoring mobile X-ray fluoroscopy and radiography during surgical procedures. Classified by power from small to large, it can be divided into orthopedic C-arms, peripheral interventional C-arms, and Digital Subtraction Angiography (DSA) X-ray machines
PET	refers to	Positron Emission Tomography (PET) is an imaging technique for molecular imaging clinical examinations. It images the distribution of positron-labeled drugs in the human body, reflecting the functional metabolic activities of human organs at the molecular level, thereby achieving diagnostic purposes. PET is mainly used for the examination and diagnosis of tumors and functional diseases of the heart and brain
PET/CT	refers to	Positron Emission Tomography/Computed Tomography (PET/CT) is an imaging device that organically combines two imaging technologies: PET functional metabolic imaging and CT anatomical structure imaging. The two technologies complement each other, featuring sensitivity, accuracy, specificity, and precise localization, thereby achieving the goal of early lesion detection and disease diagnosis
PET/MR	refers to	PET/MR (Positron Emission Tomography/Magnetic Resonance) is a large-scale functional metabolic and molecular imaging diagnostic device that integrates a positron emission tomography system with a magnetic resonance imaging system. It combines the examination functions of both PET and MR and is one of the most advanced medical imaging diagnostic devices globally, applicable to the diagnosis of diseases such as tumors, nervous system disorders, and cardiovascular system conditions
Medical Linear Accelerator	refers to	A medical linear accelerator refers to an acceleration device that uses microwave electromagnetic fields to accelerate electrons and has a linear motion trajectory, producing high-energy rays. It is a large medical device used for

		external beam radiation therapy in human medical practice, widely applied in the treatment of various tumors, especially deep-seated tumors
CT-guided Linear Accelerator	refers to	A novel diagnostic and therapeutic device that organically combines CT equipment and medical linear accelerators, significantly improving the efficiency of tumor radiotherapy through integrated simulation positioning and treatment.
US	Refers to	Ultrasound, i.e., an ultrasonic diagnostic device developed based on the principle of ultrasound, which transmits ultrasonic pulses into human tissues and forms various types of images by recording and analyzing the reflected echoes.
Image post-processing workstation	Refers to	Performing post-processing operations on medical images as an aid and support in the imaging diagnosis or scientific research process, providing radiologists with auxiliary tools for disease diagnosis. Can perform various operations including image editing, histogram analysis, image equalization, image smoothing, edge enhancement, grayscale and contrast adjustment, positive/negative rotation, image color inversion, pseudocolor rendering and calculation, grayscale rotation, etc.
PET TOF	Refers to	TOF (Time-Of-Flight), i.e., flight time, refers to the time difference in PET scanning when two 511keV gamma rays generated from positron annihilation at different positions arrive at the detector at different times. This time difference is called the flight time, and the measurement error of the flight time is called the flight time resolution.
cps/kBq	Refers to	The sensitivity unit in radioactive instruments, representing the radiation count measured by the instrument from a sample under a certain level of radiation dose.
Aperture	Refers to	Aperture refers to the diameter of the cylindrical scanning space of the equipment.
Structural imaging	Refers to	Structural imaging refers to the technique of conducting anatomical studies using imaging equipment such as CT and MR.
Magnetic field	Refers to	The magnetic force space formed by magnets, electric currents, and moving charges.
Magnet	Refers to	The magnet is the core component in MR equipment that generates the main magnetic field, maintaining high magnetic field strength and high homogeneity in the target area. Generally, it is divided into permanent magnets and superconducting magnets. Permanent magnets have weaker magnetic field strength, while superconducting magnets operate through superconducting coils, offering stronger magnetic field strength and higher stability, making them the mainstream technology in the current market. The MR products referred to in this document are all devices using superconducting magnets.

RF coil	Refers to	The RF coil is one of the core components in MR equipment, responsible for transmitting, receiving, and amplifying MR signals. Since the RF signals collected by MR equipment are very weak and highly susceptible to external noise interference, the RF receive coil, as the front end of the signal reception chain, is a critical component determining the signal-to-noise ratio of image quality.
Gradient coil	Refers to	The gradient coil is one of the core components in MR equipment, primarily used for spatial localization encoding of MR signals. It also functions to generate gradient echo signals, apply diffusion-weighting gradient fields, perform flow compensation, and encode flow velocity of fluids.
RF power amplifier (RFPA)	Refers to	Radio Frequency Power Amplifier, which provides amplified RF signals to the magnetic resonance RF transmit coil.
Gradient power amplifier (GPA)	Refers to	Gradient Power Amplifier, which provides amplified gradient signals to the magnetic resonance gradient coil.
Spectrometer	Refers to	The spectrometer is an important core component and control system of MR equipment, primarily responsible for the timing control of small signals such as magnetic resonance RF, gradients, and acquisition. The performance of the spectrometer is one of the important metrics for evaluating the performance of a magnetic resonance imaging system.
Detector	Refers to	The detector is one of the core components of medical imaging equipment, a device that converts detected signals into recordable electrical signals, including flat panel detectors used in XR products, detectors used in CT products, and detectors used in PET products.
X-ray tube	Refers to	The X-ray tube is one of the core components of medical imaging equipment. The X-ray tube consists of a tube insert, tube housing, heat exchanger, insulating oil, and some auxiliary components, and it can generate X-rays.
Power block unit	Refers to	The power block unit is one of the core components of CT and XR equipment, a device that provides high-voltage functions for filament heating and electron acceleration in X-ray equipment.
Scintillation crystal	Refers to	A scintillation crystal is a transparent crystal that can interact with particles such as X-rays, gamma rays, and charged particles, converting the kinetic energy deposited by the particles in the crystal into visible light photons. The scintillation crystals referred to in this document are LYSO (lutetium yttrium orthosilicate) crystals used in PET products.
Silicon photomultiplier tube	Refers to	SiPM (Silicon Photo multiplier) is a new type of photodetection device composed of an array of avalanche diodes operating in Geiger mode, featuring high gain, high sensitivity, low bias voltage, insensitivity to magnetic fields, and compact structure.

Accelerator tube	Refers to	The accelerator tube is one of the core components of a medical linear accelerator, where electrons injected from the electron gun are accelerated to high energy under the influence of a microwave electric field and finally strike a target to produce high-energy X-rays.
Multi-leaf collimator	Refers to	A multi-leaf collimator is a type of collimator or beam-limiting device composed of individual 'leaves' made of high atomic number material. Each leaf is controlled independently to dynamically adjust the spatial distribution of the beam synchronously, enabling dynamic beam flux modulation, and can be used in radiotherapy equipment.
Reporting period	Refers to	January 1, 2025 to December 31, 2025

Section II Company Profile and Main Financial Indicators

1. Basic information of the company

Company's Chinese name	上海联影医疗科技股份有限公司
Company's Chinese abbreviation	联影医疗
English name of the Company	Shanghai United Imaging Healthcare Co.,Ltd.
Company's English name abbreviation	UIH
Company's legal representative	Zhang Qiang
Company's registered address	No. 2258 Chengbei Road, Jiading District, Shanghai
Historical changes in the company's registered address	Not applicable
Company's office address	No. 2258 Chengbei Road, Jiading District, Shanghai
Postal code of the company's office address	201807
Company website	www.united-imaging.com
Email	IR@united-imaging.com

2. Contact person and contact information

	Board Secretary	Securities Affairs Representative
Name	TAO CAI	Su Xing
Contact address	No. 2258 Chengbei Road, Jiading District, Shanghai	No. 2258 Chengbei Road, Jiading District, Shanghai
Telephone	021-67076658	021-67076658
Fax	021-67076659	021-67076659
Email	IR@united-imaging.com	IR@united-imaging.com

3. Information disclosure and placement location

Media names and websites for the company's annual report disclosure	China Securities Journal (www.cs.com.cn), Shanghai Securities News (www.cnstock.com), Securities Times (www.stcn.com), Securities Daily (www.zqrb.cn)
Website of the stock exchange for the company's annual report disclosure	www.sse.com.cn
Placement location of the company's annual report	Company's Board Office

4. Company's stock/depositary receipt profile

(1). Company's stock profile

√ Applicable□ Not applicable

Company's stock profile

Stock type	Stock exchange and board	Stock abbreviation	Stock code	Previous stock abbreviation
A-share	SSE STAR Market	United Imaging Healthcare	688271	Not applicable

(2). Company's depositary receipt profile

□ Applicable√ Not applicable

5. Other relevant information

Accounting firm engaged by the company (domestic)	Name	Ernst & Young Hua Ming LLP (Special General Partnership)
	Office address	Rooms 01-12, 17/F, Ernst & Young Building, Oriental Plaza, No. 1 East Chang'an Avenue, Dongcheng District, Beijing
	Names of signing accountants	Fei Fan, Fan Qingyuan
Sponsor performing continuous supervision duties during the reporting period	Name	CITIC Securities Co., Ltd.
	Office address	North Tower, Excellence Times Square (Phase II), No. 8 Zhongxin Third Road, Futian District, Shenzhen, Guangdong
	Names of signing sponsor representatives	Jiao Yanyan, Shao Caijie
	Period of continuous supervision	August 22, 2022 to December 31, 2025
Financial advisor performing continuous supervision duties during the reporting period	Name	China International Capital Corporation Limited
	Office address	27th and 28th Floors, Tower 2, China World Office Building, No. 1 Jianguomenwai Avenue, Chaoyang District, Beijing
	Names of signing financial advisor sponsors	Zhang Xiaoyong, Liu Shangquan
	Period of continuous supervision	August 22, 2022 to December 31, 2025

6. Major accounting data and financial indicators for the past three years

(1). Major accounting data

Unit: Yuan Currency: RMB

Major accounting data	2025	2024	Change from the same period of the previous year (%)	2023
Operating revenue	13,800,251,663.95	10,300,104,386.97	33.98	11,410,765,602.39
Total profit	1,981,395,004.53	1,351,707,513.98	46.58	2,142,254,673.91
Net profit attributable to shareholders of	1,869,300,805.65	1,261,869,451.27	48.14	1,974,292,317.49

the listed company				
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	1,769,843,181.21	1,010,323,448.82	75.18	1,664,876,441.28
Net cash flow from operating activities	2,679,018,849.49	-619,024,253.25	Not applicable	132,511,079.76
	End of 2025	End of 2024	Change from the same period of the previous year (%)	End of 2023
Net assets attributable to shareholders of the listed company	21,571,867,029.94	19,903,165,417.53	8.38	18,866,353,649.67
Total assets	32,784,579,366.01	28,035,688,872.48	16.94	25,336,140,321.96

(2). Major Financial Indicators

Major Financial Indicators	2025	2024	Change from the same period of the previous year (%)	2023
Basic earnings per share (RMB/share)	2.28	1.54	48.05	2.40
Diluted earnings per share (RMB/share)	2.28	1.54	48.05	2.40
Basic earnings per share after deducting non-recurring gains and losses (RMB/share)	2.16	1.23	75.61	2.02
Weighted average return on equity (%)	9.00	6.53	Increased by 2.47 percentage points	10.79
Weighted average return on equity after deducting non-recurring gains and losses (%)	8.52	5.23	Increased by 3.29 percentage points	9.10
R&D expenditure as a percentage of operating revenue (%)	18.99	21.95	Decreased by 2.96 percentage points	16.81

Explanation of major accounting data and financial indicators for the three years prior to the end of the reporting period

√ Applicable□ Not applicable

(I) Operating performance, financial status, and main factors affecting operating results during the reporting period

1. Operating performance and financial status

In 2025, the company achieved total operating revenue of RMB 13,800.2517 million, a year-on-year increase of 33.98%; net profit attributable to owners of the parent company was RMB 1,869.3008 million, a year-on-year increase of 48.14%; net profit attributable to owners of the parent company after deducting non-recurring gains and losses was RMB 1,769.8432 million, a year-on-year increase of 75.18%.

At the end of 2025, the company's total assets were RMB 32,784.5794 million, a year-on-year increase of 16.94%; equity attributable to owners of the parent company was RMB 21,571.8670 million, a year-on-year increase of 8.38%.

2. Main factors affecting operating performance

During the reporting period, the company focused on building long-term competitiveness, systematically advancing the introduction of innovative products, deepening global market layout, optimizing the supply chain system, and accumulating core technological capabilities. Against the backdrop of the large-scale medical equipment renewal policy entering a normalized and specialized implementation phase in 2025, demand for equipment related to high-end medical imaging, radiotherapy, and primary-level diagnostic and treatment capacity building continued to be released, and the overall industry scale significantly recovered compared to the same period last year. The company continued to increase its market share in the domestic market and maintained its leading position in the industry. Revenue scale in the Chinese market achieved significant growth, with simultaneous improvements in operating quality and profitability.

Overseas, the company continuously strengthened its capabilities in global market expansion and innovative product introduction. Key regions such as Europe, North America, Asia-Pacific, and emerging markets maintained rapid growth momentum. The company's brand influence and penetration rate among high-end customers in the international market continued to improve, accelerating its global layout. In the future, with the accelerated introduction of innovative products in the global market, the sequential delivery of key projects, further expansion of the customer base, and the increasing maturity of the global localization organization and service system, the company will enter a new stage characterized by technology innovation-driven growth, intelligent management enhancing efficiency, and global synergy amplifying scale advantages. Overall operating scale and operational quality and efficiency are expected to further improve steadily.

(II) Explanation of the main reasons for changes exceeding 30% in the relevant items in the above table

During the reporting period, the company's total operating revenue, total profit, net profit attributable to owners of the parent company, net profit attributable to owners of the parent company after deducting non-recurring gains and losses, net cash flow from operating activities, basic earnings per share, and other items changed by more than 30%. This was mainly driven by multiple factors, including the continuous launch of innovative products, increasing market recognition of high-end products, further improvement of the global marketing and service system, rapid growth of overseas business, continuous optimization of management and operational quality, and the gradual normalization and implementation

of domestic equipment renewal policies. The company's overall business achieved steady growth, and profit quality further improved.

7. Differences in accounting data under domestic and international accounting standards

(1). Differences in net profit and net assets attributable to shareholders of the listed company between financial reports disclosed under International Accounting Standards and Chinese Accounting Standards

□ Applicable√ Not applicable

(2). Differences in net profit and net assets attributable to shareholders of the listed company between financial reports disclosed under overseas accounting standards and Chinese Accounting Standards

□ Applicable√ Not applicable

(3). Explanation of differences between domestic and international accounting standards:

□ Applicable√ Not applicable

8. Major financial data by quarter for 2025

Unit: Yuan Currency: RMB

	First Quarter (January-March)	Second Quarter (April-June)	Third Quarter (July-September)	Fourth Quarter (October-December)
Operating Revenue	2,477,948,927.49	3,537,952,474.67	2,843,014,990.57	4,941,335,271.22
Net Profit Attributable to Shareholders of Listed Company	370,082,216.76	627,935,847.36	122,216,265.88	749,066,475.65
Net Profit Attributable to Shareholders of Listed Company After Deducting Non-Recurring Gains and Losses	378,502,314.92	587,110,166.12	87,614,052.62	716,616,647.55
Net Cash Flow from Operating Activities	-353,474,219.65	402,234,019.42	58,453,464.68	2,571,805,585.04

Explanation of Differences Between Quarterly Data and Disclosed Periodic Reports

□ Applicable√ Not Applicable

9. Companies with Equity Incentives or Employee Stock Ownership Plans May Choose to Disclose Net Profit After Deducting Share-Based Payment Impact

□ Applicable√ Not Applicable

10. Non-GAAP Financial Indicators

□ Applicable√ Not Applicable

11. Items Measured at Fair Value

√ Applicable□ Not Applicable

Unit: Yuan Currency: RMB

Item Name	Opening Balance	Closing Balance	Current Period Change	Impact on Current Period Profit
Trading Financial Assets	1,705,986,636.59	4,926,542,409.75	3,220,555,773.16	80,472,509.79
Derivative Financial Assets	489,944.97	-	-489,944.97	-489,944.97
Other Non-Current Financial Assets	82,366,375.73	130,880,900.00	48,514,524.27	-38,683,507.79
Total	1,788,842,957.29	5,057,423,309.75	3,268,580,352.46	41,299,057.03

12. Explanation of deferred or exempted information due to state secrets, trade secrets, etc.

√ Applicable□ Not applicable

Based on trade secret considerations, the company discloses information after de-identification for R&D projects (using code names), names of new customers among the top five customers, and the names of entities in the top five other receivables by debtor at period-end.

Section III Management Discussion and Analysis

1. Description of the main business, business model, and industry situation during the reporting period

i. Main business, main products or services

United Imaging Healthcare is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, and life science instruments. The company's headquarters is located in Shanghai, with regional headquarters and R&D centers established in the United States, the Netherlands, the UAE, Singapore, South Africa, Colombia, etc., and production capacity layouts in Shanghai, Changzhou, Wuhan, and Houston, USA, having established a global R&D, production, and service network.

Since its establishment, the company has continuously invested heavily in R&D, committed to overcoming core technologies in large medical equipment fields such as medical imaging equipment and radiotherapy products; after years of effort, the company has built a complete product line layout including medical imaging equipment, radiotherapy products, and life science instruments. As of the end of the reporting period, the company has cumulatively launched over 150 products to the market, including Magnetic Resonance Imaging Systems (MR), X-ray Computed Tomography Systems (CT), X-ray Imaging Systems (XR), Molecular Imaging Systems (PET/CT, PET/MR), Color Doppler Ultrasound Diagnostic Systems (US), Medical Linear Accelerator Systems (RT), and life science instruments.

The company's specific product categories and their uses are as follows:

No.	Category	Product	Product Use
1	Medical Imaging Equipment	Magnetic Resonance Imaging System (MR)	MR has advantages such as no radiation, rich contrast, and high soft tissue resolution, widely used in various disease diagnosis, health screening, surgical navigation, and other clinical scenarios, and can provide important diagnostic information for basic medicine, brain science, molecular biology, and other cutting-edge research fields.
		X-ray Computed Tomography System (CT)	CT features fast scanning speed and high spatial resolution, suitable for medical institutions at all levels, capable of providing necessary information for health checks, diagnosis, and treatment.
		X-ray Imaging System (XR)	XR includes conventional DR, mobile DR, mammography machines, C-arm X-ray machines, DSA, etc., and can be used for screening and diagnosis of various diseases, as well as image guidance for surgical and interventional procedures.
		Molecular Imaging System (MI)	Includes PET/CT and PET/MR, etc., which combine molecular metabolic

No.	Category	Product	Product Use
			activity images from PET scans with morphological and functional information from CT or MR scans; it has broad clinical value in whole-body tissue diagnosis, especially in oncology, cardiovascular, and nervous system diseases; it is also highly valuable in scientific research and translational medicine.
		Ultrasound Diagnostic System (US)	US has advantages such as safety, non-invasiveness, no radiation, real-time dynamic imaging, and cost-effectiveness, widely used in screening, diagnosis, and follow-up of various diseases; it also plays an increasingly important role in minimally invasive interventional therapy and intraoperative real-time navigation.
2	Radiotherapy Products	Medical Linear Accelerator System (RT)	Radiotherapy is currently an important treatment method in cancer therapy, among which medical linear accelerators have advantages such as broad indications and wide application, making them mainstream radiotherapy equipment.
3	Life Science Instruments	Preclinical MR	Can display the tissue structure and functional information of live animals, assisting in pathological and pharmacological research of animal models, and aiding translational medicine.
		Preclinical PET/CT	Enables real-time detection of physiological, pathological, and drug metabolism processes in various animal models at the dynamic molecular level, assisting drug development and translational medicine.

Note 1: Preclinical MR and PET/CT refer to Magnetic Resonance Imaging Systems (MR) and Molecular Imaging Systems (MI) applied in the field of animal model imaging; sales data for life science instruments are combined with medical imaging equipment.

Note 2: During the reporting period, the company sold part of its medical internet software assets (i.e., patent ownership/application rights and software copyrights related to products such as Picture Archiving and Communication Systems and Medical Electronic Cloud Film) for RMB 10.30 million (excluding tax); the transferee in this transaction was Shanghai Zhiyuan. After the completion of this transaction, the company will no longer engage in Picture Archiving and Communication Systems and Medical Electronic Cloud Film related businesses and will not create any new horizontal competition. The aforementioned related-party transaction was reviewed and approved by the company's General Manager's Office meeting and did not require submission to the Board of Directors for review. The sold assets differ significantly from medical imaging equipment and radiotherapy products in terms of product form, core functions, underlying technology, application scenarios, operation and maintenance models, cost structure, and development

trends. This transaction is conducive to optimizing the company's asset structure and concentrating superior resources on forward-looking deployment in high-performance medical imaging equipment and radiotherapy products.

1. Medical Imaging Diagnosis

(1) Magnetic Resonance Imaging System

Magnetic Resonance Imaging System (MRI) is equipment that uses the magnetic resonance signals of atomic nuclei (mainly hydrogen protons) in water molecules within the human body in a strong magnetic field to reconstruct images of tissues or organs.

The company has the capability to independently design, develop, and manufacture high-field superconducting magnets, high-performance gradient coils, high-density RF coils, multi-channel distributed spectrometers, as well as MR imaging software and advanced applications. The company has launched multiple superconducting MR products such as 1.5T, 3.0T, and 5.0T to meet the needs of different market segments from basic clinical diagnosis to high-end research, with several products being industry-first or domestic-first. The uMR Jupiter 5T is the industry's first 5.0T MR model for whole-body imaging, enabling ultra-high-field whole-body clinical imaging; the uMR Ultra is equipped with the uAIFI.LIVE imaging platform, combined with an artificial intelligence imaging chain, leveraging the synergistic advantages of the ultra-high-performance gradient system and the spatiotemporal fusion AI engine to continuously capture high-definition dynamic images of anatomical structures and functional tissue activities, ensuring not only high clarity per frame but also providing coherent dynamic information, with great potential for observing, diagnosing, and researching moving parts of the human body; the uMR Max, a new-generation 3.0T MRI, is equipped with a high-performance gradient system, a new online ecological platform, and a full-process AI-assisted system, significantly improving examination efficiency and diagnostic consistency; the uMR 890 is equipped with a high-performance gradient system, with single-axis field strength and slew rate reaching 120mT/m and 200T/m/s respectively, aiding brain science research; the uMR Omega is the industry's first 75cm large-bore 3.0T MR model, better supporting intraoperative and radiotherapy positioning, and meeting the diagnostic and treatment needs of special groups such as pregnant women and overweight individuals; the uMR 600 is the industry's first silicon carbide MRI, equipped with a third-generation semiconductor technology silicon carbide (SiC) gradient power amplifier (GPA), combined with the empowerment of the uAIFI platform, improving image quality and scanning speed while significantly reducing equipment energy consumption.

The company's main MR products are as follows:

Serial Number	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uMR Jupiter 5T		• The industry's first 5.0T superconducting magnetic resonance system, supporting clinical and research applications for all body parts • Pioneering 8-channel volume transmit coil, solving the challenge of radio frequency excitation uniformity in ultra-high fields, achieving precise whole-body imaging • Equipped with a 3.5MW gradient power amplifier, supporting ultra-high gradient performance of 120mT/m & 200T/m/s, facilitating cutting-edge brain science exploration • Innovative magnet design, requiring only the installation space of a traditional 3.0T MRI, significantly enhancing the accessibility of ultra-high field systems
2	uMR Ultra		• The world's first LIVE HD video MRI, a high-performance large-bore 3.0T system, ushering in the era of whole-body LIVE video MRI • Equipped with the uAIFI.LIVE imaging platform, combined with the latest generation AI imaging chain, leveraging the synergy of the ultra-high performance gradient system (100 mT/m @ 200 T/m/s) and the spatiotemporal fusion AI engine, to continuously capture HD dynamic images of anatomical structures and functional tissue activities • While ensuring the clarity of single-frame images, it provides stable, continuous dynamic imaging information, expanding the application boundaries of MRI in motion-related tissue and functional assessment • Applicable to clinical scenarios such as the nervous system, gastrointestinal tract, pelvic cavity, and joints, providing richer imaging information support for the diagnosis and assessment of complex diseases and research applications

Serial Number	Product Model	Schematic Diagram	Product Introduction and Highlights
3	uMR Astra		• Equipped with a new generation of high-density ultra-flexible coils, achieving precise coverage of all body parts with a high channel count. Its excellent fit and inductive sensitivity significantly improve the image signal-to-noise ratio, ensuring patient comfort while laying a solid foundation for whole-body high-definition imaging • Leveraging deep learning acceleration technology, it achieves an ultimate imaging experience: 5 minutes for the head, 8 minutes for the abdomen, and 15 minutes for the heart. While ensuring clinical diagnostic-grade image quality, it helps increase the daily scanning volume per device by up to 50%, effectively optimizing departmental turnover efficiency and patient experience • Deeply integrates proprietary AI algorithms with clinical practice, building an intelligent management system covering the entire scanning process. Through customized solutions for diverse clinical scenarios, it achieves a closed loop from intelligent positioning to precise diagnosis, fully empowering efficient diagnosis and treatment of complex diseases
4	uMR Max		• A revolutionary gradient control system that surpasses traditional limitations, achieving significant improvements in precise imaging and scanning efficiency • Supported by an online ecosystem platform, enabling real-time access to rich cutting-edge technologies and diverse clinical protocols • AI empowerment throughout the process enhances the intelligence level of MRI, significantly improving examination efficiency and diagnostic consistency

Serial Number	Product Model	Schematic Diagram	Product Introduction and Highlights
5	uMR Omega		• The industry's first 75cm ultra-large bore 3.0T MR, meeting the diagnostic and therapeutic needs of pregnant women and overweight populations, supporting surgical navigation and radiotherapy simulation positioning • Equipped with a high-homogeneity large-bore superconducting magnet, achieving high-definition scanning imaging with a 60cm field of view, the largest in the industry • Equipped with a 3.5MW gradient power amplifier, meeting clinical needs for high-speed scanning and high-resolution imaging • "Quiet" mode scanning, significantly reducing acoustic noise during MRI examinations
6	uMR NX		• Ultra-high performance research-oriented 3.0T MR, suitable for high-end research scenarios • Equipped with a 3.5MW gradient power amplifier, ultra-high performance gradient system (single-axis field strength 120mT/m, slew rate 200T/m/s) and a 64-channel ultra-high density head research coil, suitable for brain science research • Equipped with a fully digital radio frequency system and optical shuttle imaging technology, enhancing scanning speed and image quality

Serial Number	Product Model	Schematic Diagram	Product Introduction and Highlights
7	uMR 880		• Whole-body high-performance research-oriented 3.0T MR, suitable for research and advanced clinical application scenarios • Equipped with a 3.5MW gradient power amplifier and high-performance gradient system (single-axis field strength 80mT/m, slew rate 200T/m/s), widely applicable to research and high-end clinical applications for various body parts • Features ultra-high density super flexible coils and a millimeter wave radar respiratory motion detection system, comprehensively improving image quality and workflow efficiency • Enables comprehensive advanced clinical and research applications for neurology, body, and heart
8	uMR 870		• Whole-body research and clinical 3.0T MR, suitable for scenarios emphasizing both clinical and research applications • Features high-density super flexible coils and a millimeter wave radar respiratory motion detection system, comprehensively improving image quality and workflow efficiency • Whole-body, full-sequence "quiet" scanning, enhancing patient experience
9	uMR 780		• The first domestically produced optical shuttle 3.0T MR, suitable for scenarios emphasizing both clinical and research applications • Equipped with optical shuttle imaging technology, paired with a high-performance optical shuttle reconstruction engine, achieving fast scanning at 0.5 seconds/phase • Clinical solutions cover static and dynamic application scenarios for all body parts, also suitable for clinical scientific research

Serial Number	Product Model	Schematic Diagram	Product Introduction and Highlights
10	uMR 680		• Large-bore flagship research-oriented 1.5T magnetic resonance imaging system, suitable for scenarios emphasizing both clinical and research applications. Single-axis gradient field strength 45mT/m, gradient slew rate 200T/m/s • Equipped with high-definition noise reduction technology, obtaining 3.0T-level high signal-to-noise ratio, higher resolution images • Full-sequence ultra-fast quiet imaging system, excellent scanning experience, comprehensive clinical and research applications
11	uMR 670 Max		• Large-bore clinical flagship 1.5T magnetic resonance system • Equipped with the latest generation SuperFlex Coil ultra-flexible coil, supporting 72-channel RF performance, achieving seamless fit and precise sensing for all body parts, providing comprehensive clinical support such as radiotherapy simulation positioning while improving image signal-to-noise ratio and patient comfort • Leveraging the dual engines of ACS and DeepRecon, achieving a leap in image quality and scanning speed. While ensuring clinical diagnostic-grade accuracy, it significantly shortens imaging time for various body parts, helping departments break through daily scanning volume bottlenecks and build an efficient high-speed imaging system. • All-in-One AI Intelligent Workflow: Deeply integrates the intelligent driving system and proprietary AI algorithms to create standardized clinical pathways covering the entire scanning process. Through customized solutions for complex scenarios, it achieves closed-loop management from intelligent positioning to precise image output, fully empowering high-level applications in research and clinical practice.

Serial Number	Product Model	Schematic Diagram	Product Introduction and Highlights
12	uMR 670		• Large-bore image-fidelity 1.5T MR, suitable for clinical scenarios. • Equipped with high-definition noise reduction technology, achieving 3.0T-level high signal-to-noise ratio and higher resolution images. • Features dual millimeter-wave radar remote life sensing technology for non-contact acquisition of physiological signals. • Full-sequence high-speed silent imaging system, providing an excellent scanning experience.
13	uMR 660		• Image-fidelity 1.5T MR, suitable for clinical scenarios. • Equipped with high-definition noise reduction technology, achieving higher signal-to-noise ratio and higher resolution images. • Equipped with a fully digital radio frequency system, achieving high-fidelity, low-noise imaging. • Equipped with light shuttle imaging technology, effectively improving clinical scanning speed.
14	uMR 630 Max		• High-end advanced 1.5T silicon carbide magnetic resonance. • Equipped with industry-leading silicon carbide (SiC) power semiconductor technology, achieving exceptional evolution of the radio frequency system and 72 high-channel performance. Through an energy-efficient hardware architecture, it provides extremely high signal-to-noise ratio and signal stability while reducing energy consumption, laying a solid technical foundation for ultra-high-definition clinical imaging. • Deeply integrates ACS intelligent light-speed scanning, DeepRecon deep learning reconstruction, and the intelligent driving system, building a high-speed imaging system covering the entire process. Through deep AI algorithm intervention in scanning and reconstruction, it significantly shortens single-site imaging time, achieving simultaneous leap in diagnostic accuracy and department operational efficiency.

Serial Number	Product Model	Schematic Diagram	Product Introduction and Highlights
			• Relying on robust gradient performance and computing platform, it achieves cardiac imaging during a single breath-hold or even free breathing. Addressing diverse clinical challenges, it provides standardized solutions covering the whole body, helping departments achieve a comprehensive advancement in the field of complex disease diagnosis.
15	uMR 600 Max		• 1.5T silicon carbide (SiC) magnetic resonance, equipped with ACS intelligent light-speed scanning and DeepRecon deep learning reconstruction technology. Through the synergistic evolution of the hardware platform and proprietary AI algorithms, it achieves dual improvement in image signal-to-noise ratio and scanning speed, defining a new height of clinical performance for 1.5T magnetic resonance. • Equipped with EasySense zero-constraint respiratory sensing technology, eliminating the physical constraints of traditional respiratory belts, achieving real-time precise perception of patient physiological status. While significantly improving examination efficiency and convenience, it effectively suppresses motion artifacts, ensuring the production of highly stable, high-quality diagnostic images in various complex clinical scenarios. • Adopts the latest generation SuperFlex Coil flexible coil, with high-density channel layout combined with advanced sensing technology, not only significantly improving the detail expression of clinical images but also providing patients with an unparalleled level of comfort during examinations.

Serial Number	Product Model	Schematic Diagram	Product Introduction and Highlights
16	uMR 600		• The industry's first silicon carbide magnetic resonance, integrated with the new uAIFI platform, achieving both efficiency and energy saving. • Equipped with the industry-first Silicon Carbide (SiC) gradient power amplifier (GPA), , the system achieves superior electrical energy utilization efficiency. Compared to traditional silicon GPA, the device loss of SiC GPA is reduced by over 60% at the same power level. When integrated with a comprehensive low-carbon energy-saving solution, the system can realize energy savings of over 57%. • The uCS & DeepRecon Hybrid dual-engine drive system simultaneously optimizes image quality and scanning speed, delivering up to a 60% reduction in scan time. It supports exclusive low-carbon sequences and incorporates Qscan silent scanning technology.
17	uMR 585e		• Fully digital 1.5T MR, suitable for clinical scenarios. • Equipped with industry-leading compressed sensing imaging and AI image reconstruction technology, achieving higher resolution and higher signal-to-noise ratio without sacrificing scanning time. • Features a more comprehensive AI positioning workflow: covers intelligent positioning functions for multiple commonly used body parts. Reduces manual positioning time for technologists, improves standardized scanning and image quality control quality, covering 2D/3D scanning, quantitative analysis, functional and metabolic imaging techniques. • Equipped with high-efficiency Radio Frequency (RF) and integrated high-density phased array coil sets, the system achieves superior signal transmission efficiency while enabling comprehensive clinical applications.

Serial Number	Product Model	Schematic Diagram	Product Introduction and Highlights
18	uMR 588		• Fully digital 1.5T MR, suitable for clinical scenarios. • Equipped with fully digital radio frequency transmission technology, achieving high-fidelity, low-noise imaging. • Automated examination workflow, improving usage efficiency. • Equipped with light shuttle imaging technology, effectively improving clinical scanning speed.
19	uMR 580		• Fully digital 1.5T MR, suitable for clinical scenarios. • Equipped with fully digital radio frequency transmission technology, achieving high-fidelity, low-noise imaging. • Automated examination workflow, improving usage efficiency. • Provides comprehensive clinical solutions.

(2) X-ray Computed Tomography System

X-ray Computed Tomography system (CT) uses an X-ray tube to emit X-rays, which penetrate human tissues and are received by a detector and converted into digital signals. After computer processing, cross-sectional or three-dimensional images of the examined body parts are formed, thereby detecting lesions in human tissues or organs.

The company has mastered the R&D and production capabilities for CT detectors, X-ray tubes, high-voltage generators, high-speed rotating gantries, and advanced image processing applications. The company's CT product line covers clinical economy products and high-end research products, meeting diverse needs such as disease screening, clinical diagnosis, and research. The company has successively launched CT products ranging from 16-slice to 320-slice, including the domestically first photon-counting spectral CT uCT Ultima, which pioneered whole-body multi-site ultra-high-resolution imaging and precise spectral imaging for domestic photon-counting spectral CT, suitable for high-end integrated clinical diagnosis and research scenarios; the world's first dual-wide dual-source CT imaging system uCT SiriuX, which for the first time combines the wide detector and dual-source configurations of ultra-high-end CT systems, achieving a breakthrough 8ms industry-leading whole-heart temporal resolution, dual-wide 16cm full-organ volume coverage, and a 470mm ultra-large spectral imaging field of view, enabling comprehensive performance improvements in time, coverage, and precision; the new-generation ultra-high-end CT uCT Atlas Pro, the domestically first 320-slice ultra-high-end CT product uCT 960+, and the domestically first 80-slice CT product uCT 780. Among them, uCT Atlas Pro, as the latest ultra-high-end 320-slice 640-layer CT released by United Imaging Healthcare, is equipped with the new-generation AIIR Pro dual-engine supercomputing imaging platform. It not only achieves a revolutionary dual-engine reconstruction algorithm architecture, maintaining advantages

in optical, noise, anatomical, and system models, ensuring accurate preservation of anatomical and pathological features while incorporating the benefits of deep learning denoising technology for natural and realistic image texture; the innovative CardioBoost dedicated deep learning algorithm for cardiac imaging, meticulously developed for cardiac reconstruction algorithms, utilizes deep learning technology to significantly enhance image resolution, eliminate artifact interference, effectively reduce radiation dose and noise, maintain natural and realistic image texture, and significantly improve the accuracy of cardiac diagnosis; uCT 960+ is equipped with a self-developed Z-Detector, achieving a gantry rotation speed of 0.25s/rotation, featuring an 82cm large bore, enabling single cardiac cycle cardiac imaging at any heart rate, single-organ perfusion, and rapid large-area vascular imaging, while possessing low-dose imaging and spectral imaging capabilities with tube voltage switching, offering significant clinical diagnostic and research value in cerebrovascular diseases, tumors, emergency, and pediatric examinations. uCT Orion Plus/Pro/Elite new-generation 40-slice practical CT: integrated imaging chain, with self-developed and self-produced detectors, tubes, and power block units, ensuring data accuracy and system stability, meeting complex clinical needs such as high-throughput and multi-site combined scanning; Orion series AI precision quality control: enhancing quality through scanning standardization and safety, supporting 8 posture AI recognition, including one-click positioning, parameter setting, etc., avoiding artifacts and safety incidents, ensuring image quality and patient safety, improving primary-level scanning capabilities; equipped with an AI intelligent clinical application platform: integrating functions such as AI for cerebral hemorrhage and lung nodule screening, facilitating efficient and precise diagnosis and treatment.

The company's main CT products are as follows:

No.	Model	Schematic	Product Introduction and Highlights
1	uCT Ultima		• Domestically first photon-counting spectral CT, pioneering whole-body multi-site ultra-high-resolution and precise spectral imaging, suitable for high-end integrated clinical diagnosis and research scenarios • In ultra-high-resolution imaging, breaking through traditional detector size limitations, reducing pixel area to 1/9 of traditional size, revealing subtle lesion structures, significantly improving spatial resolution, aiding precise diagnosis • Achieved major breakthroughs in core areas such as system design, reconstruction algorithms, and spectral applications, supporting full-collimation high-resolution imaging, especially suitable for high-definition imaging of large organs like the heart

No.	Model	Schematic	Product Introduction and Highlights
2	uCT SiriuX/ SiriuX Pro		• World's first new CT system configuration, revolutionizing traditional architecture, breakthrough combination of wide detector and dual-source technology, achieving 8ms industry-leading whole-heart temporal resolution, 16cm full-organ volume coverage, and 470mm ultra-large dual-source spectral imaging field of view • Addressing the shortcomings of traditional clinical dynamic imaging, in cardiac imaging, uCT SiriuX not only clearly presents coronary stenosis and valve motion, achieving single cardiac cycle whole-heart dynamic imaging, but also provides a stable and reliable imaging foundation for structural assessment and quantitative measurement through full-phase data acquisition and deep learning motion correction algorithms • Supports clinical acquisition of whole-body motion imaging from joint movement to organ motion

No.	Model	Schematic	Product Introduction and Highlights
3	uCT Atlas Pro		• Suitable for high-end integrated clinical and research application scenarios, equipped with the new-generation AIIR Pro dual-engine supercomputing imaging platform, achieving a revolutionary dual-engine reconstruction algorithm architecture, maintaining advantages in optical, noise, anatomical, and system models, accurately preserving anatomical and pathological features, while incorporating the benefits of deep learning denoising technology for natural image texture • Innovative CardioBoost dedicated deep learning algorithm for cardiac imaging, meticulously developed for cardiac reconstruction algorithms, utilizing deep learning technology to significantly enhance image resolution, eliminate artifact interference, effectively reduce radiation dose and noise, maintain natural and realistic image texture, significantly improving the accuracy of cardiac diagnosis • New digital intelligent post-processing engine uOmnispace platform, delivering second-level work efficiency and ultra-realistic rendering technology, offering an exceptional imaging experience

No.	Model	Schematic	Product Introduction and Highlights
4	uCT Atlas Elite		• Suitable for high-end integrated clinical and research application scenarios, as a new-generation ultra-high-end CT, uCT Atlas Elite is equipped with ECG Free deep learning non-ECG scanning, breaking free from ECG constraints, no gating limitations, no heart rate restrictions, accurately capturing cardiac rhythm for coronary CTA scans, paving the way for clear diagnosis in patients with complex heart rhythms • Comprehensive innovative CT-AI intelligent solution, offering full-spectrum coverage from second-level recognition for neurological emergencies to detailed analysis of musculoskeletal lesions, intelligent acceleration of emergency processes, reshaping clinical solutions with digital intelligence • Equipped with the uOmnispace digital intelligence engine platform, driven by a new architecture for research collaboration, multi-modality fusion, big data integration, expanding the depth of clinical exploration From breakthroughs in cardiac examination to intelligent upgrades in whole-system diagnosis and treatment, to innovations in research experience, uCT Atlas Elite, with its cutting-edge performance, breaks through diagnostic barriers, leading medical imaging towards a new era of precision and efficiency

No.	Model	Schematic	Product Introduction and Highlights
5	uCT 968		• New-generation wide-detector CT product suitable for high-end clinical and research scenarios, fully integrating deep learning artificial intelligence technology, providing innovative solutions for CT morphological and functional diagnosis and treatment as well as cutting-edge research • Fifth-generation CT imaging technology - AIIR deep learning full-model iterative algorithm, providing new solutions for whole-body low radiation dose and ultra-high-definition imaging • All-in-One cardiac multi-modality imaging technology, integrating coronary morphology, coronary blood flow, and myocardial microcirculation functional assessment, providing comprehensive information for clinical treatment path decisions; deep learning head motion artifact removal and AIIR • The integration of deep learning full-model iterative algorithm solves the challenges of head motion artifacts and whole-brain perfusion dose in emergency stroke patients, enabling lower examination dose, higher image matching accuracy, and significantly improving diagnosis and treatment efficiency
6	uCT 960+		• Domestically first 320-slice ultra-high-end CT product • Wide-detector CT product suitable for high-end clinical and research scenarios • Equipped with a self-developed 320-slice wide Z-Detector, achieving a gantry rotation speed of 0.25s/rotation, obtaining 640 high-definition layers per rotation, improving the success rate of cardiac examination scans • Can enhance the speed and imaging quality of cardiac and large-area vascular scanning, improving the success rate of cardiac scans. Possesses the capability for large-organ perfusion and dynamic imaging such as whole brain and whole liver

No.	Model	Schematic	Product Introduction and Highlights
7	uCT 868		• Wide-detector CT product suitable for high-end clinical and research scenarios • Features extreme hardware including a 0.25s/rotation gantry rotation speed, a 34MHU large heat capacity X-ray tube, and an 82cm gantry bore. • Equipped with the uSense active sensing platform, which includes various deep learning algorithms for operation, scanning, dose control, image quality, and artifact suppression, significantly improving image quality, diagnostic efficiency, and operational consistency.
8	uCT 860		• A wide-body CT product suitable for high-end clinical and research scenarios. • Equipped with a self-developed 160-row wide-body detector and a 0.25s/rotation gantry rotation speed, significantly improving the success rate of cardiac scans. • A 30MHU large heat capacity X-ray tube that meets the clinical needs for high-throughput patient examinations.
9	uCT 820		• A CT product suitable for scenarios that emphasize both clinical and research applications. • The extra-large 82cm gantry bore provides a more comfortable examination experience for high-end physical examinations, emergency situations, and other special environments. • Equipped with a self-developed detector, the system rotation speed can reach 0.25s/rotation, comprehensively enhancing cardiac scanning capability and success rate.

No.	Model	Schematic	Product Introduction and Highlights
10	uCT 788		• A CT product suitable for scenarios that emphasize both clinical and research applications. • Equipped with Deep Recon deep learning algorithm, enabling whole-body low-dose CT imaging; a 0.3s/rotation speed combined with adaptive variable speed technology expands new scenarios for complex coronary artery examinations; spectral functional imaging provides more quantitative information for clinical diagnosis.
11	uCT 780		• The first domestically produced 80-row CT product. • A CT product suitable for scenarios that emphasize both clinical and research applications. • Equipped with a self-developed detector and a 7.5MHU large heat capacity X-ray tube, the system rotation speed can reach 0.3s/rotation, comprehensively improving the success rate of cardiac scans; also features a maximum system power of 100kW, suitable for examining patients with a larger body weight base.
12	uCT 768		• A high-end 160-slice CT in the industry, equipped with United Imaging's ultra-high-end CT uSense sensing platform, achieving full-process AI empowerment. • Suitable for 17cm large-range whole brain perfusion imaging, assisting stroke centers in comprehensively assessing patient conditions. • Equipped with ePhase intelligent heart finding technology, improving the success rate of coronary artery scans. • Equipped with Tianyan AI technology, providing an intelligent CT scanning experience and improving scanning efficiency.

No.	Model	Schematic	Product Introduction and Highlights
13	uCT 760		• A CT product suitable for scenarios that emphasize both clinical and research applications. • Equipped with a self-developed detector. • Equipped with a 7.5MHU large heat capacity X-ray tube, the system rotation speed reaches 0.35s/rotation, and it has a maximum system power of 80kW, fully meeting clinical applications such as cardiac scanning and angiography.
14	uCT Orion Plus/Pro/Elite		• A new-generation 40-row practical CT with an integrated imaging chain; detectors, X-ray tubes, and power block units are fully self-developed and self-produced, ensuring precise data acquisition and stable, reliable system performance; easily meets complex clinical needs such as high-throughput scanning, multi-part combined scanning, spectral scanning, and multi-phase enhanced scanning. • The Orion series features unique AI precision quality control, enhancing scan quality from the dimensions of scan standardization and scan safety. It supports AI recognition of 8 body positions, is equipped with one-click AI precise positioning, AI scan parameter setting, AI metal foreign object detection, AI motion detection, AI breathing artifact detection, integrated AI collision notification, AI lead apron wear recognition, and an AI bore detection system, helping to avoid metal artifacts, motion artifacts, and safety accidents, ensuring standardized, safe scanning and high-definition image quality, promoting image interoperability and recognition, ensuring patient health and safety, avoiding medical disputes, and improving the scanning capability level of primary medical imaging examinations. • Equipped with a comprehensive AI intelligent clinical application platform, integrating various functions such as All-in-One brain hemorrhage AI, intelligent lung nodule screening, intelligent lung parenchyma analysis, intelligent rib and spine analysis, and intelligent

No.	Model	Schematic	Product Introduction and Highlights
			dental analysis, providing intelligent and efficient support for clinical diagnosis, and improving diagnostic and treatment efficiency and accuracy.

No.	Model	Schematic	Product Introduction and Highlights
15	uCT Orion Eco/Era/Extra		• The new-generation 20-row CT achieves AI precision quality control based on deep learning technology, supports AI recognition of 8 body positions, is equipped with one-click AI precise positioning, AI scan parameter setting, integrated AI collision notification, AI metal foreign object detection, AI lead apron wear recognition, and an AI bore detection system, effectively avoiding metal artifacts, motion artifacts, and safety accidents, ensuring standardized, safe scanning and high-definition image quality. • Self-developed and produced integrated imaging chain, equipped with the second-generation Z-Detector, a large heat capacity 3.8MHU X-ray tube, and a 48kW self-developed power block unit, achieving a comprehensive upgrade of core CT components, enabling precise data acquisition and stable, reliable system performance; easily meets complex clinical needs such as high-throughput scanning, multi-part combined scanning, and multi-phase enhanced scanning. • Equipped with a comprehensive AI-assisted diagnosis platform, integrating various functions such as All-in-One brain hemorrhage AI-assisted diagnosis, intelligent lung nodule screening, intelligent lung parenchyma analysis, intelligent rib and spine analysis, and intelligent dental analysis, providing intelligent and efficient support for clinical diagnosis, and improving diagnostic and treatment efficiency and accuracy.

No.	Model	Schematic	Product Introduction and Highlights
16	uCT 550/550+		• Equipped with a self-developed detector. • Suitable for a wide range of clinical application scenarios, achieving a 0.55mm acquisition slice thickness, providing clearer and more detailed images for the diagnosis of small lesions, and obtaining more diagnostic information. • The 5.3MHU X-ray tube heat capacity balances scanning speed and image precision, meeting the clinical needs for continuous and large-range scanning. • Using the KARL3D iterative noise reduction algorithm, uDose intelligent mA adjustment technology, and 70kV scan mode, low-dose imaging can be achieved.
17	uCT 530/530+		• Suitable for a wide range of clinical application scenarios • Equipped with a self-developed detector • Achieves a 0.55mm acquisition slice thickness, making small lesions clearly visible • 5.3MHU tube heat content provides powerful continuous exposure capability and an ultra-long service life, meeting the demands for continuous and large-area scanning in clinical practice • Integrates cutting-edge hardware and software such as KARL3D iterative reconstruction technology and an intelligent management platform, achieving a triple breakthrough in image precision, ultra-low dose, and scanning speed, effectively restoring image details

No.	Model	Schematic	Product Introduction and Highlights
18	uCT 520/528		• Suitable for routine clinical scenarios • Paired with the self-developed "Z-Detector," it achieves a 0.55mm acquisition slice thickness, providing clearer and more detailed images for the diagnosis of small lesions, obtaining more diagnostic information. It can achieve a 22mm detector coverage width, effectively improving examination speed and reducing respiratory motion artifacts • Equipped with an AI navigation system for patient scan positioning, enabling contactless precise CT scanning, significantly simplifying the clinical workflow, and effectively enhancing the standardization and normalization of the scanning process • Utilizing the KARL3D iterative noise reduction algorithm, uDose intelligent mA adjustment technology, and 70kV scan mode, enabling low-dose imaging
19	uCT 610 Sim		• A new large-bore CT system integrating diagnostic CT scanning, radiotherapy simulation and positioning, and image-guided interventional puncture procedures • 87cm ultra-large bore, provides ample patient positioning space, supporting the accommodation of various large-sized positioning accessories in radiotherapy scenarios; offers more flexible operating space for interventional image-guided surgery • 63cm ultra-large scan field of view (sFOV), compared to conventional 70cm aperture CT systems, the scan field of view is increased by 26%, presenting more complete anatomical structures for simulation and positioning scans of special patients such as those with high body weight or off-center positioning • Supports preoperative planning, intraoperative scanning (single axial scan, single helical scan, continuous axial scanning, and continuous fluoroscopy to meet different interventional puncture application

No.	Model	Schematic	Product Introduction and Highlights
			scenarios), postoperative evaluation, and provides a comprehensive and professional interventional kit • A comprehensive 4D CT solution, allowing departments to flexibly use it according to different clinical scenarios, laying a solid foundation for treating moving tumors
20	uCT 830 Hybrid		• Equipped with an 80-slice detector, capable of scanning the whole body including the heart and other parts, achieving maximum application across all departments and organs • Features the industry's largest gantry aperture of 82cm. The diagnostic-grade large bore offers greater advantages in complex intraoperative scenarios, such as providing more flexibility in handling surgical situations involving head frames, drapes, and anesthesia breathing tubes • Equipped with powerful core components, including 0.5mm thin-slice scanning capability and a precision flying focal spot liquid metal tube, making tiny lesions in the lungs and liver clearly visible, and distal minute blood vessels in the brain clearly discernible
21	Vehicle-mounted CT		• CT product used in mobile scenarios • Equipped with a contactless scanning navigation system and a dual-channel vehicle body design for medical staff and patients, avoiding cross-infection • Enhances stability through the CT reinforcement system, meeting system reliability requirements under long-term and varying distance transport conditions • Remote data transmission and processing system ensures effective and stable operation of the entire system

(3) X-ray Imaging System

The X-ray imaging system (X-ray, abbreviated as XR) generates X-rays from the tube. The X-rays penetrate human tissues and are received by the detector to create human images. It has different imaging modes according to clinical applications, including two-dimensional static imaging, two-dimensional dynamic imaging, three-dimensional tomosynthesis, etc. XR examinations can be applied for screening, diagnosis, and image guidance in surgical and interventional procedures.

Based on different clinical uses, XR products can be categorized into Digital Radiography (DR), Digital Mammography X-ray Imaging System (Mammo), Mobile C-arm X-ray Imaging System (Mobile C-arm), Angiography X-ray Imaging System (DSA), etc. Among these, DR is widely used in routine physical examinations and clinical disease diagnosis, making it the most widely used radiological imaging equipment in clinical practice; Mammo is primarily used for the screening and diagnosis of various breast diseases; Mobile C-arms are mostly used to provide image guidance for surgical procedures; DSA is commonly used for image guidance in various interventional procedures such as cardiac, neurological, and oncological interventions.

Since launching its first XR product in 2016, the company has successively introduced several representative products, including the uAngio 960 intelligent bionic minimally invasive interventional surgery system, the uAngio AVIVA intelligent bionic aerial robot angiography system, the uDR Aurora - the industry's first fully intelligent ceiling-mounted DR system covering 'positioning-shooting-processing-diagnosis-quality control' empowered by the uAID full-process intelligent imaging platform and leading AI technology, the domestically produced first breast 3D tomosynthesis system uMammo 890i, the domestically produced first contrast-enhanced mammography system uMammo Vitar, the new generation low-dose large flat panel mobile C-arm uMC Reveal, and the domestically produced first mobile DR product with visual exposure control capability, uDR 380i.

The company's main XR products are as follows:

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uAngio 960/960X/960 OR		• The uAngio 960/960X/960 OR intelligent bionic minimally invasive interventional surgery system is equipped with the industry's first uSpace digital twin space system, using computer vision technology to enhance interventional surgery efficiency, intelligently optimizing equipment movement, image acquisition, and dose control, creating a comprehensive intelligent control experience

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			• Possesses ultra-high flexibility, breaking through motion limitations, creating an ultimate user experience for all departments with the industry's largest free space, largest angulation, and largest field of view • Equipped with the unique uVera platform, deeply empowering imaging with digital intelligence, assisting clinical departments such as neurology/cardiology/oncology/surgery in precise diagnosis and treatment with excellent image quality and superior dose control • Equipped with the industry's first zero-noise imaging technology. By optimizing the imaging chain platform and combining advanced Burst Denoise technology, it increases the signal-to-noise ratio by 4 times while reducing radiation dose by 40-86% • The system leads the evolution and upgrading of hybrid operating rooms, comprehensively promoting interdisciplinary integration and clinical exploration and innovation

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
2	uAngio AVIVA Elite/Alpha/CX/CE		• Eight-axis aerial robot design, equipped with the industry's first uSpace digital twin space system, using computer vision technology to enhance interventional surgery efficiency, intelligently optimizing equipment movement, image acquisition, and dose control, creating a comprehensive intelligent control experience • Equipped with the industry's first uLingo intelligent voice system, supporting over 10,000 high-frequency clinical command operations, enabling free dialogue in all scenarios, truly freeing the doctor's hands • Industry-leading 8-axis tandem aerial robot, unlocking lateral movement to achieve full coverage of any position in the operating room, ultimate flexibility simplifies complex surgeries • Equipped with the innovative uVera platform, deeply empowering imaging with digital intelligence, with excellent image quality and superior dose control, assisting clinical departments such as neurology/cardiology/oncology/surgery in precise diagnosis and treatment • Equipped with the industry's first zero-noise imaging technology, by optimizing the imaging chain platform and combining advanced Burst Denoise technology, increases the signal-to-noise ratio by 4 times while reducing radiation dose by 40-86%

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
3	uMammo Vitar/Villa/Valent		• The latest generation integrated breast screening, diagnosis, and treatment platform, integrating multiple advanced functions such as CEM contrast enhancement, dual-angle DBT 3D tomography, and stereotactic biopsy puncture based on tomographic and contrast-enhanced images • Capable of accurately acquiring spatial and blood supply information of lesions while providing more comprehensive and precise needle biopsy localization methods • Achieves continuous completion of screening, diagnosis, and biopsy on the same platform, reducing the need for multi-device switching and repeat examinations, effectively shortening the diagnostic and treatment pathway, and reducing reliance on high-resource examinations like MRI, thereby ensuring diagnostic quality while improving overall process efficiency and patient experience
4	uMammo 890i		• China's first high-definition low-dose 3D digital Mammo, suitable for medical institutions at all levels • 3D tomosynthesis can solve the tissue overlap problem of traditional 2D imaging, effectively improving breast cancer detection rate and reducing false positive recall rate • 49.5μm micro-pixel single crystal silicon flat panel detector, can reduce radiation dose during examination
5	uMammo 870i		• A multifunctional mammography platform integrating dual-angle 3D tomography, intelligent exposure control technology, and intelligent fusion 2D technology, high quality, low dose, efficiently meeting different clinical needs, improving diagnostic efficacy

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
6	uMammo 590u		• Economy 2D digital mammography machine, rated 5 stars by the US ECRI patient safety organization • Equipped with a large-size dedicated breast flat panel detector, meeting the imaging requirements for breast soft tissue and micro-lesions • Equipped with an intelligent compression system for the examined area, enabling one-click rapid intelligent positioning
7	uMC Reveal		• New generation low-dose large flat panel mobile C-arm, equipped with industry-leading large-size flat panel detector, uRADIX full-process dose and image processing platform, achieving low-dose high-definition imaging during surgery • Adopts innovative lightweight design, reducing trolley pushing resistance and transfer burden; simultaneously provides greater intraoperative positioning freedom, bringing a relaxed daily operation experience, offering flexible and open surgical space for doctors in orthopedics, gastroenterology, urology, and other departments
8	uMC 560i		• Surgical flat panel mobile C-arm, suitable for various surgical procedures • Equipped with a single crystal silicon flat panel detector, significantly reducing radiation dose • 2-million pixel imaging chain system, greatly improving image resolution

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
9	uDR Aurora		• Equipped with the uAID full-process intelligent imaging platform, empowering clinical practice with industry-leading artificial intelligence technology, achieving full intelligent imaging covering 'positioning - shooting - processing - diagnosis - quality control' • Supports innovative functions such as intelligent voice guidance, uVision intelligent positioning, automatic FOV and intelligent parameter setting, uAID intelligent quality control, fully empowering the clinical examination process, improving examination efficiency, ensuring image quality, and assisting precise diagnosis • Provides specialized clinical solutions for multiple departments, including low-dose pediatric solutions and intelligent orthopedic solutions, supports fully automatic standing/recumbent long bone stitching application, providing high-quality orthopedic panoramic images for clinical use, enabling precise pre- and post-operative assessment of spine and lower extremity joints
10	uDR 780i Pro /780i		• Enables real-time observation of patient status, completing examination procedures in isolation rooms, suitable for various clinical scenarios • Supports over 200 fully automatic one-click positioning functions, with automatic centering and tracking, paired with dual wireless large panels, efficiently empowering clinical workflow • Supports fully automatic standing/recumbent stitching advanced application, assisting in pre-operative examination and post-operative outcome assessment of spine and lower extremity joints

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
11	uDR 760i		• Equipped with dual wireless large panels, more flexibly and efficiently meeting the examination needs of large-sized patients, supports built-in charging, durable and long-lasting • Achieves fully automatic stand movement, has automated positioning function, improving clinical work efficiency
12	uDR 380i Pro /380i		• Equipped with a remote control terminal, featuring remote visual exposure technology, enabling real-time monitoring, voice guidance, remote parameter adjustment, and remote exposure, improving shooting success rate • Has motorized motion function, 47cm compact body design, easy to use in confined spaces and bedside
13	uDR 330i		• Can adapt to extreme usage environments such as high temperature, extreme cold, high altitude, high humidity, and high salt, featuring waterproof, dustproof, and shockproof characteristics • Portable and easy to use, convenient for transport
14	uDR 596i		• Fully automatic floor-mounted digital DR • Intelligent one-click positioning function improves clinical work efficiency • Equipped with dual wireless large panels, meeting the examination needs of large-sized patients • Has fully automatic standing position stitching function, assisting clinical practice in achieving precise pre- and post-operative assessment of spine and lower extremity joints

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
15	uDR 566i		• Floor-mounted digital DR with automatic tracking function, improving clinical workflow efficiency • Equipped with dual wireless large flat panel detectors, meeting the examination needs of large-sized patients
16	uDR 266i		• U-arm DR using wireless high-definition large flat panel detectors • Features intelligent one-click positioning function, improving clinical workflow efficiency • Equipped with a wireless large flat panel detector, meeting the examination needs of large-sized patients

(4) Molecular Imaging System

Molecular Imaging System (Molecular Imaging, abbreviated as MI) can display specific molecules at the tissue, cellular, and subcellular levels, reflecting molecular-level changes in vivo, thereby enabling qualitative and quantitative research on biological behavior through imaging. Molecular imaging technology can detect abnormalities at the cellular and molecular levels during disease processes, explore the occurrence, development, and outcome of diseases (such as cancer, Parkinson's disease), and evaluate the effects of drugs and treatments.

The company is one of the few domestic enterprises that has obtained PET/CT product registration and achieved mass production of complete machines. It has mastered detector development technology, electronics technology, reconstruction and control technology, etc., enabling high spatial resolution, high time-of-flight (TOF) resolution, high sensitivity, large axial field of view, and whole-body dynamic scanning, with technical levels leading the industry. Among these, high spatial resolution can provide high diagnostic image quality for clinical use, aiding in the detection of early lesions, disease staging, treatment planning, and tracking therapeutic effects; high TOF resolution can significantly improve image signal-to-noise ratio and clarity; high sensitivity and large axial field of view can effectively enhance image quality and scanning speed; whole-body dynamic scanning can provide strong support for personalized precision diagnosis and treatment, new drug development, and other clinical and research applications. The company's MI products can be equipped with advanced post-processing applications such as multi-modal image fusion, dynamic analysis, tumor tracking, brain analysis, and cardiac analysis, providing precise analysis for the clinical diagnosis and treatment of tumors, neurological, and cardiac-related diseases. The company has successively launched multiple industry-leading products, including the industry's first PET/CT product with 4D whole-body dynamic scanning function, uEXPLORER (Total-body PET/CT); the world's

first commercial PET/CT achieving ultra-high TOF resolution at the 180ps level, uMI Panorama; uMI Panvivo, featuring a new generation of fully self-developed detector design; the first domestically produced integrated PET/MR product, uPMR 790; the first domestically produced digital TOF PET/CT product, uMI 780; and the first domestically produced PET/CT product, uMI 510.

The company's main MI products are as follows:

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uEXPLORER (Total-body PET/CT)		• The industry's first 4D panoramic dynamic PET/CT, suitable for cutting-edge research scenarios • Equipped with a 672-ring light guide detector and an 80-slice CT, it can complete whole-body high-definition scanning and imaging in just 30 seconds with 1/40th the dose • Enables real-time whole-body dynamic scanning and parameter analysis, supporting pharmacokinetic research and providing support for pathology and drug research • Selected as one of the "Top Ten Technological Breakthrough Products in the World" by Physics World in 2018

2	uMI Panorama 28C/Stellar/35C/35S/GS		• Equipped with the industry's first self-developed high-end medical imaging dedicated chip, as the world's first commercial PET/CT achieving ultra-high time resolution at the 180ps level, redefining clinical PET/CT image quality standards • Features an all-core wireless digital PET detector and a large-bore CT with a maximum rotation speed of 0.25s, leading in various performance indicators • Empowers nuclear medicine clinical practice and exploration with a fully intelligent workflow, advanced proprietary AI algorithms, and rich research applications

3	uMI Panvivo/ Panvivo S		• 2.9 mm NEMA spatial resolution and an effective sensitivity of 181 cps/kBq ensure image clarity and lesion detection capability • AI empowerment throughout the entire workflow, covering quality control, acquisition, reconstruction, and quantitative analysis, improving operational efficiency and freeing up manpower; equipped with the industry's first multi-nuclide AI iterative reconstruction algorithm, expanding its applicable radiopharmaceutical imaging range and enabling precise diagnosis for multiple diseases • Compact overall machine design, improving site accessibility; freely expandable detector platform, allowing in-place upgrade from short-axis to long-axis

4	uPMR 890		• 32cm longest PET axial field of view, 2.76mm finest crystal size, 1mm highest PET reconstruction resolution, and a new generation 80mT/m industry-leading performance MR gradient system • Full-stack AI empowerment, equipped with the industry-leading DPR deep progressive learning PET iterative reconstruction algorithm, DeepRecon MR intelligent deep reconstruction technology, and ACS intelligent light shuttle MR acceleration technology, achieving simultaneous improvement in scanning time, signal-to-noise ratio, and resolution, breaking the limits of PET/MR whole-body scanning, and further strengthening and exploring new clinical and research applications • Configured with SuperFlex Coil ultra-flexible coils, using new polymer conductor composite materials, ultra-light and ultra-flexible, fitting the patient's body more closely, improving patient scanning comfort, and achieving better image quality in some forced postures; using new preamp decoupling technology, coil density up to 103 units/m², faster imaging speed, higher image signal-to-noise ratio, significantly improving the display capability of tiny structures, and broadening clinical application scenarios

5	uPMR 790		• The first domestically produced integrated high-performance PET/MR, suitable for clinical and research scenarios • Integrates a 3.0T MR and a 112-ring PET system, equipped with AI scanning and reconstruction algorithms, achieving fast high-definition scanning • Achieves data stream fusion of physiological signals, PET, and MR
6	uMI 780		• The first domestically produced digital TOF PET/CT, suitable for clinical and research scenarios • Equipped with a 112-ring digital light guide detector and an 80-slice CT, featuring large field of view high resolution and fast high-definition scanning capabilities • Equipped with rich advanced applications, fully supporting clinical and research needs

7	uMI Vista		• Digital PET/CT, suitable for clinical scenarios • Equipped with 84-ring optical detector and 80-slice CT • Optimized cardiac scanning workflow, supporting clinical cardiac examinations
8	uMI 550		• Digital PET/CT, suitable for clinical scenarios • Equipped with 84-ring digital optical PET detector and 40-slice CT • Equipped with multiple intelligent applications to achieve more efficient workflow
9	Mobile PET/CT		• Digital mobile PET/CT, suitable for clinical scenarios, with high mobility and stability • Equipped with 84-ring digital optical PET detector and 40-slice CT • Equipped with a dedicated mobile workstation, suitable for mobile examinations

(5) Ultrasound Diagnostic System

Ultrasound Diagnostic System (Ultrasound, abbreviated as US) is a device that utilizes ultrasound Doppler technology and ultrasound echo principles to simultaneously collect blood flow and tissue motion information, and achieve imaging of human organs and tissues.

The company possesses the capability to independently design, develop, and manufacture ultrasound hosts, probes, as well as ultrasound imaging software and advanced applications. The company's US product line comprehensively covers clinical application areas such as whole-body, cardiovascular, and women's health, meeting diverse needs including disease screening, clinical diagnosis, and scientific research. The company has launched ultra-high-end ultrasound products such as uSONIQUE Genesis G, uSONIQUE Pulse G, and uSONIQUE Venus G, all equipped with the uEDGETEC intelligent ultrasound technology platform. This platform is built on the underlying technological foundation of PureGrid pure matrix probe, xCompute heterogeneous supercomputing system, DeepFocus imaging algorithm technology, and MindSpace intelligent software architecture. It combines technologies such as True 1.5D matrix array, uSpaceTime Crystal third-generation ternary piezoelectric single crystal, and OmniFocus full-range dynamic focusing. Through intelligent tools like fully automated workflow and uTarget automatic analysis, it achieves comprehensive integration of precise ultrasound imaging, intelligent applications, and an ultimate user experience.

The company's main ultrasound products are as follows:

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uSONIQUE Genesis G/T/P/Q/6/6 PRO		• Ultra-high-end whole-body application ultrasound diagnostic system, supporting clinical and research applications for all body parts • Supports fully automated abdominal workflow, improving the efficiency and quality of abdominal examinations • Rich advanced functions and auxiliary quantitative analysis tools • Comprehensive research expansion functions

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
2	uSONIQUE Pulse G/T/P/Q/6		• Ultra-high-end cardiovascular application ultrasound diagnostic system, supporting clinical and research applications in cardiology • Features specialized cardiovascular probe solutions, providing excellent 2D and 4D cardiovascular image quality • Supports specialized advanced cardiovascular imaging and quantitative functions • Supports fully automated cardiac workflow, improving the efficiency and quality of cardiac examinations
3	uSONIQUE Venus G/T/P/Q/6		• Ultra-high-end obstetrics and gynecology application ultrasound diagnostic system, supporting clinical and research applications in maternal and child health, pediatrics, etc. • Covers a full range of probe families for maternal and child health scenarios, while supporting lightweight probe design to improve comfort • Supports fully automated obstetric workflow, improving the efficiency and quality of obstetric examinations • Supports 2D and 3D quantitative analysis tools, covering scenarios such as obstetrics, gynecology, and reproduction

2. Radiation Therapy Products

Radiation Therapy System (Radiation Therapy, abbreviated as RT) utilizes alpha, beta, gamma rays produced by radioactive isotopes, and X-rays, electron beams, proton beams, and other particle beams generated by various X-ray therapy machines or accelerators to treat tumors. It is currently an important method for tumor treatment. The most mainstream radiotherapy equipment domestically and internationally includes medical linear accelerators, Gamma Knife based on cobalt sources, and a small number of proton and heavy ion devices. Among these, medical linear accelerators can be widely used for the treatment of primary or secondary tumors in multiple body parts.

The core components of RT products include the accelerator tube, multi-leaf collimator, power source, modulator, precision control module, and onboard imaging equipment. In the clinical treatment process, the Medical Linear Accelerator System (Linac), combined with Treatment Planning

System software (TPS), Oncology Information System software (OIS), and Radiotherapy Simulator (Simulator), collectively complete the radiotherapy process: First, the radiotherapy simulator locates the lesion; based on this localization image, the physician contours the tumor, organs, and other volumes of interest. Then, the Treatment Planning System software generates a treatment plan according to the treatment protocol. Finally, the Medical Linear Accelerator System executes the treatment plan. The aforementioned treatment plans and related patient information are recorded and managed by the Oncology Information System.

With the rapid development of precision medicine, precision radiotherapy has become the trend in the development of tumor radiation therapy technology. Precision radiotherapy requires destroying the tumor lesion while ensuring the maximum protection of normal human tissues or organs. Therefore, the precise definition and contouring of the tumor target volume and surrounding normal organs are the foundation of precision radiotherapy. The company's pioneering integrated diagnostic-grade CT-guided accelerator technology integrates a diagnostic-grade CT and accelerator with dual isocenters coaxially, effectively addressing changes in tumor morphology, size, or position throughout the entire course of radiotherapy. Simultaneously, it is equipped with intelligent software, significantly improving the work efficiency of medical staff while ensuring precision radiotherapy. The company has developed the industry's first integrated CT-guided linear accelerator uRT-linac 506c, the multi-photon multi-electron flagship CT linear accelerator uLinac VisionaryTx, the industry's first integrated ring CT linear accelerator uLinac HalosTx, the new-generation integrated 6MV single-photon large-bore CT linear accelerator uLinac EternaTx, the first NMPA-approved AI-driven organ and tumor contouring software uIPW, intelligent radiotherapy planning software uTPS, radiotherapy record and verification software uRVS, radiotherapy information management system uOIS, radiotherapy quality control system uAssureTx, radiotherapy remote collaboration platform, and other hardware and software products, constructing an integrated, independently controllable full-process radiotherapy solution.

The company's main RT products are as follows:

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uLinac VisionaryTx		• Multi-photon multi-electron all-round flagship CT linear accelerator with comprehensive treatment technologies, equipped with the industry's first and only double-layer equivalent 2.5mm multi-leaf collimator & full field 40cm×40cm irradiation, achieving precise stereotactic radiotherapy with sharp 'blade' • Pioneering single-isocenter non-coplanar whole-body intelligent SRS/SBRT stereotactic radiotherapy solution, enabling precise radiotherapy through rapid one-click non-coplanar planning and fully automated implementation process • Diagnostic-grade CT imaging enables precise adaptive radiotherapy, pioneering on-demand triggered adaptation, flexibly providing optimal solutions based on patient conditions • Equipped with All In One integrated radiotherapy, reducing the first radiotherapy waiting time from traditional several days to several minutes By combining integrated radiotherapy with emergency radiotherapy and SRS/SBRT, optimizing radiotherapy timeliness and improving therapeutic effect

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
2	uLinac HalosTx		• Industry's first integrated CT ring linear accelerator, equipped with a new-generation 87cm large-bore diagnostic-grade CT image guidance system, providing clinical users with more confident and comprehensive clinical basis • Through diagnostic-grade CT eagle-eye imaging, ultra-wide range in vivo dose monitoring, and intelligent software support, achieving the industry's first 'imaging-dose dual perception' innovation technology, from 'invisible dose' to 'real-time in vivo dose monitoring', maximizing patient's precise individualized radiotherapy • Online adaptive radiotherapy and integrated radiotherapy highly automated application full-process integration, reducing work time consumption, lowering dependence on personnel experience, achieving breakthrough in clinical efficiency and treatment workflow
3	uLinac EternaTx		• New-generation integrated 6MV single-photon large-bore CT linear accelerator • Equipped with 87cm integrated large-bore diagnostic-grade CT, 6.5cm/s industry's fastest MLC, and 6D high-precision treatment table • Paired with new dose-guided radiotherapy (DGRT) application, enabling transition from image guidance to dose guidance before treatment, and supporting stereotactic intelligent one-click non-coplanar treatment, online adaptive radiotherapy, and integrated radiotherapy
4	uRT-linac 506c		• Industry's first integrated CT-guided linear accelerator • High-resolution CT image guidance, combined with adaptive radiotherapy treatment planning system, providing customized treatment plans • Integrated full radiotherapy workflow support, multi-purpose machine, integrated fast workflow design, improving work efficiency

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
			• Supporting dynamic rotational intensity-modulated radiation therapy uARC technology and fast Monte Carlo algorithm, improving clinical treatment efficiency
5	uRT-linac 306		• Conventional linear accelerator system, suitable for clinical users • Supporting automatic contouring, automatic planning, automatic quality control and 540° ultra-long single-arc treatment mode, improving treatment efficiency
6	Native radiotherapy cloud ecosystem		• Innovative cloud-based architecture (B/S architecture), launching United Imaging iHealthcare radiotherapy software solution integrating AI-driven contouring system uIPW, radiotherapy treatment planning software uTPS, full-process radiotherapy quality control platform uAssureTx, radiotherapy information management system uOIS, and radiotherapy remote collaboration platform 'five-in-one', creating full-chain digital intelligent radiotherapy solution • Collaborating with integrated CT linear accelerator system to improve quality and efficiency, quickly providing individualized and precise treatment plans, empowering advanced treatment technologies such as adaptive radiotherapy and integrated radiotherapy • Supporting departmental intelligent upgrade and transformation, empowering innovation in multiple scenarios of medical treatment, education and research, helping to build efficient, flexible, and interconnected native radiotherapy cloud ecosystem

3、Life Science Instruments

Life science instruments include different types of products such as preclinical imaging equipment, optical observation equipment, electron microscopes, and chemical analysis instruments. Among them, preclinical imaging equipment mainly supports basic life science research by

performing structural and functional imaging observations on animal models. Currently, preclinical imaging equipment has been widely used in research on mechanisms, diagnosis and treatment methods of major diseases such as brain science, oncology, and cardiovascular diseases.

The company entered the life science instrument field starting with preclinical imaging equipment. Currently, two products have been launched: China's first preclinical ultra-high field magnetic resonance imaging system uMR 9.4T and China's first preclinical large animal whole-body PET/CT imaging system uBioEXPLORER, as follows:

No.	Product Model	Schematic Diagram	Product Introduction and Highlights
1	uMR 9.4T		• China's first 9.4T preclinical ultra-high field MR, suitable for research institutes, universities, pharmaceutical companies, etc. • High-performance gradient, suitable for various animal model research on mechanisms, diagnosis and treatment methods of major diseases such as brain science, oncology, and cardiovascular diseases • Equipped with ultra-low temperature radio frequency probe, improving signal-to-noise ratio and obtaining clear image quality; providing rich sequence applications, supporting users' translational medical research
2	uBioEXPLORER		• China's first preclinical large animal whole-body PET/CT imaging equipment, suitable for research institutes, universities, pharmaceutical companies, etc. • Features 50cm axial FOV, 50cm aperture, supporting large animal imaging; has ultra-high sensitivity, supporting low-dose rapid scanning • Equipped with digital light guide detector, supporting TOF high-definition reconstruction, achieving precise imaging
3	uMicroEXPLORER PET/CT		• Domestically developed preclinical ultra-high performance small animal whole-body PET/CT imaging equipment, suitable for hospitals, universities, research institutes, pharmaceutical companies, etc. • Features fine crystal dense array cutting and assembly technology and built-in light guide technology, based on semiconductor silicon

			photomultiplier tube (SiPM) and equipped with industry's first detector architecture with dual-ended readout, possessing leading industry ultra-high performance • Features 178mm ultra-long axial FOV and ultra-high sensitivity, supporting rat single-bed whole-body dynamic imaging, sub-second dynamic reconstruction and high-throughput simultaneous imaging of 4 mice • Exclusive dual-ended readout technology, paired with digital light guide detector, enabling full-field image uniformity, ensuring image quality consistency in high-throughput multi-mouse imaging • High-resolution CMOS flat panel detector CT system, achieving a minimum pixel spatial resolution of 8 μm, comparable to standalone Micro CT
4	uCT microPCCT Max/Core		• The first domestically produced photon counting energy spectrum micro-CT imaging system (uCT microPCCT series) • Utilizing a novel technical solution with photon counting detectors and micro-focus X-ray tubes, it offers excellent energy discrimination for X-ray photons and near 'zero-noise' data readout, achieving ultra-high resolution energy spectrum imaging with high signal-to-noise ratio and superior hardening artifact suppression

New significant non-core business operations
□ Applicable√ Not applicable

ii. Main business models

1. R&D Model

From the R&D process perspective, the company refers to medical device regulatory requirements and ISO quality system standards to formulate R&D systems such as the 'Product Development Process'. First, the R&D department determines R&D projects based on market and customer needs; second, it evaluates potential product solutions, preliminarily determines technical directions, and develops prototypes for system integration and detailed verification based on this; subsequently, it confirms the product definition based on anticipated user needs; finally, it makes product improvements based on feedback, completes product registration, and achieves mass production and market launch.

From the organizational structure perspective, the company's R&D departments mainly include the Product Line Business Units, Medical Power Components Business Unit, Components Business Unit, Medical Software Business Unit, and the Product and Technology Development Management Office.

(1) Product Line Business Units

The company's Product Line Business Units include the MR Business Unit, CT Business Unit, XR Business Unit, MI Business Unit, RT Business Unit, and Ultrasound Business Unit. The company establishes a product matrix based on each product line. Each product line achieves technological breakthroughs based on long-term accumulation of industry technology research, combines market demands for products and supporting solutions, and develops products and solutions to realize innovation in technology, products, and services.

(2) Medical Power Components Business Unit

The Medical Power Components Business Unit is primarily responsible for the R&D of high-power electronic components required by each product line, specifically including gradient power amplifiers, RF power amplifiers, power block units, X-ray tubes, etc., providing innovative, high-performance, and customized solutions for each product line, reducing overall machine and service costs, and providing a component foundation for the technological and product innovation of each product line's main units.

(3) Components Business Unit

The Components Business Unit is primarily responsible for the design and R&D of general hardware for each product line, specifically including electronic components, human-machine interface, motion control modules, precision machinery, and equipment heat dissipation/cooling. The establishment of the aforementioned general hardware platform enables joint R&D and sharing of the same hardware components across product lines, reducing the R&D and production costs of general hardware, and improving the efficiency of subsequent after-sales services.

(4) Medical Software Business Unit

The Medical Software Business Unit is primarily responsible for the design and R&D of general software for each product line, specifically including operating systems, workstations, user interfaces, etc. The establishment of the aforementioned general software platform can unify the imaging workstations and workflows of each product line, reduce the learning cost for end customers using different product lines, and improve the user experience.

(5) Product and Technology Development Management Office

The company has established the Product and Technology Development Management Office at its Shanghai headquarters to implement company-level technology and product portfolio management according to the company's strategy, build and optimize the R&D management system, and promote cross-modality requirement management and product planning. The Product and Technology Development Management Office complements the various R&D business units, helping to enhance collaboration among R&D business units and further improve R&D efficiency.

2. Procurement Model

(1) Material Procurement Process

The company has established a comprehensive procurement control system and implemented standardized procurement operating procedures. The company has formulated relevant operating procedures such as the 'Procurement Control Procedure' and 'Supplier Management Procedure', clarifying key aspects such as the procurement process, supplier management and selection, contract execution, and quality control, ensuring efficient procurement decision-making and execution processes.

To integrate resources from various aspects, improve personnel utilization efficiency, and enhance bargaining power with suppliers, the company regularly organizes production-supply-marketing meetings with various departments to plan material procurement and production based on customer orders and projected sales. For mass production materials, the company maintains a certain safety stock level. When the actual inventory falls below the safety stock level, the procurement department prioritizes follow-up with manufacturers for delivery to ensure normal production; for non-mass production materials and materials with long lead times, the company forecasts material demand in advance based on actual operating conditions, maintains linkage with suppliers to ensure timely supply; for low-value consumables, the company considers factors such as replacement frequency and procurement cycle to make regular purchases, maintaining an appropriate inventory level. To further rationally plan inventory, the Planning and Control Department regularly conducts raw material inventory analysis, formulates raw material supply strategies based on the company's orders and projected sales, and the Procurement Department formulates procurement strategies and conducts procurement based on actual operating conditions.

(2) Supplier Management

The company has established multiple operating procedures such as the 'Supplier Management Procedure' and 'Supplier Audit Procedure' to standardize the company's supplier management. The company evaluates suppliers' comprehensive capabilities based on their market position, supply capacity, technical capability, quality level, etc., and establishes a qualified supplier directory through processes such as supplier selection, evaluation, and onboarding. The company conducts regular assessments and daily tracking of suppliers, including annual assessments, quarterly scoring, audits, and other activities, to promote continuous improvement of suppliers and establish a supplier elimination mechanism. During the reporting period, the company maintained good cooperative relationships with its major raw material suppliers to ensure stable raw material supply and favorable procurement prices. The company signs confidentiality agreements with qualified suppliers, stipulating matters related to technical confidentiality and business cooperation to prevent potential risks of information leakage.

3. Production Model

The company adopts an in-house production model, with production capacity layout in Shanghai, Changzhou, Wuhan, Houston, USA, and other regions. United Imaging Healthcare produces the full range of products, United Imaging (Changzhou) mainly produces stands and mechanical components required by the company, United Imaging (Wuhan) conducts production of some finished systems and high-power components, and UIHT is also responsible for the production of some of the company's finished systems.

The company arranges production plans based on sales forecasts and actual orders. The company uses information technology (IT) solutions to build an intelligent production system, plans the production process with the concept of lean production to improve efficiency and reduce costs. The company's product production process includes formulating production requirements, preparing production orders, material preparation, batch production, inbound inspection, and finished product delivery. The Planning and Control Department reviews customer orders, including product model, specifications, delivery date, etc. If the order aligns with the company's current production and technical capabilities, the Planning and Control Department formulates production plans and material plans based on factors such as order quantity, material requirements, inventory status, and delivery schedules. After the plan is formulated, the production department carries out material requisition and organizes production according to the production plan. The quality control department participates in the entire production process, identifies key control points based on risk, formulates and implements quality control plans to ensure the production process complies with relevant quality standards and requirements.

4. Sales Model

(1) Market Expansion and Brand Management

The company has established the Product Marketing Department and the Brand Strategy Communication Department to lead market strategy formulation and brand management. The main approaches include: independently organizing or participating in market events hosted by other parties to conduct product presentations and academic exchanges for target customer groups; participating in international, national, and cross-regional exhibitions and promotional events for overall brand promotion and new product launches; and, based on the company's business development strategy direction, holding distributor conferences periodically to enhance interaction and loyalty between the company and distributors, and to expand the company's channel coverage.

(2) Direct Sales Model and Distribution Model

The company adopts a combined sales model of direct sales and distribution. End users primarily include medical institutions, research institutes, and universities. During the sales process, the company performs equipment installation and debugging based on customer requirements.

1) Direct Sales Model

Under the direct sales model, the company builds its own sales team responsible for a series of sales activities, including opportunity identification, intent confirmation, business negotiations, and bidding procurement. In the direct sales model, the company communicates directly with customers, promptly understands their needs, facilitates the establishment of long-term cooperative relationships, and builds a strong brand image.

2) Distribution Model

Under the distribution model, distributors handle sales activities such as intent confirmation, business negotiations, and bidding procurement. The company leverages the geographical advantages and channel resources of distributors to shorten the development cycle for end customers and enhance the company's market penetration rate.

3) Distributor Management Model

To strengthen market expansion and distributor risk control, the company has established a comprehensive distributor management system, as detailed below:

a) Distributor Management System

Based on overall strategic planning, marketing strategies, and product strategies, the company has established a management system for domestic and international distributors, systematically managing distributor qualification, classification, cultivation and development, management, and assessment.

b) Distributor Admission and Qualification Management

The company conducts due diligence on distributors to ensure they possess the necessary qualifications for operating medical devices. Additionally, through research and on-site inspections, the company assesses the reputation, integrity, operational status, and corporate strength of distributors in their respective regions. Based on the above evaluations, the company conducts tiered reviews to confirm whether distributors meet the company's requirements.

c) Distributor Support Management

Given the high level of specialization in the high-end medical equipment industry, the company provides regular training to distributors and offers comprehensive support for their sales activities. The company regularly conducts sales training, risk management training, and annual meetings. Sales training includes brand promotion, product knowledge, and sales techniques; risk management training covers compliance guidance and risk point training; annual meetings include interpretations of industry development trends, new product launches, and company policy promotions.

(3) After-Sales Service Model

The company's Customer Service Department provides services throughout the entire product lifecycle to enhance user experience, covering pre-sales site surveys and design, logistics and transportation, equipment installation and debugging, equipment maintenance, hardware and software upgrades, clinical application support, and equipment operation training. The Customer Service Department has a robust quality management system and has obtained ISO 27001, ISO 13485, and ISO 9001 certifications. The company's equipment products typically include a one-year warranty period, and customers can also purchase extended maintenance services based on their needs.

The company has established a standardized talent cultivation and certification system to achieve full-process management of after-sales services, thereby providing comprehensive after-sales solutions to customers. By upgrading its information system and leveraging IoT technology, the company offers online technical solutions, remote upgrades, and online training services.

The company has set up a headquarters call center and remote service center to handle requests from domestic and international users. Additionally, the company has established a

global customer service network based in China, the United States, Malaysia, the Netherlands, and other countries to provide timely and efficient after-sales services.

Leveraging its deep understanding of customer needs, the company adopts a combination of centralized training at headquarters, on-site hospital training, and remote training. Through professional systematic knowledge training, the company is committed to cultivating high-quality maintenance engineers for hospitals to promptly resolve common equipment failures and improve equipment operational efficiency.

iii. Industry Overview

(1). Industry development stage, basic characteristics, and main technical barriers

According to the "Industrial Classification for National Economic Activities" (GB/T 4754-2017) issued by the National Bureau of Statistics, the company's industry falls under Category 35 "Manufacture of Special Purpose Machinery (Classification Code C35)" and specifically under "Manufacture of Medical Equipment and Instruments (Classification Code C358)" and "Manufacture of Medical Diagnosis, Monitoring, and Treatment Equipment (Classification Code C3581)."

(1) Development Stage

Global aging, the increase in chronic diseases, and rising healthcare expenditures have contributed to the expansion of the global medical device market. Global public health emergencies have accelerated this market expansion. According to data from CIC, the global medical device market size exceeded USD 480 billion in 2021 and is projected to reach USD 848 billion by 2030, with a compound annual growth rate (CAGR) of 6.4% from 2021 to 2030, indicating stable growth in the global market.

Compared to the global medical device market, the Chinese medical device market is developing more rapidly. Due to limitations in productivity development, China's medical device industry started relatively late. However, driven by the strengthening of national overall strength, improved living standards, population aging, the Chinese medical device market has grown rapidly. From 2015 to 2020, the size of China's medical device market increased from RMB 312.55 billion to RMB 778.93 billion, with a CAGR of approximately 20.0%. In the future, with increasing market demand and technological advancements leading to industrial upgrades, the medical device industry is expected to maintain rapid growth. The market size is projected to reach RMB 2,492.4 billion by 2030, with a CAGR of 11.9% from 2021 to 2030.

Based on function and purpose, medical devices can be categorized into medical imaging equipment, surgery-related equipment, in vitro diagnostic equipment, etc. Among these, medical imaging equipment refers to devices that apply various physical signals such as visible light, X-rays, ultrasound, and strong magnetic fields to the human body, record the distribution of feedback signal intensities, form images, and enable doctors to interpret human structures and pathological information for diagnostic or treatment guidance purposes. Depending on the purpose, medical imaging equipment can be divided into diagnostic imaging equipment and therapeutic imaging equipment. Diagnostic imaging equipment can be broadly categorized by signal type into magnetic resonance imaging (MR) equipment, X-ray computed tomography (CT) equipment, X-ray imaging (XR) equipment, molecular imaging (MI) equipment, ultrasound (US) equipment, etc. Therapeutic imaging equipment

includes digital subtraction angiography (DSA) equipment and directional radiation equipment (e.g., orthopedic C-arms).

Medical imaging equipment represents the segment with the highest technical barriers in the medical device industry. With China's rapid economic development, increasing population aging, heightened public health awareness, and growing demand for healthcare services, the domestic market's need for high-quality medical imaging has correspondingly surged. Additionally, since the healthcare reform in 2012, relevant national authorities have issued a series of policies aimed at optimizing medical service levels, encouraging the implementation of tiered medical care, and promoting the decentralization of medical resources, opening new market opportunities for imaging equipment sales. Driven by both market demand and policy benefits, China's medical imaging equipment market will continue to grow. The market size reached RMB 53.7 billion in 2020 and is expected to approach RMB 110 billion by 2030, with an estimated CAGR of 7.3%.

(2) Basic Characteristics

The high-end medical equipment industry is a high-tech sector characterized by interdisciplinary integration, talent intensity, knowledge intensity, and innovation intensity. Compared with the global market, China's medical imaging equipment industry has long been characterized by low industry concentration, small enterprise scale, and low market share of domestic brands in the mid-to-high-end market. In recent years, with the advancement of the overall R&D level of domestic medical equipment, core technologies have been gradually overcome, and product quality and reputation have risen. Some domestic enterprises have achieved overtaking through technological innovation. The pattern of import monopoly is changing, and the domestic medical imaging equipment industry is gradually achieving the goal of keeping pace with international brands.

(3) Main Technical Barriers

The R&D of high-end medical equipment involves extremely high technical barriers, belonging to an interdisciplinary, knowledge-intensive, and innovation-intensive industry. The development of a single device often involves numerous disciplines such as biomedical engineering, mechanical engineering, algorithms, electronic information, materials science, and medical imaging technology, resulting in high R&D thresholds and long R&D cycles.

The main technical barriers in the field of magnetic resonance imaging include superconducting magnet technology, gradient technology, radio frequency technology, spectrometer design technology, and application technology. The company possesses zero-liquid-helium magnet technology, and R&D technologies for 1.5T, 3.0T, 5.0T, and higher field strength superconducting magnets. It has developed the industry's first 75cm large-bore 3.0T and 5.0T whole-body MRI products, as well as China's first 3.0T MR and 9.4T animal MR products. It has the capability to develop multi-size, high-performance gradient coils and has mastered the R&D technology for high-precision, high-power gradient power amplifiers. It possesses the design and manufacturing technology for high-channel RF receive coils suitable for various parts of the human body, and can design and manufacture multi-channel RF transmit coils for the human body from 1.5T to 3.0T and above field strengths, mastering the R&D technology for multi-channel high-power RF amplifiers. It has a self-developed distributed spectrometer system featuring multi-channel transmission, ultra-high-channel RF parallel data acquisition, nanosecond-level synchronization, and all-weather component monitoring. It has rich scientific research and clinical application technologies and is industry-leading in AI-enabled innovative applications.

The main technical barriers in the field of X-ray computed tomography imaging include detector technology, X-ray tube and high-voltage generator technology, and reconstruction algorithms. The company's self-developed Z-Detector has been applied to its CT series products, supporting multiple Z-Detector configurations with a minimum slice thickness of 0.5mm. It has mastered self-developed bipolar CT tube technology and high-voltage generator technology. It has developed correction and reconstruction algorithms based on CT products, providing excellent CT image quality and enhancing system dynamic scanning capabilities. It has also developed a fully model-based iterative reconstruction algorithm based on artificial intelligence, which minimizes the dose to the greatest extent while meeting clinical diagnostic requirements for images.

The main technical barriers in the field of X-ray imaging include high-voltage generator technology, image reconstruction and post-processing technology, and automated electromechanical control technology. Based on deep learning, the company has developed metal implant recognition and graphic noise reduction technology, which can accurately detect areas containing metal implants in medical images. It has pioneered a full-field-of-view scanning trajectory and reconstruction algorithm, expanding the reconstruction field of view for cone-beam CT on DSA systems to 431mm. It has mastered high-voltage generator technology for XR, and this component has now achieved mass production and is used in some products. The self-developed high-voltage generator reduces product volume through high-frequency inverter technology to meet end-user space requirements, reduces output ripple to optimize exposure dose and improve image quality, and increases the switching speed of kV output pulses to reduce the radiation dose received by the examinee.

The main technical barriers in the field of molecular imaging include scintillator and detector technology. The company's detector, through its SiPM-based digital detector module and large axial FOV overall design, achieves high sensitivity that can effectively improve image quality, scanning speed, and reduce scanning dose. The high-bandwidth data acquisition and transmission technology, matched with the company's high-resolution detector, can losslessly record and process data obtained from high-definition digital detectors. The company is also one of the few enterprises in the industry capable of designing and manufacturing long-axis PET products.

The main technical barriers in the field of ultrasound include high-performance probe technology, ultra-high-frequency ultra-bandwidth systems, image reconstruction and post-processing technology, and native AI agent applications. The company possesses independent R&D and manufacturing capabilities for high-resolution, high-sensitivity multi-dimensional single-crystal probes. It has developed a 50MHz ultra-high signal bandwidth system and a series of ultra-high-frequency probes, enabling ultra-high spatial resolution imaging of superficial skin, musculoskeletal structures, and other parts. The self-developed OmniFocus full-spectrum dynamic focusing technology effectively improves imaging resolution and frame rate. It has mastered key imaging technologies such as microvascular flow imaging and high-frame-rate contrast imaging, fully meeting clinical diagnostic requirements. The fully automated workflow enables intelligent ultrasound diagnosis from probe activation, scanning and storage of different clips, data analysis, to final report output. The self-developed uTarget intelligent analysis software improves diagnostic accuracy and efficiency. It possesses rich scientific research and clinical application software technologies, with outstanding advantages in clinical and research applications.

The main technical barriers in the field of radiotherapy include accelerator tube and dynamic multi-leaf collimator technology. The integrated CT imaging system technology mastered by the company can integrate the imaging system with the treatment system, achieving a coaxial, same-couch design for the CT and medical linear accelerator. This allows tumors to be seen more clearly through high-quality diagnostic images, improving the precision of clinical treatment. Meanwhile, the core algorithms of the self-developed TPS treatment planning system include dose calculation algorithms and optimization algorithms, which can improve the speed and accuracy of dose calculation and enhance the work efficiency of clinical medical physicists. The maximum dose rate output by the company's self-developed 6MV accelerator tube reaches industry-leading levels (600 MU/min@1m in flattening filter mode, 1400 MU/min@1m in flattening filter free mode), and it can achieve precise control of each dose pulse. The self-developed dynamic multi-leaf collimator technology enables the clinical application of efficient and precise volumetric modulated arc therapy. Through precise dose modulation, it reduces the irradiation dose received by the patient's normal tissues.

(2). Analysis of the Company's Industry Position and Its Changes

The company's product line covers high-end medical imaging diagnostic products and radiotherapy products, achieving a theranostics layout. A comparison of the company's product line with major players in the domestic and international markets is as follows:

Equipment type	**United Imaging Healthcare**	**GE HealthCare**	**Siemens Healthineers**	**Philips**	**Elekta**	**Wandong Medical**	**Neusoft Medical**
MR products							
5.0T and above	▲	▲	▲				
3.0T	▲	▲	▲	▲			▲
1.5T and below	▲	▲	▲	▲		▲	▲
CT products							
PCCT	▲	▲	▲				▲
320-row/640-slice	▲						
256-row/512-slice		▲	▲				▲
128-row and below	▲	▲	▲	▲		▲	▲
XR products							
Large C (DSA)	▲	▲	▲	▲		▲	▲
Mammo	▲	▲	▲			▲	▲
Conventional/mobile DR	▲	▲	▲	▲		▲	▲
Small and medium C	▲	▲	▲	▲		▲	▲
MI products							
PET/CT							

Equipment type	United Imaging Healthcare	GE HealthCare	Siemens Healthineers	Philips	Elekta	Wandong Medical	Neusoft Medical
AFOV > 120cm	▲						
AFOV 50-120cm	▲	▲	▲				
AFOV < 50cm	▲	▲	▲	▲			▲
PET/MR	▲	▲	▲				
Ultrasound products	▲	▲	▲	▲		▲	▲
RT products							
Linear accelerator	▲		▲		▲		▲
Image-guided linear accelerator	▲		▲		▲		▲
Life science instruments	▲						

Data source: CIC Consulting, etc.

As shown in the table above, in the field of high-end medical imaging and radiotherapy products, the company's product line coverage is basically consistent with international manufacturers such as GE Healthcare, Siemens Healthineers, and Philips Healthcare.

Overall, based on the new market value statistics for 2025, the company's comprehensive competitiveness in the Chinese medical imaging and radiotherapy equipment market continues to strengthen, maintaining a leading position in the industry. In China, the company ranks first in new market share for its full product line (excluding ultrasound), with advantages covering multiple key sub-segments. Specifically, the company ranks first in China in new market share for 9 sub-products, with core products such as CT with 40 slices and below, 64-80 slice CT, 128-160 slice CT, 1.5T MR, ultra-high-field MR above 3.0T, PET/CT, PET/MR, and mammography DR consistently maintaining leadership, forming a stable and replicable product portfolio advantage. At the same time, the company's radiotherapy (RT) business achieved breakthrough progress, with new market share increasing by over 18 percentage points year-on-year and rising to the top position, effectively reshaping the competitive landscape of the radiotherapy market and further solidifying the company's overall strategic position in the high-end medical equipment field.

1. CT: Based on the 2025 domestic new market value statistics, the company is a major CT equipment manufacturer in the Chinese market, ranking first in market share. The company ranks first in market share for CT with 40 slices and below; ranks first in market share for 64-80 slice CT; ranks first in market share for 128-160 slice CT; and ranks second in market share for CT with 256 slices and above.

2. MR: Based on the 2025 new market value statistics, the company is a major MR equipment manufacturer in the Chinese market, ranking first in market share. In the Chinese market for 3.0T MR and above equipment, the main market participants are GE Healthcare, Siemens Healthineers, and United Imaging Healthcare. In the Chinese market for 1.5T and below superconducting MR, the company ranks first in market share; in the Chinese 3.0T MR market, the company ranks second in market share; in the Chinese ultra-high-field MR equipment market above 3.0T, the company's market share increased significantly by over 29 percentage points year-on-year, ranking first.

3. MI: Molecular imaging products are high-end products in the medical imaging field, with main market participants being Siemens Healthineers, GE Healthcare, and the company. The company is one of the leading molecular imaging equipment manufacturers in the Chinese market. Based on the 2025 domestic new market value statistics, PET/CT has ranked first in market share in China for ten consecutive years. In 2025, the company's PET/MR market share in China increased by 40 percentage points year-on-year, ranking first.

4. XR: Fixed DR and mobile DR equipment are largely localized, with mammography DR localization rate exceeding 50%, and DSA localization rate below 20%. Based on the 2025 Chinese new market value statistics, the company ranks second in market share for diagnostic XR products (including fixed DR, mobile DR, and mammography DR). Among these, the company's mammography DR market share in China increased by nearly 10 percentage points year-on-year, ranking first; while fixed DR and mobile DR market share ranked second. In the interventional XR product field (including DSA and mobile C-arm), the company ranked fourth in new market share in 2025, with DSA market share increasing by

over 5 percentage points year-on-year, ranking fourth, and mobile C-arm product market share ranking third.

5. RT, Varian and Elekta, as leading companies in radiotherapy equipment, occupy the main share of China's RT market. In the radiotherapy equipment market, according to the 2025 domestic new market amount statistics, the company's RT product market share increased significantly by 18.1 percentage points year-on-year, ranking first in market share, reshaping the market landscape in the radiotherapy field at one stroke.

(3). Development status and future trends of new technologies, new industries, new business forms, and new models during the reporting period

(1) MR industry development status and trends

In the MR field, 1.5T field strength products are relatively mature, but with the relaxation of domestic market configuration permits, 3.0T clinical and research products will become more widespread. In ultra-high field magnetic resonance, only a few multinational companies and the company have mastered the core technology and whole machine production capability of 5.0T and above MR.

Main development trends: enhance the main magnetic field strength of the system, improve gradient performance, and digital high-channel spectrometer performance to increase imaging clarity; adopt new data acquisition and reconstruction algorithms to improve scanning imaging speed; develop large-bore, low-noise systems to improve examination comfort; empower the examination process with artificial intelligence technology to optimize the examination workflow; low energy consumption; low liquid helium.

(2) CT industry development status and trends

Currently, leading industry manufacturers can cover CT products from 16-slice to 320-slice and photon counting, while domestic manufacturers mainly focus on CT products below 64-slice.

Main development trends: reduce scanning dose during examination and achieve low-dose scanning by adapting to the subject's condition and position and designing dose parameters, combined with updates and iterations of reconstruction algorithms; provide more quantitative analysis tools for clinical diagnosis through spectral and perfusion functions, broadening CT clinical application scenarios; improve small lesion detection capability, reduce motion artifacts, and enhance cardiovascular image resolution by optimizing X-ray tube and power block unit performance.

(3) XR industry development status and trends

XR field products can be divided into diagnostic and interventional parts based on application scenarios. In the diagnostic X-ray field, DR and mobile DR have been relatively well-developed, and some leading manufacturers have begun to explore intelligent applications; traditional 2D mammography products are relatively mature, currently upgrading to 3D, contrast-enhanced, and puncture guidance, and as medical services shift from focusing solely on diagnosis and treatment to also emphasizing prevention, the demand for mammography machines will further increase in the future. In the interventional X-ray field, it is mainly dominated by leading industry manufacturers. With United Imaging Healthcare and others continuously launching domestic high-end DSA products, the domestic DSA localization rate exceeded 15% for the first time in 2025.

Main development trends: driven by factors such as population aging, increasing number of patients with cardiovascular and cerebrovascular diseases, and the development of AI and other technologies, empowering the entire clinical process from ultra-low radiation dose, image acquisition, image processing, to auxiliary diagnosis will continue to be growth points in the XR market.

(4) MI industry development status and trends

In terms of system design, digital technology based on silicon photomultiplier tubes (SiPM) can improve the spatial resolution, sensitivity, and count rate characteristics of molecular imaging systems, gradually becoming popular in the industry. Major manufacturers in the industry have launched digital PET/CT products, and a few PET/MR products have also achieved digitization. In clinical applications, artificial intelligence algorithms are beginning to be used in image post-processing to improve image processing speed and effectiveness.

Main development trends: achieve the function of detecting early lesions and metastatic lesions by developing new detectors with higher resolution and sensitivity; develop electronic technology with better time-of-flight performance and count rate characteristics; develop faster data processing and correction technology; develop low-dose scanning technology, optimize existing system design and reconstruction algorithms, simultaneously reduce PET and CT scanning radiation doses, and improve scanning safety. The above technological developments can achieve precise diagnosis and promote the development of personalized diagnosis and treatment.

(5) Ultrasound industry development status and trends

Currently, leading industry manufacturers can achieve full coverage from general application ultrasound to high-end specialized ultrasound and research-grade products; domestic manufacturers mainly focus on mid-to-high-end general ultrasound and are accelerating breakthroughs in high-end specialized fields.

Main development trends: cutting-edge intelligent technologies such as native agents, large models, and embodied intelligence are driving ultrasound systems towards autonomous perception and decision-making; break through technical barriers in key components such as high-performance probes and ultrasound-specific chips to improve system performance; empower ultrasound imaging algorithms with AI to achieve intelligent imaging and intelligent image optimization; continuously promote the application of AI technology in the examination process to achieve full-process empowerment such as automatic clip recognition, auxiliary lesion diagnosis, and automatic parameter measurement, improving diagnostic efficiency and consistency; promote the integration of diagnosis and treatment, integrate development, and expand clinical application scenarios; promote equipment towards portability and wearability, extending to multiple scenarios such as emergency treatment and home health monitoring.

(6) RT industry development status and trends

Radiotherapy is one of the common methods for treating malignant tumors, with image-guided radiation therapy and adaptive radiotherapy being representative directions of current precise tumor radiotherapy technology. Future industry development trends include multi-modality image-guided therapy systems, dose-guided adaptation, real-time online adaptation, intelligent treatment plan planning, intelligent quality control, remote collaboration, and efficient execution.

Image-guided radiation therapy ensures treatment is concentrated within the tumor area, protecting surrounding organs, and achieving precise radiotherapy by making the target volume highly conformal. Before and during patient treatment, image-guided radiation therapy can use advanced imaging equipment to locate tumors and potential organs at risk, and adjust treatment conditions based on changes in tumor position and shape, thereby making the irradiation field conform to the target volume and confining the tumor within the dose range designed by the treatment planning system. Additionally, due to the uncertainty of tumor morphology during the treatment course, treatment plans need to be adaptively adjusted based on tumor changes. In the future, online adaptive radiotherapy technology integrated with diagnostic-grade imaging can monitor tumor changes at any time and adjust treatment plans.

(7) Life science instrument industry status and trends

In preclinical magnetic resonance imaging instruments, only a few companies master the design and manufacturing process of ultra-high field magnets, high-power components, and the design and manufacturing process of gradient and radio frequency systems, logic control component design and processing, software and algorithm component design and integration.

Main development trends: preclinical magnetic resonance imaging instruments develop high-sensitivity acquisition technology, molecular imaging technology, fast imaging technology, etc., to help scientists complete higher-definition research images, see more microscopic structures, capture functional information of living organisms, touch and broaden the boundaries of science.

In animal PET/CT, master key core technologies such as sub-millimeter unit parsing technology based on dedicated domestic ASIC chips, detector depth effect recognition and correction technology, and online recovery technology for small unit detector scattering effects.

Main development trends: based on the above technologies, animal PET/CT equipment can be promoted towards higher resolution, higher sensitivity, higher animal scanning throughput, and more accurate quantitative consistency. A single bed can meet whole-body dynamic scanning and achieve single-session multi-animal scanning.

2. Business situation discussion and analysis

2025 was a year when United Imaging Healthcare anchored its strategic focus and advanced steadily, a critical year when innovation momentum shifted from accumulation to release, and a year when the company connected the past and the future and bravely opened new horizons.

During the reporting period, the company's R&D innovation system, global marketing service system, and resilient supply chain system were deeply coupled. Driven by a robust technological foundation and strong market insights, the company achieved significant growth in both scale and profitability. This success was supported by favorable market dynamics globally, including ongoing investments in healthcare modernization and the growing demand for accessible, high-quality medical resources. By aligning our innovations with these broader industry trends, we transformed our technical expertise into strong growth momentum. Concurrently, as global demand for advanced medical technologies remained

robust, we enhanced our brand presence and deepened our market engagement internationally, successfully transitioning from initial expansion to establishing sustainable, localized operations across our global markets.

Driven by the interplay of internal and external dynamics, United Imaging Healthcare's revenue scale reached a new level: achieving annual operating revenue of 13.8 billion yuan, a year-on-year increase of 33.98%; net profit attributable to shareholders of the parent company was 1.869 billion yuan, a year-on-year increase of 48.14%; net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was 1.77 billion yuan, a year-on-year increase of 75.18%, with profitability significantly optimized.

The simultaneous leap in revenue scale and profit quality in 2025 confirms the clear and steady strategic resilience of the company's management in responding to the external environment intertwined with multiple challenges. During the previous industry adjustment phase, the company focused on consolidating its development foundation, optimizing its business structure, firmly advancing core technology breakthroughs and innovative product iterations, and steadily promoting the introduction of innovative products and global market penetration while improving the global supply chain system layout around building long-term competitiveness. With the normalization of domestic procurement rhythms and the deepening of global high-end market expansion, United Imaging Healthcare, through its comprehensive multi-level innovative product portfolio and integrated clinical solutions, took the lead in capturing incremental demand from industry structural upgrades, maximizing clinical benefits across multiple dimensions such as research, high-end, and accessibility, further consolidating its comprehensive competitive advantages and excellent industry reputation in the global medical imaging and radiotherapy markets.

In the future, the company will steadfastly advance its globalization and localization development strategy, deepen the construction of global R&D, marketing, service, and supply chain systems, leverage digital and AI innovation capabilities, accelerate the introduction of innovative product portfolios in global markets, and participate in global medical technology competition with a more stable and open posture, creating differences for global health harmony.

(I) Financial Data and Operational Performance: Steady Leap in Revenue Scale, Continuous Optimization of Profit Structure

In 2025, facing the structural growth in market demand for high clinical-value, high-performance imaging equipment, United Imaging Healthcare adhered to innovation-driven development, leveraging agile R&D iteration mechanisms and the smooth introduction of new products to build a highly competitive product matrix. Coupled with the deep-rooted marketing and service system, it effectively captured the benefits of domestic medical infrastructure development and demand recovery, achieving core breakthroughs in the high-end and ultra-high-end imaging equipment sectors, driving a steady increase in market share across all product lines in China. Simultaneously, the globalization layout accelerated further,

with the company achieving a qualitative leap in brand recognition and channel influence in developed countries and emerging markets in Europe, America, and Asia-Pacific.

By region, during the reporting period, the company achieved revenue of 10.369 billion yuan in the Chinese market, a year-on-year increase of 29.07%, leading the domestic high-end medical equipment track in comprehensive market share. In 2025, the new market share for all product lines (excluding ultrasound) in China increased by 4.5 percentage points year-on-year, ranking first. Innovative technology advantages covered multiple sub-segments, with 9 sub-categories ranking first in market share in China; MR increased by 2.7 percentage points year-on-year, RT increased by over 18 percentage points year-on-year, both ranking first in market share in China for the first time; sub-products such as 40-slice CT, 64–80 slice CT, 128–160 slice CT, 1.5T MR, 3.0T and above ultra-high-field MR, PET/CT, PET/MR, and breast DR maintained their top market positions, with the PET/CT product line ranking first for ten consecutive years, the CT product line ranking first for three consecutive years, and the core product echelon advantage continuously consolidated.

Relying on the "theranostics" strategy, the company accelerated breakthroughs in radiotherapy and interventional fields, with product lines represented by RT and DSA achieving strong growth, building a full-chain competitive advantage of "dual-drive, synergistic enhancement" in diagnosis and treatment. In the radiotherapy segment, the RT business performed outstandingly, with new market share increasing by 18.1 percentage points year-on-year, ranking first in the Chinese market for the first time, reshaping the competitive landscape in radiotherapy and solidifying the company's strategic position in the high-end medical equipment field. In the interventional field, during the reporting period, the uAngio AVIVA DSA system successively obtained CE and FDA certifications, becoming the first and only domestically produced DSA system to simultaneously obtain NMPA, CE, and FDA triple authoritative certifications, achieving a key leap from domestic leadership to global recognition. In 2025, the uAngio series became the first domestically produced DSA to exceed 100 annual orders, driving the DSA product line's market share up by 5.2 percentage points year-on-year, rising to fourth place in the industry, effectively promoting the localization process of the DSA industry; additionally, the new large-bore CT system uCT 610 Sim, integrating diagnostic CT scanning, radiotherapy simulation positioning, and image-guided interventional puncture surgery, saw rapid volume growth in its first year on the market, driving the CT-Sim product line's market share up by 12.4 percentage points year-on-year, ranking fourth in the industry.

Focusing on overseas markets, against the backdrop of evolving global medical technology competition and a complex and changing international environment, the company's overseas business officially entered a high-quality harvest period centered on innovative technological strength, high-end brand influence, and systematic delivery capabilities.

In 2025, the company's overseas business achieved revenue of 3.431 billion yuan, a significant year-on-year increase of 51.39%; overseas revenue accounted for 24.86% of the company's total operating revenue, an increase of over 2.86 percentage points year-on-year,

making the overall revenue structure more balanced. During the reporting period, the company established a strategically clear, complementary synergistic advancement path in global regional markets, fully deploying the "high-profile, full-line breakthrough" globalization strategy.

During the reporting period, the company's business footprint cumulatively covered over 100 countries and regions worldwide, with over 80 new products launched for various regions in 2025. Significant achievements were made in product approvals: by the end of the reporting period, over 150 products had been approved for market launch (44 new additions during the year), including 75 with EU CE certification (29 new additions during the year), 58 products with FDA (510K) clearance (19 new additions during the year). The new flagship 3.0T MR uMR Ultra successively completed market access in Europe, the US, and China, the three major mainstream markets, and uAngio AVIVA became the only domestically produced DSA device in China to have obtained NMPA, FDA, and CE triple approvals. Regarding strategic product exports, the integrated CT-linac high-end radiotherapy equipment was officially put into use at Siloam Cancer Hospital, part of Indonesia's largest private hospital group, achieving the first breakthrough in overseas clinical application of this equipment. In flagship matrix expansion, high-end and ultra-high-end products such as the whole-body PET/CT uMI Panorama GS, uMR Jupiter 5T MR, uMI Panvivo, and uNeuroEXPLORER were accelerated to international customers, successively entering core markets with high potential and regional demonstration effects like Germany, Singapore, Canada, and Turkey. Flagship products continued to be adopted by top global clinical and research institutions such as the Department of Nuclear Medicine at Hannover Medical School (MHH) in Germany, KU Leuven in Belgium, Singapore General Hospital (SGH).

By region, leveraging the comprehensively covered innovative product matrix, the company accelerated deep cultivation and penetration in high-end markets across multiple global regions, building a globalization business pattern with multiple breakthroughs and in-depth progression: In the North American market, the high-end footprint continued to widen, with products not only cumulatively entering nearly 90% of US states, with over 640 units/systems installed, but also partnering with a leading international neuroscience research institution to introduce the first ultra-high sensitivity whole-body PET/CT uMI Panorama GS in a North American country, further demonstrating the company’s global technological authority in molecular imaging; In the European market, the hub radiation effect accelerated, with business deeply covering 24 European countries and regions relying on the newly established Rotterdam regional headquarters. Germany's first long-axis PET/CT uMI Panorama GS was officially launched at the top medical center Hannover Medical School (MHH), and flagship products like uMI Panvivo were also batch-deployed in core markets such as the UK, France, Germany, and Denmark, comprehensively winning widespread recognition in international mainstream high-end markets; In the Asia-Pacific market, local deep-cultivation advantages were continuously solidified. Six years after entering the Indian market, the company's penetration rate in leading private hospital groups there exceeded 90%, with digital PET/CT and 1.5T MR market share leading for many consecutive years; In emerging markets, strong expansion was achieved in the vast blue ocean, with the business footprint spanning nearly

50 countries and regions including Latin America, Africa, CIS, and the Middle East. In Latin America, the first local digital PET/CT installations were successfully completed in multiple countries including Mexico, Argentina, Colombia, Peru, and Panama. In the Middle East, the first overseas 5T MR was installed in the Turkish market, achieving a two-way breakthrough in high-end benchmark leadership and market breadth penetration.

With the comprehensive deepening of the overseas layout, United Imaging Healthcare's global business not only achieved breakthroughs in scale and physical footprint but also made substantial leaps in brand recognition and customer trust. The significantly increased recognition of the company's comprehensive competitiveness by top global clinical and research users is strongly driving the company's strategic transition from "product export" and "system export" to "brand export," fully entering a new stage of high-quality, deep-level global development.

As of the end of the reporting period, the company's global cumulative installed base has exceeded 39,000 units/sets, with its business footprint radiating to over 100 countries and regions worldwide. Leveraging the growing installed base and a mature global service network, the company has fully established a value management system covering the entire lifecycle of its equipment. Through multi-dimensional and forward-looking service models such as preventive maintenance, intelligent diagnosis, and customized extended warranties, the company has effectively promoted a virtuous cycle of global equipment expansion and service monetization.

On this basis, the flywheel effect of "innovation-driven technology, equipment scale expansion, and in-depth service cultivation" has been fully unleashed. The continuously growing global installed base is accelerating the conversion into high-stickiness service revenue, building a solid ballast to safeguard the company's stable cross-cycle growth. During the reporting period, the company's equipment and service businesses developed synergistically, further optimizing the overall revenue structure. Full-year equipment revenue reached 11.390 billion yuan, a year-on-year increase of 34.87%, accounting for 82.53% of total operating revenue; service revenue was 1.708 billion yuan, a year-on-year increase of 25.96%, accounting for 12.38% of total operating revenue, with overseas service revenue growing over 50% year-on-year.

With the accelerated expansion of the global installed base and the comprehensive advancement of the operation and maintenance system, the service business has gradually transformed into a key engine supporting the company's stable cross-cycle growth. During the reporting period, the company focused on deepening the global service network, expanding the coverage of the response and delivery system, implementing lean cost control, and innovating digital-intelligent operations to comprehensively enhance service monetization and value-added capabilities throughout the equipment lifecycle. Initial achievements were made in overseas organization and mechanism building, with regional capability centers largely established across major regions, team size and capabilities

significantly improved, key position fill rate reaching 93%, and marketing management mechanisms initially implemented.

Currently, United Imaging Healthcare has established a global service team comprising over 1,000 professional engineers. During the reporting period, the company established regional service centers in 12 countries and regions globally, increasing the number of overseas service locations to 44, adding service points in 6 countries including the UK and Turkey. Simultaneously, the global spare parts warehouse network expanded to 39 locations, effectively reducing the physical service radius and providing solid support for the long-term stable operation of over 4,500 units/sets of equipment overseas and efficient customer response.

While densifying the global service network, the company comprehensively deepened lean management and digital-intelligent innovation, driving a systematic leap in operational efficiency. In terms of lean control, the company implemented a "combination punch" for quality improvement and efficiency enhancement:

In service management, through measures like logistics dispatch optimization and deep revitalization of the spare parts repair system, resource turnover efficiency was significantly improved, cumulatively saving tens of millions of yuan in costs; in after-sales personnel efficiency, refined workflow management drove an approximate 10% year-on-year increase in per-engineer service efficiency, achieving a substantial leap in overall operation and maintenance quality and efficiency. In terms of service innovation, the company used technology empowerment to reshape operational boundaries: frontline introduction of AI intelligent operation assistants accurately addressed over 300 technical requests daily, effectively improving on-site troubleshooting efficiency; backstage, leveraging intelligent image recognition technology, comprehensive monitoring of key equipment installation and maintenance nodes was implemented, cumulatively completing over 44,000 precise quality inspections, building a technical defense line for equipment safety from the source. With its comprehensively advanced integrated operation capabilities, the company has won five first-place awards in Shanghai's medical equipment after-sales service quality assessment for seven consecutive years, continuously consolidating its industry benchmark status and professional reputation. Additionally, the company dispatched over 10 senior management personnel for long-term overseas assignments, implanting United Imaging Healthcare's unified service standards and management system into the global service network, promoting the continuous maturation of the overseas service system.

Looking ahead, with the steady accumulation of the global installed base, the in-depth advancement of the high-value-added service system, and the accelerated release of scale effects and profit momentum from the service business, United Imaging Healthcare will firmly advance the densification of the global response network, strengthen agile operations through "digital-intelligent integration," comprehensively elevate customer value management throughout the equipment lifecycle, drive industry service standard upgrades,

and open up broader development space for the long-term sustainable growth of service revenue and profitability.

With the deepening of globalization, accelerated volume increase of high-end flagship products, and rapid growth of the service business, United Imaging Healthcare achieved a historic leap in revenue scale and business structure during the reporting period. Simultaneously, benefiting from the scale dividends released by the revenue leap, effective dilution of fixed costs, and comprehensive deepening of lean management, the company's overall expense control demonstrated a high-quality development trend characterized by "reasonable absolute growth to support strategy and significant rate decline to release profits."

In terms of R&D investment, United Imaging Healthcare's R&D expenses in 2025 were 1.842 billion yuan, a year-on-year increase of 4.57%; the R&D expense ratio was 13.35%, a decrease of 3.75 percentage points year-on-year, indicating a solid foundation for forward-looking investment and continuous improvement in the efficiency of translating innovation into tangible results. The company consistently regards technological innovation as the core driver of its development. During the reporting period, R&D resources continued to focus on breakthroughs in underlying technologies for next-generation ultra-high-end medical equipment and core components. Building on this, the company systematically strengthened the R&D system construction, driving a comprehensive leap in R&D efficiency:

On one hand, United Imaging Healthcare comprehensively deepened the implementation of the uIPD (Integrated Product Development) management system, deeply empowering nearly 300 product and underlying technology development projects within the year. Through cross-departmental collaborative reviews, process module upgrades, and optimization of key node specifications, the maturity levels of several core R&D process modules advanced to the "Performed" and "Managed" stages, significantly enhancing the standardization and systematization of the R&D system; on the other hand, the company firmly promoted empowerment through digital-intelligent tools, fully embedding AI technology into the entire R&D chain including industry research, development testing, process workflow, and knowledge management, achieving large-scale deployment of intelligent R&D tools in multiple scenarios. Relying on the renewal of the underlying R&D management system and the mature mechanism of platform-based, modular development, the company effectively improved the efficiency of innovation commercialization, steadily optimizing the R&D return on investment (ROI) while continuously solidifying its global technological leadership advantage.

In terms of sales expenses, United Imaging Healthcare's sales expenses in 2025 were 2.261 billion yuan, a year-on-year increase of 24.04%; the sales expense ratio was 16.39%, a decrease of 1.31 percentage points year-on-year. During the reporting period, the company's global marketing network and service system steadily expanded, and the effectiveness of rate control gradually became apparent. The absolute increase in expenses was primarily due to the company's active layout in overseas markets, preemptive increases in efforts to explore

high-potential global markets, continuous deepening of overseas marketing network penetration, improvement of localized service systems, and steady advancement of global brand building. With the effective absorption of various market investments by strong overall revenue growth, the sales expense ratio achieved a steady decline. The scale advantages of front-end business expansion are gradually transforming into substantial profit support, providing efficient resource guarantees for breakthroughs in overseas business and high-end products.

In terms of administrative expenses, to adapt to the increasingly complex multi-dimensional operational demands of globalization, the company empowered organizational iteration comprehensively with digital intelligence, systematically deepened lean operations and mid-back office system construction, with internal governance and control effectiveness continuously manifesting. In 2025, the company's administrative expenses were 627 million yuan, a year-on-year increase of 12.76%; the administrative expense ratio was 4.54%, a decrease of 0.85 percentage points year-on-year. Facing the challenges of increased management complexity and granularity brought by transnational expansion, the company, relying on the efficient empowerment of AI systems, the systematic elevation of organizational efficiency, and the effective revitalization of corporate support functions, ensured steady and reasonable investment in administrative expenses. The steady decline in the administrative expense ratio not only effectively offset the cost pressure from the expanding management radius but also confirmed the company's strong internal governance resilience and high-level precision management and control capability during the global expansion cycle.

In 2025, United Imaging Healthcare firmly advanced the resilience building of its global supply chain network, incorporating the concept of lean operations throughout the entire business chain. During the reporting period, facing multiple tests from cross-regional coordination and extended delivery links in the global supply chain, the company effectively hedged against various friction costs in transnational distribution channels through technological innovation, overseas pre-positioning of inventory, and diversified flexible scheduling, cumulatively saving over $10 million in cross-border delivery related expenses for the year.

Simultaneously, the company vigorously promoted the systematic upgrade of MR cold magnet transportation and logistics models. The cold magnet shipment business now covers nearly 70 countries and regions globally, with cumulative safe delivery of over 500 MRI systems. The large-scale application of this model has significantly enhanced global response and delivery agility while cumulatively generating logistics cost savings exceeding 370 million yuan, effectively transforming economies of scale into a comprehensive operational cost advantage.

During the reporting period, the company actively advanced the construction of its global production system, driving horizontal expansion and vertical upgrades in production capacity through digital and intelligent transformation. During the reporting period, the company

achieved a leap forward in its global delivery capabilities: Domestically, the construction of the Shanghai Phase II Smart Manufacturing Base progressed steadily and is expected to gradually commence operations within 2026; the Changzhou and Wuhan Phase II production bases have been successfully launched and are operating at full capacity, significantly expanding core components and complete systems such as X-ray tubes, magnets, MI crystals, RT, and DSA. Overseas, the Houston Production Center in the U.S. completed a threefold capacity expansion and upgrade, markedly enhancing supply agility for the North American market. Meanwhile, strategic production and R&D bases in other high-potential overseas regions are also steadily advancing.

Additionally, the company systematically strengthened the independent supply and diversified procurement strategies for key core components. During the reporting period, the company adhered to driving cost restructuring through technological breakthroughs, steadily implementing over 200 lean technology cost-reduction projects, successfully completing the localization and mass production transition of more than 50 core components, achieving direct material cost savings exceeding 300 million yuan. Leveraging global production synergy and technological cost reductions, the company further solidified its cost leadership in the global high-end medical equipment sector while strengthening supply security.

With the rapid commercialization of innovative flagship products, the deepening application of digital management tools, the continuous improvement of the supply chain system, and the ongoing expansion of the global marketing and service network, driven by rapid revenue growth, the company's sales expense ratio, R&D expense ratio, and administrative expense ratio all achieved varying degrees of optimization, with operational efficiency continuously improving. While maintaining strategic investment intensity, the company steadily improved operational quality by continuously enhancing management and operational efficiency, accelerating the transition from scale-driven to quality-driven development, laying a solid foundation for consolidating its competitive advantage in the global high-end medical equipment industry.

(II) Domestic Market: In-depth Breakthroughs in the Chinese Market, Synergistic Growth Across Multiple Product Lines

In 2025, driven by both recovering demand and technological upgrades, China's high-end medical equipment industry accelerated into a new phase of standardization and high-quality development.

As industry consolidation deepened, the competitive environment evolved towards greater order and specialization, effectively helping leading enterprises with independent innovation capabilities to stand out. Simultaneously, the principle of 'fair competition and rational pricing' advocated by the National Healthcare Security Administration shifted market access from a singular focus on price competition to a comprehensive consideration of 'quality, cost, and innovation,' creating broader development space for leading manufacturers focused on clinical pain points and committed to original technology. Furthermore, the accelerated inclusion of innovative medical devices in health insurance and the improvement of

diversified payment systems provided manufacturers focused on clinical needs and original technology with broader market access opportunities and value returns.

Against this backdrop, the 'Large-Scale Equipment Renewal' policy promoted by the state entered a normalized phase in 2025, significantly stimulating the willingness of medical institutions at all levels to update innovative diagnostic and therapeutic equipment such as imaging and radiotherapy systems. Particularly in the field of primary healthcare system development, with the accelerated advancement of the 'Healthcare Strengthening Foundation Project' and county-level medical consortia, addressing the shortcomings in primary care diagnostic capabilities has become a core driver of market growth. This has formed a multi-tiered demand matrix led by national medical centers for research breakthroughs, high-level public hospitals for high-end replacements, and primary healthcare systems for widespread penetration, providing fertile ground for the company's full range of products.

Building on a strong commitment to R&D and a comprehensive portfolio of diagnostic and therapeutic equipment, United Imaging Healthcare pursued a balanced strategy focused on advancing premium technologies and broadening market access. This approach has driven sustainable growth within the Chinese market, expanding our impact from initial product introductions to widespread adoption across all product categories. Through continuous technological innovation, the company has enhanced its product capabilities, delivering diversified solutions tailored for premier academic research centers, leading public hospitals, and community healthcare facilities—ultimately improving accessibility to advanced medical technology across all levels of care.

During the reporting period, the company's revenue in the Chinese market reached 10.369 billion yuan, a year-on-year increase of 29.07%. According to third-party authoritative statistics, the company's comprehensive market share in China increased by 4.5 percentage points year-on-year. Following top rankings in 2022 and 2024, the company maintained its position as number one in comprehensive market share for new installations in China in 2025. This performance, significantly exceeding industry growth, fully demonstrates the strategic effectiveness of synergistic efforts across all product lines and the rapid introduction of the high-end product matrix.

Adapting to the industry's new cycle of high-quality and standardized development, United Imaging Healthcare firmly implemented an innovation strategy of 'aiming high and achieving full coverage.' In centralized procurement, the company maintained industry leadership through scalable production capacity, standardized delivery processes, and highly reliable innovative solutions, strongly supporting the efficient implementation of new healthcare infrastructure. In individual procurement, leveraging its significant technological advantage and rising brand premium, the company stood out in the independent selections of medical and research institutions at all levels, earning high trust and recognition from clinical users. Through multi-dimensional efforts, the company secured the top position in China's overall market share in 2025.

By product line, benefiting from the rapid volume growth of mid-to-high-end, ultra-high-end, and flagship innovative products, along with the precise implementation of multi-level solutions, market share, operational efficiency, and profitability across all segments were further enhanced:

During the reporting period, the Magnetic Resonance (MR) product line performed strongly, becoming the core pillar driving the company's performance growth. In 2025, MR business revenue reached 4.548 billion yuan, a year-on-year increase of 42.46%. Driven by the synergistic efforts of the full product line, the company's MR product market share in China increased significantly by 6.5 percentage points year-on-year, with its comprehensive market share rising to first place in the Chinese market for the first time, achieving a milestone leap and further consolidating its leading position in the high-end medical imaging field.

From an industry development trend perspective, the demand for magnetic resonance in China maintained steady growth overall in 2025. With the continuous upgrading of medical institutions' diagnostic capabilities and the development of precision medicine, the trend towards high-end products became more pronounced. 3T MR gradually became a key driver of market growth, with expanding applications in large hospitals and regional medical centers. Simultaneously, demand for ultra-high-field MR, represented by the uMR Jupiter 5T, accelerated significantly, deepening its application in research-oriented medical institutions and top-tier medical centers. In this context, through continuous technological innovation and a comprehensive MR product portfolio, coupled with precise and flexible market strategies, the company achieved full-level penetration from basic clinical to top-tier research markets, driving substantial volume growth in mid-to-high-end and ultra-high-end product segments.

In the basic clinical market, the company maintained its number one market share in China, building a solid business foundation through the innovative technology and stability of its 1.5T and below superconducting products. Concurrently, the heavyweight 1.5T Intelligent Silicon Carbide MR family launched during the reporting period, leveraging the efficient synergy of SiC GPA (Silicon Carbide Gradient Power Amplifier) hardware technology and proprietary AI algorithms, achieved comprehensive upgrades in low energy consumption, high image quality, and high scanning speed. With its outstanding performance in diagnosing complex diseases such as cardiac imaging, this product series is poised to lead the transformation of the 1.5T segment towards high-end and intelligent solutions.

In the 3.0T MR segment, a key growth engine for the industry, the company ranked second domestically in market share. The new-generation 3.0T 8-series products, with their excellent clinical performance, secured orders for over 130 units during the reporting period, expanding their application in top clinical institutions and regional medical centers. In a milestone achievement during 2025, the launch of the industry's first 3.0T high-definition 'cinematic' MR, the uMR Ultra, marked the company's successful entry into the new field of 'dynamic high-definition procedural imaging.' Currently, this product has obtained regulatory

clearances across major global markets and is being rapidly adopted by premier academic medical centers and leading clinical institutions to further advance high-end patient care.

With the first-mover advantage of securing CE, FDA, and NMPA approvals, the uMR Ultra is expected to set a new industry benchmark with its LIVE technology. By introducing high-definition dynamic imaging capabilities into clinical practice, it aims to evolve medical imaging from a diagnostic tool into a platform empowering full-cycle research and clinical decision-making, opening up a new track for intelligent imaging. The global market demand for cross-generational imaging equipment will continue to be released in the future, and uMR Ultra will also leverage its industry-leading ability to define market segments to help the company gain a broader market share and business growth in overseas markets.

In the ultra-high field segment above 3.0T, the company's market share increased significantly by 29.7 percentage points year-on-year, maintaining its leading position in the industry. The ultra-high-end uMR Jupiter 5T magnetic resonance system has been deployed in over 30 provinces, municipalities, and autonomous regions across China, with cumulative orders exceeding 60 units, and has successfully entered more than 50 top-tier clinical and research institutions. With the coordinated development of the 1.5T, 3.0T, and 5T product systems, the company continues to improve its magnetic resonance product matrix covering different clinical needs levels. High-field and ultra-high-field magnetic resonance are gradually becoming important growth pillars for the company's medical imaging business.

Additionally, the company continues to advance the construction of the magnetic resonance research ecosystem. Through multi-center research collaborations with leading domestic and international medical institutions, it continuously promotes the application and validation of the MR online ecosystem platform in clinical scenarios. As of the end of the reporting period, the company has established cooperative relationships with 33 top-tier clinical research hospitals, sharing over 700 scanning protocols and research sequences, building an industry-leading library of magnetic resonance scanning protocols and research sequences. Simultaneously, the company has engaged in cutting-edge technology collaborations with 14 research institutions, promoting the development of 25 innovative technologies and conducting 5 multi-center research studies. By continuously improving the mechanisms for research collaboration and clinical translation, the company is gradually building a complete innovation system spanning from basic research, technology development, clinical application to industrial transformation.

At the forefront of medical imaging transformation, United Imaging Healthcare continues to build a high-performance magnetic resonance ecosystem covering the 'clinical-research' hierarchy, consolidating the advantages of its magnetic resonance product system and continuously enhancing its high-end technology competitiveness. While consolidating the market advantage of its 1.5T products, it further strengthens the layout of its 3.0T magnetic resonance products and promotes the gradual expansion and penetration of the ultra-high-end 5T magnetic resonance system uMR Jupiter 5T from top-tier medical institutions to regional medical centers, expanding its technological advantage in the high-end clinical

market and accelerating the deep penetration of cutting-edge technologies into high-end clinical scenarios.

In the CT business sector, leveraging its profound market accumulation and excellent product competitiveness, the company has ranked first in comprehensive market share in China's new market for three consecutive years, further consolidating its absolute leading advantage in this field. In 2025, United Imaging Healthcare's CT product line achieved revenue of 3.545 billion yuan, a year-on-year increase of 16.31%, with market share in all major sub-segments steadily increasing. In the mainstream and high-end markets, the company ranked first in the industry in the ≤40-slice, 64-80 slice, and 128-160 slice CT segments, demonstrating a solid market foundation. In the ultra-high-end CT segment representing cutting-edge technology (≥256 slice), the company ranked second in market share. The rapid volume growth of high-end products has driven the continuous enhancement of the company's brand influence and core competitiveness.

Meanwhile, the company performed excellently in national medical equipment centralized procurement projects, reaching new heights in market execution capability and coverage depth. During the reporting period, the company's CT products won bids in over 700 projects annually, with the total bid amount ranking first in the industry. Significant progress was made particularly in provinces such as Zhejiang, Hebei, Henan, Hainan, Jiangsu, and Hunan, marking a further deepening of trust in and penetration of United Imaging Healthcare's CT solutions within the public healthcare system. In terms of product structure, the company's high-end and ultra-high-end CT products continued to gain recognition from users at all levels. Ultra-high-end CT products represented by the uCT Atlas series achieved a breakthrough of over 100 units won annually, further enhancing the company's competitiveness in the high-end CT market. Simultaneously, the intelligent CT product uCT Orion (Tianqi CT), launched for primary healthcare institutions, also gained recognition in domestic and international markets. This product, based on deep learning algorithms, builds an AI quality control system. It enhances device usability and image quality through an intelligent perception system and a precision diagnosis and treatment platform, while also considering operational costs and maintenance efficiency. During the reporting period, it achieved a breakthrough of over 300 orders. The AI quality control and intelligent perception systems significantly improved device usability and imaging stability, further promoting the penetration of high-end imaging capabilities into primary healthcare institutions.

With the advent of the precision medicine era, clinical demand for CT imaging is upgrading from traditional structural imaging to functional assessment, dynamic diagnosis, and multi-dimensional clinical decision support. The company is continuously advancing breakthroughs in core imaging technologies, steadily propelling domestic high-end CT into a new stage of development.

During the reporting period, the domestically produced first photon-counting spectral CT, uCT Ultima, was successfully approved for market launch. Currently, uCT Ultima has been installed at West China Hospital Xiamen, Sichuan University, and officially put into clinical

use. This is China's first commercially available and clinically used domestically produced photon-counting spectral CT, marking a historic leap for domestic ultra-high-end CT equipment from R&D to clinical implementation. In January 2026, the world's first dual-wide-detector dual-source CT, uCT SiriusX, also officially received innovative medical device marketing authorization from the National Medical Products Administration (NMPA) and is gradually entering the clinical application stage. This equipment has achieved multiple technological breakthroughs in areas such as ultra-large field-of-view spectral imaging, full cardiac cycle coronary artery dynamic imaging, and whole-heart structural dynamic assessment, providing more precise and dynamic diagnostic and therapeutic capabilities for complex clinical scenarios like cardiovascular diseases, and advancing CT imaging from traditional structural imaging to a new stage of integrated structural-functional assessment.

Addressing the diagnostic and therapeutic needs for complex diseases such as cardiovascular conditions, the company's newly released next-generation ultra-high-end CT product, uCT 968 Ultra, achieves multi-dimensional diagnostic capabilities—from coronary arteries to the whole heart, from static to dynamic, and from structure to function—through its cardiac Live imaging technology. Simultaneously, United Imaging Healthcare continuously promotes the deep application of AI technology in clinical scenarios, building multiple AI agent modules for the nervous system, emergency care, and musculoskeletal system, further enhancing CT's auxiliary decision-making capability in the diagnosis and treatment of complex diseases. In terms of the research ecosystem, United Imaging Healthcare continuously strengthens the validation of clinical value for its technologies through cooperation with globally leading medical centers. During the reporting period, the company consistently published research findings related to CT technology in international academic conferences and journals such as RSNA and ECR, including 11 RSNA-related studies, 26 ECR studies, 13 SCI papers, and 42 papers in domestic core journals, continuously enhancing the influence of domestic high-end CT technology on the international academic stage.

In the future, as cutting-edge technologies such as photon-counting CT and dual-wide-detector dual-source CT gradually enter the clinical application stage, the company's high-end and ultra-high-end CT product system is expected to be continuously improved, its competitiveness in the ultra-high-end CT market will be significantly enhanced, and it will drive the coverage of domestic high-end CT technology in top-tier clinical and research centers.

In 2026, the company will continue to advance its market strategy in the CT field, focusing on the synergistic efforts of its multi-level product matrix and cutting-edge technologies: The new-generation CT platform, represented by the dual-wide-detector dual-source CT uCT SiriusX, will accelerate the clinical application of key technologies such as cardiovascular dynamic imaging and ultra-large field-of-view spectral imaging; the industry's only full-width ultra-clear spectral photon-counting CT, uCT Ultima, will continue to promote the clinical implementation of photon-counting technology. By breaking the physical limits of traditional CT imaging in spatial resolution, spectral imaging, and low-dose imaging, it will assist top medical institutions in conducting cutting-edge research and innovative

diagnostics/therapeutics, and gradually promote the transition of advanced imaging technologies from research centers to broader clinical application scenarios. Meanwhile, iterative upgrades of the company's multiple ultra-high-end CT products, including the uCT 960+, uCT Atlas Elite, uCT Atlas Pro, and uCT 968 Ultra series, will further enhance the complex disease diagnosis/treatment capabilities and multi-scenario application levels of clinical institutions at all levels.

In 2025, the global molecular imaging industry evolved rapidly amidst structural adjustments. Although the overall market size faced stage-wise pressure, China's molecular imaging field maintained a development trend of continuous technological innovation and deepening clinical applications. With the integrated advancement of precision medicine, radionuclide therapy, and artificial intelligence technologies, molecular imaging is gradually transitioning from a traditional diagnostic imaging tool to a key platform for 'theranostics,' with its strategic value continuously increasing.

Against this backdrop, the company's molecular imaging business achieved breakthrough growth against the trend. In 2025, the company's MI product line achieved revenue of 1.908 billion yuan, a year-on-year increase of 46.86%, with the proportion of MI in equipment revenue rising to 16.75%. Amidst the ongoing adjustment in industry demand structure, the company achieved comprehensive improvement in sales value, installation scale, and market share, further consolidating its leading position in the Chinese molecular imaging market. By product line, the company's PET/CT business continued to achieve steady growth, with market share expanding consistently. The PET/CT product line maintained its position as the market leader in China for ten consecutive years, with its market share increasing by 13.5 percentage points year-on-year during the reporting period. The PET/MR business showed more significant growth, with its market share in China rising by 40 percentage points year-on-year, retaining its top position in the Chinese market and further strengthening the company's comprehensive competitive advantage in the high-end molecular imaging field.

In terms of technology and product layout, the company continued to refine its integrated product system of "long-axis + short-axis + PET/MR" during the reporting period. Represented by the uEXPLORER and uMI Panorama GS, the long-axis PET/CT systems continued to be promoted and applied in top-tier medical institutions worldwide. With their ultra-fast imaging capabilities, whole-body dynamic tracking, and high-precision quantitative analysis, they significantly enhanced the ability for early disease detection and response evaluation, reshaping the core role of molecular imaging in the precision medicine system. At the same time, the company continued to upgrade its short-axis PET/CT product system. Through high-performance and cost-effective product combinations, it further expanded its coverage in regional medical centers, primary healthcare institutions, and emerging markets, establishing a solid foundation for business scale. In PET/MR, leveraging leading multi-modality fusion technology, the company continued to drive its expansion from research-oriented to clinical applications, unlocking its potential in areas such as neurological diseases, oncology diagnosis and treatment, and pediatric medicine.

From the perspective of industry development trends, long-axis PET/CT is gradually becoming a key direction driving the leap in molecular imaging technology. The core of future competition in molecular imaging will not only lie in the performance of the equipment itself but also in the ecosystem capabilities built around clinical pathways, data intelligence, and academic consensus. Leveraging the data dimension advantages brought by long-axis PET/CT, the company is driving the upgrade of molecular imaging from a traditional "equipment tool" to a "clinical standard platform," gradually building an innovative collaborative system formed by "hospitals and intelligent agents—equipment and data—algorithms and consensus—more clinical applications," and promoting China's molecular imaging from technological application to global standard co-creation.

At the clinical application level, the company continued to collaborate with top domestic medical institutions to advance the construction of intelligent agents for specialized disease diagnosis and treatment, exploring the deep value of molecular imaging in the precision medicine system. For example, the nasopharyngeal carcinoma diagnosis and treatment intelligent agent developed in collaboration with Sun Yat-sen University Cancer Center innovatively formed an efficient "multi-examination, one diagnosis" model through deep integration of long-axis PET/CT, PET/MR, and radiotherapy systems, significantly improving the efficiency of complex cancer diagnosis and treatment. The liver cancer intelligent agent project jointly promoted with West China Hospital and Shanghai Renji Hospital established a new paradigm for precise treatment of hepatobiliary tumors by combining Y90 therapy-specific long-axis PET systems with AI-assisted decision-making models. In key disease areas such as prostate cancer and lung cancer, the company also promoted the precision upgrade of the entire patient management process through the synergy of molecular imaging data platforms and AI intelligent agents.

With the continuous deepening of these clinical practices, molecular imaging is transforming from a single imaging tool into an important infrastructure supporting diagnosis and treatment decisions for complex diseases. At the same time, the company continued to advance the upgrade of its molecular imaging technology platform. The new-generation uMI Panvivo molecular imaging platform achieved significant improvements in image quality, scanning efficiency, and intelligence level, receiving high recognition in international authoritative evaluations, further demonstrating the company's global competitiveness in core molecular imaging technologies.

In 2026, the company will focus on three key pillars: "breakthrough in long-axis, popularization of PET/MR, and deepening of short-axis," continuously iterating product capabilities while driving the molecular imaging business to achieve higher operational efficiency in the global market. In the long-axis PET/CT market, the company will closely align with cutting-edge diagnosis and treatment trends and clinical needs, accelerating deployment in key scenarios such as high-level hospitals, proton/heavy ion centers, and pediatric specialty hospitals. It will promote deep integration of research and clinical practice, and lead multicenter research and industry technical standard setting through demonstration projects, further consolidating its advantages in high-end clinical and academic ecosystems.

For short-axis PET/CT, the company will launch a new generation of products with better performance and higher cost-effectiveness, focusing on covering prefecture-level hospitals, primary healthcare institutions, and private medical markets to achieve channel synergy and broad market coverage. The PET/MR business will accelerate its transition from research-exclusive to clinical-standard, focusing on promoting clinical implementation in areas such as neurodegenerative diseases, pediatric medicine, and oncology treatment. It will build a dual-drive development model of "neurology + therapy," and enhance market penetration through multi-modality data platforms and automated clinical pathway optimization.

In the radiotherapy (RT) business field, as a core pillar of the modern oncology treatment system, radiotherapy plays an irreplaceable key role in the comprehensive treatment of malignant tumors. Research data shows that approximately 60% to 70% of cancer patients require radiotherapy during their treatment cycle. With the continuous rise in the global cancer burden and the deepening of precision medicine concepts, the demand for high-quality, high-precision radiotherapy services in the clinical sector is in a period of rapid release.

Despite strong demand, the industry still faces structural challenges such as imbalanced resource allocation and complex diagnosis and treatment processes. Looking at the overall picture, there are still objective differences in the distribution of radiotherapy resources across different regions and medical institutions. At the same time, the high dependence on multidisciplinary collaboration and the complexity of the treatment process somewhat constrains the accessibility of high-quality medical resources and clinical efficiency.

Meanwhile, the radiotherapy technology system is in a period of generational transition from "single-machine performance-driven" to "intelligent solution-driven." With the deep integration of artificial intelligence, multi-modality imaging, and automation technologies, the focus of industry competition has extended from isolated equipment physical parameters to comprehensive solution capabilities covering the entire diagnosis and treatment process, adaptive therapy, and multi-modality collaboration. This evolution towards intelligence, adaptability, and ecosystemization is reshaping the technological boundaries of radiotherapy and injecting new momentum into the high-quality development of the industry.

Against the backdrop of technological iteration and demand upgrading in the radiotherapy industry, United Imaging Healthcare's radiotherapy (RT) business achieved a substantial leap. In 2025, the RT product line generated revenue of 591 million yuan, a year-on-year increase of 85.52%, with business scale significantly expanding. During the reporting period, the company achieved the top ranking in annual market share in the Chinese radiotherapy equipment market for the first time, with an increase of over 18 percentage points year-on-year, and achieved significant market breakthroughs in key regions such as Jilin, Tianjin, Henan, and Beijing. At the same time, radiotherapy software business accelerated its implementation. Core systems like uOIS and uTPS successfully entered top-tier medical institutions such as Ruijin Hospital, Tongji Hospital, The First Affiliated Hospital of Sun Yat-sen University, and Sichuan Provincial People's Hospital, initially forming a dual-drive

model of synergistic development of "hardware + software," further enhancing the company's comprehensive competitiveness in the radiotherapy industry chain.

Focusing on the industry transformation towards precision radiotherapy, United Imaging Healthcare drove its radiotherapy business perspective from "single-product supply" to a "full-chain ecosystem." During the reporting period, the company successfully built an intelligent closed-loop system covering simulation and positioning, target volume contouring, plan design, rapid quality control, and precise treatment. Different from the commonly seen add-on intelligent solutions in the industry, the company achieved endogenous integration of AI technology with the underlying equipment architecture, driving the radiotherapy process from "assistive tool" to an essential "endogenous driver," significantly improving clinical workflow efficiency.

In 2025, the company's core products, represented by uLinac HalosTx and uLinac EternaTx, formed a "twin stars" layout. Through differentiated innovation in ring and C-arm system structures, they achieved simultaneous improvement in treatment efficiency and precision. The CT-Sim product quickly completed market introduction after its release, rising to the fourth position in the Chinese market share in its first year, effectively enhancing the company's radiotherapy product matrix.

In the radiotherapy software field, the company continued to advance innovations in online adaptive radiotherapy (ART), achieving dynamic assessment and compensation during the treatment process through dose-guided technology. During the reporting period, the innovative technology of online adaptive radiotherapy (ART), due to its significant clinical benefits, is gradually being incorporated into the medical insurance payment guarantee system. This marks that the company's radiotherapy business is accelerating its transition from technological leadership to widespread clinical application, enhancing the accessibility of high-quality medical resources through innovative treatment paradigms, further consolidating the company's strategic advantage in the precision radiotherapy track.

On April 21, 2025, United Imaging Healthcare's self-developed intelligent radiotherapy contouring software uIPW (Intelligent Physician Workspace) officially obtained Class III medical device certification from the National Medical Products Administration, becoming China's first radiotherapy system with AI contouring capabilities for multiple target volumes and organs at risk. This product utilizes deep learning algorithms to achieve intelligent, precise, and efficient automatic contouring of target volumes and OARs, significantly improving the efficiency and consistency of radiotherapy target volume design, providing a domestic AI solution for clinical precision radiotherapy, and further enhancing United Imaging's full-process radiotherapy product ecosystem.

Looking ahead, the company will promote the evolution of its radiotherapy business from single-point breakthroughs to systematic development through deep synergy in "technological innovation, clinical application, and ecosystem development." On one hand, the company will continue to deepen the clinical translation of cutting-edge technologies

such as AI-driven adaptive radiotherapy and multi-modality image fusion, and enhance the adaptability and implementation efficiency of solutions through combination strategies like "linear accelerator + CT-Sim" and "equipment + software"; on the other hand, the company is committed to improving the industrial ecosystem through regional medical collaboration and talent cultivation systems. During the reporting period, the company conducted regional radiotherapy assistance programs in collaboration with leading hospitals and launched the "Qingyun Plan," establishing smart radiotherapy laboratories with several universities, including Southern Medical University, to strengthen professional talent reserves and discipline development. With the continuous improvement of technological capabilities, product portfolio, and clinical ecosystem, the company will continue to contribute to the widespread accessibility of precision radiotherapy and the high-quality development of the industry.

In 2025, as hospital equipment replacement demand gradually increased and regional centralized procurement policies entered a normalized implementation phase, the domestic XR and DSA markets overall showed a steady recovery trend. The conventional digital radiography (DXR) market maintained steady growth, and the procurement pace for interventional radiography (IXR) also accelerated significantly. Simultaneously, the increasing clinical demand for high-efficiency imaging equipment and intelligent workflows is driving the continuous upgrade of XR products from traditional imaging devices to intelligent, scenario-based solutions, with industry competition gradually shifting from single-device capabilities to comprehensive competition in multi-scenario applications and systematic solution capabilities.

Against this backdrop, the company's XR business achieved rapid growth. In 2025, the XR product line generated revenue of 798 million yuan, a year-on-year increase of 35.98%. Among these, the DXR product line continued to deepen its product layout and market coverage, ranking second in market share in China; the breast DR product line maintained its leading advantage, with market share ranking first, increasing by 10.2 percentage points year-on-year, and both breast DR and fixed DR market shares reached record highs. Leveraging the synergistic layout of core products such as ceiling-mounted DR, column DR, mobile DR, and breast imaging, the company has built a multi-level imaging solution system covering large hospitals and primary medical institutions. Simultaneously, the fully intelligent imaging system represented by the new-generation uDR Aurora continues to be promoted, enhancing diagnostic and treatment efficiency and operational consistency through AI image quality control and automated workflows, driving the continuous upgrade of the XR product line towards an intelligent imaging platform.

In terms of product innovation, the company plans to launch several innovative products in the XR field in 2026, continuously improving the high-end DR product system. Among these, the new-generation intelligent ceiling-mounted DR system will be further upgraded based on the uDR Aurora platform, achieving intelligent management of the examination process through AI imaging and full-process image quality control, which can improve examination efficiency by approximately 60%, reduce ineffective radiation by about 44%, and increase

the rate of high-quality image acquisition by about 30%. Additionally, the company launched the latest-generation integrated breast screening, diagnosis, and treatment platform uMammo Vitar. This product integrates multiple advanced functions, including CEM contrast enhancement, dual-angle DBT 3D tomography, and stereotactic biopsy puncture based on tomographic and contrast-enhanced images. It enables precise acquisition of lesion spatial and blood supply information while providing more comprehensive and accurate needle biopsy positioning methods, allowing key diagnostic and treatment steps such as screening, enhancement, and minimally invasive biopsy to be completed on the same device, significantly improving the efficiency of breast disease diagnosis and treatment and shortening the patient's treatment cycle. The launch of these innovative products will further strengthen the company's technological accumulation and clinical application value in the DXR field.

In the interventional imaging field, the company's DSA business continues to advance product innovation and market expansion. In 2025, the company's IXR product line ranked fourth in market share, with the DSA product line's market share increasing by 5.2 percentage points year-on-year. During the reporting period, the company released several innovative technologies for cardiac, neurological, and oncology interventional fields and promoted the continuous upgrade of the interventional diagnosis and treatment AI platform uVera. Represented by the ceiling-mounted DSA system uAngio AVIVA, the company continuously optimizes system integration, operational efficiency, and spatial adaptability around clinical application needs, providing interventional imaging solutions that combine high performance with flexible deployment for medical institutions. During the reporting period, annual orders for uAngio AVIVA exceeded 100 units for the first time, with cumulative users exceeding 180 over three years since launch, approximately 70% of which are tertiary hospitals, and it has entered several leading domestic hospital systems. This product has successively obtained NMPA, FDA, and CE certifications, becoming the first domestically produced DSA system to receive all three major authoritative certifications, and was rated as a global four-star system with four-dimensional "excellence" in performance, safety, workflow, and compatibility by the international authority ECRI. Its integrated "zero-noise" DSA technology significantly improves image quality and effectively reduces radiation dose, demonstrating good clinical value in complex interventional procedures.

At the Transcatheter Cardiovascular Therapeutics 2025 (TCT 2025) conference, Professor Ge Junbo's team from Zhongshan Hospital Affiliated with Fudan University presented research findings based on the company's "zero-noise" DSA technology. The research showed that, while maintaining high-quality imaging performance, the "zero-noise" technology significantly reduces radiation dose during interventional procedures compared to traditional systems: coronary angiography dose reduced by approximately 62%, complex CTO procedure dose reduced by about 74%, and healthcare worker exposure dose reduced by about 72%. This research further validates the company's technological advantages in improving image quality and radiation safety, providing important evidence-based support for the application of high-end interventional imaging equipment in complex clinical scenarios.

In the future, the company will continue to deepen the construction of the XR product system and accelerate the expansion of the DSA business into high-end and international markets. In the DXR field, the company will continuously enhance product performance and clinical adaptability through intelligent imaging algorithms and multi-scenario solutions, consolidating the competitive advantages of DXR and breast imaging in key market segments. In the IXR field, the company will further strengthen the technical approach of "balancing image quality with low-dose safety," accelerate the clinical validation and application promotion of innovative technologies such as zero-noise DSA, continuously expand the domestic and international demonstration center network, promote the application breakthrough of domestically produced high-end interventional imaging equipment in more core medical institutions, and continuously enhance the company's comprehensive competitiveness in the global digital imaging and interventional imaging fields. In DXR, the company will further enrich its high-end XR product layout, planning to launch a new-generation intelligent ceiling-mounted DR and a new 3D breast imaging system, further improving multi-scenario diagnosis and treatment efficiency in breast screening, enhanced diagnosis, and minimally invasive intervention through AI imaging capabilities and multi-functional integrated design.

As the most accessible, widely available, and safest medical imaging diagnostic technology, the ultrasound product line is a key component in United Imaging Healthcare's integrated medical imaging diagnosis and treatment ecosystem.

Currently, driven by the new wave of technological revolution centered on artificial intelligence, AI, advanced transducer technology, and new materials are continuously maturing, coupled with the sustained growth in global medical demand, ultrasound is facing an unprecedented window of technological transformation. In November 2025, United Imaging Healthcare's self-developed uSONIQUE Pulse series, Genesis series, and Venus series ultrasound products successfully obtained NMPA marketing authorization, establishing a full-range product matrix covering the ultra-high-end to economy markets, fully supporting diverse scenarios such as whole-body, cardiac, obstetrics, intensive care, and emergency anesthesia. This series of products, based on the native intelligence concept and the fully embedded uEDGETEC technology platform, achieves a generational leap from multi-dimensional active perception to large model-driven intelligent thinking, and then to active lesion analysis execution, marking the company's official entry into a new stage of comprehensive intelligence in ultrasound diagnosis and treatment.

At the operational and market level, the company adheres to a core strategy of strategic leadership and innovation-driven branding, ensuring the stable establishment and rapid scaling of its ultrasound business in the global market through systematic capability building. The company strictly follows its established business roadmap, achieving a tiered extension from high-end technological breakthroughs to full-line application scenarios, and systematically advancing the large-scale delivery of key models. In internal management, the company continuously optimizes operational efficiency and market response mechanisms; on the client side, it builds a robust benchmark demonstration network in core medical

institutions through differentiated competitive strategies and professional service systems. Through deep clinical collaboration and strategic brand positioning, the company is accelerating the transformation of technological potential into industry-wide recognition, establishing a sustainable brand moat in the ultrasound field.

Leveraging strong platform capabilities and deep technological reserves, the company focuses on the deep integration of core underlying technologies and intelligent algorithms, driving performance leaps in next-generation intelligent ultrasound products across key dimensions such as imaging platforms, clinical workflows, transducer technology, and specialized applications: first, building an industry-leading high-performance imaging platform; second, deeply closing the loop of the entire clinical diagnostic process, continuously optimizing operational interaction and user experience with a human-centric approach; third, accelerating the implementation of next-generation intelligent imaging and proprietary AI algorithms; fourth, strengthening in-house R&D barriers in core underlying technologies such as acoustic sensors and high-end probes; fifth, extensively expanding diversified clinical scenarios from general whole-body imaging to high-value specialized diagnostics and treatments.

With precise market entry strategies and differentiated positioning in niche segments, by 2026, the company will solidify its position in the high-end ultrasound market while actively promoting the penetration and popularization of high-quality medical resources, achieving deep penetration across multi-tier medical markets. Meanwhile, the global market access process for the company's ultrasound product line is progressing smoothly, and it is expected to accelerate the potential of the ultrasound business as a key growth driver for the company's medical imaging segment through synergistic effects of overseas channels and key opinion leaders (KOLs), as well as tailored promotion strategies, contributing robust momentum to the diversified development of global operations.

Looking ahead, the company is confident in rapidly advancing its ultrasound business into the top tier of the domestic market and, in the medium to long term, building a globally competitive ultrasound business segment, establishing a leading position in the global intelligent imaging ecosystem through high-quality value creation.

(III) Internationalization: Deep Breakthroughs in Global Markets, Continuous Enhancement of High-End Brand and Academic Influence

Amid the wave of accelerated restructuring and demand upgrading in the global healthcare industry, the company deeply implements its "one core, multiple wings, comprehensive development" globalization strategy, driving dual leaps in the scale and quality of its international business. Despite macroeconomic fluctuations during the reporting period, the company's overseas business maintained steady growth, achieving annual revenue of RMB 3.43 billion, a year-on-year increase of 51.39%, with its share of total revenue steadily rising to 24.86%.

With the continuous expansion of global terminal coverage, as of the end of the reporting period, the company's cumulative global installed base exceeded 39,000 units/sets, driving accelerated release of service costs and a surge of over 50% year-on-year in overseas service revenue. The company's business footprint has deeply expanded to over 100 countries and regions worldwide. From the order perspective, overseas customers' demand for high-end and innovative products remains strong, with multiple high-value orders secured in key markets such as North America, Europe, India, and Latin America, significantly optimizing the order structure. Simultaneously, the company proactively enhanced overseas channel empowerment and delivery system construction, effectively improving the closed-loop conversion efficiency from new order acquisition to revenue realization.

By region, North America, as the core market with the highest concentration of global medical technology innovation and high-end medical resources, the company consistently adopts a strategy centered on high-end product penetration and academic collaboration, deepening strategic partnerships with top-tier medical institutions and industry authorities (KOLs), gradually building a high-end brand demonstration system based on innovative equipment and synergistic clinical and research development.

Supported by our dedicated local teams across clinical, manufacturing, and service functions, we continue to deliver advanced imaging solutions tailored to the needs of North American healthcare providers. Our commitment to clinical excellence has driven steady adoption, transitioning our focus from initial product introduction to delivering proven clinical value. To date, our imaging systems are supporting patient care and medical research with over 640 installations across the region.

In 2025, the company achieved dual growth in orders and revenue in the North American market, with the overall business continuing an upward trend. During the reporting period, the company's revenue in North America increased by over 55% year-on-year. Focusing on core product lines such as MR, MI, and XR, the company continued to expand its coverage of high-end customers, successfully entering and completing installations in several globally leading clinical and research institutions, effectively driving new order releases and increasing the service revenue share. During the reporting period, service revenue in the U.S. market grew by over 50% year-on-year, further optimizing the regional business structure.

Within our core molecular imaging portfolio, our advanced diagnostic systems are increasingly being adopted by top-tier global research and clinical centers, reflecting their strong technical capabilities. In the critical field of major brain disease research, our next-generation, dedicated brain PET/CT system, the NeuroExplorer (NX)—developed in collaboration with leading clinical and academic partners—has been successfully installed at premier academic and national health research institutions in North America.

This system overcomes the geometric constraints of traditional general-purpose equipment, featuring a brain-specific 52.4 cm compact bore and a 49.5 cm ultra-long axial FOV, enabling precise whole-brain coverage in a single bed position. Leveraging core technological

advancements, the NX achieves an exceptional time-of-flight (TOF) resolution of 236 ps and an outstanding system sensitivity of 46.8 kcps/MBq. This significant performance enhancement allows the system to capture the dynamic metabolic processes of tiny deep-brain nuclei with high clarity at very low doses. Driven by these innovative technical specifications, the NX serves as a vital tool for advancing cutting-edge research in major neurological conditions, such as Parkinson's and Alzheimer's diseases, as well as supporting neuropharmaceutical development.

Concurrently, our other flagship molecular imaging systems continue to see steady adoption across the North American market. In the realm of ultra-high sensitivity applications, following the successful installation of the uMI Panorama GS at a premier academic medical center in the region, another leading neurological research institute has also integrated the system. The technology has garnered positive clinical feedback for its exceptional image quality, with additional installations planned at other major academic healthcare networks across North America.

Beyond the full bloom in the molecular imaging (MI) field, the company's other core product lines, such as magnetic resonance, CT, and X-ray imaging, are also actively advancing and making substantial progress in the U.S. market. Focusing on the synergistic development of multi-modality high-end equipment, the company continues to broaden its coverage of core customer groups, with related innovative products successfully installed and applied in several regional benchmark clinical and research institutions. Additionally, the consecutive acquisition of large-volume, long-cycle orders not only drive rapid expansion of the North American business scale and continuous increase in service share but also fully validates the effectiveness of the company's "comprehensive high-end medical equipment collaborative overseas expansion" strategy. This signifies that the company is gradually breaking the existing oligopoly with its robust product competitiveness, establishing a solid business foundation and scalable growth engine in the vast North American clinical market.

In terms of industry-academia-medicine collaboration, during the reporting period, the company, in partnership with Yale University and the University of California
To further strengthen the strategic connection between headquarters and the North American market and enhance operational efficiency, during the reporting period, the company comprehensively upgraded the organizational structure of the North American market, deeply implementing the organizational strategy of "executive forward command." The overseas business management team, led by key executives, dispatched a pioneer team composed of core talents to the front lines, comprehensively establishing a North American regional business management hub centered in the United States. This not only ensured seamless transmission of strategic decisions and agile responses to market demands but also greatly promoted the deep integration and collaboration between Chinese expatriate talents and the localized North American team.

Through the relentless efforts of this multinational team, which combines local forces with expatriate empowerment, the business expansion in the North American market is

experiencing significant development opportunities. Leveraging the strong influence and exemplary effect of top U.S. universities and research hospitals in the global medical community, the North American team of over 300 members is overcoming objective market challenges with high professionalism and cohesion, steadily and widely introducing the company's cutting-edge technologies and innovative products from core research hubs to various levels of clinical hospitals, independent imaging centers, and primary care clinics. This organizational model, rooted in local operations and Sino-foreign collaboration, not only truly achieves comprehensive localization of advanced technologies but also injects strong organizational momentum into the company's market share growth in North America.

In the realm of clinical research support, our advanced neuroimaging technologies have been utilized by leading North American academic institutions to advance the NeuroEXPLORER (NX) brain PET project. This initiative has yielded significant progress in neuroimaging, offering new pathways for the precise diagnosis and treatment of neurological diseases. The resulting research findings, published in the Journal of Nuclear Medicine and recognized with 'Best Clinical Paper' and 'Paper of the Year' awards, underscore the clinical value and reliability of our imaging solutions in supporting advanced medical research.

North America remains a key region for our international operations. By focusing on practical clinical utility, the steady adoption of our advanced imaging systems, and ongoing investments in our local supply chain and service capabilities, we have continued to strengthen our ability to support healthcare providers across the region.

As healthcare facilities seek to upgrade their imaging capabilities to meet evolving patient needs, we are well-positioned to provide innovative, high-quality solutions. Moving forward, by optimizing our localized operational efficiencies, we aim to steadily broaden the reach of our advanced imaging technologies in North America. Our commitment remains firmly rooted in delivering consistent clinical value and supporting the advancement of patient care, which in turn steadily builds our reputation as a trusted partner in the global healthcare community.

In 2025, United Imaging Healthcare's European operations achieved strong growth, with annual revenue increasing by nearly 50% year-on-year, steadily establishing the strategic position of the European market as a core engine for globalization. Adhering to the long-term commitment of 'In Europe, Serve Europe' and leveraging the hub role of its Rotterdam headquarters in the Netherlands, the company's European operations have substantially advanced toward deep operational engagement.

During the reporting period, the company's organizational structure in Europe continued to expand, achieving deep integration between Chinese expatriate talents and the localized team, while fostering strong team cohesion with a high sense of cultural identity. By collaborating with core distributors to deeply cultivate the market, the company hosted culturally immersive themed events at top academic conferences such as the European Congress of Radiology (ECR) in Vienna, earning high praise and strategic trust from a wide range of

clients and partners, including top KOLs. The high-end brand image of 'truly global, deeply local' has been widely recognized.

Facing the dual opportunities of equipment replacement in Western Europe and high-end expansion in Eastern Europe, United Imaging Healthcare further expanded its commercial footprint and benchmark presence in the European region in 2025. Following the full commercialization layout in the five major Western European markets in 2024, the company precisely focused on mainstream European public healthcare systems, strategic clients, and clinical research hubs in the UK, France, and Germany during the reporting period, achieving batch deliveries of high-end CT, MR, and PET/CT equipment in Western Europe.

Particularly in the field of molecular imaging, flagship products demonstrated absolute leading advantages: the next-generation brain-dedicated PET/CT Neuro Explorer (NX) successfully entered KU Leuven in Belgium and impressed the industry with its unprecedented high sensitivity and high-resolution imaging at a leading brain science conference; uMI Panorama GS was strongly introduced at Hannover Medical School in Germany, receiving endorsements from major clinical research institutions, with its agile and innovative industry-academia collaboration model highly praised by top clinical experts. Simultaneously, the uMI Panvivo series was successfully launched in France and rapidly achieved sales of over 20 units in Europe due to its precise fulfillment of comprehensive clinical needs; uMI Panorama 35 stood out in a strict bidding process for a new hospital in Denmark, achieving a batch installation and application of five units at once. The successful implementation of these high-end flagship systems has solidly reinforced the company's professional authority in top-tier research fields, marking the steady start of the direct sales system in Western Europe.

Leveraging the 'high-profile' brand momentum established by flagship molecular imaging products in top European clinical and academic circles, the company actively implemented its market expansion strategy of 'leading with high-end, achieving breakthroughs across all lines' during the reporting period. Utilizing the strategic customer channels and trust foundation opened by high-end molecular imaging equipment, core product lines such as MR, CT, and X-ray imaging (XR) accelerated their penetration and achieved multiple successes in the European market.

During the reporting period, the large-bore magnetic resonance uMR Omega successfully entered the Spanish and Polish markets, receiving extremely high evaluations for its excellent clinical experience; meanwhile, the company's high-end CT equipment and XR ceiling-suspended DR systems completed benchmark installations and applications in Portugal and Poland, respectively. The continuous deployment of this series of cross-modality high-end imaging equipment in mainstream Western European clinical institutions, along with accelerated radiation into emerging markets such as Central and Eastern Europe, not only confirms the outstanding comprehensive competitiveness of the full product line but also comprehensively strengthens the overall depth and high-end brand moat of the European

business, laying an extremely solid market foundation for the large-scale, normalized promotion of the entire product line in the future.

Simultaneously, the European business has formed a tiered matrix for introducing innovative products: the performance of high-value-added product lines such as MI and RT in cutting-edge research and complex clinical scenarios has strongly validated the company's comprehensive solution capabilities; particularly in February 2026, the RT product successfully obtained CE certification, marking the substantive implementation stage of the company's 'theranostics' strategy in Europe, which is expected to further accelerate the deep penetration of the full product line in the local market. Additionally, demand for magnetic resonance and CT in high-end medical institutions remained stable, while XR products effectively met local large-scale, standardized equipment configuration needs through the distribution network.

In terms of channel and team building, the company, centered on its European headquarters, continued to deepen the management system for local business partners, further stimulating channel efficiency through mechanism optimization. With the enhancement of brand influence, the company's customer ecosystem in Europe continued to expand, with partners including Spain's leading imaging diagnostics service provider HT Médica, KU Leuven in Belgium, the Niguarda Metropolitan Hospital in Italy, and the Léon Bérard Cancer Center in Lyon, France, among other top institutions. At the same time, the localization process of the direct sales and service systems accelerated: the direct sales structure in Western Europe has initially taken shape, with personnel allocations in Northern and Southern Europe being expanded in an orderly manner. By reshaping the service team and improving after-sales response speed, the synergy between sales and services is increasingly evident. By the end of the reporting period, the company's European business team had grown to over 130 members, with approximately 57% possessing senior or higher professional backgrounds.

While deepening regional markets, the company actively enhanced its business dimensions through global strategic collaboration. In March 2026, United Imaging Healthcare signed a Memorandum of Understanding (MOU) with Bayer Group to explore in-depth cooperation in the fields of medical imaging and digital health. The two parties will jointly explore potential areas for solution integration and commercial cooperation, focusing on the synergistic layout of technological products and the expansion of global healthcare resource accessibility. This cross-border collaboration will not only uncover new growth opportunities in Europe and globally but also align with the trend of the global healthcare industry moving towards connectivity and ecosystem development, contributing to the construction of an efficient and integrated clinical diagnosis and treatment ecosystem.

With the significant expansion of terminal equipment installations, the service business in the European market has entered a period of value release. During the reporting period, leveraging a cumulative installed base of over 450 units/sets, regional service revenue steadily climbed and exceeded the annual target, with contract renewals and new contracts jointly building a robust performance increment. Among them, service revenue in markets

represented by Poland achieved rapid growth, effectively validating the business logic of converting the installed base into aftermarket revenue. In response to project lifecycle transitions in parts of Western Europe, the company optimized its delivery network and deepened business potential exploration. While strengthening strategic collaboration with core customers, it further enriched its long-term order reserves, solidifying the foundation for sustained business growth.

Currently, the localized European system integrating R&D, marketing, service, and operations has been firmly established. Leveraging the demonstration effect of high-end flagship products and continuous cultivation of the localized network, United Imaging Healthcare has formed a virtuous cycle of scale growth and brand elevation in the European market. Looking ahead, the company will continue to adhere to a high-quality, sustainable development path, continuously improve operational efficiency and professional service capabilities, and drive the European region's comprehensive transition from 'market entry' to 'deep cultivation and efficiency enhancement,' positioning it as a core growth engine and long-term strategic pivot supporting the company's globalization strategy.

During the reporting period, the Asia-Pacific and emerging markets demonstrated strong momentum, with regional revenue reaching new heights. Among them, the Asia-Pacific region grew steadily with an increase of over 40%, while emerging markets broke through strongly with a growth rate exceeding 80%. Benefiting from the accelerated introduction of the high-end product matrix and the improvement of localized marketing and service systems, the company's brand influence and order-winning capabilities in key countries significantly leaped. To solidify the foundation for scaled development, the company focused on increasing resource allocation to high-potential markets such as developed Asia-Pacific regions, India, Southeast Asia, the Middle East, and Latin America. Through the strategy of 'empowerment by dispatched key personnel + leadership by local elites,' it drove the organizational structure and operational systems to deeply embed into frontline business, comprehensively enhancing the delivery capability for complex large-scale medical equipment and regional response efficiency.

In developed Asia-Pacific markets (DAP), leveraging superior product quality and formidable technological barriers, the company has repeatedly achieved breakthroughs in collaboration with leading healthcare networks.

In 2025, the company not only established a strategic partnership with the Singaporean healthcare group IHH and successfully entered Singapore General Hospital (SGH), but also set a benchmark for this demanding high-end market. In Japan, the renowned university-affiliated hospital where the company's first overseas unit was installed has confirmed a repurchase plan for a high-end PET/CT, demonstrating high customer loyalty; in Hong Kong, the company's high-end products not only successively entered leading local private hospital groups but also successfully completed challenging installations in super high-rise buildings at core commercial landmarks, fully validating the company's excellent complex project implementation capability. Furthermore, in Australia, the company not only stabilized its

base in private clinics, completing the installation of the 8th PET/CT unit, but also won a bid for the first time with a top-three ranked public university hospital – successfully introducing the uMI Panorama 35, marking the company's official entry into the influential Australian public healthcare system.

In the Latin American market, the company not only broke the long-standing dominance of international brands offering non-digital PET but also rapidly established a leading market position with high-end molecular imaging equipment such as the uMI 550. During the reporting period, the company successfully secured an order for the first new-generation high-performance MRI in a key emerging market in Central America, and the leading Chilean institution, Universidad de los Andes Hospital, successfully introduced the company's high-end CT, further validating the company's overall upward breakthrough in the Latin American market. In the CIS region, United Imaging Healthcare's business achieved leapfrog development, with an overall market share reaching 25%. Among these, PET/CT and MRI products held market shares as high as 67% and 42% respectively within the region, and the company secured the top market position in Kazakhstan.

The deployment process for high-end equipment in emerging markets such as South Asia and the Middle East and North Africa (MENA) accelerated comprehensively. In the Indian subcontinent, the company has established a localized team of about a hundred people and achieved an absolute leading position in the field of molecular imaging (MI). During the reporting period, the company reached cooperation agreements with three hospitals under the Apollo Group for multiple high-end imaging devices, marking a substantive step forward in the high-end medical market of South Asia. In the Middle East and North Africa, Turkey successfully received an order for the first uMR Jupiter 5T in an emerging market and completed its installation; Kuwait successfully installed its first uMI Panorama 35; Morocco also achieved the first delivery of the uMI Panvivo and a PET/MR system, successfully introducing integrated nuclear medicine solutions into the heart of North Africa.

Looking ahead, the company will firmly deepen its presence in international markets, using the accelerated deployment of innovative products as a driver to extensively develop core hospital and strategic customer networks. Relying on diversified regional layouts and deep localized operations to effectively hedge external risks; simultaneously, it will continuously refine global supply chain, financing support, and complex project delivery capabilities, injecting sustained momentum for the high-quality, sustainable growth of overseas business.

(IV) Management and Sustainable Development: Innovation-Driven, Win-Win Cooperation, Building a Sustainable and Resilient Global Supply Chain System

In 2025, the company continued to advance its 'innovation-driven, win-win cooperation' strategy, accelerating breakthroughs in underlying technologies and the industrialization conversion process, propelling the company from product leadership towards leading the entire industry chain ecosystem. This year, leveraging sustained high-intensity R&D investment and the coordinated layout of its global R&D network, the company made

multiple advancements in underlying technology R&D, core component breakthroughs, and system integration capabilities, with several strategic products achieving commercial deployment.

As of the end of the reporting period, the cumulative number of products launched by the company exceeded 150 models, of which 75 obtained EU CE certification, with 29 new products certified in 2025; 58 products received US FDA (510(k)) clearance, with 19 new clearances during the year; additionally, the company had 8 products approved through the National Innovative Medical Device Special Review Procedure, and over 20 products received FDA approval as AI-enabled devices, continuously consolidating the company's technological and product advantages in the high-end medical equipment field.

Currently, as a new wave of technological change led by artificial intelligence is unfolding, the company, with innovation and breakthroughs as the core driver, is building a sustainable R&D and innovation system integrating forward-looking scientific research, engineering innovation, clinical collaboration, and industrial transformation. During the reporting period, the company increased R&D investment, optimized innovation resource allocation, and successfully launched multiple industry-first products, helping to elevate global medical diagnosis and treatment standards to new heights:

The natively intelligent uSONIQUE series ultrasound was officially launched in November 2025, marking United Imaging Healthcare's completion of a full portfolio in major medical imaging; the first domestically produced photon-counting spectral CT system, uCT Ultima, officially received approval from the National Medical Products Administration (NMPA) in August 2025, and successfully won a bid in December of the same year for West China Hospital of Sichuan University's affiliated Xiamen Hospital, marking the official entry into medical practice of China's first clinically applicable photon-counting CT; the world's first dual-wide-detector dual-source CT imaging system, uCT SiriuX, which officially received NMPA market approval in 2026, successfully resolved the traditional high-end CT dilemma of 'cannot have both' coverage and temporal resolution. Completely overturning traditional architecture, it breakthroughly combines wide detector and dual-source technology to achieve an 8ms industry-leading whole-heart temporal resolution, 16cm whole-organ volume coverage, and a 470mm ultra-large dual-source spectral imaging field of view. Additionally, the industry's first all-new generation 3T MRI system, uMR Ultra, is driving the MRI evolution from static 'photography' to a dynamic 'cinematography' leapfrog upgrade.

In terms of the global industry-university-research-medicine collaborative innovation ecosystem, the company further built barriers in underlying technologies. As of the end of the 2025 reporting period, the company's cumulative patent applications exceeded 10,000, with high-value invention patents accounting for 82%, proactively securing a foothold in next-generation platform technologies and key frontier areas. During the reporting period, the company formed stable and efficient networks by collaborating with leading domestic and international research institutions, with multiple core research findings published in succession in international authoritative academic journals such as 'Nature' and 'Radiology';

at global top-tier academic conferences like ISMRM 2025, the company jointly exhibited over 40 cutting-edge innovations with top-tier research and clinical institutions, and won gold medals, silver medals, and the runner-up prize in the engineering group. From high-value patent layout to empowerment through top journals and conferences, this comprehensively validates the company's international competitiveness derived from deep integration of industry, academia, research, and medicine, building a solid technical pillar for its global high-end brand strategy.

Sustainable development and green, low-carbon transformation have become essential paths for the high-quality development of global enterprises. For many years, United Imaging Healthcare has deeply integrated the concept of sustainable development into its corporate strategy, continuously investing in key areas such as R&D innovation, quality and compliance management, supply chain collaboration, talent development, and green operations, gradually building a corporate development system that combines technological leadership and responsibility. During the reporting period, United Imaging Healthcare continued to deeply integrate environmental, social, and governance (ESG) factors into its corporate strategy, aligning with the development philosophy of 'technology-driven, sustainability-led' to promote green, efficient, and resilient growth in the global medical technology sector.

Thanks to long-term investment in corporate governance, social responsibility, and sustainable development, United Imaging Healthcare achieved outstanding performance in authoritative ESG rating systems in 2025: its MSCI ESG rating rose to AA, officially placing it among the global leaders in the medical technology industry; it received an AAA rating in the CSI ESG rating, ranking first in the industry (top 8%); in the S&P Global Corporate Sustainability Assessment (CSA), the company not only remained in the top 10% of the medical equipment industry but was also successfully included in the S&P Sustainability Yearbook (China Edition) 2026 list of over 190 leading enterprises in China, and was awarded the 'Industry Top Improver' title. This series of authoritative recognitions not only deeply validates the company's outstanding ESG governance but also establishes United Imaging Healthcare as a benchmark for sustainable development in the high-end medical technology field.

Additionally, in December 2025, United Imaging Healthcare, in collaboration with Jingzhou Central Hospital affiliated with Yangtze University—a regional medical center in Hubei Province—successfully had their research paper titled 'Energy-saving Efficiency of a Novel Silicon Carbide MRI Gradient Power Amplifier' selected for oral presentation at the 2025 Radiological Society of North America (RSNA) annual meeting. Based on the industry's first silicon carbide MRI system—the uMR 600—this study systematically validated the energy-saving potential of silicon carbide gradient amplifiers in a clinical environment for the first time, providing important technical pathways and clinical evidence for the transition of MRI equipment toward high-efficiency and low-carbon operations.

In terms of carbon management, the company systematically advanced environmental governance and carbon emission management system construction, setting 2023 as the baseline year and aiming to reduce Scope 1 and Scope 2 carbon emission intensity by 50% by 2035. During the reporting period, United Imaging Healthcare set detailed phased emission reduction targets for various emission sources across production operations, energy usage, and facility optimization, accompanied by multiple carbon reduction measures. In 2025, United Imaging Healthcare's greenhouse gas emissions were 69,958.32 tons of CO2e (Scope 1 and Scope 2, market-based), a reduction of 7.80% (5,917.65 tons of CO2e) compared to the 2023 baseline year. During the same period, greenhouse gas emission intensity decreased to 5.06 tons of CO2e per million yuan in revenue, a year-on-year decline of 4.24%. The company has achieved 47.8% progress toward its medium-term goal of reducing emission intensity by 50% by 2035.

Furthermore, to continuously improve the quality of greenhouse gas data and management levels, the company engaged a professional third-party organization to verify its organizational greenhouse gas emissions and consistently participated in CDP climate change disclosure and rating, maintaining a B-level management rating.

In terms of green product transformation, United Imaging Healthcare continues to promote low-carbon design and full lifecycle management. In July 2025, the uCT 780 X-ray computed tomography (CT) system successfully passed the ISO 14067 product carbon footprint verification, becoming the first CT product in China's large medical equipment sector to receive this certification; in December 2025, the company's new-generation 1.5T MRI system, uMR 680, also completed the ISO 14067 product carbon footprint verification. This certification quantifies the carbon emissions across the entire process from raw material acquisition, component production, to final assembly, achieving a 'cradle-to-gate' lifecycle carbon footprint assessment, providing a scientific basis for optimizing processes and reducing carbon emissions, and setting a green benchmark for the industry. Guided by the 'Ecodesign' concept, the company systematically advances green transformation in product design, manufacturing, and supply chain processes, continuously accelerating energy-saving renovations and environmental innovation, deeply integrating environmental management with business development to support the national 'Dual Carbon' strategic goals.

While pursuing technological breakthroughs, United Imaging Healthcare always regards product quality and compliance management as the cornerstone of corporate development. Since its establishment, the company has ensured compliance, safety, and precision in delivery through the construction of a full lifecycle quality management system, strengthened safety production, and the promotion of digital manufacturing. By the end of 2025, the company's quality management system had achieved 100% coverage across all global production bases. Additionally, in 2025, the company underwent 32 audits by domestic and international regulatory bodies and third-party certifications, achieving 100% compliance with the regulatory requirements of target markets. Audit types included: China Medical Device GMP registration and change system inspections, ISO 13485:2016 and ISO 9001:2015 system certifications, MDSAP single audit program, audits and unannounced

inspections under the EU MDD directive and MDR regulations, as well as specialized factory inspections such as INMETRO, NRTL (Nationally Recognized Testing Laboratory), and CTF (Laboratory Qualification). On the product testing front, in 2025, the company conducted over 14.14 million core tests and over 5.9 million reliability tests, covering more than 400 key components and systems, with test cases reaching 23,000 and achieving 100% test case coverage. Reliability testing covered all product lines and components including CT, MR, MI, RT, XR, and US. Through rigorous internal and external quality control loops, all launched products have obtained multiple international authoritative certifications, including the MDSAP certification spanning the U.S., Canada, Japan, Brazil, and Australia, further solidifying the company's competitiveness in the global market.

Excellent products rely on a robust global service network and a resilient supply chain ecosystem. United Imaging Healthcare always adheres to a customer-centric approach, continuously improving its customer service management system, enhancing service quality and response speed, and optimizing the overall customer service experience. By the end of 2025, the company's service network covered over 100 countries and regions worldwide, with a professionally qualified service team of over 1,000 members. It established regional service centers in 12 countries and regions, increased overseas service points to 44, and maintained a global spare parts warehouse network of 39 locations, capable of providing 7x24 real-time response to ensure stable equipment operation and timely clinical support in various complex environments. According to the 2025 Shanghai medical equipment after-sales service satisfaction survey results, the company ranked first in after-sales service satisfaction for four major high-end equipment categories: radiology MR, CT, conventional X-ray, and PET/CT, marking ten consecutive years of leading among domestic brands in such evaluations. The company consistently upholds the principle of 'centered on clinical needs, serving the frontline,' deeply integrating technical responsiveness and a sense of responsibility into the entire terminal service process, continuously consolidating its professional and stable brand reputation.

While advancing its own intelligent manufacturing capabilities, United Imaging Healthcare always considers building a responsible supply chain ecosystem as an inherent corporate responsibility. During the reporting period, the company continued to deepen supply chain ecosystem construction, regularly empowering upstream and downstream partners through annual supplier quality conferences, JQE Club, and various specialized technical exchange trainings. In 2025, the company conducted specialized audits and on-site guidance for over 60 suppliers, effectively improving their process control and quality management baselines; it held over 180 quality-focused meetings for core suppliers. In terms of green supply chain collaboration, the company provided specialized online Green Product Management (GPM) training to over 80 partners, emphasizing environmental regulations and hazardous substance control requirements, and actively guided partners to adopt clean energy. By systematically communicating core ESG requirements such as environmental governance, legal compliance, and carbon emissions, the company is steadily building a safe, stable, and green global high-end medical device supply chain system.

Human capital is the core element supporting the company's global business expansion and continuous advancement. During the reporting period, the company deepened and refined its 'strategy-oriented, diverse coverage' human resources system. In talent acquisition, the company actively implements talent attraction strategies to widely recruit outstanding professionals with international perspectives and specialized backgrounds. By the end of 2025, the company's global workforce exceeded 8,700 employees, distributed across more than 40 branches/subsidiaries and offices worldwide, with over 1,000 new hires during the year. To strengthen the talent pipeline, the company invested a cumulative total of over 290,000 hours in employee training in 2025, with training sessions exceeding 400,000 person-times, achieving 100% coverage of all employees. The training covered various types, including product technology, business ethics, anti-corruption, responsible marketing, information security, and quality safety. In terms of long-term incentives, the company has introduced multi-level equity incentive plans tailored to different development stages, covering Employee Stock Ownership Plans (ESOP), second-class restricted stocks, and strategic placement shares. By the end of 2025, these plans had cumulatively granted 83.526 million shares, benefiting over 5,400 person-times. By establishing a cross-border, cross-hierarchical enterprise development sharing mechanism, United Imaging Healthcare has effectively achieved deep alignment between the core team and the company's long-term strategic goals.

In terms of information security, United Imaging Healthcare continuously safeguards the privacy and information security of all stakeholders. Through data risk prevention and control practices, it effectively avoids the negative impacts and commercial losses caused by information security incidents to the group, enhances the trust of consumers and partners, and thereby improves the group's industry competitiveness. Meanwhile, the company continuously optimizes its own data security management measures, striving to collaborate with the entire industry to promote the sustainable development of the digital economy and information society. By the end of the reporting period, United Imaging Healthcare had obtained relevant system certifications such as Information Security Management (ISO 27001), Personal Privacy Protection (ISO 27701), and Cloud Service Information Security Management (ISO 27017), and passed supervisory and recertification audits during the year. Additionally, the company is conducting a security assessment certification for the NIST Cybersecurity Framework 2.0 (NIST CSF 2.0) at United Imaging America, ensuring comprehensive protection of information and privacy security.

In terms of social responsibility and medical equity, United Imaging Healthcare continues to uphold the vision of 'Making a Difference, For Universal Health,' promoting the accessibility of precision diagnosis and treatment solutions worldwide. The company actively empowers the construction of primary healthcare systems in developing countries while focusing on the balance of medical services within developed countries. Through affordable, high-performance products and inclusive technology, it promotes the practical implementation of 'inclusive healthcare' from concept to practice, effectively enhancing the health experiences of patients from different regions, body types, and cultural backgrounds.

Looking ahead, United Imaging Healthcare will continue to drive innovation with technology as the core, focusing on global trends in medical imaging and precision diagnosis and treatment. It will accelerate the construction of a resilient, responsive, and efficient global operational system and organizational capabilities, solidifying the foundation for the company's sustainable growth strategy.

The company will leverage more advanced intelligent solutions as technological carriers, supported by a more flexible global delivery and service system, and driven by deeper original R&D and ecosystem innovation capabilities. It will assist the global healthcare industry at deeper levels and broader dimensions, achieving greater innovation and medical equality.

Analysis and Outlook of Changes in Non-GAAP Financial Indicators

□ Applicable√ Not Applicable

3. Analysis of Core Competitiveness During the Reporting Period

i. Core Competitiveness Analysis

√ Applicable□ Not Applicable

The company is a leading domestic and one of the few global medical technology enterprises that master core technologies in high-end medical imaging diagnostic products, radiotherapy products, and life science instruments. It possesses full lifecycle management capabilities from R&D, production, sales, to after-sales maintenance.

1. Comprehensive Product Portfolio and Leading Product Performance

(1) Comprehensive Product Coverage

The company has developed a rich product line centered around high-end medical imaging equipment, covering diagnostic products such as MR, CT, XR, PET/CT, PET/MR, US, radiotherapy products including conventional RT and CT-guided RT, and life science instruments like animal MR and animal PET/CT, meeting needs from preclinical research to diagnosis and treatment. The company's equipment is equipped with self-developed medical image processing software and advanced applications, enabling the organic integration of research, diagnosis, and treatment plans, providing an all-in-one solution for precision diagnosis and treatment.

(2) Advanced Product Performance

Mutiple products developed by the company have achieved industry or domestic 'firsts,' including the industry's first PET/CT product with 4D whole-body dynamic scanning capability, uEXPLORER (Total-body PET/CT), which was named one of the 'Top 10 Breakthrough Technologies in the World' by Physics World in 2018; the industry's first ultra-high-field whole-body magnetic resonance uMR Jupiter 5T, which broke the previous limit of ultra-high-field MR being limited to neurological scans and achieved ultra-high-field whole-body clinical imaging for the first time, demonstrating unique advantages in cardiac, neurological, and abdominal applications for better disease understanding, differentiation, and diagnosis; the industry's first high-definition 'cinematic' magnetic resonance equipment uMR Ultra, equipped with the uAIFI.LIVE imaging platform, combined with an AI imaging chain, leveraging the synergistic advantages of ultra-high-performance gradient systems and spatiotemporal fusion AI engines to continuously capture high-definition dynamic images of

anatomical structures and functional tissue activities, with great potential for observing, diagnosing, and researching moving parts of the human body; the industry's first smart bionic minimally invasive interventional surgery system uAngio 960, also the first domestic DSA system with a multi-degree-of-freedom robotic gantry structure, meeting the needs of high-precision, complex surgical scenarios in multi-disciplinary fields such as pan-vascular, orthopedics, thoracic surgery, and digestive tract; the domestic first photon-counting spectral CT uCT Ultima, pioneering domestic photon-counting spectral CT for ultra-high-resolution multi-part whole-body imaging and precise spectral imaging, suitable for high-end clinical diagnosis, treatment, and integrated research scenarios; the world's first dual-wide dual-source CT imaging system uCT SiriuX, which for the first time combines wide-detector and dual-source ultra-high-end CT system configurations, breakthrough achieving the industry's highest whole-heart temporal resolution of 8ms, dual-wide 16cm full-organ volume coverage, and 470mm ultra-large spectral imaging field of view, achieving comprehensive performance improvements in time, coverage, and precision; and the industry's first diagnostic-grade CT-guided integrated radiotherapy accelerator uRT-linac integrated CT linear accelerator, among other products.

2. Strong Comprehensive R&D Capabilities

(1) Vertical R&D System

The company has established a vertical innovation system spanning technology, products, and software, conducting core technology R&D around the key components of each product line, laying a solid foundation for achieving self-controlled core technologies and building competitive barriers for products. The company's self-developed proportion ranks among the top in the industry, with major core components of each product line being self-developed and self-produced.

(2) Platform-based R&D Model

The company has built general software and hardware R&D platforms, providing a foundation for technology reference and exchange, as well as product integration and iteration through a cross-product-line platform-based R&D model. At the R&D level, the common underlying architecture facilitates innovation for developing multi-modality products; at the project level, shared software and hardware designs enhance R&D efficiency and accelerate product iteration; at the product level, unified systems coupled with unified industrial and interface design ensure high consistency in brand image and user experience across different product lines, aiding in brand influence enhancement and continuous product promotion.

(3) Forward-looking Innovation Strategy

The company guides its innovation direction through forward-looking research and market trends. On one hand, the company has established future labs in Shanghai and Houston, USA, actively strategizing its footprint in frontier research to explore new opportunities in industry transformation and development, providing technological reserves for the company's R&D innovation. On the other hand, each product division maintains close connections with the market, continuously driving technological innovation and iterative upgrades of the full product line through rapid feedback on market demands.

(4) Global R&D Talent Reserve

Talent is the foundation of the company's continuous R&D innovation. Through internal cultivation and external recruitment, the company has built a global R&D echelon led by several top scientists and individuals with extensive industry management and R&D

experience. By the end of the reporting period, the company had a total of 3,497 R&D personnel, accounting for 40.18% of the total workforce.

3. Comprehensive Intellectual Property Layout

The intellectual property system is the core support for technological innovation and an important guarantee for the company's sustainable development and globalization. The company has established a comprehensive database and intellectual property management platform, achieving platform-based management of intangible assets throughout their entire lifecycle. The company's intellectual property system covers patents, trademarks, copyrights, and technical secrets. As of the end of the reporting period, the company has filed over 11,500 intellectual property applications, primarily patents, with invention patent applications accounting for over 80% of all patent applications. The company has cumulatively obtained over 6,100 intellectual property authorizations, including over 3,990 invention patent authorizations. Simultaneously, the company strictly protects its technical secrets in accordance with the "Information Security Management Measures" and "Trade Secret Management System," striving to build a comprehensive intellectual property layout system to protect the company's technological innovation achievements from different angles.

(1) Forward-looking Layout Strategy

Since its establishment, the company has consistently regarded patent layout strategy as an important means to strengthen its competitiveness, continuously building patent barriers by combining its own technological path, industry frontier technologies, and market expansion directions. The company's patent mining mechanism runs through the entire lifecycle of technology research and development, with patent applications widely covering the full range of products. At the same time, the company plans ahead and secures patent protection for technologies that may be implemented in the future during the R&D process to gain a first-mover advantage, ensuring the company obtains more basic patents and higher layout efficiency.

Regarding trademarks, the company initiated trademark layout in line with product launch plans during its early establishment phase, leveraging the advantages of the Madrid trademark system for global trademark layout, laying the foundation for overseas market expansion.

By combining its own technological path, industry frontier trends, and market expansion directions, the company has formed a comprehensive intellectual property layout that balances offense and defense.

(2) Systematic System Establishment

The company has established a comprehensive and systematic intellectual property management system aligned with its development strategy, covering the acquisition, maintenance, and utilization control of intellectual property. At the risk control level, it supports intellectual property risk identification and legal dispute resolution; at the document and regulation level, the company has established control procedures including intellectual property documents and laws/regulations; at the information security level, the company implements strict confidentiality management for intellectual property information resources.

4. Multi-dimensional Marketing Network

The company combines direct sales and distribution models to build a diversified, multi-dimensional marketing system covering domestic and international markets, including top

research institutes, universities, tertiary hospitals, and grassroots institutions. The company actively implements the national hierarchical diagnosis and treatment strategy, penetrating the grassroots medical market through a rich product portfolio, and promoting the decentralization of medical resources by integrating innovative equipment with technologies like the internet. In overseas markets, as of December 31, 2025, the company has established sales networks in multiple countries and regions globally, including the United States, United Kingdom, Singapore, Japan, South Korea, Australia, New Zealand, South Africa, Morocco, Malaysia, Colombia, etc. The company's products have successfully entered over 100 countries and regions, including the United States, Japan, South Korea, New Zealand, Italy, etc.

5. Comprehensive After-sales Service

Centered on customer experience, the company has built a comprehensive customer service system addressing routine after-sales needs, emergency response needs, and feedback needs. The company has established an after-sales team that pays attention to detail and strives for excellence, providing customers with comprehensive services covering training, installation, maintenance, upgrades, and upkeep. Furthermore, the company highly values continuous communication with customers and obtaining feedback to promote product optimization and upgrades by the R&D team.

6. Integration of Industry, Academia, Research, and Medicine for Innovation

The company is gradually transitioning from a single dimension of empowering clinics with products and technology to building a deeply integrated innovation system supported by comprehensive technology across industry, academia, research, and medicine. The company has connected the entire chain of "basic research - clinical application - translational medicine - industrial transformation," using clinical needs and major medical challenges to drive product definition, performance optimization, application expansion, and clinical demonstration, forming a closed-loop management from innovation to commercial transformation, continuously expanding innovation leadership and commercial competitiveness.

ii. Events during the reporting period that significantly impacted the company's core competitiveness, impact analysis, and countermeasures

□ Applicable√ Not Applicable

iii. Core Technologies and R&D Progress

(1). Core Technologies and Their Advancement, and Changes During the Reporting Period

After years of R&D accumulation, the company has mastered the following core technologies:
(1) Core Technologies of Magnetic Resonance Imaging System (MR)

Serial Number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
1	Core Hardware Design and Production Technology	Superconducting Magnet Design and Production Technology	1. The company is one of the few enterprises mastering core technologies for 5.0T and above high-field human superconducting magnets. 2. Possesses magnet uniformity indicators at an industry-advanced level. 3. The first in the industry to achieve a 3.0T superconducting magnet featuring an 75cm ultra-large patient bore. 4. Has mature zero-liquid-helium boil-off magnet technology. 5. Masters the development technology for low-liquid-helium and zero-liquid-helium magnets.	Independent R&D	Superconducting magnet design and manufacturing	MR, PET/MR
2		High-Performance Gradient Coil Design and Production Technology	1. Gradient amplitude covers 33mT/m to 300mT/m, gradient slew rate covers 125T/m/s to 220T/m/s, at an industry-leading level. 2. Utilizes vacuum potting technology and advanced material formulations, possessing high mechanical performance and operational reliability.	Independent R&D	Gradient coil design and manufacturing	MR, PET/MR
3		Fully Digital Megawatt-level Gradient Power	1. The industry's first third-generation semiconductor SiC gradient amplifier (GPA) technology and its industrialization.	Independent R&D	Gradient power amplifier design	MR, PET/MR

Serial Number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
		Amplifier (GPA) Technology	2. Gradient amplifier power covers 0.5 megawatt to 3.5 megawatt power levels, reaching industry-leading standards. 3. Fully digital control technology improves gradient magnetic field fidelity and stability.		and manufacturing	
4		Fully Digital Radio Frequency Power Amplifier (RFPA) Technology	1. Adopts all-solid-state power amplification and high-density, high-integration structural optimization technology, reducing volume and cost. 2. Adopts all-digital nonlinear compensation technology to improve signal fidelity and stability	Independent R&D	RF power amplifier design and manufacturing	MR, PET/MR
5		High-field multi-channel RF transmission technology	Mastered multi-channel independent control technology, which can improve RF transmission magnetic field homogeneity, leading the industry	Independent R&D	RF transmission coil design and manufacturing	MR, PET/MR
6		RF receive coil design and production technology	1. High-channel dedicated receive coils can cover all body parts, leading the industry 2. Mastered low-noise preamplifier RF amplifiers and new coil technologies	Independent R&D	RF receive coil design and manufacturing	MR, PET/MR
7		Distributed spectrometer and optical fiber digital transmission technology	High number of receive channels and signal stability reach industry-leading levels	Independent R&D	Magnetic resonance spectrometer design and manufacturing	MR
8	Core software applications and	Magnetic resonance fast imaging technology	1. Industry's first dynamic imaging technology LIVE platform, achieving breakthrough from 'photography' to 'videography' in magnetic resonance imaging	Independent R&D	Magnetic resonance imaging sequence and	MR, PET/MR

Serial Number	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Application Product
	algorithm technology		2. Industry-first Light Vessel imaging technology platform, achieving 0.5 seconds/phase fast dynamic high-definition imaging 3. Intelligent Light Vessel imaging technology platform integrates advantages of artificial intelligence and Light Vessel imaging technology, enabling whole-body imaging in hundreds of seconds		clinical application development	
9		Magnetic resonance automated scanning technology	1. Full-process intelligent empowerment, achieving intelligent scanning for head, heart, spine, abdomen and other body parts 2. Features intelligent functions including one-click table in, multi-protocol convenient planning, automated post-processing, key component failure warning, sleep/wake-up	Independent R&D	Magnetic resonance intelligent scanning workflow implementation	MR, PET/MR
10		Magnetic resonance advanced applications and post-processing technology	1. Possesses industry-first advanced application technologies including complex domain diffusion reconstruction technology, multi-echo advanced susceptibility weighted imaging technology, 3D high-definition MATRIX technology 2. Possesses multiple quantitative imaging technologies including liver fat quantification FACT technology, dynamic scanning DCE technology 3. Possesses multiple advanced post-processing applications including deep learning-based fully automatic cardiac chamber segmentation software, dynamic contrast-enhanced liver scanning quantitative analysis software	Independent R&D	Magnetic resonance advanced applications and post-processing product development	MR, PET/MR

(2) X-ray computed tomography system (CT) core technologies

Serial Number	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
1	Key component design and manufacturing technology	Detector	"Space-Time Detector" can significantly reduce electronic noise, improving image resolution while reducing dose, with performance leading the industry	Independent R&D	CT detector manufacturing and processing	CT
2		X-ray tube	Features high power capability, high heat capacity, long lifespan, improves image resolution through flying focal spot technology	Independent R&D	CT X-ray tube design and manufacturing	CT
3		High voltage generator	1. Reduces high voltage generator volume and weight through all-digital controlled high-frequency inversion and high voltage transformer step-up technology and high-frequency rectification technology, improves kV output pulse switching speed 2. Possesses high-speed grid control technology and flying focal spot technology	Independent R&D	CT high voltage generator design and manufacturing	CT
4	Full-chain low-dose technology	Precise organ dose modulation technology	Uses artificial intelligence technology for precise dose modulation for different examination subjects and body parts	Independent R&D	Used to achieve low-dose scanning, reduce patient dose	CT
5		Deep learning noise reduction reconstruction technology	Can improve small lesion imaging capability while reducing radiation dose through noise reduction	Independent R&D	Reduces dose, improves lesion detection capability, assists doctor diagnosis	CT
6		Iterative reconstruction noise reduction technology	Effectively reduces image noise, improves signal-to-noise ratio, can improve image quality while reducing radiation dose	Independent R&D	Reduces dose, improves lesion detection capability	CT

Serial Number	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
7	Efficient Automated Scanning Technology	"Sky Eye" Platform Technology	Automatically identifies patient anatomy via camera and intelligently matches scanning protocols to optimize CT workflow	Self-developed	Assists in CT scan preparation to improve scanning workflow efficiency	CT
8		Easylogic Automated Prediction Technology	Improves image reconstruction speed through algorithms to accelerate scanning workflow	Self-developed	Enhances scanning workflow efficiency	CT
9		ePhase Automated Phase Recommendation	Automatically selects optimal reconstruction phases from different cardiac cycles, reducing operator manual judgment and selection steps, improving coronary image quality and physician processing efficiency	Self-developed	Improves image quality and work efficiency	CT
10		CardioCapture Coronary Tracking Technology	Performs motion artifact correction on coronary arteries in cardiac CT images, reducing diagnostic difficulties caused by pulsation artifacts, significantly improving the success rate of cardiac scans	Self-developed	Improves image quality and work efficiency	CT
11	Post-processing Technology	Automated Post-processing Technology	Comprehensive CT image analysis applications, including efficient automated cerebrovascular extraction and dynamic analysis, tissue segmentation, and report generation functions. Provides functional assessment results based on structural evaluation	Self-developed	Precise post-processing, improves post-processing accuracy and efficiency, assists in diagnosis	CT

(3) X-ray Imaging System (XR) Core Technologies

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Applied Products
1	Image Reconstruction and Post-processing Technology	Full-Field Cone Beam CT Reconstruction Technology	Based on proprietary full-field scanning trajectory and reconstruction algorithm, expands the reconstruction field of view of cone beam CT to 431mm, achieving full abdominal field coverage	Self-developed	Increases cone beam CT reconstruction field of view size	DSA
2		Image Reconstruction Technology in Breast Tomosynthesis Systems	Leverages imaging characteristics of tomosynthesis systems to suppress artifacts caused by data undersampling, thereby improving resolution in different directions	Self-developed	Improves image resolution	Mammography System
3		Multi-scale Image Enhancement and Equalization Technology in Static DR Imaging	Based on human visual recognition patterns, performs non-linear multi-scale decomposition of images, achieving enhancement and noise reduction for specific features	Self-developed	Highlights lesion locations	DR
4		Real-time Multi-scale Image Processing Technology in Dynamic Fluoroscopy	During real-time dynamic processes, based on human visual recognition patterns, performs multi-scale dynamic range equalization and multi-level detail enhancement on ROI human structures	Self-developed	Enhances real-time performance and image clarity in dynamic imaging	Mobile C-arm
5	Low-Dose Imaging Technology	Automatic Exposure Parameter Adjustment Technology in X-ray Fluoroscopy Equipment	Uses target image brightness as a feedback parameter to ensure consistent image quality across different anatomical regions during real-time imaging while reducing radiation dose	Self-developed	Reduces radiation dose	DSA, Mobile C-arm
6		Radiation-free Positioning Technology Based on Optical Encoding	Integrates the motion behavior of mobile X-ray equipment with the image acquisition process, enabling radiation-free positioning, avoiding additional test exposures, improving surgical efficiency, at an industry-leading level	Self-developed	Improves positioning accuracy, reduces test exposures	DSA, Mobile C-arm

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Applied Products
7		Zero-Noise Imaging Technology	Reduces noise levels in real-time through Burst-Denoise technology, thereby reducing radiation dose, at an industry-leading level	Self-developed	Reduces radiation dose, improves signal-to-noise ratio	DSA
8	Automated Mechatronic Control Technology	Multi-Degree-of-Freedom Mechatronic System Control Technology	Based on kinematic modeling and dexterous point-to-point planning technology, achieves precise motion and automatic path planning for high-degree-of-freedom equipment	Self-developed	Gantry motion control and obstacle avoidance	DSA
9		Medical Equipment Speed Control and Motor Dynamic Output Adjustment Technology	Based on angle sensors and automatic motion control technology, achieves real-time adjustment of energy requirements for motors at different angles, implements electric speed control based on trolley tilt position, enhancing the user experience for operators controlling the equipment	Self-developed	Improve the operational experience of motorized motion	DR
10		Mobile X-ray machine auxiliary positioning system and technology	Using automatic spatial position detection technology to achieve automatic planning and memory functions for spatial positions	Independently developed	Auxiliary positioning during movement	Mobile C-arm
11		X-ray machine motion trajectory planning technology	Using artificial potential field technology to plan the motion trajectory of moving components	Independently developed	Motion obstacle avoidance	DR
12		Remote monitoring and exposure control technology based on wireless communication technology	Based on wireless communication technology and video monitoring, achieving remote monitoring and exposure control functions, reducing radiation dose received by clinical medical staff	Independently developed	Remote video monitoring and remote exposure control	DR

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Purpose	Applied Products
13	Core component technology	Power block unit technology	Using high-frequency power electronic switch parallel technology to increase output power, using high-frequency inverter technology to reduce component size and output ripple, improving kV output pulse switching speed, reducing invalid radiation dose	Independently developed	As the electronic control device for the X-ray tube, providing the high voltage, tube current, filament current, and rotating anode drive required to generate X-rays	DSA, DR, mammography machine

(4) Molecular imaging system (MI) core technology

Serial number	Category	Core technology	Technical advancement	Technology source	Main purpose	Applied products
1	PET detector technology	Digital light guide PET detector design	A new digital modular PET detector based on SiPM and LYSO crystals, with built-in light guide design, achieving industry-leading sensitivity and spatial resolution	Independently developed	PET detector design and manufacturing	PET/CT PET/MR
2		Crystal growth and assembly technology	Manufacturing methods and processes for large-size, high-luminescence efficiency scintillation crystals, supporting high-performance detectors, at an industry-advanced level	Independently developed	PET detector crystal material manufacturing and processing	PET/CT PET/MR
3		High-precision PET detector	Efficiently extracting detector status information, improving PET	Independently developed	Maintaining PET system stability	PET/CT PET/MR

Serial number	Category	Core technology	Technical advancement	Technology source	Main purpose	Applied products
		calibration technology	detector signal processing accuracy, thereby enhancing image quality, at an industry-leading level			
4		PET detector temperature control technology	Low-cost, high-efficiency cooling design, improving PET detector system temperature uniformity and stability, at an industry-leading level	Independently developed	Maintaining PET system stability	PET/MR
5	Electronics technology	Coincidence processing technology capable of discriminating continuous events	Improving coincidence efficiency and system count rate characteristics, at an industry-leading level	Independently developed	High count rate coincidence processing	PET/CT PET/MR
6		Cross-unit coincidence technology	Achieving ultra-high sensitivity in long-axis PET systems, at an industry-leading level	Independently developed	Long-axis PET system coincidence processing	PET/CT
7		Load balancing technology for parallel acquisition	Real-time balancing of multiple loads during parallel acquisition, significantly improving long-axis system data acquisition and processing capabilities, at an industry-leading level	Independently developed	High-speed PET data acquisition	PET/CT
8	Reconstruction and image processing technology	Parallel image reconstruction method	Efficient parallel reconstruction algorithm based on GPU acceleration can effectively improve computational speed, enhance quantitative accuracy with comprehensive physical	Independently developed	PET image reconstruction	PET/CT PET/MR

Serial number	Category	Core technology	Technical advancement	Technology source	Main purpose	Applied products
			correction, output high-quality images, at an industry-leading level			
9		Regularized iterative reconstruction algorithm	Incorporating noise control in iterative reconstruction, improving quantitative accuracy while suppressing image noise, enhancing lesion detection capability, at an industry-leading level	Independently developed	Improving lesion detection capability	PET/CT PET/MR
10		Artificial intelligence reconstruction algorithm	Reducing image noise, improving image quality, shortening scan time, at an industry-leading level	Independently developed	Reducing image noise, achieving low-dose fast scanning	PET/CT PET/MR
11		Artificial Intelligence Attenuation Correction Technology	Accurate segmentation of whole-body tissues, first-time inclusion of skeletal tissue information in the body, significantly improving image quality and quantitative accuracy, at an industry-leading level	Independently developed	Attenuation correction in the image reconstruction process	PET/MR
12		Motion Artifact Reduction Technology	Based on a data-driven approach, reduces PET image artifacts caused by respiratory motion and head motion, improves image quality, at an industry-leading level	Independently developed	Reduces motion artifacts, improves image quality	PET/CT
13		Tumor Analysis	Fully supports PERCIST and RECIST standards, supports multi-time point comparative analysis,	Independently developed	Rapid and accurate diagnosis of tumor diseases	PET/CT PET/MR

Serial number	Category	Core technology	Technical advancement	Technology source	Main purpose	Applied products
			one-click completion of analysis, at an industry-leading level			
14		Parametric Imaging and Analysis Technology	Provides quantitative analysis of drug metabolism based on multiple models, obtaining pharmacokinetic information, at an industry-leading level	Independently developed	Improves diagnostic accuracy	PET/CT

(5) Ultrasound Diagnostic System (US) Core Technologies

Serial Number	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
1	Key Component Design and Manufacturing Technology	Probe Interface Control Board	Supports high-element count probes and full probe interface interoperability	Independently developed	Ultrasound system design and manufacturing	US
2		Front-end System	Features 256 high channels and wide aperture to enhance penetration and signal-to-noise ratio; 50MHz ultra-wide bandwidth ensures high-frequency signal integrity; high-precision transmission and focusing delay control significantly improve spatial resolution	Independently developed	Ultrasound system design and manufacturing	US
3		Back-end System	Computing power up to 52 TFlops, flexible configuration, leveraging the advantages of each computing unit to meet the computational demands of advanced imaging and software applications for ultrasound systems	Independently developed	Ultrasound system design and manufacturing	US

Serial Number	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
4		Power System	Multiple programmable high-voltage power supplies, digital and analog circuit power supplies, improving system signal-to-noise ratio through precise control of the power system	Independently developed	Ultrasound system design and manufacturing	US
5		Third-Generation Ternary Single Crystal Probe	The industry's first mass-produced third-generation ternary single crystal probe, with superior voltage tolerance and acoustic emission capability compared to traditional materials, and less depolarization and better thermal stability	Independently developed	Probe design and manufacturing	US
6		Multi-Dimensional Matrix Probe	Simultaneously reduces slice thickness in both near-field and far-field through dynamic focusing, significantly improving spatial resolution and frame rate in both near-field and far-field	Independently developed	Probe design and manufacturing	US
7		Active Heat Dissipation	The industry's first large-scale application of active heat dissipation technology in ultrasound probes; uses unique active heat dissipation technology to significantly improve heat dissipation efficiency and imaging mode performance	Independently developed	Probe design and manufacturing	US
8	Core Imaging Algorithms and Post-processing Technology	Full-Field Dynamic Focusing	Uses a pixel-by-pixel beamforming algorithm to achieve precise delay calculation and phase correction; real-time beamforming computation based on a heterogeneous supercomputing system ensures uniform high resolution across the entire field of view	Independently developed	Ultrasound imaging and post-processing	US

Serial Number	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
9		Ultra-Sensitive Blood Flow	Effectively suppresses tissue motion artifacts through joint time-frequency algorithms, significantly improving signal-to-noise ratio; maintains imaging stability through real-time motion artifact suppression; uses a data-driven hemodynamic model and enhances blood flow morphology through computational fluid dynamics simulation	Independently developed	Ultrasound imaging and post-processing	US
10	Software Technology	Microservices Software Architecture	Effectively addresses the needs for complex data processing and intelligence with its elastic, scalable, and maintainable characteristics; loosely coupled services are easier to interface across systems Ensures the continuity of clinical diagnosis and treatment processes through service isolation and fault-tolerant design	Independently developed	Intelligent ultrasound software architecture	US
11		Fully Automated Workflow	A real-time automated workflow applicable to multiple scenarios, including probe auto-activation, automatic clip recognition and storage, automatic clip measurement and quality evaluation, etc.; effectively improves diagnostic efficiency with high accuracy	Independently Developed	Intelligent Workflow Implementation	US

(5) Core Technologies of Radiotherapy System (RT)

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
1	Electrovacuum Technology	High Dose Rate Isocentric Dual-Beam Accelerator Tube Technology	Simultaneously outputs high dose rate therapy beam and ultra-low energy imaging beam; therapy beam maximum output exceeds 1400 MU/min in FFF mode, significantly improving treatment efficiency; low-energy imaging beam outputs electron beam below 1.5MV, greatly reducing imaging dose required for image guidance	Independently Developed	Improve radiotherapy efficiency and precision	CT-guided linear accelerator, linear accelerator
2	Electronic Control Technology	Precision Dose Control System	Through fully digitized real-time control system, dynamic trajectory planning algorithm, dose closed-loop algorithm, etc., minimum control dose tracking accuracy reaches below 0.1 MU, long-term stability below 1%; dual-channel dose system fully independent design avoids failure risk	Independently Developed	Precision dose control	CT-guided linear accelerator, linear accelerator
3	Precision Mechanical and Control Technology	Dynamic Multi-Leaf Collimator System	Key technology for intensity modulation, enables precise conformal therapy, repositioning accuracy less than 0.5mm, minimum leaf width 5mm; supports real-time dynamic control, dynamic rotational intensity modulation, covering entire radiation field	Independently Developed	Precise conformal therapy	CT-guided linear accelerator, linear accelerator
4	Imaging Integration Technology	Integrated CT Imaging Integration Technology	Precise registration before treatment, easily detects changes in target volume and surrounding tissues/organs; during treatment, monitors patient dose distribution using imaging information and adjusts treatment plan for personalized adaptive radiotherapy Enables complete radiotherapy workflow in single room, achieving fast all-in-one treatment process	Independently Developed	Radiotherapy simulation and contouring, pre-treatment image-guided positioning correction, personalized adaptive radiotherapy, online	CT-guided linear accelerator

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
					treatment plan modification	
5	Precision Mechanical and Control Technology	High-Precision Treatment Table and Automatic Deformation Compensation Technology	Through special dimension design, graded motion, CT imaging combined with laser displacement sensors, achieves treatment table with industry's longest motion range, highest stiffness, smallest error	Independently Developed	Tumor patient fixation, positioning	CT-guided linear accelerator
6	Physical Algorithm Technology	Monte Carlo Dose Calculation Algorithm	Ensures calculation accuracy while achieving routine plan calculation time under 1 minute, comparable to conventional clinical application algorithms	Independently Developed	Treatment plan design	CT-guided linear accelerator, linear accelerator
7	Physical Algorithm Technology	Treatment Plan Optimization Calculation Algorithm	Through advanced functions like direct optimization, fast move down gradient, supports multiple plan types, rapid plan creation, automatic planning and online adaptive radiotherapy	Independently Developed	Treatment plan design	CT-guided linear accelerator, linear accelerator

(6) General Software and Hardware Core Technologies

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
1	Software Technology	Medical Image Post-processing Technology Based	1. Developed based on server multi-concurrency technology, flexible deployment, provides IT cost	Independently Developed	Medical image post-processing	Full range of medical imaging equipment

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
		on Server Multi-concurrency	solutions for small to large medical institutions 2. Applicable for intra-department or cross-department post-processing tools, supports remote use across hospital campuses 3. Can integrate with existing hospital information systems like PACS/RIS			
2		Cross-Modality Software Workflow Technology	1. Emphasizes clinical needs during development, product development and iterative upgrades aimed at improving clinical efficiency 2. Achieves interaction consistency across different product lines, improves user efficiency, reduces end-customer learning costs 3. Facilitates expansion from single products to integrated products 4. Preprocesses based on data characteristics, users see preprocessing results when opening data, improving patient throughput	Independent R&D	User Interaction Workflow	Full range of medical imaging equipment, radiotherapy equipment
3		3D Medical Imaging Visualization Engine Technology	1. Deep integration of visualization with equipment data acquisition, reconstruction, and image preprocessing to achieve optimized display of vascular details near bones and precise visualization of ultra-high	Independent R&D	Image Visualization Effect Optimization	Full range of medical imaging equipment, radiotherapy equipment, imaging cloud

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
			resolution sub-pixel level micro lesions. 2. Hyper Realistic Rendering (HRR) technology, which presents more detailed tissue surface and internal details with ultra-realism, providing stronger depth and spatial perception, thereby achieving results closer to real tissue texture, vascular pathways, lesion spatial relationships, etc. 3. Supports full-body true rendering for all parts including CT and MR head, abdomen, shoulder, hip, breast, foot, etc., providing corresponding tissue color tables for tissues with different grayscale values, giving different tissues the best color presentation and rendering effects. 4. Zero-wait second-level real-time rendering, allowing users to view rendering preview effects in real-time during interaction and complete detail iteration after interaction stops.			
4		Medical Image Segmentation and Registration Technology	1. Accurate segmentation of complex structural tissues such as organs, blood vessels, bones, and lesion areas in multi-modal images.	Independent R&D	Post-processing Application Image Segmentation	Full range of medical imaging equipment, radiotherapy equipment, imaging cloud

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
			2. Supports motion correction and registration fusion of data from different modalities and time phases.			
5	Hardware Technology	Hardware Circuit Design Technology in Complex Electromagnetic Environments	1. Electronic component design from conventional 1.5T to 9.4T strong magnetic field environments, with hardware magnetic field compatibility design capability at the domestic first-class level. 2. The first domestic manufacturer to achieve a 39*4Gps high-speed data acquisition system at 0.25s rotation speed. 3. To cope with strong radiation interference during radiotherapy, anti-single event upset technology from the aerospace field is introduced into the RT system, effectively reducing single event upset effects and improving the reliability and product service life of the equipment control system.	Independent R&D	Hardware design related to system control, data acquisition, and data reconstruction systems	PET/CT, PET/MR, MR, CT, RT
6		ECG Gating Extraction Technology under Strong Gradient Fields	1. The first domestic ECG gating technology that can support 5.0T MR applications. 2. Can detect ECG signals up to 300bpm, not only suitable for human scanning but also supporting scientific research applications for	Independent R&D	MR Physiological Signal Gating Equipment	MR, PET/MR

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
			animal ECG detection. 3. The independently developed technical solution uses high-performance hardware circuits and intelligent adaptive filtering algorithms. The product can suppress gradient fields above 300mt/m/s, significantly improving image quality.			
7		Multi-modal Equipment Registration and Balancing Technology	1. Achieves six-degree-of-freedom full-range registration, with cumulative registration error less than the minimum resolution of each modality. 2. Supports precise registration within 0.5mm for up to 9 modal devices over a length of 3m, ensuring image fusion accuracy. 3. High-speed rotation balancing technology achieves CT rotating body unbalanced mass less than 0.02% of the total weight, maximum CT scan field vibration less than 0.1mm, supporting the highest rotation speed among mainstream high-end CT products in the industry.	Independent R&D	Multi-modal Equipment Registration and CT Gantry Dynamic Balancing	PET/CT, CT, RT
8		High-Payload High-Precision Motion Control Technology	1. Adapts to special patient needs, achieving a leading industry indicator of 0.1mm motion repeatability	Independent R&D	Precision Motion Control	Full range of products

No.	Category	Core Technology	Technical Advancement	Technology Source	Main Application	Applied Products
			accuracy under 300kg payload and 55mm/s motion speed. 2. The CT gantry can achieve a rotation speed of 0.25s/revolution, with an angular control accuracy of 0.1 degrees under a rotational inertia of 500kg.m^2.			
9		High-Precision Cooling Temperature Control Technology	1. Uses precise thermal simulation technology and accurate temperature control technology to achieve temperature control accuracy for core components. 2. Through high-precision cooling temperature control technology, the company masters temperature control analysis technology at the system, core component, circuit board, and chip levels, achieving overall system temperature control.	Independent R&D	System Cooling Temperature Control	MR, PET/CT, PET/MR, CT-guided linear accelerator, linear accelerator

National Science and Technology Awards

√Applicable□Not applicable

Award Name	Award Year	Project Name	Award Level
National Science and Technology Progress Award	2020	Independent Development and Industrialization of High-Field Magnetic Resonance Medical Imaging Equipment	First Prize

(2). R&D Achievements Obtained During the Reporting Period

As of the end of the reporting period, the company had cumulatively applied for 11,517 intellectual property rights and obtained 6,123; during the reporting period, the company added 1,057 intellectual property applications and obtained 843, including 623 invention patent applications and 636 invention patent grants. In addition to the above granted invention patents, the company also possesses multiple non-patented technologies, which also constitute an important part of the company's technological competitiveness and play a significant role in the company's business operations.

List of Intellectual Property Rights Obtained During the Reporting Period

	Newly Added This Year		Cumulative Quantity	
	Applications (units)	Grants (units)	Applications (units)	Grants (units)
Invention Patents	623	636	8,385	3,993
Utility Model Patents	115	82	1,386	936
Design Patents	47	13	419	275
Software Copyrights	54	52	348	293
Others	218	60	979	626
Total	1,057	843	11,517	6,123

Note 1: The "Cumulative Quantity" being greater than the sum of the previous year's "Cumulative Quantity" and "Current Year Additions" is due to patent transfers and European patents granted and effective during the reporting period from previous years; the "Cumulative Quantity" being less than the sum of the previous year's "Cumulative Quantity" and "Current Year Additions" is due to the expiration of intellectual property rights from prior years.

Note 2: Others include "Works Copyright" and "Trademarks".

(3). R&D Investment Statement

Unit: Yuan Currency: RMB

	Current Year	Previous Year	Change Rate (%)
Expensed R&D Investment	1,841,943,294.35	1,761,466,670.35	4.57
Capitalized R&D Investment	779,413,689.11	499,360,429.12	56.08
Total R&D Investment	2,621,356,983.46	2,260,827,099.47	15.95
Total R&D Investment as a Percentage of Operating Revenue (%)	18.99	21.95	Decreased by 2.96 percentage points
Proportion of Capitalized R&D Investment (%)	29.73	22.09	Increased by 7.64 percentage points

Reason for Significant Change in Total R&D Investment Compared to the Previous Year

□ Applicable√ Not Applicable

Explanation for Significant Change in the Proportion of Capitalized R&D Investment and Its Rationality

√ Applicable□ Not Applicable

According to the company's accounting policy, during the reporting period, several R&D projects completed clinical trial filings with the medical device regulatory authorities/obtained inspection qualification reports issued by medical device quality supervision and inspection institutions, meeting the capitalization conditions, thus the proportion of capitalized R&D investment increased in this reporting period.

(4). Projects in Progress

√ Applicable □ Not Applicable

Unit: Ten Thousand Yuan

No.	Project Name	Estimated Total Investment Scale	Investment Amount This Period	Cumulative Investment Amount	Progress or Stage Results	Target to be Achieved	Technical Level	Specific Application Prospects
1	MR R&D Project One	10,400.00	1,390.32	9,734.04	Registration Certificate Obtained	Obtain Registration Certificate	Industry Leading	Applicable to Clinical Scenarios
2	MR R&D Project Two	11,000.00	3,875.44	9,507.15	Partially Obtained Registration Certificate	Obtain Registration Certificate	Industry Leading	Applicable to Clinical and Research Scenarios
3	MR R&D Project Three	28,000.00	11,393.97	19,876.85	Partially Obtained Registration Certificate	Obtain Registration Certificate	Industry Leading	Applicable to Clinical Scenarios
4	MR R&D Project Four	35,000.00	11,459.09	27,402.31	Partially Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable for Clinical and Research Scenarios
5	MR R&D Project Five	25,000.00	3,388.92	13,469.91	Already Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable for Clinical Scenarios
6	MR R&D Project Six	30,000.00	1,366.44	8,249.23	Already Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable for Clinical and Research Scenarios
7	MR R&D Project Seven	7,000.00	1,339.66	5,986.72	In Progress	Obtained Registration Certificate	Industry Leading	Applicable for Clinical and Research Scenarios
8	MR R&D Project Eight	6,400.00	2,370.07	6,144.93	Already Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable for Clinical and Research Scenarios
9	CT R&D Project One	4,600.00	813.30	4,545.26	In Progress	Obtained	Industry	Applicable for Clinical

						Registration Certificate	Leading	Scenarios
10	CT R&D Project Two	25,000.00	1,114.26	13,213.12	Already Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable for Clinical and Research Scenarios
11	CT R&D Project Three	9,500.00	609.96	5,602.86	Already Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable for Clinical and Research Scenarios
12	CT R&D Project Four	9,000.00	253.78	4,430.99	Already Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable for Clinical Scenarios
13	CT R&D Project Five	14,000.00	3,971.29	11,618.87	Partially Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable for Clinical and Research Scenarios
14	CT R&D Project Six	3,200.00	805.11	2,117.81	Already Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable for Clinical Scenarios
15	CT R&D Project Seven	15,000.00	2,617.61	12,553.60	Already Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable for Clinical and Research Scenarios
16	CT R&D Project Eight	35,000.00	14,052.71	22,738.02	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Applicable to clinical and research scenarios
17	CT R&D Project Nine	8,000.00	3,541.29	6,958.32	Already obtained registration certificate	Obtained registration certificate	Industry leading	Applicable to clinical scenarios
18	CT R&D Project Ten	6,800.00	1,910.79	3,854.65	In progress	Obtained registration certificate	Industry leading	Applicable to clinical and research scenarios
19	CT R&D Project Eleven	8,000.00	2,886.09	4,042.18	In progress	Obtained registration certificate	Industry leading	Applicable to clinical and research scenarios
20	RT R&D Project One	10,000.00	2,309.20	7,175.58	In progress	Obtained registration certificate	Industry leading	Applicable to clinical scenarios

21	RT R&D Project Two	50,000.00	12,914.91	39,476.46	Already obtained registration certificate	Obtained registration certificate	Industry leading	Applicable to clinical scenarios
22	RT R&D Project Three	18,800.00	2,622.75	13,251.99	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Applicable to clinical scenarios
23	RT R&D Project Four	16,000.00	4,798.15	9,651.97	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Applicable to clinical scenarios
24	Software R&D Project One	38,000.00	10,779.39	36,815.06	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Applicable to clinical scenarios
25	Software R&D Project Two	23,000.00	2,381.54	15,263.23	Partially obtained registration certificate	Obtained registration certificate	Industry leading	Applicable to clinical scenarios
26	Software R&D Project Three	13,600.00	2,854.17	10,609.93	Already obtained registration certificate	Supports mass production of imaging products and new product development	Industry leading	Applicable to clinical scenarios
27	XR R&D Project One	20,000.00	4,990.63	15,388.65	Already obtained registration certificate	Obtained registration certificate	Industry leading	Applicable to clinical scenarios
28	XR R&D Project Two	43,000.00	10,262.36	32,174.96	Already obtained registration certificate	Obtained registration certificate	Industry leading	Applicable to clinical scenarios
29	XR R&D Project Three	6,100.00	2,497.52	5,975.19	Registration certificate obtained	Obtain registration certificate	Industry leading	Applicable to clinical scenarios
30	MI R&D Project One	5,000.00	572.59	2,865.85	Registration certificate obtained	Obtain registration certificate	Industry leading	Applicable to clinical and research scenarios
31	MI R&D Project Two	11,000.00	1,968.29	8,408.80	Registration certificate obtained	Obtain registration certificate	Industry leading	Applicable to clinical and research scenarios
32	MI R&D Project Three	13,500.00	1,066.21	7,946.56	Registration certificate obtained	Obtain registration certificate	Industry leading	Applicable to clinical scenarios
33	MI R&D Project Four	16,800.00	4,234.68	15,025.72	Partially obtained	Obtain registration	Industry	Applicable to clinical

					registration certificate	certificate	leading	scenarios
34	MI R&D Project Five	3,000.00	207.83	1,660.38	In progress	Obtain registration certificate	Industry leading	Applicable to clinical and research scenarios
35	MI R&D Project Six	3,000.00	2,510.70	2,801.58	Partially obtained registration certificate	Obtain registration certificate	Industry leading	Applicable to clinical and research scenarios
36	MI R&D Project Seven	13,000.00	4,752.17	7,817.60	In progress	Obtain registration certificate	Industry leading	Applicable to clinical scenarios
37	MI R&D Project Eight	1,600.00	684.00	684.00	Partially obtained registration certificate	Obtain registration certificate	Industry leading	Applicable to clinical scenarios
38	Component R&D Project One	15,000.00	4,258.02	10,188.10	Partially obtained registration certificate	Obtain registration certificate	Industry leading	Applied to equipment components
39	Component R&D Project Two	1,900.00	734.35	1,795.46	Registration certificate obtained	Obtain registration certificate	Industry leading	Applied to equipment components
40	Component R&D Project Three	5,800.00	1,830.69	3,406.96	In progress	Obtain registration certificate	Industry leading	Applied to equipment components
41	Component R&D Project Four	11,000.00	1,606.24	7,950.93	In progress	Obtain registration certificate	Industry Leading	Applied to Equipment Components
42	Ultrasound R&D Project One	64,000.00	21,322.88	42,251.39	Partially Obtained Registration Certificate	Obtained Registration Certificate	Industry Leading	Applicable to Clinical Scenarios
43	Ultrasound R&D Project Two	10,000.00	2,337.07	3,694.22	In Progress	Obtained Registration Certificate	Industry Leading	Applicable to Clinical Scenarios
44	Ultrasound R&D Project Three	7,500.00	3,904.22	5,484.00	In Progress	Obtained Registration Certificate	Industry Leading	Applicable to Clinical Scenarios
45	Life Science Instrument Project One	3,600.00	895.14	3,308.85	Mass Production and Market Launch	Research Promotion and Mass Production Launch	Internationa lly Leading	Applicable to Research Scenarios
46	Life Science Instrument Project	5,000.00	710.84	2,737.53	In Progress	Research Promotion and Mass	Industry Leading	Applicable to Research Scenarios

	Two					Production Launch		
47	Life Science Instrument Project Three	12,000.00	2,386.08	8,825.13	In Progress	Obtained Registration Certificate	Industry Leading	Applicable to Research Scenarios
48	Next-Generation Product Pre-research Project	23,000.00	7,881.95	14,259.46	In Progress	Obtained Next-Generation Product and Technology Planning	Industry Leading	Applicable to Clinical Scenarios
Total	/	755,100.00	189,434.67	528,942.36	/	/	/	/

Situation Description

The company's total investment scale for R&D projects in progress is adjusted based on the actual R&D progress of the project and the overall planning of the company's R&D projects; the statistical period for cumulative investment is from January 1, 2022, to December 31, 2025.

(5). R&D Personnel Information

Unit: Ten Thousand Yuan Currency: RMB

Basic Information		
	Current Period	Previous Period
Number of Company R&D Personnel (Persons)	3,497	3,271
Proportion of R&D Personnel to Total Company Personnel (%)	40.18	40.02
Total R&D Personnel Compensation	176,725.50	155,062.28
Average R&D Personnel Compensation	50.54	47.41

R&D Personnel Education Structure	
Education Structure Category	Number of People by Education Structure
Doctoral Degree	396
Master's Degree	2,390
Bachelor's Degree	650
Associate Degree	61
High School and Below	-
R&D Personnel Age Structure	
Age Structure Category	Number of People by Age Structure
Under 30 Years Old (Excluding 30)	1,262
30-40 Years Old (Including 30, Excluding 40)	1,819
40-50 years old (including 40, excluding 50)	376
50-60 years old (including 50, excluding 60)	34
60 years old and above	6

Reasons for significant changes in R&D personnel composition and their impact on the company's future development

□ Applicable√ Not applicable

(6). Other explanations

□ Applicable√ Not applicable

4. Risk factors

(i) Risk of not yet being profitable

□ Applicable√ Not applicable

(ii) Risk of significant decline in performance or loss

□ Applicable√ Not applicable

(iii) Core competitiveness risk

√ Applicable□ Not applicable

1. Risk of infringement of key core technologies or leakage of technical secrets

The company is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments, and medical digital and intelligent solutions. Its product lines cover Magnetic Resonance Imaging Systems (MR), X-ray Computed Tomography Systems (CT), X-ray Imaging Systems (XR), Molecular Imaging Systems (MI), Color Doppler Ultrasound Diagnostic Systems (US), Radiotherapy Systems (RT), Ultrasound (US), and life science instruments. Through over a decade of continuous R&D, the company has mastered the core technologies related to the development and production of different product series, and protects these key core technologies through authorized invention patents, technical secrets, and confidentiality agreements signed with R&D personnel.

If the company's key core technologies are infringed upon or leaked, it will reduce the output effectiveness of the company's R&D investments, hinder the continuous maintenance of the technological advantages of its products, and adversely affect the company's profitability. To address the above risks, the company has established a comprehensive intellectual property layout system to protect its technological innovation achievements from various angles, as detailed in the earlier section on intellectual property layout strategy and systematic system construction.

(iv) Operational risks

√ Applicable□ Not applicable

1. Business cooperation risk under the distribution model

The company primarily adopts a sales model combining distribution and direct sales. During the reporting period, distribution revenue from the company's main business was 8.41 billion yuan, accounting for 63.91% of the main business revenue. The continuous expansion of the company's distributor network imposes higher requirements on the management capabilities of its distribution system. The company needs to increase the allocation of sales management personnel and raise management costs related to distributor contract fulfillment and payment collection. Meanwhile, if the company fails to simultaneously enhance its management capabilities over distributors, any issues such as internal management chaos, violations of laws and regulations by distributors, or disputes of interest between the company and distributors could adversely affect the growth of the company's distribution revenue.

To address the above risks, the company continuously strengthens the system construction and capability building of its own marketing team, improves the capabilities of professional sales personnel, and broadens sales models. Additionally, the company continuously improves the 'Distributor Management System', implementing systematic management and assessment of distributor qualification, classification management, cultivation and development, management, and evaluation. Due to the high specialization of the high-end medical equipment industry, the company regularly conducts sales training, risk management training, and annual meetings. Sales training includes company brand promotion and product knowledge; risk management training includes compliance guidance and training on compliance risk points; annual meetings include interpretations of industry development trends, new product releases, and company policy promotion, aiming to achieve long-term, stable, and continuous strategic integration with distributors.

2. International operation and business expansion risks

The company places importance on the expansion and sales of high-end medical imaging diagnostics and radiotherapy products in overseas markets, having achieved sales in countries and regions such as the United States, Japan, Europe, Africa, and Southeast Asia. During the reporting period, the company's overseas main business revenue was 3.393 billion yuan (statistics based on the installation location of end customers), a year-on-year increase of 52.81%, accounting for 25.79% of the company's main business revenue, showing an overall upward trend year by year.

However, regulatory policies and laws for medical devices typically differ across various overseas markets and regions. The international situation is uncertain, and there are variations in the intensity of regulation regarding intellectual property protection, unfair competition, consumer protection, etc. As the scale of overseas business further expands, the legal environments the company encounters overseas will become more complex and volatile. If the company cannot promptly respond to changes in the overseas market and policy environments, it will adversely affect the company's overseas business expansion and operations.

Details are as follows:

(1) Policy and approval risks: In recent years, the international situation has been volatile, with frequent uncertainties and instabilities. The international trade environment has become increasingly complex, trade friction disputes persist, and geopolitical factors may adversely affect the economy and trade of certain countries or regions. Some countries have historically had strong approval barriers for the operation and sales of high-end medical devices, with long time cycles for product registration and significant difficulties in market access. Regulatory policies and laws for medical devices typically differ across various overseas markets and regions. The political and economic situation is uncertain, and there are variations in the intensity of regulation regarding intellectual property protection, unfair competition, consumer protection, etc.

(2) Market competition risks: Companies such as GE Healthcare, Siemens Healthineers, and Philips Healthcare have long dominated many areas of medical equipment, possessing significant advantages in academic reserves, clinical evidence, customer recognition, global supply chain integration, product technology development, overseas after-sales service, and brand influence. Facing international market competition, if the company cannot maintain and continuously strengthen its competitive advantages and core competitiveness, the market share and price of its products may decline due to intensified market competition.

(3) Risks in expanding overseas sales channels: In the overall layout of its overseas strategy, the company will promote the development of its overseas business by focusing on target markets from aspects such as overseas product registration, team and network building, production base and supply chain layout. As of the end of the reporting period, the company had established an overseas team through 30 overseas subsidiaries and offices. However, the establishment of overseas sales channels has been relatively short. If the company cannot effectively integrate its overseas sales team and local distributor channels, preventing its products from quickly penetrating overseas markets, it will adversely affect the company's overseas market share and business development.

To address the above risks, the company will comprehensively strengthen the management and layout of global R&D, production, sales, service, supply chain, etc., make scientific

decisions, and promote the implementation of various strategic plans and business layouts in a reasonable and orderly manner. Through effective market activities and industry-academia-medicine cooperation, the company will further enhance its brand influence and recognition in the international market.

(v) Financial risks

√ Applicable□ Not applicable

1. Risk of changes in tax policies

The company and some of its subsidiaries are recognized as high-tech enterprises by law and can enjoy preferential corporate income tax policies for high-tech enterprises when all conditions for enjoying such tax benefits are met. If the aforementioned tax preferential policies change in the future, or if the company fails to meet the conditions for tax benefits and cannot continue to enjoy the relevant preferential policies, it will increase the company's tax burden, thereby having a certain impact on its business operations. The company will continue to monitor the trends in tax policies, consolidate and strengthen its R&D capabilities, continuously increase R&D investment, and solidify its qualification as a high-tech enterprise.

2. Exchange rate fluctuation risk

The company's overseas business is growing rapidly. The company prices and settles transactions with some overseas customers and suppliers in foreign currencies such as USD and EUR. Influenced by factors such as changes in the international situation and environment, the difficulty of exchange rate risk management may increase in the future. Exchange rate fluctuations directly affect the company's foreign exchange gains and losses, which may have a certain impact on the company's business operations. The company attaches importance to exchange rate risk management, implementing both short-term and medium-to-long-term measures, and reasonably utilizes financial and operational methods to address exchange rate fluctuation risks.

3. Accounts Receivable Recovery Risk

Accounts receivable account for a significant proportion of the company's current assets. Although the company's major customers have a good historical credit record, and the likelihood of bad debts is low, if a customer's financial condition deteriorates or their credit status changes significantly, the company's future production, operations, and debt repayment capacity may still be adversely affected. The company strictly assesses the credit risk of accounts receivable and provides for impairment losses in accordance with the requirements of the Accounting Standards for Business Enterprises. In the future, the company will further strengthen the investigation and analysis of customer creditworthiness, strictly organize production and sales according to contracts, enhance the supervision and assessment of accounts receivable, improve the responsibility system for sales collection and the write-off system for bad debt losses, to ensure the company's overall credit risk remains controllable.

(vi) Industry Risks

√ Applicable□ Not Applicable

1. Market Competition Risk

According to industry research (CIC), the medical imaging equipment market in China exceeded RMB 50 billion in 2020, with a compound annual growth rate of 12.4% from 2015

to 2020. While potential demand is continuously supported by the rapid expansion of the broader healthcare sector and ongoing investments in modernizing regional and community healthcare infrastructure, the company still faces a highly competitive market environment.

Historically, the high-end medical imaging equipment market in China has been led by established multinational corporations, which have traditionally held significant market share. Following over a decade of technological advancement, local innovators have become increasingly competitive, leading to a more diversified market landscape. However, multinational manufacturers maintain robust market positions due to their longstanding brand recognition, established channels, and technological heritage. Concurrently, the company faces competition from other regional medical equipment manufacturers that are actively expanding their portfolios in XR, CT, MR, and PET/CT. Facing this dynamic competition from both global incumbents and regional peers, the company must continuously strengthen its core competencies; otherwise, it may face risks of declining market share and pricing pressure.

In response to the above risks, the company will continuously strengthen its core technology R&D and investment in next-generation products, and promptly assess market trends and demands. The company focuses on cost management, product quality management, and service quality management, paying attention to the full lifecycle quality requirements of its products. The company will conduct talent reserves, technology reserves, product reserves, and customer expansion globally, deepen its international strategic layout, and enhance its competitiveness in the global market.

2. Industry Regulatory Risk

The company's medical imaging diagnostics and radiotherapy products are primarily used for disease diagnosis and treatment. According to the 'Regulations on the Supervision and Administration of Medical Devices,' these are classified as Class II and III medical devices, meaning they have moderate risk requiring strict control management, or higher risk requiring special measures for strict control management to ensure their safety and effectiveness. The R&D, production, and sales processes of the company's aforementioned products must strictly comply with the national supervision and management systems in the medical device field, including the classification management system, production filing and licensing system, product filing and registration management system, and business filing and licensing management system. If the national requirements for medical device registration and applications become more stringent in the future, or if the supervision of medical device production and operation tightens, it will adversely affect the development and registration of the company's new products, as well as the production and sales of existing products.

In response to the above risks, the company will continuously monitor relevant policy developments, actively participate in the formulation of medical industry standards, and consolidate and strengthen its own R&D management.

(vii) Macro-Environmental Risks

√ Applicable□ Not Applicable

1. Trade Friction and Geopolitical Risk

In recent years, the international situation has been volatile, the international trade environment has become increasingly complex, trade friction disputes have continued, and geopolitical factors may adversely affect the economy and trade of certain countries or

regions. In June 2018, the U.S. Trade Representative issued a formal list of goods subject to additional tariffs, imposing a 25% tariff on approximately USD 50 billion worth of goods imported from China. Tariffs on approximately USD 34 billion of these goods were implemented starting July 2018, while public comment was sought for tariffs on the remaining approximately USD 16 billion. In May 2019, the U.S. announced additional tariffs on USD 200 billion worth of goods imported from China. According to the tariff list published by the U.S. Trade Representative, the company's MR and CT products exported to the U.S. were included in the list of goods subject to additional tariffs. Simultaneously, China's Customs Tariff Commission began imposing additional tariffs on some U.S. imports as countermeasures. Components or materials used in the production of medical imaging equipment, such as X-ray tube assemblies, superconducting wires, and scintillation crystals, were included in China's list of U.S. imports subject to additional tariffs and have been dynamically adjusted subsequently. In April 2025, Sino-U.S. trade friction escalated further, with both sides engaging in multiple rounds of geopolitical maneuvering over 'reciprocal tariffs'.

Therefore, some of the company's products exported to the U.S. face the risk of additional tariffs leading to reduced market competitiveness, while adjustments to the import tariff list may increase the company's procurement costs, adversely affecting its net profit.

In response to the above risks, the company will continuously monitor and assess the impact of trade policy changes on its business and supply chain. Simultaneously, the company will actively promote the diversified layout of international markets to mitigate risks arising from geopolitics, continuously strengthen exchanges with international health systems, broaden the deep integration of industry, academia, research, and medicine within the global industry, advance the localization construction in key markets across various regions, and consolidate the construction of production, sales, and service systems.

(viii) Depositary Receipt Related Risks

□ Applicable√ Not Applicable

(ix) Other Significant Risks

□ Applicable√ Not Applicable

5. Major Operating Conditions During the Reporting Period

Please refer to 'Section III Management's Discussion and Analysis' of this report.

(i) Analysis of Main Business Operations

(1). Analysis of Changes in Income Statement and Cash Flow Statement Related Items

Unit: Yuan Currency: RMB

Item	Current Period Amount	Amount for Same Period of Previous Year	Change Percentage (%)
Operating Revenue	13,800,251,663.95	10,300,104,386.97	33.98
Operating Cost	7,312,582,446.96	5,300,161,724.44	37.97
Selling Expenses	2,261,407,623.18	1,823,187,055.28	24.04

Administrative Expenses	626,904,263.90	555,965,099.19	12.76
Financial Expenses	-30,626,038.58	-112,290,178.67	Not Applicable
Research and Development Expenses	1,841,943,294.35	1,761,466,670.35	4.57
Net Cash Flow from Operating Activities	2,679,018,849.49	-619,024,253.25	Not Applicable
Net Cash Flow from Investing Activities	-3,357,456,795.40	-1,244,307,712.70	Not Applicable
Net Cash Flow from Financing Activities	152,919,336.43	198,972,823.31	-23.15
Gains from Changes in Fair Value	-37,113,946.49	37,000,082.01	Not Applicable
Credit Impairment Loss	194,450,990.75	140,717,437.52	38.19
Asset Impairment Loss	-1,303,061.74	-13,842,775.25	Not Applicable
Gains from Disposal of Assets	-641,405.91	-869,838.94	Not Applicable
Non-operating Income	6,189,198.45	5,546,317.51	11.59
Non-operating Expenses	25,102,821.54	20,194,712.78	24.30

Explanation for the change in operating revenue: Mainly due to the company's stable operation and steady revenue growth during the reporting period.
Explanation for the change in operating costs: Mainly due to the increase in revenue and corresponding cost growth during the reporting period.
Explanation for the change in financial expenses: Mainly due to exchange rate fluctuations and a decrease in interest income during the reporting period.
Explanation for the change in net cash flow from operating activities: Mainly due to the company's stable operation and significant improvement in sales collection during the reporting period.
Explanation for the change in net cash flow from investing activities: Mainly due to the purchase and redemption of financial products during the reporting period.
Explanation for the change in gains from changes in fair value: Mainly due to the decline in the stock prices of the financial assets invested by the company.
Explanation for the change in credit impairment loss: Mainly due to the increase in the original value of receivables compared to the same period last year, resulting in an increase in the required impairment loss provision.
Explanation for the change in asset impairment loss: Mainly due to the increase in the net realizable value of inventory resulting from market channel expansion during the reporting period.

Detailed explanation of significant changes in the company's business types, profit composition, or profit sources during the current period
□ Applicable√ Not Applicable

(2). Revenue and Cost Analysis

√ Applicable□ Not Applicable

Please refer to the table below for revenue and cost details.

(1). Breakdown of Main Business by Industry, Product, Region, and Sales Mode

Unit: Yuan Currency: RMB

Breakdown of Main Business by Industry						
By Industry	Operating Revenue	Operating Cost	Gross Profit Margin (%)	Change in Operating Revenue Compared to Previous Year (%)	Change in Operating Cost Compared to Previous Year (%)	Change in Gross Profit Margin Compared to Previous Year (%)
Medical Device Industry	13,152,331,220.92	6,758,368,632.67	48.61	33.07	35.14	Decreased by 0.79 percentage points
Breakdown of Main Business by Product						
By Product	Operating Revenue	Operating Cost	Gross Profit Margin (%)	Change in Operating Revenue Compared to Previous Year (%)	Change in Operating Cost Compared to Previous Year (%)	Change in Gross Profit Margin Compared to Previous Year (%)
Sales of Medical Imaging Diagnostic Equipment and Radiotherapy Equipment	11,389,846,539.58	6,086,583,577.32	46.56	34.87	36.13	Decreased by 0.49 percentage points
Provision of Maintenance Services	1,707,983,196.16	651,356,741.94	61.86	25.96	31.37	Decreased by 1.57 percentage points
Software	54,501,485.18	20,428,313.41	62.52	-34.49	-39.63	Increased by 3.2 percentage points
Breakdown of Main Business by Region						
By Region	Operating Revenue	Operating Cost	Gross Profit	YoY Change in Operating Revenue	YoY Change in Operating Cost	YoY Change in Gross Profit Margin

			Margin (%)	(%)	(%)	(%)
Domestic	9,759,811,040.99	4,948,169,648.98	49.30	27.35	29.38	Decreased by 0.8 percentage points
Overseas	3,392,520,179.93	1,810,198,983.69	46.64	52.81	53.87	Decreased by 0.37 percentage points
Breakdown of Main Business by Sales Mode						
Sales Mode	Operating Revenue	Operating Cost	Gross Profit Margin (%)	YoY Change in Operating Revenue (%)	YoY Change in Operating Cost (%)	YoY Change in Gross Profit Margin (%)
Direct Sales	4,746,593,013.40	2,335,060,587.18	50.81	25.87	20.75	Increased by 2.09 percentage points
Distribution	8,405,738,207.52	4,423,308,045.49	47.38	37.50	44.22	Decreased by 2.45 percentage points

Explanation of Main Business Breakdown by Industry, Product, Region, and Sales Mode

In 2025, the domestic medical equipment market showed a recovery trend of 'recovery-acceleration'. Leveraging industry demand and its core strengths, the company's revenue expanded significantly, with substantial growth in the Chinese market. In overseas markets, the company maintained rapid growth in key regions such as Europe, North America, Asia-Pacific, and emerging markets, continuously enhancing its international brand influence and penetration rate among high-end customers, further accelerating its global layout.

1. Main Business Revenue by Product
(1) Sales of Medical Imaging Diagnostic Equipment and Radiotherapy Equipment
The company presents the year-on-year changes in equipment sales revenue by business line for the reporting period as follows:

Unit: RMB 10,000

Business Line	2025 Equipment Sales Revenue	2024 Equipment Sales Revenue	YoY Change (%)
CT	354,530.90	304,816.27	16.31
MI	190,786.87	129,909.62	46.86
MR	454,768.60	319,227.51	42.46

XR	79,807.33	58,688.93	35.98
RT	59,090.95	31,851.79	85.52
Total	1,138,984.65	844,494.12	34.87

Influenced by the recovery of the domestic medical equipment market, the revenue scale in the Chinese market achieved significant growth, while the overseas market continued to maintain a rapid growth pace.

(2) Provision of Maintenance Services
During the reporting period, the company achieved maintenance service revenue of 1,707.98 million RMB, an increase of 25.96% compared to the same period last year, mainly due to the continuous accumulation of installed equipment leading to a high growth trend in service revenue.

(3) Software
During the reporting period, software product revenue was 54.50 million RMB, a decrease of 34.49% compared to the same period last year, mainly due to the long acceptance cycle of software projects, with projects not completed and accepted during the reporting period.

2. Main Business Revenue by Region
During the reporting period, the domestic medical equipment market showed a recovery trend of 'recovery - acceleration'. Leveraging industry demand and its core strengths, the company's revenue expanded significantly, achieving domestic revenue of 9,759.81 million RMB, an increase of 27.35% year-on-year; the overseas market continued its high growth momentum, with overseas revenue of 3,392.52 million RMB, an increase of 52.81% year-on-year.

3. Breakdown of Operating Revenue by Sales Model
During the reporting period, the company's sales model structure remained largely stable compared to the same period last year. Specifically, revenue under the distribution model amounted to RMB 8,405.74 million, an increase of 37.50% year-on-year, while revenue under the direct sales model reached 4,746.59 million yuan, up 25.87% year-on-year.

(2). Analysis of Production and Sales Volume

√ Applicable□ Not applicable

Major Products	Unit	Production Volume	Sales Volume	Inventory Volume	YoY Change in Production Volume (%)	YoY Change in Sales Volume (%)	YoY Change in Inventory Volume (%)

CT	unit	1364	1501	141	-6.77	7.37	-49.28
MR	unit	722	664	149	17.97	13.50	63.74
XR	unit	1124	1170	153	7.66	13.15	-23.12
MI	unit	177	175	65	13.46	31.58	3.17
RT	unit	59	51	10	73.53	50.00	400.00

Explanation of Production and Sales Volume

1. During the reporting period, the sales volume of all product lines increased to varying degrees compared to the previous year. The company's products gained market recognition, with enhanced competitiveness, leading to higher production and sales volumes, improved overall inventory turnover efficiency, and a corresponding decrease in ending inventory.
2. The inventory volume of MR/RT products increased during the reporting period, primarily due to sales stockpiling.

(3). Performance of Major Procurement and Sales Contracts

□ Applicable√ Not applicable

(4). Cost Analysis Table

Unit: Yuan Currency: RMB

Breakdown by Industry							
Industry	Cost Component	Current Period Amount	Percentage of Total Cost in Current Period (%)	Amount in Same Period Last Year	Percentage of Total Cost in Same Period Last Year (%)	YoY Change in Current Period Amount (%)	Situation Explanation
Medical Device Industry	Direct Materials	5,991,407,165.27	88.65	4,452,546,547.18	89.04	34.56	

Medical Device Industry	Direct Labor	189,387,171.19	2.80	151,835,595.94	3.04	24.73	
Medical Device Industry	Manufacturing Overhead	577,574,296.21	8.55	396,493,755.51	7.92	45.67	
Breakdown by Product							
Product	Cost Component	Current Period Amount	Percentage of Total Cost in Current Period (%)	Amount in Same Period Last Year	Percentage of Total Cost in Same Period Last Year (%)	YoY Change in Current Period Amount (%)	Situation Explanation
Sales of Medical Imaging Diagnostic Equipment and Radiotherapy Equipment	Direct Materials	5,485,814,067.84	81.17	4,038,578,465.23	80.76	35.84	
Sales of medical imaging diagnostic equipment and radiotherapy equipment	Direct labor	186,142,526.08	2.75	148,433,526.84	2.97	25.40	
Sales of medical imaging diagnostic equipment and radiotherapy equipment	Manufacturing expenses	414,626,983.40	6.14	284,204,132.03	5.68	45.89	
Provision of maintenance revenue	Cost amount	651,356,741.94	9.64	495,818,710.50	9.91	31.37	
Software	Cost amount	20,428,313.41	0.3	33,841,064.03	0.68	-39.63	

Other explanations regarding cost analysis

1. During the reporting period, the company continued to strengthen lean production, expanded its business scale, significantly increased production and sales volume, and corresponding costs increased due to the rise in sales volume;
2. During the reporting period, maintenance service costs increased by 31.37% compared to the same period last year, due to the rapid growth in the company's installed base;
3. During the reporting period, software project costs decreased by 39.63% compared to the same period last year, mainly because software projects have long acceptance cycles, and the projects were not completed and accepted during the reporting period.

(5). Changes in the scope of consolidation due to equity changes in major subsidiaries during the reporting period

□ Applicable√ Not applicable

(6). Significant changes or adjustments in the company's business, products, or services during the reporting period

□ Applicable√ Not applicable

(7). Major sales customers and major suppliers

Customers or suppliers controlled by the same controlling party are considered as a single customer or supplier and presented on a consolidated basis, except for those under the actual control of the same state-owned asset management institution.
Explanation of the consolidation of the following customer and supplier information under the same control basis
The company has considered customers or suppliers controlled by the same controlling party as a single customer or supplier and presented them on a consolidated basis, except for those under the actual control of the same state-owned asset management institution.

A. Company's major sales customers
√ Applicable□ Not applicable
Sales to the top five customers amounted to 120,786.25 million yuan, accounting for 8.75% of total annual sales; among these, sales to related parties in the top five customers amounted to 0 million yuan, accounting for 0% of total annual sales.

Company's top five customers
√ Applicable□ Not applicable

Unit: 10,000 yuan Currency: RMB

Serial number	Customer name	Sales amount	Percentage of total annual sales (%)	Whether there is an affiliated relationship with the listed company
1	Customer 1	53,910.95	3.91	No
2	Customer 2	23,502.89	1.70	No
3	Customer 3	15,169.95	1.10	No
4	Hainan Tailan Technology Co., Ltd.	14,614.15	1.06	No
5	Chongqing Pharmaceutical Group Sichuan Medical Equipment Co., Ltd.	13,588.31	0.98	No
Total	/	120,786.25	8.75	/

During the reporting period, sales to a single customer exceeded 50% of total sales, new customers appeared among the top 5 customers, or there was significant reliance on a small number of customers

√ Applicable□ Not applicable

Customer 2, Hainan Tailan Technology Co., Ltd., and Chongqing Pharmaceutical Group Sichuan Medical Equipment Co., Ltd. were not among the company's top five customers in the previous year. During the reporting period, the company's equipment sales to the aforementioned customers increased.

Top five sales customers in trade business where trade business revenue accounted for more than 10% of operating revenue during the reporting period

□ Applicable√ Not applicable

B. Company's major suppliers

√ Applicable□ Not applicable

Purchases from the top five suppliers amounted to 151,025.96 million yuan, accounting for 15.00% of total annual purchases; among these, purchases from related parties in the top five suppliers amounted to 0 million yuan, accounting for 0% of total annual purchases.

Top five suppliers of the company

√ Applicable□ Not applicable

Unit: 10,000 yuan Currency: RMB

Serial number	Supplier name	Purchase amount	Percentage of total annual purchases (%)	Whether there is an affiliated relationship with the listed company
1	First place	34,514.02	3.43	No
2	Second place	33,044.58	3.28	No
3	Third place	30,344.32	3.01	No
4	Fourth place	29,874.48	2.97	No
5	Fifth place	23,248.56	2.31	No
Total	/	151,025.96	15.00	/

During the reporting period, the proportion of purchases from a single supplier exceeded 50% of the total, there were new suppliers among the top five suppliers, or there was a situation of heavy reliance on a few suppliers
□ Applicable√ Not applicable

Top five suppliers of trade business with trade business revenue accounting for more than 10% of operating revenue during the reporting period
□ Applicable√ Not applicable

C. The company had trade business revenue during the reporting period
□ Applicable√ Not applicable

(3). Expenses

√ Applicable□ Not applicable

Unit: yuan

Item	Current period amount	Amount for the same period of the previous year	Change percentage (%)	Explanation
Selling expenses	2,261,407,623.18	1,823,187,055.28	24.04	Increased expansion into overseas markets during the reporting

				period.
R&D expenses	1,841,943,294.35	1,761,466,670.35	4.57	Expenses remained flat compared to the previous year during the reporting period.
Financial expenses	-30,626,038.58	-112,290,178.67	Not applicable	Due to exchange rate fluctuations and a decrease in interest income during the reporting period.
Administrative expenses	626,904,263.90	555,965,099.19	12.76	Labor costs and information technology construction during the reporting period

(4). Cash flow

√ Applicable□ Not applicable

Item	Current period amount	Amount for the same period of the previous year	Change percentage (%)	Explanation
Net cash flow from operating activities	2,679,018,849.49	-619,024,253.25	Not applicable	Mainly due to the company's stable operations and significant improvement in sales collection during the reporting period.
Net cash flow from investing activities	-3,357,456,795.40	-1,244,307,712.70	Not applicable	Mainly due to the purchase and redemption of wealth management products

				during the reporting period.
Net cash flow from financing activities	152,919,336.43	198,972,823.31	-23.15	Mainly due to the repayment of loans from the previous period during the reporting period.

(ii) Explanation of significant changes in profit due to non-core business activities

□ Applicable√ Not applicable

(iii) Analysis of assets and liabilities

√ Applicable□ Not applicable

1. Asset and liability status

Unit: yuan Currency: RMB

Item name	Current Period Ending Balance	Percentage of Current Period Ending Balance to Total Assets (%)	Previous Period Ending Balance	Percentage of Previous Period Ending Balance to Total Assets (%)	Percentage Change of Current Period Ending Amount Compared to Previous Period Ending Amount (%)	Explanation
Monetary Funds	5,502,937,108.96	16.79	8,399,997,063.38	29.96	-34.49	Mainly due to the company's purchase of wealth management products during the reporting period
Financial Assets at Fair Value through Profit or Loss	4,926,542,409.75	15.03	1,705,986,636.59	6.09	188.78	Mainly due to changes in the balance of wealth management products purchased and redeemed by the company during the reporting period
Notes Receivable	91,603,965.94	0.28	1,056,048.00	0.00	8,574.22	Mainly due to some customers

						using bills for settlement, and an increase in undiscounted bills at the end of the period
Accounts Receivable	5,590,248,672.01	17.05	4,358,808,221.15	15.55	28.25	Mainly due to the company's stable operations and steady revenue growth during the reporting period
Prepayments	264,137,851.08	0.81	195,777,640.89	0.70	34.92	Mainly due to increased advance payments for raw material procurement and strategic stockpiling
Long-term Receivables	175,204,564.76	0.53	114,605,452.67	0.41	52.88	Mainly due to an increase in installment sales of goods by the company during the reporting period
Other Non-current Financial Assets	130,880,900.00	0.40	82,366,375.73	0.29	58.90	Mainly due to the company's new equity investment in Shanghai Intelligent
Construction in Progress	2,868,572,615.90	8.75	1,770,074,723.58	6.31	62.06	Mainly due to continued investment in the construction of the second-phase intelligent factory during the reporting period
Right-of-use Assets	265,003,292.18	0.81	82,847,128.12	0.30	219.87	Mainly due to the expansion into overseas markets and increased leasing by overseas subsidiaries during the reporting period
Intangible Assets	1,512,812,075.51	4.61	1,004,333,811.10	3.58	50.63	Mainly due to an increase in non-patented technology meeting capitalization conditions during the reporting period
Development Expenditure	429,588,646.46	1.31	329,169,118.87	1.17	30.51	Mainly due to increased R&D investment meeting

						capitalization conditions during the reporting period
Other Non-current Assets	556,180,212.23	1.70	97,227,715.69	0.35	472.04	Mainly due to an increase in fixed deposit certificates maturing in more than one year during the reporting period
Short-term Borrowings	944,721,233.21	2.88	557,489,368.89	1.99	69.46	Mainly due to an increase in borrowings
Contract Liabilities	2,975,154,056.73	9.07	2,139,304,950.07	7.63	39.07	Mainly due to the increase in advance receipts from product sales and services during the reporting period.
Employee compensation payable	806,276,577.83	2.46	578,225,593.32	2.06	39.44	Mainly due to the talent team development during the reporting period.
Taxes payable	639,996,649.60	1.95	326,702,443.76	1.17	95.90	Mainly due to the company's stable operations and steady revenue growth during the reporting period, resulting in an increase in taxes payable.
Other payables	898,235,871.92	2.74	677,339,798.99	2.42	32.61	Mainly due to the increase in project payments accrued according to the progress of construction projects.
Other current liabilities	187,384,320.84	0.57	134,355,301.68	0.48	39.47	Mainly due to the company's stable operations and steady revenue growth during the reporting period, resulting in an increase in the output VAT to be transferred.
Lease liabilities	252,568,441.01	0.77	83,997,441.38	0.30	200.69	Mainly due to the expansion into overseas markets during the reporting period, resulting in increased leasing by overseas subsidiaries.

Long-term employee compensation payable	-	-	5,642,483.55	0.02	-100.00	Mainly due to the expiration of long-term retention plans.
Other non-current liabilities	1,202,627,471.57	3.67	490,453,489.65	1.75	145.21	Mainly due to the company's stable operations and steady revenue growth during the reporting period, resulting in an increase in advance receipts.

Other explanations
None

Causes of the company's non-profitability and its impact
□ Applicable√ Not applicable

2. Overseas assets

√ Applicable□ Not applicable

(1). Asset scale

Including: overseas assets of 4,915,126,524.93 (Unit: Yuan, Currency: RMB), accounting for 14.99% of total assets.

(2). Explanation for the high proportion of overseas assets

□ Applicable√ Not applicable

3. Major restricted assets as of the end of the reporting period

√ Applicable□ Not applicable

Item	Carrying value at period-end	Reason for restriction
Cash and cash equivalents	48,129,233.09	Security deposits
Other non-current assets	11,523,047.22	Security deposits

Total	59,652,280.31	/

4. Other explanations

□ Applicable√ Not applicable

(iv) Analysis of industry operational information

√ Applicable□ Not applicable

For analysis of industry operational information, please refer to the section 'II. Description of the company's main business, operating model, industry situation, and R&D during the reporting period' in 'Section III Management Discussion and Analysis' of this report.

(v) Investment analysis

Overall analysis of external equity investments
√ Applicable□ Not applicable

Unit: Yuan, Currency: RMB

Investment amount during the reporting period (Yuan)	Investment amount in the same period of the previous year (Yuan)	Change rate
98,487,200.00	189,580,119.87	-48.05%

Note: During the reporting period, the company acquired a 0.9849% equity stake in Shanghai Intelligent for RMB 98.4872 million. As of the end of the reporting period, the capital contribution has been fully paid.

(1). Major equity investments

□ Applicable√ Not applicable

(2). Major non-equity investments

√ Applicable□ Not Applicable

Serial	Project Name	Implementing	Estimated Total Investment	Project Progress	Funding Source
1	Next-Generation R&D Product	United	6.168 Billion Yuan	60.33%	Raised Funds and Own
2	High-End Medical Imaging	United	3.126 Billion Yuan	64.37%	Raised Funds

(3). Financial Assets Measured at Fair Value

√ Applicable□ Not Applicable

Unit: Yuan Currency: RMB

Asset Category	Opening Balance	Fair Value Change in Current Period	Cumulative Fair Value Change Included in Equity	Impairment Provision in Current Period	Purchase Amount in Current Period	Sale/Redemption Amount in Current Period	Other Changes	Closing Balance
Trading Financial Assets	1,705,986,636.59	2,097,785.16			35,933,500,000.00	32,715,042,012.00		4,926,542,409.75
Derivative Financial Assets	489,944.97	-489,944.97			-	-		-
Other Non-current Financial Assets	82,366,375.73	-38,721,786.68			98,487,200.00	10,929,293.45	-321,595.60	130,880,900.00
Total	1,788,842,957.29	-37,113,946.49			36,031,987,200.00	32,725,971,305.45	-321,595.60	5,057,423,309.75

Securities Investment Details
√ Applicable□ Not Applicable

Unit: Yuan Currency: RMB

Securities Type	Securities Code	Securities Abbreviation	Initial Investment Cost	Funding Source	Opening Book Value	Fair Value Change in Current Period	Cumulative Fair Value Change Included in Equity	Purchase Amount in Current Period	Sale Amount in Current Period	Disposal Gain/Loss	Closing Book Value	Accounting Category
Domesti	2522.H	Yimai	11,042,4	Own	52,622,6	-	-	-	10,929,2	38,278.8	-	Other

c and Overseas Stocks	K	Sunshine	01.93	Funds	75.73	41,371,786.68			93.45	9		Non-current Financial Assets
Total	/	/	11,042,401.93	/	52,622,675.73	-41,371,786.68	-	-	10,929,293.45	38,278.89	-	/

Derivative Investment Details

√ Applicable□ Not Applicable

(1). Derivative Investments for Hedging Purposes During the Reporting Period

√ Applicable□ Not Applicable

Unit: Ten Thousand Yuan Currency: RMB

Derivative Investment Type	Initial Investment Amount	Beginning book value	Fair value change gains/losses for the period	Cumulative fair value changes recognized in equity	Amount purchased during the reporting period	Amount sold during the reporting period	Ending book value	Percentage of ending book value to the company's net assets at the end of the reporting period (%)
Foreign exchange options - Collar options	5,750.72	48.99	-48.99			5,750.72	-	-
Total	5,750.72	48.99	-48.99			5,750.72	-	-
Explanation of the accounting policies and specific accounting principles for hedging activities during the reporting period, and whether there have been significant changes compared to the previous reporting period	The company conducts corresponding accounting treatment, presentation, and disclosure in accordance with the Ministry of Finance's 'Accounting Standards for Business Enterprises No. 22 - Recognition and Measurement of Financial Instruments,' 'Accounting Standards for Business Enterprises No. 24 - Hedge Accounting,' and other relevant regulations and guidelines.							

Explanation of actual gains and losses during the reporting period	To hedge and mitigate foreign exchange risks arising from exchange rate fluctuations for the company, based on the company's operational and business needs, the company conducts hedging and other related activities for its foreign exchange business at a certain proportion. The business scale remains within the expected range and has a clear business foundation. During the reporting period, the actual gains and losses from the company's foreign exchange hedging derivative contracts, net of spot market gains and losses, had a positive impact on the company's operations.
Explanation of hedging effectiveness	The financial derivatives used by the company for hedging activities are linked to the company's foreign exchange exposure, offsetting the exchange rate fluctuation risks present in spot market transactions and achieving the expected risk management objectives.
Source of funds for derivative investments	Self-owned funds
Risk analysis and control measures for derivative positions during the reporting period (including but not limited to market risk, liquidity risk, credit risk, operational risk, legal risk, etc.)	(I) Risk Analysis 1. Market risk: Due to significant fluctuations in foreign exchange markets, there may be market risks arising from price changes in foreign exchange derivatives caused by fluctuations in underlying interest rates, exchange rates, and other market prices, leading to losses. 2. Liquidity risk: There is a risk of being unable to complete transactions due to insufficient market liquidity. 3. Performance risk: Default risk arising from the inability to perform foreign exchange derivative transactions upon maturity due to overdue receivables from customers. 4. Other risks: When conducting transactions, if the terms of the transaction contracts are unclear, legal risks may be faced. (II) Risk Control Measures 1. The foreign exchange derivative transactions conducted by the company and its subsidiaries adhere to the principles of legality, prudence, safety, and effectiveness. All foreign exchange derivative transactions are based on normal production and operations, supported by genuine transaction backgrounds, and aimed at locking in costs and hedging against exchange rate and interest rate risks. The company does not engage in foreign exchange transactions for speculative purposes. 2. The company has established the 'Foreign Exchange Derivative Transaction Business

	Management System,' which clearly defines the staffing, operational principles, approval authorities, management and internal operational procedures, information isolation measures, internal risk reporting system and risk handling procedures, and information disclosure for foreign exchange derivative transactions conducted by the company and its subsidiaries. This system complies with the relevant requirements of regulatory authorities, meets practical operational needs, and the established risk control measures are effective. 3. The company will prudently review the contract terms signed with banks to mitigate legal risks. 4. The company's finance department will continuously monitor the market prices or fair value changes of foreign exchange derivatives, promptly assess changes in risk exposure from foreign exchange derivative transactions, and report regularly to the company's management. Any abnormalities will be reported promptly, risks will be highlighted, and emergency measures will be implemented. 5. The company's internal audit department will regularly supervise and inspect the compliance of the decision-making, management, and execution of foreign exchange derivative transactions.
Changes in market prices or fair value of invested derivatives during the reporting period; the analysis of derivative fair value should disclose the specific methods used and the assumptions and parameters set	The main parameter for the fair value assessment of the company's foreign exchange derivatives is the central parity of the RMB exchange rate announced by the central bank
Litigation involvement (if applicable)	Not applicable
Disclosure date of the board of directors' announcement for derivative investment approval (if any)	April 25, 2025
Disclosure date of the shareholders' meeting announcement for derivative investment approval (if any)	Not applicable

(2). Derivative investments for speculative purposes during the reporting period

□ Applicable√ Not applicable

Other explanations

None

(4). Investments in private equity funds

□ Applicable√ Not applicable
Other explanations
None

(5). Specific progress of major asset restructuring and integration during the reporting period

□ Applicable√ Not applicable

(vi) Major asset and equity sales

□ Applicable√ Not applicable

(vii) Analysis of major controlled and affiliated companies

□ Applicable√ Not applicable

(viii) Structured entities controlled by the company

□ Applicable√ Not applicable

6. Company's discussion and analysis of future development

(i) Industry landscape and trends

√ Applicable□ Not applicable

1) High-quality healthcare development drives the evolution of hospital development models

High-quality development is the action guide for China's current and future economic and social development. High-quality development of public hospitals has already established advanced demonstrations:

First, promoting disciplinary innovation by focusing on major diseases and key issues affecting public health, strengthening core specialty capabilities, and enhancing the diagnosis, treatment capacity, and outcomes for major diseases.

Second, advancing technological innovation by keeping pace with international medical frontiers, deepening collaborative efforts in medical education, research, production, and application in key areas such as brain science, regenerative medicine, and biomedical science, to develop a number of internationally leading, clinically applicable original technologies.

Third, driving service innovation by promoting new models such as multidisciplinary diagnosis and treatment and one-stop services, and applying new technologies like artificial intelligence, surgical robots, and internet healthcare to meet public medical service needs.

Fourth, fostering management innovation by introducing advanced management concepts and modern management tools to enhance the scientific, refined, and intelligent level of hospital management.

Fifth, promoting talent development by recruiting outstanding talent with an international perspective, strengthening the training and development of technical backbones and young professionals, and building composite innovation teams and high-level specialty talent echelons.

The development model of public hospitals has shifted from extensive growth to strategic, comprehensive, and long-term refined management that meets national high-quality development requirements. Medical institutions are no longer seeking mere equipment suppliers and service providers but partners for mutual development and growth.

After years of accumulation, the company has integrated layouts in areas such as integrated diagnosis and treatment, equipment informatization, localized agile response, and open innovation, building capabilities in technology application, talent development, and resource integration deeply embedded in China's healthcare service system, and forming targeted overall solutions. For example, supporting major medical breakthroughs through translational medicine platforms to achieve autonomous and controllable medical innovation around the goal of building medical peaks at national medical centers; promoting integrated diagnosis and treatment with specialized disease solutions and regional digital intelligence interconnection solutions at regional and provincial medical centers to build medical highlands; strengthening county-level healthcare with 'digital-intelligence integrated' solutions for imaging, oncology, stroke, chest pain, and trauma centers; and connecting multi-level medical institutions through high-quality development specialty alliances to

enhance diagnostic and treatment technologies, cultivate specialty talent, and improve medical service capabilities. Through overall solutions, deeply collaborating with medical institutions at all levels to jointly scale peaks, drive innovation, gather talent, and secure the network foundation, achieving high-quality development.

2) Driving Medical Equipment Upgrades with New Quality Productive Forces
According to the 'Medical Imaging Equipment Age and Distribution' report by the European Coordination Committee of the Radiological, Electromedical and Healthcare IT Industry (COCIR), some medical imaging equipment in China has been in use for over 10 years, especially CT, MR, DSA, and PET equipment, urgently requiring renewal. The 'Regulations on the Supervision and Administration of Medical Devices' also mandate the phasing out of expired, invalid, and outdated equipment. Such equipment updates are both an inevitable trend for the high-quality development of medical institutions and a historic opportunity to enhance the capabilities of China's medical equipment industry.

In the future, this series of equipment update policies will not only impact technological innovation in the medical equipment industry and the coordinated development of the upstream and downstream industrial chain but will also, through the integration of advanced manufacturing, health services, and technological innovation, facilitate the effective transformation and upgrading of China's economic structure, further meet the increasingly diverse health needs of the public, improve the quality and efficiency of medical services, and achieve dual enhancement of economic and social benefits.

As national plans for expanding high-quality medical resources and achieving balanced regional distribution are gradually implemented, new medical infrastructure and the enhancement of primary hospital capabilities will continue to drive the allocation of large medical equipment, leading to significant growth in the large medical equipment market. The company will leverage its comprehensive product line and integrated solutions to expand market share in the incremental market, fully supporting the high-quality development of the national healthcare sector.

3) Integrated Healthcare Service System Construction Drives Market Demand Upgrade
The new integrated healthcare service system encompasses top-level design, organizational structure, institutional relationships, personnel collaboration, public health, clinical diagnosis and treatment, service processes, and health management.

The company leverages its foundation in multi-modality imaging, radiotherapy, and interventional equipment, combined with digital and information technology capabilities, to provide customers with integrated solutions that combine hardware and software, linking in-hospital and out-of-hospital services. For example, using specialized disease databases and platforms for specialty disease alliances to help regions establish standardized diagnosis and treatment protocols and pathways; closely-knit urban medical group and county-level medical community platforms to support the construction of a tiered diagnosis and treatment system; county-level sub-center platforms to enhance the medical service capacity of the regional grassroots grid system; combining public health solutions to build regional disease prevention and control systems; and diverse regulatory platforms to assist health departments at all levels in strengthening healthcare management, covering all key areas of the integrated healthcare service system.

4) Industry upgrading and deepening, accelerated mid-to-high-end substitution, precision medicine, and theranostics leading clinical trends

The core concepts of modern medicine are constantly evolving, with precision medicine gradually becoming mainstream. Traditional treatment methods often lack personalization and precision, whereas precision medicine emphasizes providing more accurate diagnosis and treatment plans based on the patient's specific condition and biomarkers, thereby improving therapeutic effects and reducing side effects. For example, in cancer treatment, PET imaging technology has become an important tool for improving treatment precision and effectiveness. In the field of neurology, molecular imaging technology plays a crucial role. In recent years, several FDA-approved drugs for Alzheimer's disease have been evaluated based on PET imaging results, which play a key role in the early detection and intervention of Alzheimer's disease.

Medical imaging diagnosis not only enhances treatment precision but also significantly improves the overall efficiency of healthcare services. Taking orthopedic surgery as an example, doctors can use imaging results from CT or XR equipment to precisely measure patient joints, thereby better determining surgical plans. Against the backdrop of high costs for personalized medical devices, high-end medical imaging equipment that provides precise diagnosis before surgery can not only assist in the surgical process but also avoid unnecessary consumable and surgical expenses.

In terms of theranostics, the medical imaging equipment industry must not only provide high-performance devices to medical institutions but also assist doctors in developing integrated diagnosis and treatment solutions. The ultimate goal is to reduce patient treatment costs and improve treatment efficiency. Therefore, multi-modality fusion and theranostics will become the main directions of industry development, with more medical imaging diagnosis and treatment equipment featuring multi-modality functions being introduced to the market. Taking MR-guided linear accelerators as an example, radiotherapy is one of the important means of cancer treatment. However, traditional image-guided accelerator systems often lack effective imaging guidance for soft tissues and cannot locate tumors in real-time during treatment, which greatly limits the precision and effectiveness of radiotherapy for tumors in various parts of the body, especially in the treatment of thoracic and abdominal tumors. Although the radiotherapy industry has been striving to integrate magnetic resonance systems with medical linear accelerators, true integration still faces many challenges due to numerous technical difficulties in the design principles of these two types of equipment.

In the future, United Imaging Healthcare will continue to focus on cutting-edge technologies in the medical imaging field, overcome key core technologies, and accelerate innovative breakthroughs. The company will further launch innovative equipment with multi-modality, precision, intelligence, and theranostics capabilities to meet clinical needs across multiple scenarios and diseases, significantly improving the accuracy, effectiveness, and accessibility of clinical disease diagnosis and treatment.

5) Trends and transformations in the global healthcare field: from aging challenges and infectious disease control to intelligent innovation

Global healthcare is also facing numerous significant challenges, which not only concern individual health and life but also profoundly impact the stability and development of society as a whole. The first major challenge is the increasingly severe aging population worldwide. With changes in population structure, the proportion of the elderly population is continuously

rising. According to the United Nations' "World Population Prospects 2022" data, "the growth rate of the population aged 65 and over exceeds that of the population under 65. The proportion of the population aged 65 and over is growing faster than that under 65. By 2050, the global proportion of people aged 65 and over is projected to increase from 10% in 2022 to 16%. By then, the global population aged 65 and over will be twice the size of the population under 5 and nearly equal to the number of children under 12." The rapid increase in the proportion of the elderly population, coupled with insufficient growth momentum in the labor force, will further highlight the imbalance between the supply and demand of medical resources. The elderly population is often accompanied by more chronic and degenerative diseases, which will lead to a significant increase in future healthcare service demands. However, the existing healthcare systems in many countries worldwide still face challenges such as strained healthcare workforce resources and even negative situations like burnout due to overwork, leading to increased medical safety risks and decreased quality of healthcare services. Secondly, the threat of infectious diseases worldwide cannot be ignored. In recent years, various new infectious diseases have continuously emerged. Infectious diseases spread rapidly and widely, posing serious threats to public health security. The prevention and control of infectious diseases require substantial investment in medical resources, including medical equipment, pharmaceuticals, and human resources. Furthermore, the global healthcare sector also faces the issue of uneven distribution of medical resources. In developing countries and impoverished regions, medical resources are scarce, and the level of medical services is low, resulting in many people being unable to receive timely and effective medical treatment. This imbalance in resource distribution not only exacerbates social inequality but also hinders the overall development of global healthcare. With the continuous advancement of medical technology, people have higher expectations for the quality and efficiency of medical services. Some existing medical systems still suffer from cumbersome service processes, lack of transparency in information, and poor communication, causing inconvenience and distress to patients.

In response to these challenges, medical technology is undergoing profound changes and innovations to meet the demands and development of global healthcare. First is the development of intelligence and personalization. By integrating advanced technologies such as artificial intelligence, big data, and large models, medical equipment can achieve precise analysis of patients' conditions and the formulation of personalized treatment plans. This not only improves the efficiency and quality of medical services but also reduces the waste of medical resources, alleviating the issue of resource shortages. Second, telemedicine and mobile healthcare are gaining increasing attention. With the continuous upgrade of communication technologies such as 5G, doctors can overcome geographical barriers through remote connectivity to provide more timely and higher-quality medical services to patients in resource-scarce areas. The rise of the Internet of Things and mobile healthcare technologies enables patients to access medical information and health management services anytime and anywhere, significantly improving the accessibility and convenience of medical services. Moreover, with the development of medical and technological levels, and in conjunction with advanced technologies such as AI and large models, medical equipment is increasingly being applied in prevention and health management, enabling early intervention and effective management of chronic diseases, thereby reducing the incidence and recurrence rates of diseases. This not only alleviates the burden on the medical system but also enhances people's quality of life and health levels.

With the implementation and advancement of the aforementioned multi-level policies both domestically and internationally, the demand in the global medical market will be fully

unleashed, and the trend of steady growth in the medical equipment industry will become more evident.

(ii) Company Development Strategy

√ Applicable□ Not Applicable

With the vision of 'becoming a world-class leader in medical innovation,' the company has consistently focused on breakthroughs in core technology R&D over the past 15 years, adhering to the market strategy of 'aiming high and achieving comprehensive coverage.' It has achieved self-sufficiency across the entire chain and product lines and continues to expand its market share both domestically and internationally. In the future, building on the solid foundation of previous development, the company will advance technology reserves, talent reserves, product reserves, and customer expansion globally, further deepening its international strategic layout and comprehensively enhancing its competitiveness and resilience in the global market. Specific strategies include:

1. R&D and Innovation Strategy

The company will pursue forward-looking initiatives in cutting-edge technology fields such as imaging equipment, steadily increasing R&D investment. Starting from the actual clinical needs of end customers, it will conduct independent R&D and product innovation to build reserves of next-generation core technologies, thereby solidifying its technological innovation advantages.

In terms of product innovation, the company will adhere to the principle of 'comprehensive independent R&D, mastery of all core technologies, and benchmarking against international top standards,' continuously launching a series of high-end medical equipment that are 'industry-first and deeply reflect clinical value.' This will open new possibilities for clinical and scientific research, enabling the transition from being an 'industry changer' to an 'industry leader,' meeting the self-imposed requirement of progressing from 'benchmarking international top standards' to 'surpassing international top standards.'

In terms of key components and underlying technologies, the company will continue to tackle core components and foundational technologies internally, actively promoting the deep integration of cutting-edge technologies such as artificial intelligence, 5G, cloud technology, and new materials with next-generation diagnostic and therapeutic equipment. It will explore new applications and scenarios for these technologies in the broader health field, setting new technological benchmarks for the industry.

In terms of industry-academia-medicine collaboration, the company will grow and co-create with the best doctors and scholars in the industry both domestically and internationally, fostering multidisciplinary innovation and synergy. Leveraging the strong traction of the innovation ecosystem, it will connect the entire chain from basic research and clinical research to industrial transformation, promoting precision diagnosis and treatment of major diseases and exploration of significant medical challenges.

2. Marketing and Operations Strategy

Leveraging its technological R&D advantages, the company will establish and improve its global production and sales systems, actively expanding into markets.

Within the Chinese market, the company is advancing its long-term growth strategy. By focusing on operational excellence, channel optimization, and service accessibility, we are aligning our business with broader macroeconomic trends, including the advancement of public health, modernization of manufacturing, and improvement of healthcare equity. Furthermore, we are actively supporting the development of regional healthcare hubs, urban medical networks, and community-based healthcare infrastructure. By broadening access to premium medical resources, United Imaging provides advanced solutions that empower a more efficient and accessible multi-tiered healthcare delivery system.

In the international market, the company will further accelerate its global expansion strategy, adhering to a market-driven approach aimed at comprehensive growth. UIH will continue to optimize international marketing systems and deepen local integration across global markets.

In the short term, the company will continue to actively integrate resources and plan production capacity from a global perspective, using high-end equipment to break into key countries in target markets. It will accelerate the construction of local teams in key countries within regions, strengthen pre-sales and after-sales service responsiveness, and enhance service quality as well as the recognition and influence of the company brand in the market.

In the medium term, the company will deepen its presence in key countries within focus regions, increasing investment in the construction of existing regional centers and enhancing 'industry-academia-medicine' collaboration with local doctors and hospitals to build a global innovation integration system. Simultaneously, it will continuously accelerate the capacity building and market expansion efforts of each regional center, achieving full product coverage in key markets within the regions.

In the long term, it will ensure the independent operation of subsidiaries and branches of each regional center within their respective regional markets, meaning mature deployment of localized sales networks and after-sales teams. At the same time, it will widely recruit global talent, strengthen international market recognition and trust in the company brand, enhance user loyalty, transform the world's ingrained perceptions of domestic brands, and achieve reverse export of large medical equipment to high-end markets such as the US and Europe, as well as sustained penetration into emerging market countries.

3. Organization and Talent Strategy

Aiming to 'build a dynamic organization oriented to customer needs and establish a value-driven, full-chain collaborative combat mechanism,' the company will cultivate world-class management and expert teams, deepen incentive systems for value creation, and build a corporate culture system that supports strategy execution.

In terms of localization and diversification, to better adapt to the cultures and market environments of different countries and regions and deepen the construction of a global talent system, the company adheres to a talent strategy focused on local construction and diversified operations. In the future, it will further increase platform investment and capacity building in regional headquarters within strategic key countries and markets, consolidating and enhancing the capabilities of major subsidiaries/branches in areas such as marketing management, market management, clinical training, after-sales service, and supply chain management.

In terms of organizational operations, the company will improve operational efficiency and innovation capability by building a value-driven, full-chain collaborative combat mechanism. Based on market demand, it will continuously explore the innovative value of product technology and services, closely monitor market dynamics, and use 'cross-departmental, multi-modal, project-based' team-building approaches to respond promptly to market needs, accelerate organizational collaboration and information sharing efficiency, and enhance organizational resilience and agility.

In terms of talent cultivation and career development, adhering to the core incentive system of "Customer-Centricity, Innovation-Driven, and Striver-Orientation," the company will continuously build and optimize a comprehensive compensation and incentive system that combines base salary, long-term incentives, benefits, and non-monetary incentives. On this basis, the company will establish a performance management system guided by 'value creation and efficient collaboration,' as well as 'open, equal, and competency-oriented' career development and promotion channels for talent. It will provide employees with ample training and career development plans, effectively improving employee and organizational capabilities, stimulating employees' initiative and value creation, and facilitating mutual growth for both the company and its employees.

4. Merger and Integration Strategy

In the future, the company will combine major industry development trends, characteristics of key market regions, and the current development status to identify, explore, research, and track relevant targets globally, aiming to acquire advanced technologies, products, channels, and other resources. The company will continue to uphold the principle of 'Innovation-driven, Win-win Cooperation,' adopting a more open attitude, deeper strategic layout, and stronger resilience and determination to enhance R&D, market, management, marketing, talent systems, and capability building.

(iii) Business Plan

√ Applicable□ Not Applicable

After more than a decade of relentless effort, the company has rapidly grown into an industry leader.

2026, the company will unite with determination, act pragmatically, respond swiftly, innovate agilely, and collaborate internally and externally to further strengthen R&D in core components and key technologies. It will also focus on innovation and upgrades for next-generation products, breaking through a series of industry bottlenecks, comprehensively enhancing competitiveness in R&D, technology, quality, marketing, service, supply chain, and more. The company will scientifically and orderly advance the implementation of strategic plans and business layouts, continuously optimize and improve the global supply chain management and marketing systems, laying a solid foundation for stable and healthy growth in financial and social indicators, and providing strong support for the construction of global medical service systems.

The company's business plan for 2026 is as follows:

1. Strengthen R&D and design upgrades for the full range of high-end medical imaging diagnostic products and radiotherapy products

The company will continue to increase technology development and independent innovation efforts. Building on the existing R&D department, it will boost R&D investment, purchase equipment, expand the R&D team, and closely follow market demands. Through collaborations with domestic and international universities and top research institutions, it will advance the development of new technologies in MR, CT, XR, MI, RT, US, and other fields, rapidly translate cutting-edge technologies into applications, and enhance technological barriers through patent protection to maintain leadership in core technologies.

In the areas of core technology innovation and component localization, the company will continue to prioritize R&D in core components and key technologies, further increasing the proportion of self-developed components across product series, laying a solid foundation for achieving full product line and key technology independence and enhancing innovation freedom. The company will continue to actively explore forward-looking industry technology directions, aiming to seize new opportunities in industry transformation. It will focus on R&D for next-generation products and integrated devices, driving product upgrades and reinforcing its leading industry position. Based on comprehensive coverage of mainstream technology routes in relevant fields, the company will further promote the application of intelligence, precision diagnosis and treatment, cost efficiency, autonomy, accessibility, and sustainability in products, offering users more platform-based and diversified solutions to build a complete product ecosystem in the high-end medical equipment field.

In product design innovation, the design team will deeply engage in the entire process from definition to development, adhering to minimalist, human-centered design principles. Design will drive the integration of technology, art, and humanities, leading the industry-wide upgrade in design awareness, brand awareness, and craftsmanship standards.

2. Further promote industry-university-research-medicine collaborative innovation to advance the global high-end medical equipment ecosystem

Throughout the entire process from product design to final production, the company consistently emphasizes deep collaboration with hospitals, research institutions, universities, and other stakeholders. By understanding unmet needs in hospital product usage and challenges in cutting-edge research, it engages in close cooperation and joint product development with clients, facilitating the translation of advanced international technologies and guiding future technological development in the high-end medical equipment industry. The company will further launch upgraded products and customized solutions for different departments and application scenarios, maximizing the value of its products in research and clinical settings. This will provide new insights for early disease diagnosis and precision medication, enhancing user recognition and brand influence for entry into international high-end markets.

3. Focus on high-quality development of medical institutions, creating integrated solutions for various medical scenarios

The company is committed to focusing on the entire disease diagnosis and treatment process, integrating imaging, interventional procedures, radiotherapy, AI, and digital intelligence technologies from the source. It will continuously upgrade solutions including the All-in-One Digital Intelligence Stroke/Chest Pain/Trauma Center for emergency critical care, the All-in-One Digital Intelligence Oncology Center for precision cancer diagnosis and

treatment, the Multi-modality All-in-One Brain Disease Diagnosis and Treatment Solution for major brain diseases, and the Maternal and Child Health Care Solution for key population health management.

For public health prevention and service scenarios, integrating United Imaging Healthcare's multi-modality intelligent equipment, 5G remote platforms, and AI clinical applications, the company will create smart public health solutions. These include regional lung cancer mobile screening vehicles for early lung cancer screening in counties and townships, the industry's first Mobile Smart Health Management Center for early screening of cancer, cardiovascular, cerebrovascular, and respiratory diseases and chronic disease management, and the industry's first vehicle-mounted medical imaging center covering five scenarios: two-cancer screening, maternal and child health check-ups, COPD, brain diseases, and follow-up examinations.

To better address China's high-quality medical development, focusing on radiotherapy, nuclear medicine, breast imaging, mental health, and other fields, the company, together with top hospitals and experts, has initiated a series of high-quality development specialty alliances. It will continue to commit to tackling major diseases, multi-center research, standard setting, talent cultivation, and supporting lower-tier hospitals, including:

(1) Radiotherapy High-Quality Development Alliance: Jointly initiated with the Chinese Society of Therapeutic Radiology and Oncology, Fudan University Shanghai Cancer Center, Sun Yat-sen University Cancer Center, Peking Union Medical College Hospital, Shandong First Medical University Affiliated Cancer Hospital, Chinese Academy of Medical Sciences Cancer Hospital, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, and Peking University Third Hospital. It aims to collaboratively develop new radiotherapy products and technologies, expand cloud-based radiotherapy applications, guide standard setting, and support grassroots talent development.

(2) Remote United Nuclear Cloud Platform: Jointly initiated with the Chinese Society of Nuclear Medicine, Zhongshan Hospital Affiliated to Fudan University, Sun Yat-sen University Cancer Center, Shanxi Medical University, The First Affiliated Hospital of China Medical University, and The Affiliated Hospital of Southwest Medical University. Through remote nuclear medicine diagnosis, consultation, and training, it enhances precision cancer diagnosis capabilities across 70 hospitals.

(3) Breast Crescent Alliance: Jointly initiated with Fudan University Shanghai Cancer Center, Zhongda Hospital Affiliated to Southeast University, Peking University Third Hospital, Sichuan Cancer Hospital, and The First Affiliated Hospital of Zhengzhou University. It promotes precision diagnosis and treatment capabilities and technological innovation in breast diseases, now with nearly 200 member institutions nationwide.

(4) China Mental Imaging Alliance: Jointly initiated with West China Hospital of Sichuan University and the Brain Science and Brain-Like Research Institute of Shandong First Medical University. It unites 128 domestic medical institutions to create an integrated innovation ecosystem for mental health diagnosis and treatment through industry-university-research-medicine collaboration.

3. Deepen domestic and international sales network layout and market promotion efforts

The company will continue to stabilize existing clients while increasing brand promotion efforts, gradually improving its marketing capabilities domestically and internationally. For the domestic market, the company will leverage trends such as tiered healthcare, primary care development, and domestic substitution of medical equipment. By continuously establishing marketing service centers nationwide, it will strengthen its multi-level marketing network coverage. Simultaneously, the company will continue to develop a mature after-sales service system characterized by 'speed, quality, and reliability,' efficiently responding to client needs. It will provide installation, maintenance, and technical services for the full range of high-end medical imaging products. To better support our clients, we are expanding into secure, compliance-driven digital service solutions and comprehensive customer training, ensuring optimal system performance and enhancing customer loyalty while strictly adhering to local data privacy regulations.

For the international market, the company will continue to build professional, localized teams overseas. By establishing regional sales centers in key countries, it will effectively expand local service network coverage and strengthen service capabilities. Guided by its overseas sales network strategy, the company will continuously improve the layout of overseas regional and secondary centers, creating a multi-level, localized rapid-response sales platform to increase product visibility and market share abroad. By establishing a systematic overseas sales network, the company will gain insights into overseas market sales, effectively enhancing its management decision-making and operational capabilities.

Additionally, the company will increase investment in brand promotion, showcase products to customers through product demonstration centers, while continuously organizing pre-sales and after-sales expert seminars, customer training activities, customer presentations, regional product market promotions, regional channel development promotions, clinical application training courses, and other activities in key domestic and international cities. The company will also actively participate in high-end international industry conferences such as the North American Radiological Society Annual Meeting, European Congress of Radiology, Arab Health International Medical Equipment Exhibition, Indian Radiological and Imaging Association Annual Conference, and Japan Radiological Society Congress, hosting more high-quality marketing activities that are close to customers to enhance the company's global brand influence.

4. Continuously cultivate and recruit high-end composite talents with an international perspective

To maintain the overall stability of the company's R&D team and its internationally leading R&D level, the company will continue to improve employee compensation plans, employee performance evaluation systems, and employee internal training and management systems based on the existing talent cultivation mechanism. By establishing R&D centers worldwide, the company will widely recruit high-level technical talents from renowned domestic and international enterprises and top universities, enhancing the attractiveness of the employment environment and talent cultivation system. The company will continue to establish effective technological innovation incentive mechanisms, improve comprehensive assessment mechanisms such as performance bonuses, equity incentives, and job promotions, fully mobilize and leverage the enthusiasm, creativity, and sense of mission of R&D personnel, and promote the continuous emergence and early application of innovative R&D achievements. Simultaneously, the company will continue to strategically deploy talent across the entire industry chain, including core technology R&D, preclinical research,

clinical trials, regulatory approval and certification, equipment mass production and quality supervision, and product sales, achieving corresponding talent reserves at each stage of product development.

5. Improve the company's internal governance structure and quality system

2026 is a critical year for the company to further deepen its globalization strategy. The company will fully leverage the power of the capital market, continuously explore governance structures suitable for efficient and flexible operations, improve platform-based and professional management systems, and continuously optimize daily operational management mechanisms, corporate decision-making mechanisms, and risk prevention mechanisms to adapt to the company's rapid growth and comprehensively enhance its competitiveness. The company will continue to optimize the product lifecycle management system, build a top-down, lean, and efficient organizational structure, continuously strengthen quality management and improve product quality, continuously optimize costs and expenses, strengthen operational risk control, ensure that the company's products meet advanced industry quality standards while maintaining technological leadership, and expand the global market with high-quality products.

(iv) Other

□ Applicable√ Not applicable

Section IVCorporate Governance, Environment, and Society

1. Explanation of Corporate Governance Related Matters

√ Applicable□ Not applicable
In accordance with laws and regulations such as the Company Law, Securities Law, Guidelines for Corporate Governance of Listed Companies, and the Shanghai Stock Exchange Sci-Tech Innovation Board Stock Listing Rules, and related guidelines, the company has formulated the Articles of Association, established a corporate governance structure comprising the Shareholders' Meeting, Board of Directors, and senior management, forming a coordinated and mutually restrictive mechanism with clear powers, responsibilities, and standardized operations among the authority, decision-making, and management bodies, providing organizational assurance for the company's efficient and stable operation.

The company's Shareholders' Meeting, Board of Directors, and senior management all exercise their powers and perform their obligations in accordance with the Company Law and the Articles of Association. For related meeting details, Board of Directors performance, and special committee performance, investors are kindly requested to refer to the corresponding content in this section.

Whether there are significant differences between the company's corporate governance and the provisions of laws, administrative regulations, and the China Securities Regulatory Commission regarding the corporate governance of listed companies; if there are significant differences, the reasons shall be explained
□ Applicable√ Not applicable

2. Specific measures taken by the company's controlling shareholder and actual controller to ensure the independence of the company's assets, personnel, finance, organization, and business, as well as solutions, progress, and subsequent plans adopted to address any issues affecting the company's independence

□ Applicable√ Not applicable

Situation regarding the controlling shareholder, actual controller, and other entities they control engaging in the same or similar business as the company, and the impact of significant changes in competition or competitive situation on the company, measures taken to resolve the issue, progress made, and subsequent resolution plans
□ Applicable√ Not applicable

Situation where the controlling shareholder, actual controller, and other entities they control engage in competition that has a significant adverse impact on the company
□ Applicable√ Not applicable

3. Implementation and changes of voting rights differential arrangements during the reporting period

□ Applicable√ Not applicable

4. Corporate governance situation of the red-chip structure company

□ Applicable√ Not applicable

5. Information on Directors and Senior Management

(i) Changes in shareholdings and remuneration of current and former directors, senior management, and core technical personnel during the reporting period

√ Applicable□ Not applicable

Unit: share

Name	Position	Gender	Age	Term Start Date	Term End Date	Number of Shares Held at Beginning of Year	Number of Shares Held at End of Year	Change in Number of Shares During the Year	Reason for Change	Total Pre-tax Remuneration Received from the Company During the Reporting Period (10,000 yuan)	Whether Remuneration is Received from Company Affiliates
Zhang Qiang	Chairman, Co-CEO, Core Technical Personnel	Male	57	2020-09	2026-08	-	-	-	Not applicable	328.45	No
GUOSHENG TAN	Director, General Manager, Co-CEO	Male	63	2020-09	2026-08	-	-	-	Not applicable	266.26	No
JUN BAO	Director, President	Male	61	2022-12	2026-08	-	-	-	Not applicable	259.56	No
TAO CAI	Employee Director, Chief Investment Officer, Board Secretary	Male	54	2020-09	2026-08	-	-	-	Not applicable	194.55	No
DING JUN	Director	Male	56	2023-08	2025-04	-	-	-	Not applic	-	No

(Departed)									able		
SHEN SIYU	Director	Male	44	2021-10	2026-08	-	-	-	Not applicable	-	No
BAO CHEN	Director	Male	35	2025-06	2026-08	-	-	-	Not applicable	-	No
JIA HONG GAO	Independent Director	Male	65	2020-11	2026-08	-	-	-	Not applicable	20.00	No
SHENG LEIMING	Independent Director	Male	56	2020-11	2026-08	-	-	-	Not applicable	20.00	No
WANG SHAOFEI	Independent Director	Male	49	2020-11	2026-08	-	-	-	Not applicable	20.00	No
XIA FENGHUA	Senior Vice President	Male	56	2020-09	2026-08	-	-	-	Not applicable	222.44	No
HONGDI LI	Senior Vice President, Chief Technology Officer, Core Technical Personnel	Male	59	2020-09	2026-08	-	-	-	Not applicable	262.54	No
YU YE HENG	Senior Vice President	Female	47	2020-09	2026-08	-	-	-	Not applicable	206.51	No
Miao Hong	Senior Vice President	Male	54	2022-12	2026-08	-	-	-	Not applicable	200.84	No

Wang Jianbao	Chief Financial Officer, Financial Controller	Male	42	2024-05	2026-08	-	-	-	Not applicable	180.89	No
Lv Yunlei	Vice President	Male	48	2020-09	2026-08	-	-	-	Not applicable	187.94	No
Wang Shumei	Vice President	Female	49	2020-09	2026-08	-	-	-	Not applicable	153.15	No
QUN CHEN	Core Technical Personnel	Male	65	2020-09	-	-	-	-	Not applicable	Not applicable	No
Huang Xiangyu	Core Technical Personnel	Male	56	2020-09	-				Not applicable	Not applicable	No
YANFENG DU	Core Technical Personnel	Male	57	2020-09	-	-	-	-	Not applicable	Not applicable	No
Li Guobin	Core Technical Personnel	Male	46	2020-09	-	-	-	-	Not applicable	Not applicable	No
Xiang Jun	Core Technical Personnel	Male	48	2020-09	-	-	-	-	Not applicable	Not applicable	No
Wang Chao	Core Technical Personnel	Male	47	2020-09	-	-	-	-	Not applicable	Not applicable	No
An Shaohui	Core Technical Personnel	Male	47	2020-09	-	-	-	-	Not applicable	Not applicable	No
Hu Wei	Core technical	Mal	47	2020-	-	-	-	-	Not	Not applicable	No

	personnel	e		09					applic able		
Total	/	/	/	/	/	-	-	-	/	2,523.13	/

Note 1: The number of shares held in the above table is counted based on the attribution basis.

Name	Main work experience
Zhang Qiang	Born in 1969, Chinese nationality, holds U.S. permanent residency. Studied Biomedical Engineering at Shanghai Jiao Tong University from 1985 to 1989, obtaining a bachelor's degree; studied Biomedical Engineering at Shanghai Jiao Tong University from 1989 to 1992, obtaining a master's degree; studied Biomedical Engineering at Case Western Reserve University from 1996 to 2000, obtaining a doctoral degree. Previously worked at Shanghai Jiao Tong University, Unisys Corporation Shanghai Office, Siemens Medical Solution USA, Inc., Siemens (China) Co., Ltd. Shanghai Branch; from 2011 to 2020, served as General Manager and Director of United Imaging Limited; from 2020 to 2022, served as Chairman, General Manager, and CEO of United Imaging Healthcare; from 2022 to present, serves as Chairman and Co-CEO of United Imaging Healthcare.
GUOSHENG TAN	Born in 1963, U.S. nationality. Studied Radio Electronics at Tsinghua University from 1981 to 1986, obtaining a bachelor's degree; studied Electrical and Electronic Engineering at Georgia Institute of Technology from 1990 to 1992, obtaining a master's degree; studied Physics at Georgia Institute of Technology from 1986 to 1992, obtaining a doctoral degree. Previously worked at Medical College of Wisconsin, General Electric Company; from 2013 to 2020, served as CEO of the Medical Software Division, Co-CEO of the Diagnosis and Treatment Business Group, and CEO of the MR Division of United Imaging Limited; from 2020 to 2022, served as Director and President of United Imaging Healthcare; from 2022 to present, serves as Director, General Manager, and Co-CEO of United Imaging Healthcare.
JUN BAO	Born in 1965, U.S. nationality. Studied Automatic Control at Shanghai Jiao Tong University from 1982 to 1986, obtaining a bachelor's degree; studied Image Processing and Pattern Recognition at Shanghai Jiao Tong University from 1986 to 1989, obtaining a master's degree; studied Electrical Computer Engineering at Vanderbilt University from 1990 to 1993, obtaining a master's degree. Previously worked at the Image Processing and Pattern Recognition Institute of Shanghai Jiao Tong University, Siemens Medical Solutions USA, Inc.; from 2013 to 2020, served as CEO of the MI Division, Co-CEO of the Diagnosis and Treatment Business Group, and CEO of the CT&MI Division of United Imaging Limited; from 2020 to 2022, served as Senior Vice President of United Imaging Healthcare; from 2022 to present, serves as Director and President of United Imaging Healthcare.
TAO CAI	Born in 1972, U.S. nationality. Studied Materials Science and Engineering at Tsinghua University from 1990 to 1995, obtaining a bachelor's degree; studied at Stern School of Business, New York University from 2000 to 2001, obtaining a master's degree. Previously worked at Kodak (China) Co., Ltd., Shanda New Technology Development Company, Spinnaker Partners LLC, Tsing Capital (Hong Kong) Limited, Vimicro Corporation, A-Power Energy Generation Systems, Ltd., China Biotics Inc., Beijing

	Shengkangda Health Technology Development Co., Ltd., Power Environmental & Energy Research Institute; from 2016 to 2020, served as Senior Vice President and Chief Investment Officer of United Imaging Limited; from 2020 to 2022, served as Board Secretary and Chief Investment Officer of United Imaging Healthcare; from 2022 to May 2024, served as Chief Financial Officer and Financial Officer of United Imaging Healthcare; from 2022 to June 2025, served as Director, Chief Investment Officer, and Board Secretary of United Imaging Healthcare; from June 2025 to present, serves as Employee Director, Chief Investment Officer, and Board Secretary of United Imaging Healthcare.
Ding Jun (Departed)	Born in 1970, Chinese nationality, no permanent residency abroad. Studied Materials Science at Shanghai University of Technology from 1988 to 1992, obtaining a bachelor's degree. Previously served as Deputy Manager of Finance Department and Deputy Manager of Audit Department at Shanghai United, currently serves as Manager of Audit Department at Shanghai United. Served as Director of United Imaging Healthcare from August 2023 to April 2025.
Shen Siyu	Born in 1982, Chinese nationality, no permanent residency abroad. Studied Plant Science at Shanghai Jiao Tong University from 2000 to 2004, obtaining a bachelor's degree; studied Molecular Biology and Biochemistry at Fudan University from 2006 to 2012, obtaining a doctoral degree. From 2012 to 2021, served as Analyst, Investment Associate Manager, Senior Investment Manager, and Deputy General Manager of Investment Department III at Shanghai United; currently serves as General Manager of Investment Department III at Shanghai United, and has served as Director of United Imaging Healthcare from 2020 to present.
Bao Chen	Born in 1991, Chinese nationality, no permanent residency abroad. Studied Bioengineering at Huazhong Agricultural University from 2011 to 2015, obtaining a bachelor's degree. Studied Control Science and Engineering at Tsinghua University from 2015 to 2018, obtaining a master's degree. Previously served as Analyst and Investment Associate Manager at Shanghai United Investment Co., Ltd., currently serves as Investment Manager at Shanghai United Investment Co., Ltd. Served as Supervisor of United Imaging Healthcare from August 2023 to June 2025, and has served as Director of United Imaging Healthcare from June 2025 to present.
JIA HONG GAO	Born in 1961, U.S. nationality. From 1979 to 1984, studied Physics at the University of Science and Technology of China, obtaining a bachelor's degree; from 1985 to 1991, studied Applied Physics at Yale University, obtaining a doctoral degree. Previously held positions at the Massachusetts Institute of Technology, the University of Texas System, and the University of Chicago; since 2013, has served as the Director of the Magnetic Resonance Imaging Research Center at Peking University and the Director of the Beijing Key Laboratory of Medical Physics and Engineering; since 2020, has served as an independent director of United Imaging Healthcare.
Sheng Leiming	Born in 1970, Chinese nationality, no permanent residency abroad. From 1989 to 1993, studied Law at East China University of Political Science and Law, obtaining a bachelor's degree; from 2005 to 2008, studied Economic Law at East China University of Political Science and Law, obtaining a master's degree; from 2014 to 2020, studied Procedural Law at East China University of Political Science and Law, obtaining a doctoral degree. Previously held positions at Shanghai Foreign Trade and Commerce Law Firm, East China University of Political Science and Law, and Shanghai Zhongmao Law Firm; since 2016, has served as a lawyer at Guantao Zhongmao (Shanghai) Law Firm; since 2020, has served as an independent director of United Imaging Healthcare.

Wang Shaofei	Born in 1977, Chinese nationality, no permanent residency abroad. From 1995 to 1999, studied Statistics at Shanghai University of Finance and Economics, obtaining a bachelor's degree; from 2000 to 2003, studied Statistics at Shanghai University of Finance and Economics, obtaining a master's degree; from 2003 to 2007, studied Statistics at Shanghai University of Finance and Economics, obtaining a doctoral degree. Previously held a position at Shanghai Donghu (Group) Co., Ltd.; from 2007 to 2013, served as a postdoctoral researcher and faculty member at the School of Accountancy and Business School of Shanghai University of Finance and Economics; since 2020, has served as an independent director of United Imaging Healthcare.
Xia Fenghua	Born in 1970, Chinese nationality, no permanent residency abroad. From 1988 to 1992, studied Infrared Technology at Changchun Institute of Optics and Fine Mechanics (now renamed Changchun University of Science and Technology), obtaining a bachelor's degree; from 1992 to 1994, studied Industrial Foreign Trade at Nanjing University of Science and Technology, obtaining a bachelor's degree; from 2002 to 2003, studied Business Administration at City University Cass Business School, obtaining a master's degree. Previously held positions at China Machinery Engineering Corporation (formerly China National Machinery Import & Export Corporation), Marconi Medical Systems, Inc., Philips Medical Systems, and Shanghai Siemens Medical Equipment Co., Ltd.; from 2017 to 2020, served as Senior Vice President and Chief Operating Officer, then Co-President of United Imaging Limited; since 2020, has served as Senior Vice President of United Imaging Healthcare.
HONGDI LI	Born in 1967, American nationality. From 1985 to 1990, studied Nuclear Electronics at the University of Science and Technology of China, obtaining a bachelor's degree; from 1990 to 1993, studied Nuclear Electronics at the University of Science and Technology of China, obtaining a master's degree; from 1993 to 1996, studied Nuclear Physics and Nuclear Electronics at the University of Science and Technology of China, obtaining a doctoral degree. Previously held positions at the Hong Kong University of Science and Technology and the University of Texas MD Anderson Cancer Center; since 2013, has served as CEO of United Imaging America; since 2020, has served as Senior Vice President and Chief Technology Officer of United Imaging Healthcare.
Yu Yeheng	Born in 1979, Chinese nationality, no permanent residency abroad. From 1998 to 2002, studied Accounting at North China Electric Power University, obtaining a bachelor's degree; from 2003 to 2006, studied Business Administration at University Dortmund, obtaining a master's degree. Previously held positions at Shanghai Siemens Medical Equipment Co., Ltd. and Ingram Micro; from 2011 to 2020, served as Product Manager, Director of Design Innovation Center, Director of Design Innovation Center & Brand Strategy and Communication Center, Vice President, and CEO of Market & Brand Strategy Center & Design Innovation Center at United Imaging Limited; since 2020, has served as Senior Vice President of United Imaging Healthcare.
Miao Hong	Born in 1972, Chinese nationality, no permanent residency abroad. From 1989 to 1993, studied Electronic Communication Engineering at Shanghai Jiao Tong University, obtaining a bachelor's degree; from 1999 to 2001, studied EMBA at Fudan University School of Management. Previously held positions at Siemens (China) Medical Systems Division, Philips (China) Healthcare Division, and bioMérieux (China); from 2016 to 2020, served as CEO of Global Business Development and Vice President of China Business at United Imaging Limited; from 2020 to 2022, served as Vice President of China Business at United Imaging Healthcare; since 2022,

	has served as Senior Vice President of United Imaging Healthcare.
Wang Jianbao	Born in 1984, Chinese nationality, no permanent residency abroad. From 2002 to 2006, studied Advertising at Peking University, obtaining a bachelor's degree. Previously held positions as Auditor, Manager, Director, and Partner at PricewaterhouseCoopers Zhong Tian LLP; from 2023 to May 2024, served as Vice President of Strategic Planning Department at United Imaging Healthcare; since May 2024, has served as Chief Financial Officer and Financial Head of United Imaging Healthcare.
Lv Yunlei	Born in 1978, Chinese nationality, no permanent residency abroad. From 1996 to 2000, studied Mechanical Design and Manufacturing at Wuhan University of Technology, obtaining a bachelor's degree. Previously held positions at Xiamen Ruifeng Sealing Co., Ltd., China-Japan Electric Heating (Xiamen) Co., Ltd., Johnson Electric (Shenzhen) Co., Ltd., Siemens (Shenzhen) Magnetic Resonance Ltd. (formerly Siemens Medison (Shenzhen) Magnetic Resonance Ltd.), and Carl Zeiss Optical Technology (Guangzhou) Co., Ltd.; from 2019 to 2020, served as Vice President of Supply Chain Management at United Imaging Limited; since 2020, has served as Vice President of United Imaging Healthcare.
Wang Shumei	Born in 1977, Chinese nationality, no permanent residency abroad. From 1995 to 1997, studied Business Accounting at Nanchang Hangkong University; from 2016 to 2019, studied Business Administration at Shanghai Jiao Tong University. Previously held positions at Nantong Jinlun Card Clothing Co., Ltd., Guangzhou Tianyu Footwear Co., Ltd., Ningbo Yingtai Metal Products Co., Ltd., Dongguan Guangping Electronics Factory, and Siemens (Shenzhen) Magnetic Resonance Ltd. (formerly Siemens Medison (Shenzhen) Magnetic Resonance Ltd.); from 2011 to 2020, served as Director of Quality Management Department and Vice President of Quality Management Department at United Imaging Limited; since 2020, has served as Vice President of United Imaging Healthcare.
QUN CHEN	Born in 1961, American nationality. From 1978 to 1982, studied Nuclear Physics at Fudan University, obtaining a bachelor's degree; from 1982 to 1985, studied at the China Institute of Atomic Energy, obtaining a master's degree; from 1987 to 1993, studied Condensed Matter Physics at the University of Kentucky, obtaining a doctoral degree. Has previously held positions at University of Kentucky, China Institute of Atomic Energy, Harvard University, Northwestern University, New York University, and Shanghai Advanced Research Institute; from 2012 to present, serves as a Distinguished Professor at ShanghaiTech University; from 2015 to present, serves as an Adjunct Professor at Shanghai Jiao Tong University; from 2011 to 2020, served as Senior Vice President of United Imaging Limited; from August 2020 to August 2023, served as Senior Vice President of United Imaging Healthcare.
Huang Xiangyu	Born in 1970, Chinese nationality, holds U.S. permanent residency. From 1987 to 1991, studied Mechanics at Peking University, obtained a bachelor's degree; from 1991 to 1994, studied Fluid Mechanics at Peking University, obtained a master's degree; from 1995 to 1997, studied Applied Science at The College of William & Mary, obtained a master's degree. Has previously held positions at The College of William & Mary, Marconi Medical Systems, Inc., and Philips Medical Systems; from 2011 to 2020, served successively as CEO of the CT Business Unit, CEO of the Enterprise Information Technology and Security Management Department, CEO of the U+ Business Unit, CEO of the Ultrasound Business Unit, and Co-CEO of the Digital Technology Industry Business Group at United

	Imaging Limited; from August 2020 to August 2023, served as Senior Vice President of United Imaging Healthcare.
YANFENG DU	Born in 1969, U.S. nationality. From 1987 to 1992, studied Engineering Physics at Tsinghua University, obtained a bachelor's degree; from 1992 to 1995, studied Nuclear Physics at China Institute of Atomic Energy, obtained a master's degree; from 1996 to 2001, studied Radiation Measurement and Imaging at The University of Michigan, obtained a doctoral degree. Has held a position at GE Global Research Center; from 2012 to 2020, served successively as Vice President of the CT Business Unit and CTO of the CT&MI Business Unit at United Imaging Limited; from 2020 to present, serves as President of the Computed Tomography Business Unit at United Imaging Healthcare.
Li Guobin	Born in 1980, Chinese nationality, no permanent residency abroad. From 2000 to 2004, studied Communication Engineering at Harbin Institute of Technology, obtained a bachelor's degree; from 2004 to 2006, studied Information and Communication Systems at Harbin Institute of Technology, obtained a master's degree; from 2011 to 2015, studied Biomedical Engineering at Universität Freiburg, obtained a doctoral degree. Has held a position at Siemens (Shenzhen) Magnetic Resonance Ltd. (formerly known as 'Siemens Medison (Shenzhen) Magnetic Resonance Ltd.'); from 2015 to 2020, served successively as Senior and Expert R&D Engineer, and R&D Director at United Imaging Limited; from 2020 to present, serves as President of the Magnetic Resonance Business Unit at United Imaging Healthcare.
Xiang Jun	Born in 1978, Chinese nationality, no permanent residency abroad. From 1998 to 2002, studied Biomedical Engineering at Xi'an Jiaotong University, obtained a bachelor's degree. Has previously held positions at Neusoft Medical Systems Equipment Co., Ltd. (formerly known as 'Neusoft Philips Medical Systems Co., Ltd.') and Shanghai Siemens Medical Equipment Co., Ltd.; from 2011 to 2020, served successively as R&D Director, Vice President, and President of the XR Business Unit at United Imaging Limited; from 2020 to present, serves as President of the X-ray Business Unit at United Imaging Healthcare.
Wang Chao	Born in 1979, Chinese nationality, no permanent residency abroad. From 1997 to 2002, studied Applied Physics at University of Science and Technology of China, obtained a bachelor's degree; from 2002 to 2007, studied Physical Electronics at University of Science and Technology of China, obtained a doctoral degree. Has held a position at University of Texas, MD Anderson Cancer Center; from 2011 to 2020, served successively as Manager of the Electronics and Electrical Department, Senior Manager of the Electronics and Electrical Department, Senior Manager of the Project Management Department, and Director of the Project Management Department in the MI Business Unit at United Imaging Limited; from 2020 to present, serves as President of the Molecular Imaging Business Unit at United Imaging Healthcare.
An Shaohui	Born in 1979, Chinese nationality, no permanent residency abroad. From 1998 to 2002, studied Nuclear Electronics at University of Science and Technology of China, obtained a bachelor's degree; from 2002 to 2007, studied Particle Physics and Nuclear Physics at University of Science and Technology of China, obtained a doctoral degree. Has held a position at University of Texas, MD Anderson Cancer Center; from 2011 to 2020, served successively as Department Manager, R&D Director, and Vice President in the MI Business Unit at United Imaging Limited; from 2020 to present, serves as Vice President of the Molecular Imaging Business Unit at United

	Imaging Healthcare.
Hu Wei	Born in 1979, Chinese nationality, no permanent residency abroad. From 1997 to 2001, studied Computer Science at Shanghai University, obtained a bachelor's degree. Has previously held positions at VIA Technologies (Shanghai) Co., Ltd. (formerly known as 'S3 Graphics (Shanghai) Co., Ltd.') and Shanghai Siemens Medical Equipment Co., Ltd.; from 2011 to 2020, served successively as Project Manager, Project Director, and Vice President of the CT&MI Business Unit at United Imaging Limited; from 2020 to present, serves as Vice President of the Computed Tomography Business Unit at United Imaging Healthcare.

Other Information

√ Applicable□ Not applicable

The above statistics on shareholdings refer to direct individual shareholdings. Remuneration information for core technical personnel who do not serve as directors or senior management of the company is not disclosed due to commercial confidentiality reasons. As of the end of the reporting period, the changes in shareholdings of directors, senior management, and core technical personnel are as follows:

On August 4, 2025, the company disclosed the 'United Imaging Healthcare Shareholder Share Reduction Plan Announcement' (Announcement No.: 2025-030) on the Shanghai Stock Exchange website (www.sse.com.cn). Ningbo Yingju, Ningbo Yingli, Ningbo Yingjian, Ningbo Yingkang, and Shanghai Yingdong (collectively referred to as the 'Employee Shareholding Platforms') plan to reduce their shareholdings by a total of no more than 13,376,600 shares through block trades or centralized bidding, representing no more than 1.6231% of the total shares of United Imaging Healthcare. On November 20, 2025, the company disclosed the 'United Imaging Healthcare Announcement on the Result of Share Reduction by a Shareholder Holding More Than 5% and a Prompt Disclosure Announcement of Equity Change Upon Reduction to Below 5%' (Announcement No.: 2025-047) on the Shanghai Stock Exchange website (www.sse.com.cn). During this share reduction plan period, the Employee Shareholding Platforms cumulatively reduced their shareholdings by 13,376,600 shares through centralized bidding and block trades, accounting for 1.6231% of the company's total share capital. As of the end of the reporting period, the changes in indirect shareholdings of directors, senior management, and core technical personnel are as follows:

Name	Position	Indirect Shareholding at Beginning of Period (shares)	Indirect Shareholding at End of Period (shares)	Reason for Change
Zhang Qiang	Chairman, Co-CEO, Core Technical Personnel	1,507,041.00	599,242.00	Personal funding needs
GUOSHENG TAN	Director, General Manager, Co-CEO	2,178,810.00	2,178,810.00	/
JUN BAO	Director, President	2,178,810.00	2,178,810.00	/

TAO CAI	Employee Director, Board Secretary, Chief Investment Officer	1,561,677.00	1,254,769.00	Personal funding needs
XIA FENGHUA	Senior Vice President	1,473,828.00	1,096,887.00	Personal funding needs
HONGDI LI	Senior Vice President, CTO, Core Technical Personnel	2,355,305.00	2,316,942.00	Personal funding needs
YU YE HENG	Senior Vice President	775,699.00	775,699.00	/
MIAO HONG	Senior Vice President	1,665,104.00	1,295,104.00	Personal funding needs
LV YUNLEI	Vice President	90,427.00	67,409.00	Personal funding needs
WANG SHUMEI	Vice President	590,559.00	396,180.00	Personal funding needs
QUN CHEN	Core Technical Personnel	2,918,531.00	2,918,531.00	/
HUANG XIANGYU	Core Technical Personnel	1,584,964.00	1,063,234.00	Personal funding needs
YANFENG DU	Core Technical Personnel	777,412.00	700,685.00	Personal funding needs
LI GUOBIN	Core Technical Personnel	512,023.00	214,437.00	Personal funding needs
XIANG JUN	Core Technical Personnel	921,641.00	748,255.00	Personal funding needs
WANG CHAO	Core Technical Personnel	307,214.00	307,214.00	/
AN SHAOHUI	Core Technical Personnel	117,135.00	78,090.00	Personal funding needs
HU WEI	Core Technical Personnel	100,841.00	100,841.00	/

The company's senior management, core technical personnel, and other key employees participated in the company's IPO strategic placement through the CITIC Securities United Imaging Healthcare Employee Participation in Sci-Tech Innovation Board Strategic Placement No. 1 Collective Asset Management Plan (hereinafter referred to as the "UIH Employee Asset Management Plan No. 1", allocated 4,493,640 shares,

with 800,111 shares held at the end of the reporting period), CITIC Securities United Imaging Healthcare Employee Participation in Sci-Tech Innovation Board Strategic Placement No. 2 Collective Asset Management Plan (hereinafter referred to as the "UIH Employee Asset Management Plan No. 2", allocated 3,695,573 shares, with 837,566 shares held at the end of the reporting period), CITIC Securities United Imaging Healthcare Employee Participation in Sci-Tech Innovation Board Strategic Placement No. 3 Collective Asset Management Plan, and CITIC Securities United Imaging Healthcare Employee Participation in Sci-Tech Innovation Board Strategic Placement No. 4 Collective Asset Management Plan.

As of the end of the reporting period, the changes in indirect shareholdings of senior management and core technical personnel are as follows:

Name	Position	Indirect Shareholding at Beginning of Period	Indirect Shareholding at End of Period	Reason for Change
XIA FENGHUA	Senior Vice President	Directly held 2,351,113.19 units of UIH Employee Asset Management Plan No. 1	-	Personal funding needs
MIAO HONG	Senior Vice President	Directly held 7,000,079.09 units of UIH Employee Asset Management Plan No. 2	Directly held 6,000,000.09 units of UIH Employee Asset Management Plan No. 2	Personal funding needs
Lv Yunlei	Vice President	Directly holds 8,490,171.56 shares in United Imaging Healthcare Employee Asset Management Plan No. 2	Directly holds 8,490,171.56 shares in United Imaging Healthcare Employee Asset Management Plan No. 2	/
Wang Chao	Core technical personnel	Directly holds 14,069,996.25 shares in United Imaging Healthcare Employee Asset Management Plan No. 2	Directly holds 14,069,996.25 shares in United Imaging Healthcare Employee Asset Management Plan No. 2	/

The specific details of director compensation for the year 2025 are as follows:

Unit: 10,000 yuan

Name	Allowance	Paid compensation	Employer contributions for various social insurances, housing provident fund, etc.	Total pre-tax
Zhang Qiang	-	309.35	19.09	328.45
GUOSHENG TAN	-	262.41	3.85	266.26
JUN BAO	-	255.71	3.85	259.56

TAO CAI	-	190.70	3.85	194.55
Shen Siyu	-	-	-	-
Bao Chen	-	-	-	-
Sheng Leiming	20.00	-	-	20.00
Wang Shaofei	20.00	-	-	20.00
JIA HONG GAO	20.00	-	-	20.00

(ii) Employment details of current and former directors and senior management during the reporting period

(1). Positions held at shareholder units

√ Applicable□ Not applicable

Name of the person holding the position	Name of shareholder unit	Position held at the shareholder unit	Term start date	Term end date
Zhang Qiang	United Imaging Group	Director	2019-03	-
Zhang Qiang	Shanghai Yingdong	Executive Partner	2021-07	-
Zhang Qiang	Ningbo Yingju	Executive Partner	2021-08	-
Zhang Qiang	Ningbo Yingli	Executive Partner	2017-07	-
Zhang Qiang	Ningbo Yingjian	Executive Partner	2021-08	-
Zhang Qiang	Ningbo Yingkang	Executive Partner	2021-08	-
Ding Jun (Former)	Shanghai United	Audit Department Manager	2000-07	-
Shen Siyu	Shanghai United	Department General Manager	2012-02	-
Bao Chen	Shanghai United	Investment Manager	2019-05	-
Explanation of positions held in shareholder units	None			

(2). Positions held in other units

√ Applicable□ Not applicable

Name of the person holding the position	Name of the other unit	Position held in the other unit	Term start date	Term end date
Zhang Qiang	Shanghai Intelligent	Director	2019-05	2025-11
Zhang Qiang	Wuhan Medical Engineering Institute	Chairman	2018-12	-
Zhang Qiang	Shenzhen High Energy	Director	2019-09	-
Zhang Qiang	Wuhan Zhirong	Director	2019-02	-
Zhang Qiang	China Association of Medical Equipment	Vice Chairman	2022-04	2027-04
Zhang Qiang	Chinese Hospital Association	Council Member	2022-12	2027-12
Zhang Qiang	Shanghai Nuclear Society	Vice Chairman	2020-10	2025-12
Zhang Qiang	Chinese Society of Biomedical Engineering	Vice Chairman	2023-12	-
Zhang Qiang	Shanghai Association for Science and	Vice Chairman	2023-10	-

	Technology			
Zhang Qiang	Shanghai Entrepreneurs Association	Vice President	2023-11	-
Zhang Qiang	China Invention Association	Council Member	2025-4	-
Ding Jun (Departed)	Shanghai Liansheng Investment Management Co., Ltd.	Director	2014-05	2025-01
Ding Jun (Departed)	Shanghai Zizhu Hi-tech Industrial Park (Group) Co., Ltd.	Supervisor	2016-09	2025-01
Ding Jun (Departed)	Shanghai Xinwei Semiconductor Co., Ltd.	Supervisor	2020-04	-
Shen Siyu	Shanghai Fushi Medical Technology Co., Ltd.	Director	2019-05	-
Shen Siyu	Guangzhou Jiayue Pharmaceutical Technology Co., Ltd.	Director	2020-04	-
Shen Siyu	Shanghai Xuantai Pharmaceutical Technology Co., Ltd.	Director	2018-09	-
Shen Siyu	Hejing Pharmaceutical Technology (Shanghai) Co., Ltd.	Director	2021-03	-
Shen Siyu	Aipuqiang	Director	2023-03	-
Shen Siyu	Shanghai Research Institute	Director	2024-12	-
Shen Siyu	Shanghai Wisdom	Director	2024-03	-
Shen Siyu	Shanghai Intelligent	Director	2024-10	-
Shen Siyu	Innostellar Biotherapeutics Co., Ltd	Director	2021-09	-
JIA HONG GAO	Beijing Municipal Key Laboratory of Medical Physics and Engineering, Peking University MRI Research Center	Director	2013-03	-
Sheng Leiming	Guantao Law Firm (Shanghai)	Lawyer	2016-12	-
Sheng Leiming	Tsingtao Brewery Co., Ltd.	Independent Director	2020-06	-
Sheng Leiming	Kweichow Moutai Co., Ltd.	Independent Director	2022-06	-
Wang Shaofei	Shanghai Hehe Information Technology Co., Ltd.	Independent Director	2020-05	-
Wang Shaofei	Qingdao Rural Commercial Bank Co., Ltd.	Independent Director	2020-06	-

Wang Shaofei	Baowu Resources Co., Ltd.	Director	2023-08	-
Wang Shaofei	Baosteel Resources (International) Co., Ltd.	Director	2023-08	
Bao Chen	Shanghai Rimut Technology Co., Ltd.	Supervisor	2021-05	-
Bao Chen	Aipuqiang	Supervisor	2023-03	-
Bao Chen	Shanghai Wisdom	Supervisor	2024-03	-
TAO CAI	Shanghai Wisdom	Director	2016-10	-
TAO CAI	Wuhan Zhirong	Director	2019-02	-
TAO CAI	Changzhou United Imaging Surgical Medical Technology Co., Ltd.	Director	2019-12	-
TAO CAI	Shanghai Honglin Technology Investment Co., Ltd.	Director	2020-06	-
TAO CAI	Qingneng Aike (Shenzhen) Energy Technology Co., Ltd.	Director	2018-05	
TAO CAI	Shanghai Intelligence	Director	2025-05	-
Yu Yeheng	Shanghai Intelligence	Supervisor	2019-05	-
Explanation of positions held in other entities	None			

(iii) Compensation of directors, senior management, and key technical personnel

√ Applicable□ Not applicable

Unit: 10,000 yuan Currency: RMB

Decision-making process for compensation of directors and senior management	According to the Company's Articles of Association, the Board's Compensation and Assessment Committee is responsible for drafting compensation plans. The compensation of directors is reviewed by the Board and implemented after approval by the shareholders' meeting. The compensation of senior management is determined by the Board.
Whether directors recuse themselves from Board discussions on their own compensation matters	Yes
Specific circumstances of recommendations by the Compensation and Assessment Committee or special meetings of independent directors regarding compensation matters for directors and senior management	During the reporting period, the Board's Compensation and Assessment Committee issued favorable review opinions on compensation matters for directors and senior management. For details, refer to 'Section IV, Item 9: Status of Special Committees under the Board'.

Basis for determining compensation of directors and senior management	Independent directors receive fixed compensation. Directors holding positions in the Company or its subsidiaries receive compensation based on their roles and do not receive separate director compensation, and are assessed according to the Company's compensation system. Directors not holding positions in the Company do not receive compensation from the Company. Senior management receive compensation and are assessed based on their roles and the Company's compensation system.
Actual Payment of Compensation for Directors and Senior Management	During the reporting period, the actual payment of compensation for the company's directors and senior management was consistent with the company's disclosures.
Total actual compensation received by all directors and senior management at the end of the reporting period	2,523.13
Total actual compensation received by core technical personnel at the end of the reporting period	2,340.56
Basis and completion status of performance evaluation for actual compensation received by all directors and senior management at the end of the reporting period	In 2025, independent directors received fixed allowances, non-independent directors did not receive director compensation, and performance evaluation is not applicable; senior management received corresponding compensation based on the company's operating conditions and evaluations, with performance evaluations conducted in accordance with the company's performance evaluation regulations, effectively implemented and completed.
Deferred payment arrangements for actual compensation received by all directors and senior management at the end of the reporting period	In 2025, independent directors received fixed allowances, non-independent directors did not receive director compensation, and relevant regulations are not applicable; a certain proportion of senior management compensation is paid after the disclosure of the annual report and completion of performance evaluation.
Recovery and clawback status of actual compensation received by all directors and senior management at the end of the reporting period	Not applicable

(iv) Changes in the company's directors, senior management, and core technical personnel

√ Applicable□ Not applicable

Name	Position Held	Change Type	Reason for Change
Ding Jun	Director	Resignation	Job Transfer
Bao Chen	Director	Election	Job Transfer
TAO CAI	Director	Resignation	Job Transfer

TAO CAI	Employee Director	Election	Job Transfer

(v) Explanation of Penalties Imposed by Securities Regulatory Authorities in the Past Three Years

□ Applicable√ Not applicable

(vi) Other

□ Applicable√ Not applicable

6. Directors' Performance of Duties

(i) Directors' Attendance at Board and Shareholders' Meetings

Director Name	Independent Director	Board Meeting Attendance						Shareholders' Meeting Attendance
		Number of Board Meetings Scheduled for the Year	Number of In-Person Attendances	Number of Attendances via Communication	Number of Proxy Attendances	Absences Number	Consecutive Two Absences from Meetings	Number of Shareholders' Meeting Attendances
Zhang Qiang	No	9	9	0	0	0	No	2
GUOSHENG TAN	No	9	9	0	0	0	No	2
JUN BAO	No	9	9	0	0	0	No	2
TAO CAI	No	9	9	0	0	0	No	2
Ding Jun (Resigned)	No	2	2	2	0	0	No	1
Shen Siyu	No	9	9	9	0	0	No	2
Bao Chen	No	6	6	6	0	0	No	1
JIA HONG GAO	Yes	9	9	9	0	0	No	2
Sheng Leiming	Yes	9	9	9	0	0	No	2
Wang Shaofei	Yes	9	9	9	0	0	No	2

Explanation for failing to attend board meetings in person for two consecutive times
□ Applicable√ Not applicable

Number of board meetings held during the year	9
Among which: Number of on-site meetings	0
Number of meetings held via communication means	0
Number of meetings held via on-site combined with communication means	9

(ii) Directors' objections to company matters

□ Applicable√ Not applicable

(iii) Others

□ Applicable√ Not applicable

7. Special committees under the board of directors

√ Applicable□ Not applicable

(i) Members of special committees under the board of directors

Type of special committee	Member names
Audit Committee	Wang Shaofei (Chairman), Shen Siyu, Sheng Leiming
Nomination Committee	JIA HONG GAO (Chairman), Zhang Qiang, Sheng Leiming
Compensation and Evaluation Committee	Sheng Leiming (Chairman), Shen Siyu, Wang Shaofei
Strategy and Social Responsibility Committee	Zhang Qiang (Chairman), JIA HONG GAO, GUOSHENG TAN, JUN BAO, TAO CAI

(ii) The Audit Committee held 3 meetings during the reporting period

Meeting date	Meeting content	Important opinions and suggestions	Other duties performed
2025.4.25	The First Meeting of the Second Board Audit Committee in 2025	After thorough communication and discussion, the following proposals were unanimously reviewed and approved: 'Proposal on the Company's 2024 Annual Report and Summary', 'Proposal on the Company's 2024 Internal Control Evaluation Report', 'Proposal on the Company's 2024 Financial Final Accounts Report', 'Proposal on the Company's 2025 First Quarter Report', 'Proposal on Reappointing the Accounting Firm	None

		for 2025', 'Proposal on the Company's 2024 Audit Department Work Report'	
2025.8.28	The Second Meeting of the Second Board Audit Committee in 2025	After thorough communication and discussion, the 'Proposal on the Company's 2025 Semi-Annual Report and Summary' was unanimously reviewed and approved	None
2025.10.28	The Third Meeting of the Second Board Audit Committee in 2025	After thorough communication and discussion, the 'Proposal on the Company's 2025 Third Quarter Report' was unanimously reviewed and approved	None

(iii) The Nomination Committee held 1 meeting during the reporting period

Meeting date	Meeting content	Important opinions and suggestions	Other duties performed
2025.4.25	The First Meeting of the Second Board Nomination Committee in 2025	After thorough communication and discussion, the 'Proposal on Electing Additional Directors' was unanimously reviewed and approved	None

(iv) The Compensation and Evaluation Committee held 4 meetings during the reporting period

Meeting date	Meeting content	Important opinions and suggestions	Other duties performed
2025.4.25	The First Meeting of the Second Board Compensation and Evaluation Committee in 2025	After thorough communication and discussion, the following proposals were unanimously reviewed and approved: 'Proposal on the Company's 2025 Director Compensation', 'Proposal on the Company's 2025 Senior Management Compensation', 'Proposal on Purchasing Directors' and Senior Management Liability Insurance'	None
2025.6.13	The Second Meeting of the Second Board	After thorough communication and discussion, the following proposals were unanimously reviewed and approved: 'Proposal on the Company's <2025 Restricted Stock Incentive	None

	Compensation and Evaluation Committee in 2025	Plan (Draft)> and Its Summary', 'Proposal on the Company's <2025 Restricted Stock Incentive Plan Implementation and Assessment Management Measures>', 'Proposal on Requesting Shareholders' Meeting to Authorize the Board to Handle Matters Related to the Company's 2025 Restricted Stock Incentive Plan'	
2025.8.25	Second Board of Directors Compensation and Assessment Committee Third Meeting of 2025	After thorough communication and discussion, the committee unanimously reviewed and approved the 'Proposal on Adjusting the Initial Grant Price of the Company's 2025 Restricted Stock Incentive Plan' and the 'Proposal on the Initial Grant of Restricted Stock to Incentive Recipients under the Company's 2025 Restricted Stock Incentive Plan'.	None
2025.10.14	Second Board of Directors Compensation and Assessment Committee Fourth Meeting of 2025	After thorough communication and discussion, the committee unanimously reviewed and approved the 'Proposal on Adjusting the Grant Price of the Company's 2025 Restricted Stock Incentive Plan' and the 'Proposal on Granting the Reserved Portion of Restricted Stock to Incentive Recipients under the Company's 2025 Restricted Stock Incentive Plan'.	None

(v) The Strategy and Social Responsibility Committee held 1 meeting during the reporting period.

Meeting Date	Meeting Content	Important Opinions and Suggestions	Other Duties Performed
2025.4.25	Second Board of Directors Strategy and Social Responsibility Committee First Meeting of 2025	After thorough communication and discussion, the committee unanimously reviewed and approved the 'Proposal on the Company's 2024 Environmental, Social, and Governance Report' and the 'Proposal on the Assessment Report of the Company's 2024 'Enhance Quality and Efficiency, Reward Shareholders' Action Plan and the 2025 'Enhance Quality and Efficiency, Reward Shareholders' Action Plan'.	None

(vi) Specifics of Dissenting Matters

□ Applicable√ Not Applicable

8. Explanation by the Audit Committee Regarding Identified Company Risks

□ Applicable√ Not Applicable

The Audit Committee has no objections regarding the matters supervised during the reporting period.

9. Employee Status of the Parent Company and Major Subsidiaries at the End of the Reporting Period

(i) Employee Status

Number of Employees in the Parent Company	5,313
Number of Employees in Major Subsidiaries	3,390
Total Number of Employees	8,703
Number of Retired Employees for Whom the Parent Company and Major Subsidiaries Bear Expenses	23
Professional Composition	
Professional Category	Number of Personnel by Category
Production Personnel	1,747
Sales Personnel	1,759
Technical Personnel	3,497
Financial Personnel	90
Administrative Personnel	56
Service Personnel	1,019
Other Personnel	535
Total	8,703
Education Level	
Education Level Category	Quantity (Persons)
Doctorate	435
Master's Degree	3,224
Bachelor's Degree	3,116
Associate Degree / College	936
Below High School	992
Total	8,703

(ii) Compensation Policy

√ Applicable□ Not Applicable

The company strictly complies with the laws and regulations of the countries and regions where it operates, such as the Labor Law, the Employment Rights Act, and the Pay Transparency Directive, to ensure the legality and compliance of compensation management. By continuously optimizing the performance and compensation management system, the company designs scientifically sound and reasonable compensation incentive mechanisms tailored to the characteristics of each position. It has established a compensation structure for all eligible employees, including fixed income, variable income, and long-term incentives. The company conducts comparative analysis based on market compensation levels, promptly updates the compensation framework for each job grade, and ensures the market competitiveness of employee compensation. The company has launched diversified employee equity incentive plans at different stages of development,

including Employee Stock Ownership Plans (ESOP), Type II Restricted Stock Incentive Plans, and Employee Strategic Placement Share Plans.

(iii) Training Plan

√ Applicable□ Not Applicable

Through a systematic talent development system, diversified training resources, clear career development paths, and a sound compensation and performance incentive mechanism, the company fosters a proactive organizational atmosphere, achieving deep integration of employees' personal value with the company's strategic goals. It constructs a panoramic talent development plan, effectively enhancing managerial leadership while continuously expanding employees' international perspectives and professional skills. In 2025, the employee training participation rate reached 100%, covering three groups: new employees, incumbent employees, and managers, with a focus on enhancing professional skills, leadership, and cross-cultural communication skills.

(iv) Labor Outsourcing Situation

□ Applicable√ Not Applicable

10. Profit Distribution or Capital Reserve Conversion Plan

(i) Formulation, Implementation, or Adjustment of Cash Dividend Policy

√ Applicable□ Not Applicable

1. Formulation of Cash Dividend Policy

The company has established its dividend distribution policy in the Company's Articles of Association, with complete relevant decision-making procedures and mechanisms. The company will strictly implement the profit distribution plan in accordance with the relevant profit distribution policy and review procedures stipulated in the Company's Articles of Association, effectively safeguarding the interests of all shareholders.

2. Implementation of Cash Dividend Policy

During the reporting period, the company implemented the following profit distribution plan: The 2024 Annual General Meeting of Shareholders held on June 30, 2025, reviewed and approved the 'Proposal on the 2024 Profit Distribution Plan'. The Board of Directors proposed to distribute a cash dividend of RMB 0.80 per share (tax inclusive) to all shareholders based on the total share capital registered on the record date for the equity distribution. On the equity distribution record date, the company's total share capital was 824,157,988 shares. After deducting 4,134,116 shares in the special securities account for repurchase, a cash dividend of RMB 65,601,909.76 (including tax) was distributed based on this amount. This plan has been completed.

Authorized by the 2024 Annual Shareholders' Meeting on June 30, 2025, and in accordance with the 'Proposal on the Company's 2025 Interim Profit Distribution Plan,' the company distributed a cash dividend of RMB 1.30 per 10 shares (including tax) to all shareholders. On the equity distribution record date, the company's total share capital was 824,157,988 shares. After deducting 4,134,116 shares in the special securities account for repurchase, a cash dividend of RMB 106,603,103.36 (including tax) was distributed based on this amount. This plan has been completed.

The 2025 annual profit distribution plan is as follows: The company proposes to distribute a cash dividend of RMB 1.80 per 10 shares (including tax) based on the total share capital registered on the equity distribution record date, minus the total shares in the special securities account for repurchase. This profit distribution does not include bonus shares or capital reserve conversion into share capital. As of March 31, 2026, the company's total share capital was 824,157,988 shares. After deducting 4,134,116 shares in the special securities account for repurchase, the total proposed cash dividend is RMB 147,604,296.96 (including tax) based on this amount. If the company's total share capital or the total number of shares participating in profit distribution changes before the equity distribution record date, the company intends to maintain the per-share distribution ratio unchanged and adjust the total distribution amount accordingly.

The above profit distribution plan has been reviewed and approved by the company's Second Board of Directors' Thirtieth Meeting and is still subject to approval by the shareholders' meeting.

If the company remains profitable in the first half of 2026 and meets the conditions for cash dividends, the company plans to add an interim dividend. The expected interim cash dividend for 2026 will be no less than 10% and no more than 100% of the net profit attributable to the listed company's shareholders for the corresponding period.

(ii) Special Explanation on Cash Dividend Policy

√ Applicable□ Not Applicable

Whether it complies with the company's articles of association or the requirements of the shareholders' meeting resolution	√ Yes□ No
Whether the dividend standards and ratios are clear and specific	√ Yes□ No
Whether the relevant decision-making procedures and mechanisms are complete	√ Yes□ No
Whether the independent directors have performed their duties diligently and played their due role	√ Yes□ No
Whether minority shareholders have sufficient opportunities to express their opinions and demands, and whether their legitimate rights and interests are fully protected	√ Yes□ No

(iii) If the company is profitable during the reporting period and the parent company's distributable profits to shareholders are positive, but no cash profit distribution plan is proposed, the company shall disclose in detail the reasons and the intended use of the undistributed profits.

□ Applicable√ Not Applicable

(iv) Profit Distribution and Capital Reserve Capitalization Plan for the Current Reporting Period

√ Applicable□ Not Applicable

Unit: Yuan Currency: RMB

Number of bonus shares per 10 shares (shares)	-
Dividend per 10 shares (Yuan) (including tax)	3.10
Number of shares converted per 10 shares (shares)	-
Cash dividend amount (including tax)	254,207,400.32
Net profit attributable to ordinary shareholders of the listed company in the consolidated financial statements	1,869,300,805.65
Ratio of cash dividend amount to net profit attributable to ordinary shareholders of the listed company in the consolidated financial statements (%)	13.60
Amount of cash dividends included in cash dividends from share repurchases	-
Total dividend amount (including tax)	254,207,400.32
Ratio of total dividend amount to net profit attributable to ordinary shareholders of the listed company in the consolidated financial statements (%)	13.60

Note: Dividend per 10 shares (Yuan) (including tax) includes the 2025 interim dividend.

(v) Cash Dividend Situation in the Last Three Accounting Years

√ Applicable□ Not Applicable

Unit: Yuan Currency: RMB

Net profit attributable to ordinary shareholders of the listed company in the consolidated financial statements for the most recent accounting year	1,869,300,805.65
Undistributed profit at the end of the most recent accounting year in the parent company's financial statements	8,039,528,915.04
Cumulative cash dividend amount in the last three accounting years (including tax) (1)	622,832,989.52
Cumulative amount of shares repurchased and canceled in the last three accounting years (2)	-
Cumulative amount of cash dividends and shares repurchased and canceled in the last three accounting years (3) = (1) + (2)	622,832,989.52
Average annual net profit amount in the last three accounting years (4)	1,701,820,858.14
Cash dividend ratio in the last three accounting years (%) (5) = (3) / (4)	36.60
Cumulative R&D investment amount in the last three accounting years	6,800,801,471.32
Ratio of cumulative R&D investment to cumulative operating revenue in the last three accounting years (%)	19.15

11. Situation and impact of the company's equity incentive plans, employee stock ownership plans, or other employee incentive measures

(i) Overall Situation of Equity Incentives

√ Applicable□ Not Applicable

(1). Equity Incentive Plan Schemes During the Reporting Period

Unit: Yuan Currency: RMB

Plan Name	Incentive Method	Number of Underlying Shares	Percentage of Underlying Shares (%)	Number of Incentive Recipients	Percentage of Incentive Recipients (%)	Grant Price of Underlying Shares
2023 Restricted Stock Incentive Plan Initial Grant	Category II Restricted Stock	3,571,200	0.43	1,510	20.30	77.63
2023 Restricted Stock Incentive Plan Reserved Grant	Category II Restricted Stock	258,100	0.03	12	0.16	87.63
2024 Restricted Stock Incentive Plan Initial Grant	Category II Restricted Stock	2,112,900	0.26	833	11.20	87.75
2024 Restricted Stock Incentive Plan Reserved Grant	Category II Restricted Stock	509,000	0.06	36	0.48	87.75
2025 Restricted Stock Incentive Plan Initial Grant	Category II Restricted Stock	4,471,300	0.54	1,368	16.74	94.79
2025 Restricted Stock Incentive Plan Reserved Grant	Category II Restricted Stock	528,700	0.06	36	0.44	94.79

Note 1: The adjustment in the number of incentive recipients is due to resignations or waivers.
Note 2: The adjustment in the grant price of underlying shares is due to cash dividend distributions.

(2). Progress of Equity Incentive Implementation During the Reporting Period

√ Applicable□ Not Applicable

Unit: Shares

Plan Name	Number of Equity	Number of New	Number of Shares	Number of Shares	Grant Price/E	Number of Equity	Number of Shares

	Incentives Granted at the Beginning of the Year	Equity Incentives Granted During the Reporting Period	Eligible for Vesting/Exercise/Unlocking During the Reporting Period	Vested/Exercised/Unlocked During the Reporting Period	xercise Price (Yuan)	Incentives Granted by the End of the Period	Vested/Exercised/Unlocked by the End of the Period
2023 Restricted Stock Incentive Plan Initial Grant	3,741,900	-	-	-	77.63	/	-
2023 Restricted Stock Incentive Plan Reserved Grant	258,100	-	-	-	87.63	/	-
2024 Restricted Stock Incentive Plan Initial Grant	2,112,900	-	-	-	87.75	/	-
2024 Restricted Stock Incentive Plan Reserved Grant	509,000	-	-	-	87.75	/	-
2025 Restricted Stock Incentive Plan Initial Grant	-	4,471,300	-	-	94.79	/	-
2025 Restricted Stock Incentive Plan Reserved Grant	-	528,700	-	-	94.79	/	-

Note: The adjustment of the grant price/exercise price is due to the distribution of cash dividends.

(3). Completion of equity incentive assessment indicators and recognized share-based payment expenses during the reporting period

√Applicable□Not applicable

Unit: Yuan Currency: RMB

Plan Name	Completion status of company-level assessment indicators during the reporting period	Share-based payment expenses recognized during the reporting period
2023 Restricted Stock Incentive Plan	Did not reach the target value	-32,966,211.54
2024 Restricted Stock Incentive Plan	Target value not achieved	-9,311,674.72

2025 Restricted Stock Incentive Plan	Achieve the target value	48,552,873.30
Total	/	6,274,987.04

(ii) Relevant incentive matters have been disclosed in the interim announcement and there has been no progress or changes in subsequent implementation.

√Applicable□Not applicable

Overview of Matters	Query Index
On October 14, 2025, the company held the 24th meeting of the second board of directors, where it reviewed and approved the 'Proposal on the Initial Grant of Restricted Shares to Incentive Targets under the Company's 2025 Restricted Share Incentive Plan' and the 'Proposal on Adjusting the Grant Price of the Company's 2025 Restricted Share Incentive Plan.' The relevant matters have been reviewed and approved by the Remuneration and Assessment Committee, which also issued a verification opinion.	For specific details, please refer to the relevant announcement disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn) and designated information disclosure media on October 16, 2025.

Other remarks
□Applicable√Not applicable

Employee Stock Ownership Plan Status
□Applicable√Not applicable

Other incentives
□Applicable√Not applicable

(iii) Equity incentives granted to directors, senior management, and key technical personnel during the reporting period

(1). Stock Options

□Applicable√Not applicable

(2). Type I Restricted Stock

□Applicable√Not applicable

(3). Type II restricted stock

√Applicable□Not applicable

Unit: shares

Name	Position	Number of restricted shares granted at the	Number of restricted shares newly granted	Grant Price of Restricted Stock (RMB)	Attributable quantity during the	Number of vested units during the	Number of restricted shares granted at the	Market price at the end of the reporting

		beginning of the year	during the reporting period		reporting period	reporting period	end of the period	period (yuan)
Wang Jianbao	Chief Financial Officer, Head of Finance	200,000	200,000	94.79	-	-	-	125.50
Hu Wei	Core technical personnel	10,000	8,000	94.79	-	-	-	125.50
Total	/	210,000	208,000	/	-	-	-	/

(iv) Evaluation mechanism for senior management during the reporting period, and the establishment and implementation of incentive mechanisms

√Applicable□Not applicable

The company's board of directors has established a Compensation and Evaluation Committee, which is responsible for formulating evaluation standards for senior management and conducting evaluations. The company implements a comprehensive compensation system for senior management that combines short, medium, and long-term incentives, establishing a performance evaluation and incentive-constraint mechanism that links senior management compensation to company performance.

12. Establishment and implementation of internal control systems during the reporting period

√Applicable□Not applicable

During the reporting period, the company strictly complied with legal and regulatory requirements, and in accordance with the 'Basic Standards for Enterprise Internal Control' and its supporting guidelines, continuously assessed and improved the internal control system by integrating internal and external operating environments and the actual development situation of the company. The company's Board of Directors has established an Audit Committee to guide and supervise the work of the company's internal audit department. The company has established an audit department, whose responsibility is to promote the effective operation and management of the company and assist the board of directors and the audit committee in fulfilling their respective responsibilities.

Explanation of Significant Deficiencies in Internal Control during the Reporting Period
□Applicable√Not applicable

13. Management and control of subsidiaries during the reporting period

√Applicable□ Not applicable

During the reporting period, subsidiaries operated in accordance with the management systems established by the Company, and the Company maintained good control over its subsidiaries, with clear internal organizational structures and well-defined functions.

Risk notification regarding abnormal management control of subsidiaries
□ Applicable√ Not applicable

14. Explanation of the internal control audit report

√ Applicable□ Not applicable

For details, please refer to the 'United Imaging Healthcare 2025 Internal Control Audit Report' disclosed by the Company on the same day on the Shanghai Stock Exchange website (www.sse.com.cn).
Whether the internal control audit report is disclosed: Yes
Type of opinion in the internal control audit report: Unmodified opinion

15. Rectification status of self-inspection issues from the corporate governance special action

There are no rectification issues from the self-inspection.

16. Board of Directors' statement on ESG

Sustainable development and green, low-carbon transformation have become the essential path for high-quality development of global enterprises. During the reporting period, United Imaging Healthcare continued to deeply integrate environmental, social responsibility, and corporate governance into its corporate strategy, adhering to the development philosophy of 'technology-driven, sustainability-led,' to promote green, efficient, and resilient development in the global medical technology field.

For many years, United Imaging Healthcare has consistently integrated the concept of sustainable development deeply into its corporate strategy, continuously investing in key areas such as R&D innovation, quality and compliance management, supply chain collaboration, talent development, and green operations, gradually building a corporate development system that combines technological leadership and responsibility.

Leveraging its profound foundation in corporate governance, social responsibility, and sustainable operations, the Company achieved a milestone leap in the 2025 global authoritative ESG assessment: its MSCI ESG rating jumped to AA, officially entering the ranks of global leaders in the medical technology industry; its CSI ESG rating received AAA, ranking first in the industry (top 8%); in the S&P Global Corporate Sustainability Assessment (CSA), the Company not only remained in the top 10% of the medical equipment industry but was also successfully included in the list of over 190 leading enterprises in China in the S&P 'Sustainability Yearbook (China Edition) 2026,' and was awarded the honor of 'Industry Best Progress Enterprise.' This series of authoritative recognitions not only deeply validates the outstanding effectiveness of the Company's ESG governance but also establishes United Imaging Healthcare's exemplary value as a benchmark for sustainable development in the high-end medical technology field.

Technological innovation is the core driver of long-term corporate development. United Imaging Healthcare continues to advance key technology breakthroughs and product iteration upgrades, and engages in deep collaborative innovation with global universities, medical institutions, and research partners, continuously expanding the boundaries of medical technology. As of the end of 2025, the Company had cumulatively delivered over 150 products to the market. With the successive launches of the world's first dual-wide-body dual-source CT, the industry's first 'cine' MR, the first domestically produced photon-counting spectral CT uCT Ultima, and the uSONIQUE intelligent ultrasound series, the Company not only filled multiple technological gaps domestically and internationally but also successfully completed the comprehensive closure of its full product line portfolio in major imaging.

Focusing on clinical needs, the Company continues to promote the deep integration of artificial intelligence and diagnostic/therapeutic equipment, leveraging digital and intelligent design to enhance diagnostic and therapeutic accuracy and the accessibility of medical resources. Simultaneously, the Company firmly implements the concept of sustainable development, integrating ecological design and energy consumption management throughout the entire product lifecycle.

In terms of carbon management, the Company systematically promotes the construction of environmental governance and carbon emission management systems, clearly aiming to reduce Scope 1 and Scope 2 carbon emission intensity by 50% by 2035, using 2023 as the baseline.

Regarding green product transformation, United Imaging Healthcare continues to promote low-carbon design and full lifecycle management. In July 2025, the uCT 780 X-ray computed tomography device successfully passed the ISO 14067 product carbon footprint verification, becoming the first CT product in China's large medical equipment field to obtain this certification; in December 2025, the Company's new generation 1.5T MR uMR 680 also successfully completed the ISO 14067 product carbon footprint verification. This certification quantitatively assesses the carbon emissions of the product from raw material acquisition, component production, to final assembly, achieving a 'cradle-to-gate' lifecycle carbon footprint calculation, providing a scientific basis for optimizing processes and reducing carbon emissions, and setting a green benchmark for the industry. Centered on the concept of 'Ecodesign,' the Company systematically promotes the green transformation of product design, manufacturing, and supply chain processes, continuously accelerating energy-saving renovations and environmental process innovation, deeply integrating environmental management with business development, and contributing to the national 'Dual Carbon' strategic goals.

In terms of social responsibility and medical equity, United Imaging Healthcare, guided by the vision of 'Making a Difference for Universal Health,' continues to promote the accessibility of precision diagnostic and therapeutic solutions worldwide. The Company actively empowers the construction of primary healthcare systems in developing countries, while also focusing on the equity of medical services within developed countries. Through affordable, high-performance products and inclusive technology, it promotes the practical implementation of 'inclusive healthcare,' effectively enhancing the health experiences of patients from different regions, body types, and cultural backgrounds.

Looking ahead, United Imaging Healthcare will continue to focus on technological innovation as its core driver, aligning with global trends in medical imaging and precision diagnostics/therapeutics, accelerating the construction of a resilient, responsive, and efficient global operational system and organizational capabilities, and solidifying the foundation for its sustainable growth strategy. The Company will leverage more advanced intelligent solutions as technological carriers, supported by a more flexible global delivery and service system, and driven by deeper original R&D and ecological innovation capabilities, continuously promoting the diversified implementation and enhanced accessibility of precision medicine, helping global healthcare systems become more efficient, equitable, and sustainable, and advancing global equitable access to innovative healthcare.

17. Overall ESG achievements

√ Applicable□ Not applicable

On March 23, 2026, the internationally authoritative ESG index provider MSCI announced the latest MSCI ESG (Environmental, Social, and Governance) rating results. United Imaging Healthcare's ESG rating jumped from 'A' to 'AA,' entering the leading echelon of the global medical technology industry. Following the rating improvement in the previous year, the Company achieved consecutive annual MSCI ESG rating leaps. For many years, United Imaging Healthcare has consistently integrated the concept of sustainable development deeply into its corporate strategy, continuously investing in key areas such as R&D innovation, quality and compliance management, supply chain collaboration, talent development, and green operations, gradually building a corporate development system that combines technological leadership and responsibility.

Technological innovation is the core driver of long-term corporate development. United Imaging Healthcare continues to advance key technology breakthroughs and product iteration upgrades, and engages in deep collaborative innovation with global universities, medical institutions, and research partners, continuously expanding the boundaries of medical technology. As of the end of 2025, the Company had cumulatively delivered over 150 products to the market. With the successive launches of the world's first dual-wide-body dual-source CT, the industry's first 'cine' MR, the first domestically produced photon-counting spectral CT uCT Ultima, and the uSONIQUE intelligent ultrasound series, the Company not only filled multiple technological gaps domestically and internationally but also successfully completed the comprehensive closure of its full product line portfolio in major imaging.

Focusing on clinical needs, the Company continues to promote the deep integration of artificial intelligence and diagnostic/therapeutic equipment, leveraging digital and intelligent design to enhance diagnostic and therapeutic accuracy and the accessibility of medical resources. Simultaneously, the Company firmly implements the concept of sustainable development, integrating ecological design and energy consumption management throughout the entire product lifecycle.

In December 2025, the research results of the collaborative study between United Imaging Healthcare and Jingzhou Central Hospital Affiliated to Yangtze University, a regional medical center in Hubei Province, titled 'Energy-saving Efficiency of a Novel Silicon Carbide MRI Gradient Power Amplifier,' were successfully selected for oral presentation at the 2025 Annual Meeting of the Radiological Society of North America (RSNA). This study, based on the industry's first silicon carbide magnetic resonance system—the uMR 600—systematically validated the energy-saving potential of silicon carbide gradient power

amplifiers in a clinical setting for the first time, providing crucial technical pathways and clinical evidence for advancing magnetic resonance equipment towards high-efficiency and low-carbon operation. Standardized tests demonstrated that the SiC GPA system achieved significant energy savings across all imaging sequences: its energy consumption dropped to 5.40 kWh per person, a substantial reduction of 53.45% compared to traditional systems (11.60 kWh per person) ($p < 0.001$); during a two-month real-world clinical operation, the average power per sequence for the SiC GPA was 2.91 ± 1.12 kW, far lower than the 8.40 ± 2.86 kW for traditional silicon GPAs, resulting in a 65.36% reduction in energy consumption. More importantly, blind evaluations by two radiology experts confirmed that the energy-saving effects of the SiC GPA did not come at the expense of image quality, with no statistically significant differences observed between the two groups in terms of resolution, contrast, and artifacts.

Simultaneously, the carbon management system has been extended deeper into products. In July 2025, the company's uCT 780 received the ISO 14067 product carbon footprint verification certification, making it the first CT device in the large-scale radiology medical equipment industry to achieve this certification. The verification was conducted by the authoritative organization SGS, systematically calculating the product's carbon footprint throughout its entire lifecycle, from raw material acquisition to final assembly.

While pursuing technological breakthroughs, United Imaging Healthcare has always regarded product quality and compliance management as the cornerstone of corporate development. Since its establishment, the company has comprehensively ensured compliance, safety, and precision in the delivery process by building a full lifecycle quality management system, strengthening safety production, and advancing digital manufacturing. By the end of 2025, the company's quality management system had achieved 100% coverage across all global production bases. Additionally, in 2025, the company underwent 32 audits by domestic and international regulatory bodies and third-party certifications, achieving 100% compliance with the regulatory requirements of target markets. The audit types included: China Medical Device GMP registration and change system inspections, ISO 13485:2016 and ISO 9001:2015 system certifications, MDSAP single audit program, audits and unannounced inspections under the EU MDD directive and MDR regulations, as well as various specialized factory inspections such as INMETRO, NRTL (Nationally Recognized Testing Laboratory), and CTF (Laboratory Qualification). On the product testing front, in 2025, the company cumulatively performed over 14.14 million core tests and over 5.9 million reliability tests, covering more than 400 key components and systems, with test case coverage reaching 23,000 and achieving 100% test case coverage. The reliability testing scope encompassed the entire product line and components, including CT, MR, MI, RT, XR, and US. Relying on a rigorous internal and external quality control closed-loop, all launched products have obtained multiple international authoritative certifications. Among these, the MDSAP certification spanning the US, Canada, Japan, Brazil, and Australia has further solidified the company's foundation for enhancing global market competitiveness.

Excellent products are inseparable from a robust global service network and a resilient supply chain ecosystem. United Imaging Healthcare consistently adheres to a customer-centric approach, continuously improving the customer service management system, enhancing service quality and response speed, and comprehensively optimizing the customer service experience. By the end of 2025, the company's service network covered over 100 countries and regions worldwide, with a professionally qualified service team exceeding 1,000 members. It had established regional service centers in over 30 countries and territories across major global regions, maintained over 30 global spare parts warehouses, and

possessed 7×24 real-time response capability, ensuring stable equipment operation and timely clinical support in various complex environments. According to the 2025 Shanghai regional medical equipment after-sales service satisfaction survey results, the company ranked first in after-sales service satisfaction for four major high-end equipment categories: radiology MR, CT, general X-ray, and PET-CT, marking the tenth consecutive year that a domestic brand has topped such evaluations. The company always upholds the principle of 'focusing on clinical needs, serving the frontline,' deeply integrating technical responsiveness and a sense of responsibility throughout the end-user service process, thereby continuously consolidating its professional and stable brand reputation.

While refining its own intelligent manufacturing capabilities, United Imaging Healthcare consistently regards building a responsible supply chain ecosystem as an inherent corporate responsibility. During the reporting period, the company continued to deepen the construction of its supply chain ecosystem, regularly empowering upstream and downstream partners through annual supplier quality conferences, JQE Club, and various specialized technical exchange trainings. In 2025, the company conducted specialized audits and on-site guidance for over 60 suppliers, effectively enhancing their process control and quality management baselines; it held over 180 quality-focused project meetings for core suppliers. Regarding green supply chain collaboration, the company provided specialized online Green Product Management (GPM) training to over 80 partners, emphasizing the communication of environmental regulations and hazardous material control requirements, and actively guiding partners to adopt clean energy. By systematically conveying core ESG requirements such as environmental governance, legal compliance, and carbon emissions, the company is steadily solidifying a safe, stable, and green global high-end medical device supply chain system.

Human capital is the core element supporting the company's global business expansion and continuous ascent to new heights. During the reporting period, the company deepened and refined its 'strategy-oriented, diversely covered' human resources system. On the talent acquisition front, the company actively recruited outstanding talents with international perspectives and professional backgrounds through proactive hiring strategies. By the end of 2025, the company's global workforce exceeded 8,700 employees, distributed across over 40 subsidiaries/branches and offices worldwide, with over 1,000 new hires during the year. To strengthen the talent pipeline, in 2025 the company invested a cumulative total of over 290,000 hours in employee training, with training instances exceeding 400,000, achieving 100% coverage of all employees. The training covered various types including product technology, business ethics, anti-corruption, responsible marketing, information security, and quality safety. On the long-term incentive front, the company introduced multi-tiered equity incentive plans tailored to different development stages, encompassing Employee Stock Ownership Plans (ESOP), second-class restricted stock, and strategic placement shares. By the end of 2025, these plans had cumulatively granted 83.526 million shares, benefiting over 5,400 individuals. By establishing a cross-border, cross-hierarchical corporate development sharing mechanism, United Imaging Healthcare has effectively achieved deep alignment between its core team and the company's long-term strategic goals.

Regarding information security, United Imaging Healthcare continuously safeguards the privacy and information security of all stakeholders. Through data risk prevention and control practices, it effectively avoids the negative impacts and commercial losses that information security incidents could cause the group, thereby increasing trust among consumers and partners and enhancing the group's industry competitiveness. Simultaneously, the company continuously optimizes its own data security management methods, striving to

collaborate with the entire industry to promote the sustainable development of the digital economy and information society. By the end of the reporting period, United Imaging Healthcare had obtained relevant system certifications including Information Security Management (ISO 27001), Personal Privacy Protection (ISO 27701), and Cloud Service Information Security Management (ISO 27017). During the year, it passed surveillance audits and recertification audits. Additionally, the company conducted a NIST Cybersecurity Framework 2.0 (NIST CSF 2.0) security assessment certification at United Imaging America, ensuring comprehensive information and privacy security.

In the areas of green development and climate response, the company is steadily transitioning towards a low-carbon production and operation model. Centered on the strategic goal of 'reducing Scope 1 and Scope 2 carbon emission intensity by 50% compared to the 2023 baseline by 2035,' the company is comprehensively deepening green innovation practices throughout the entire product lifecycle. In 2025, the company received a B rating in both the Climate and Water questionnaires of the Carbon Disclosure Project (CDP), and ranked in the top 10% globally among its peers in the October S&P Global Corporate Sustainability Assessment (CSA). This series of achievements objectively validates the effectiveness of the company's climate change management mechanisms.

Unite hearts and efforts, and practice leads to far-reaching achievements. Looking ahead, United Imaging Healthcare will leverage more advanced intelligent solutions as technological carriers, supported by a more flexible global delivery and service system, and driven by deeper original R&D and ecosystem innovation capabilities; continuously promoting the diversified implementation and enhanced accessibility of precision medicine, helping global healthcare systems become more efficient, equitable, and sustainable, and fostering equitable access to innovative healthcare on a broader global scale.

(i) Industry-specific ESG practices for the current year

√ Applicable□ Not applicable

Technological innovation is the core driver of long-term corporate development. United Imaging Healthcare continuously advances key technology breakthroughs and product iteration upgrades, while engaging in deep collaborative innovation with global universities, medical institutions, and research partners to constantly expand the boundaries of medical technology. By the end of 2025, the company had cumulatively delivered over 150 products to the market. With the successive launches of the world's first dual-wide-body dual-source CT, the industry's first 'cinematic' magnetic resonance system, the first domestically produced photon-counting spectral CT uCT Ultima, and the uSONIQUE intelligent ultrasound series, the company has not only filled numerous technological gaps domestically and internationally but also successfully completed the comprehensive closure of its full product line portfolio in major imaging modalities.

Focusing on clinical needs, the company continuously promotes the deep integration of artificial intelligence with diagnostic and therapeutic equipment, leveraging digital and intelligent design to enhance diagnostic and therapeutic precision and the accessibility of medical resources. Simultaneously, the company firmly implements the concept of sustainable development, integrating ecological design and energy consumption management throughout the entire product lifecycle.

In December 2025, United Imaging Healthcare, in collaboration with Jingzhou Central Hospital affiliated with Yangtze University, a regional medical center in Hubei Province, successfully had their research findings titled 'Energy-saving Efficiency of a Novel Silicon Carbide MRI Gradient Power Amplifier' selected for oral presentation at the 2025 Annual

Meeting of the Radiological Society of North America (RSNA). This study, based on the industry's first silicon carbide magnetic resonance system—the uMR 600—systematically validated the energy-saving potential of the silicon carbide gradient power amplifier in a clinical environment for the first time, providing an important technical pathway and clinical evidence for magnetic resonance equipment to move towards high-efficiency and low-carbon operation. Standardized tests indicated that the silicon carbide GPA system achieved significant energy savings across all imaging sequences: its energy consumption dropped to 5.40 kWh per person, a substantial reduction of 53.45% compared to traditional systems (11.60 kWh per person) ($p < 0.001$); during a two-month real-world clinical operation, the average single-sequence power of the silicon carbide GPA was 2.91 ± 1.12 kW, significantly lower than the 8.40 ± 2.86 kW of traditional silicon-based GPA, representing an energy consumption reduction of 65.36%. More importantly, blind evaluations by two radiology experts confirmed that the energy-saving effect of the SiC GPA did not come at the expense of image quality, with no statistically significant differences observed between the two image groups in terms of resolution, contrast, and artifacts.

While pursuing technological breakthroughs, United Imaging Healthcare consistently regards product quality and compliance management as the cornerstone of corporate development. Since its establishment, the company has comprehensively ensured the compliance, safety, and precision of the delivery process by building a full lifecycle quality management system, strengthening safety production, and advancing digital manufacturing. By the end of 2025, the company's quality management system had achieved 100% coverage across all global production bases. Additionally, during the 2025 fiscal year, the company underwent 32 audits by domestic and international regulatory agencies and third-party certifications, achieving 100% compliance with the regulatory requirements of target markets. The audit types included: China Medical Device GMP registration and change system inspections, ISO 13485:2016 and ISO 9001:2015 system certifications, MDSAP single audit program, audits and unannounced inspections under the EU MDD directive and MDR regulation, as well as various specialized factory inspections such as INMETRO, NRTL (Nationally Recognized Testing Laboratory), and CTF (Laboratory Qualification). On the product testing front, in 2025, the company cumulatively performed over 14.14 million core tests and over 5.9 million reliability tests, covering more than 400 key components and systems, with test case coverage reaching 23,000 and a test case coverage rate of 100%. Reliability testing scope encompassed the entire product line and components including CT, MR, MI, RT, XR, US. Relying on a rigorous internal and external quality control, all launched products have obtained multiple internationally authoritative certifications. Among these, the MDSAP certification spanning five countries—the US, Canada, Japan, Brazil, and Australia—has further solidified the company's foundation for enhancing its global market competitiveness.

While refining its own intelligent manufacturing capabilities, United Imaging Healthcare consistently considers building a responsible supply chain ecosystem as an inherent corporate responsibility. During the reporting period, the company continued to deepen the construction of its supply chain ecosystem, regularly empowering upstream and downstream partners through annual supplier quality conferences, JQE Club, and various specialized technical exchange trainings. In 2025, the company conducted specialized audits and on-site guidance for over 60 suppliers, effectively improving their process control and quality management baselines; it held over 180 quality-focused project meetings for core suppliers. Regarding green supply chain collaboration, the company provided specialized online Green Product Management (GPM) training to over 80 partners, focusing on disseminating environmental regulations and hazardous substance control requirements, and actively

guiding partners to adopt clean energy. By systematically communicating core ESG requirements related to environmental governance, legal compliance, and carbon emissions, the company is steadily building a safe, stable, and green global high-end medical device supply chain system.

(ii) ESG rating performance for the current year

√ Applicable□ Not applicable

ESG rating system	ESG rating agency	Company's rating result for the current year
MSCI ESG Rating	MSCI Inc. (Morgan Stanley Capital International)	AA
S&P Global Corporate Sustainability Assessment (CSA)	S&P Global	Top 10% among global peers
CSI Index ESG Rating	CSI (China Securities Index)	AAA

(iii) Tracking status by ESG-themed index funds for the current year

√ Applicable□ Not applicable

As of the report disclosure date, the company has been included in the tracking scope of multiple domestic and international ESG-themed index funds globally, including but not limited to the following major ESG-related indices: MSCI China A Low Carbon Leaders Index (USD), MSCI CHINA A RMB ESG UNIVERSAL, MSCI China A ESG 300 Index, China Life Asset Management ESG Green Low Carbon 100, 300 ESG Leaders, and STAR Market ESG Index. The inclusion in these indices fully reflects the company's outstanding performance in the environmental, social, and governance (ESG) fields, further highlighting its leading position in sustainable development, low-carbon transition, and ESG practices, while also providing strong support for the company's long-term value growth in the capital market.

18. Environmental information status of listed companies and their major subsidiaries included in the mandatory environmental information disclosure list

□ Applicable√ Not applicable

Other explanations

□ Applicable√ Not applicable

19. Social responsibility work situation

(i) Social contribution of main business and key industry indicators

During the reporting period, the company's R&D innovation system, global marketing and service network, and distributed supply chain system operated synergistically, forming a multi-dimensional support synergy, demonstrating robust development resilience and sustained growth momentum, laying a solid foundation for the company's high-quality development. As the domestic medical equipment industry structure continues to deepen and the demand structure continues to optimize, the market momentum accumulated by the company has gradually been released, and its operating performance has re-entered a phase

of rapid growth, reflecting its cross-cycle operational capability and long-term development resilience. Meanwhile, the demand for expanding high-end medical resources globally remains strong, the development potential of the company's overseas market continues to emerge, and the growth momentum of its international business has further strengthened.

Driven by multiple internal and external factors, United Imaging Healthcare actively seized the window of opportunity for high-quality development in the industry, achieving rapid recovery and growth in its operating performance. During the reporting period, the company achieved annual operating revenue of 138.00 billion yuan, a year-on-year increase of 33.98%; net profit attributable to shareholders of the parent company was 18.69 billion yuan, a year-on-year increase of 48.14%; net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was 17.70 billion yuan, a year-on-year increase of 75.18%.

Looking ahead, leveraging the ecosystem foundation formed by its market network covering over 100 countries and regions, an installed base of 39,000 units/sets, and over 16,400 clinical and research users, United Imaging Healthcare will continue to focus on original R&D and ecosystem innovation capabilities as its core driving force, utilize intelligent solutions as a key technological support, and rely on its flexible and efficient global delivery and service system to continuously promote the application and accessibility of precision medicine in more scenarios, assist the global healthcare system in developing towards greater efficiency, equity, and sustainability, and drive innovative healthcare to benefit patients and society more broadly.

(ii) Promotion of Technological Innovation

In 2025, the company continued to deepen its development strategy of 'Innovation-driven, Win-win Cooperation', accelerated breakthroughs in underlying core technologies and the industrialization of achievements, and promoted the enterprise's continuous leap from a single product advantage to leadership in the entire industry chain ecosystem. During the reporting period, relying on sustained high-intensity R&D investment and the synergistic layout of its global R&D network, the company made significant progress in underlying technology R&D, breakthroughs in key core components, and system-level integration capabilities. Several strategic innovative products achieved commercial application, further strengthening the company's technological leadership in the high-end medical equipment field.

As of the end of the reporting period, the cumulative number of products launched by the company exceeded 150 models, of which 75 obtained EU CE certification, with 27 new CE-certified products added in 2025; 58 products obtained U.S. FDA (510(k)) clearance, with 19 new clearances in the year; additionally, 8 products entered the National Innovative Medical Device Special Review Procedure, and over 20 products received FDA-approved AI-enabled device certification, continuously consolidating the company's technological and product advantages in the high-end medical equipment field.

Against the backdrop of the accelerated development of the new wave of technological revolution represented by artificial intelligence, the company, with innovation breakthroughs as its core driver, continuously improved its R&D innovation system composed of forward-looking research, engineering innovation, clinical collaboration, and industrial transformation, fostering sustainable innovation capabilities for long-term

development. During the reporting period, the company further increased its R&D investment intensity, continuously optimized the allocation of innovation resources, and successively launched several innovative products with industry-leading significance, propelling global medical diagnosis and treatment capabilities to new heights.

Specifically, the natively intelligent uSONIQUE series ultrasound was officially launched in November 2025, marking United Imaging Healthcare's achievement of a complete product system closure in the broad medical imaging field; the domestically produced first photon-counting spectral CT system, uCT Ultima, received approval from the National Medical Products Administration (NMPA) in August 2025 and was successfully bid for by West China Hospital of Sichuan University's Xiamen Hospital in December of the same year, marking the official entry of China's first clinically applicable photon-counting CT into medical practice; the world's first dual-wide-detector dual-source CT imaging system, uCT SiriuX, obtained NMPA marketing authorization in 2026. By breaking through traditional architectural limitations and innovatively integrating wide-detector and dual-source technologies, it successfully resolved the technical bottleneck of the 'trade-off' between coverage and time resolution in traditional high-end CT, achieving the industry's highest whole-heart temporal resolution of 8ms, 16cm full-organ volumetric coverage, and a 470mm ultra-large dual-source spectral imaging field of view; simultaneously, the launch of the industry's first new-generation 3T MRI system, uMR Ultra, promoted a leapfrog upgrade in MRI from static 'photography' to dynamic 'videography', expanding the boundaries of clinical applications.

(iii) Compliance with Scientific and Technological Ethics

United Imaging Healthcare strictly adheres to domestic and international regulations and guiding principles related to scientific and technological ethics, such as the 'World Medical Association Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects', 'Measures for Ethical Review of Life Sciences and Medical Research Involving Humans', 'Quality Management Norms for Clinical Trials of Medical Devices', 'Regulations on the Supervision and Administration of Medical Devices', and 'Guiding Principles for the Classification and Definition of Artificial Intelligence Medical Software Products', ensuring that all clinical trials and data processing procedures comply with ethical and regulatory requirements.

Regarding clinical trials, domestically, the company has developed standardized 'Clinical Trial Protocols' and 'Informed Consent Form Templates' for all clinical trials, clearly informing subjects of key information such as device purpose, potential risks, and withdrawal mechanisms, and each case is approved by the hospital's ethics committee. All personnel participating in clinical trials must obtain the 'Good Clinical Practice (GCP) for Medical Device Clinical Trials Certificate of Completion' and the company's procedural document 'QP-205 Clinical Evaluation Procedure Certificate of Completion'. During the trial period, the company and the hospital will conduct supervision of ethical norms at the initial, mid-term, and final stages. In the United States, the company has established a systematic scientific and technological ethics management system covering the entire process from project initiation, implementation, data management to result publication. All projects involving volunteer participation, human data, or clinical-related research must be reviewed and approved by an independent IRB before commencement and are subject to ongoing compliance supervision.

In the area of artificial intelligence, the company has established the 'WI-223 AI Data Management Process' and 'WI-224 AI System Lifecycle Process' specifications to manage AI data and products, ensuring the development process complies with national and company regulations. During the data collection process, the company has built a series of document systems including the 'Data Collection Specification', 'Raw Data Verification Form', 'Data Sorting Record', 'Data Annotation Record', and 'Dataset Report' to ensure that all stages—data acquisition, sorting, annotation, dataset construction, and data archiving—comply with the corresponding specifications. During algorithm development and validation, the company has also established the 'Algorithm Design Specification' and 'Algorithm Validation Report' to ensure the safety and effectiveness of the algorithms.

United Imaging Healthcare has established a regular training mechanism for scientific and technological ethics, adhering to the bottom line of responsibility. Before initiating clinical research, the company provides training to authorized investigators on ethical regulatory requirements, research protocols, and device GCP requirements, ensuring that participating investigators and relevant personnel fully understand the project and regulatory requirements and comply with ethical norms. We also provide training on internal policies such as 'WI-223 AI Data Management Process' and 'WI-224 AI System Lifecycle' to product managers, clinical application engineers, quality management personnel, R&D engineers, etc., requiring all trainees to pass an examination to obtain a certificate of completion. During the reporting period, United Imaging Healthcare continued to conduct ethics training and education, covering core topics such as protection of subjects' rights, informed consent norms, and data anonymization, strengthening the ethical awareness and practical capabilities of all employees. United Imaging Healthcare implements a zero-tolerance policy for violations of ethical norms, and upon discovery, will promptly initiate investigation, rectification, and accountability procedures. During the reporting period, the company had no violations of scientific and technological ethics.

(iv) Data Security and Privacy Protection

United Imaging Healthcare continuously improves information security and privacy protection management,健全 ing privacy protection policies and data security management systems. By constructing a full-process, multi-layered data risk prevention and control strategy, it comprehensively guards against information security risks, providing safe and reliable services to customers and partners, and fulfilling its commitment to data security through practical actions, thereby enhancing the trust and cooperation of stakeholders.

The company is committed to the highest standards of data security and privacy, strictly adhering to the applicable legal and regulatory frameworks in every jurisdiction where we operate. Within the Chinese market, we operate in full compliance with relevant national regulations, including the Data Security Law and Personal Information Protection Law, supported by a comprehensive suite of internal information security protocols.

Concurrently, our U.S. operations maintain a localized and independent compliance framework. We have further strengthened the information security management system for our U.S. production base, implementing robust regulations and practices that strictly align with U.S. federal and state data privacy laws. This localized approach ensures that stringent data protection and privacy standards are embedded into all U.S. business processes, safeguarding customer and operational data.

United Imaging Healthcare has established a top-down information security management architecture with clear responsibilities and authorities. The Information Security and Privacy Protection Supervision and Management Committee serves as the highest decision-making body, responsible for formulating compliance policies, ensuring that data processing, storage, and transmission comply with relevant legal requirements, and defining the strategic direction and objectives for the company's information security and privacy protection. The Corporate and Product Information Security and Privacy Protection Teams are responsible for overseeing the management, auditing, and execution of corporate operations and product research and development throughout their entire lifecycle. At the same time, the collaborative linkage among the Information Security and Privacy Protection Officers, the Information Security Department, the Information Technology Department, the Legal and Compliance Department, the Product Cybersecurity Committee, the Product Information Security and Privacy Protection Team, and the Quality Management Department ensures the effective implementation of information security and privacy protection policies.

During the reporting period, the company held four meetings of the Information Security and Privacy Protection Supervision and Management Committee, conducting in-depth discussions on information security risk prevention and control and key privacy protection issues, and formulating targeted management decisions accordingly. Relevant departments regularly hold information security management communication meetings, both scheduled and unscheduled, to continuously optimize workflows and ensure the efficient operation of the management system. Additionally, the U.S. production base established a Regional Information Security and Privacy Protection Working Group (Region ISPPWG), adopting a governance model of 'headquarters coordination, regional autonomy,' achieving localization and agility in security decision-making.

During the reporting period, United Imaging Healthcare fully implemented data security and privacy protection measures, with no data security or information leakage incidents occurring.

(v) Types and Contributions of Public Welfare and Charitable Activities

Type	Quantity	Description
External Donations		
Of which: Funds (in 10,000 yuan)	622.00	During the reporting period, United Imaging Healthcare actively fulfilled its corporate social responsibility, continuously supported public welfare and charitable causes, and contributed to the development of public welfare through various forms such as emergency disaster relief, medical assistance, and educational and scientific research support. On November 26, 2025, a severe fire accident occurred in Tai Po, Hong Kong. To support local emergency rescue and post-disaster recovery efforts, Shanghai United Imaging Healthcare Co., Ltd., together with its Hong Kong subsidiary, donated HKD 5 million to the disaster area for emergency rescue, humanitarian assistance, and

		post-disaster reconstruction. Simultaneously, United Imaging Healthcare continued to support the development of medical education and scientific research. During the reporting period, the company provided donations and research scholarships to institutions such as the Xi'an Jiaotong University Education Foundation, Zhejiang University Education Foundation, and Dalian Medical University, supporting medical discipline construction, research development, and talent cultivation. Additionally, the company supported development projects of educational institutions like the Second Clinical Medical College of Zhejiang University School of Medicine and Hangzhou Medical College, contributing to the construction of the medical education system and medical technology innovation. In terms of medical assistance and social welfare, the company also participated in supporting public welfare projects such as the Beijing Wu Lien-teh Public Welfare Foundation, Nanjing First Hospital Medical Development and Medical Assistance Foundation, Dongrun Public Welfare Foundation, and Beijing Huatong Guokang Public Welfare Foundation, actively providing support for medical assistance, care for vulnerable groups, and public health initiatives.
Value of Materials Donated (in 10,000 yuan)	/	On January 7, 2025, a magnitude 6.8 earthquake struck Dingri County, Shigatse City, Tibet Autonomous Region, causing severe casualties and property damage. Following the disaster, United Imaging Healthcare responded swiftly, donating one mobile DR device each to Dingri County People's Hospital and Lhaze County People's Hospital, with a total value exceeding 3 million yuan, to enhance the emergency diagnostic capabilities of local medical institutions and support medical rescue efforts in the disaster area.
Public Welfare Projects		
Of which: Funds (in 10,000 yuan)	1,730.06	During the reporting period, United Imaging Healthcare actively fulfilled its corporate social responsibility, continuously supported public welfare and charitable causes, and contributed to the development of public welfare through various forms such as emergency disaster relief, medical assistance, and educational and scientific research support. On November 26, 2025, a severe fire accident occurred in Tai Po, Hong Kong. To support local emergency rescue and post-disaster recovery efforts, Shanghai United Imaging Healthcare Co.,
Number of People Assisted (persons)	/	

		Ltd., together with its Hong Kong subsidiary, donated HKD 5 million to the disaster area for emergency rescue, humanitarian assistance, and post-disaster reconstruction. Simultaneously, United Imaging Healthcare continued to support the development of medical education and scientific research. During the reporting period, the company provided donations and research scholarships to institutions such as the Xi'an Jiaotong University Education Foundation, Zhejiang University Education Foundation, and Dalian Medical University, supporting medical discipline construction, research development, and talent cultivation. Additionally, the company supported development projects of educational institutions like the Second Clinical Medical College of Zhejiang University School of Medicine and Hangzhou Medical College, contributing to the construction of the medical education system and medical technology innovation. In terms of medical assistance and social welfare, the company also participated in supporting public welfare projects such as the Beijing Wu Lien-teh Public Welfare Foundation, Nanjing First Hospital Medical Development and Medical Assistance Foundation, Dongrun Public Welfare Foundation, and Beijing Huatong Guokang Public Welfare Foundation, actively providing support for medical assistance, care for vulnerable groups, and public health initiatives.
Rural Revitalization		
Of which: Funds (in 10,000 yuan)	/	/
Value of Materials Donated (in 10,000 yuan)	/	/
Number of People Helped with Employment (persons)	/	/

1. Specific Details of Public Welfare and Charitable Activities

√ Applicable□ Not Applicable

United Imaging Healthcare is committed to promoting the balanced allocation of medical resources and advancing health equity. Focusing on three key directions—county-level medical universalization, global medical equity, and collaborative development of medical talent—the company continuously builds a multi-level, comprehensive medical and health ecosystem. The company continues to deepen its 'Change in the 'County' Field' special initiative, activating the potential of primary medical services through technological empowerment. It actively shares cutting-edge medical technology achievements to promote fairer and more accessible global medical resources. Furthermore, it advances the deep

integration of industry, academia, research, and medicine, accelerates the translation of frontier research results into clinical applications, and systematically cultivates medical professionals to support the long-term sustainable development of the medical system.

United Imaging Healthcare actively responds to the 'Healthy China' strategy and the national 'Thousand Counties Project' deployment, conducting health screening and medical assistance activities in multiple county regions across the country. By combining public service with professional training, it promotes the cultivation of primary medical talent and the construction of diagnostic capabilities, continuously enhancing the service capacity and diagnostic level of county-level medical institutions. The company consistently practices corporate social responsibility, deeply engages in county-level medical development, and uses activities like the Mobile Medical Public Welfare Tour as key practical vehicles. It regularly conducts public welfare screenings and health service activities to effectively improve the capacity and accessibility of primary medical and health services.

In May 2025, the third stop of United Imaging's 'Change in the 'County' Field—Mobile Medical Public Welfare Tour' was launched. With the support of the Shule County and Yumin County Health Commissions and local hospitals, it provided health services to groups including elderly Uyghur individuals, firefighters, and solitary elderly people. This initiative focused on lung cancer screening, utilizing vehicle-mounted CT and intelligent chest diagnosis and treatment solutions to conduct multiple screenings simultaneously, significantly improving screening efficiency and coverage.

In June 2025, the fourth stop of United Imaging Healthcare's public welfare screening campaign entered Luoping County, Qujing, Yunnan. With the support of local health departments and medical institutions, it collaborated with multiple parties to conduct primary medical training and public welfare screening activities. Given the susceptibility of local industry workers to respiratory and joint diseases, this screening focused on pulmonary function testing. During the screening in Zhongshan Township, multiple early-stage lung cancer cases were detected, fully demonstrating the clinical value of early screening and diagnosis, effectively reducing the public's medical burden and improving disease cure rates.

In October 2025, United Imaging Healthcare, in collaboration with Diqing Shangri-La City People's Hospital in Yunnan and the New Moon Alliance, jointly launched the "Soft, Brave, Beautiful" Breast Health Public Welfare Project. This project is an important component of the company's annual public welfare initiatives and a continuation of the same themed public welfare activities from 2024. The activity integrates cutting-edge imaging academic exchanges with public welfare screening, promoting breast health knowledge to the public through academic seminars, health education lectures, and free mammography screenings.

Additionally, a special session on the development of expert departments in tertiary hospitals was added, providing technical support and experience sharing for medical institutions in remote ethnic areas. County-level hospitals, as fundamental units of China's medical system, are known as the "capillaries" of the healthcare system, serving the medical needs of nearly 950 million people. To promote the sustainable development and "self-sustaining capacity" of grassroots medical institutions, United Imaging Healthcare proactively fulfills its social responsibility by continuously supporting the "County Hospital Medical Equipment Management and Utilization Capacity Enhancement Training Program" jointly organized by the National Health Commission International Exchange and Cooperation Center and the Health Commission of Xinjiang Uygur Autonomous Region. In October 2025, the training

program was successfully held in Urumqi, focusing on the establishment of standardized and scientific medical management systems. It emphasized key areas such as improving medical equipment utilization efficiency, enhancing the diagnosis and treatment capabilities for common and major diseases, building smart hospitals, and strengthening public health emergency response capabilities, providing strong support for the development of closely-knit county medical communities and effectively meeting the public's growing demand for multi-level, high-quality health services.

In December 2025, the strategic cooperation signing ceremony between United Imaging Healthcare and Southern Medical University and the unveiling ceremony of the "Qingyun Plan" were held at the Shunde campus. The two parties formally signed the "Strategic Cooperation Framework Agreement," jointly launched the talent cultivation special project "Qingyun Plan," and unveiled the "Smart Radiotherapy Joint Laboratory." According to the agreement, the two parties will conduct in-depth cooperation in key areas such as joint R&D of high-end medical equipment, construction of key laboratories, cultivation of interdisciplinary professionals, and transformation of scientific research achievements, collaboratively promoting medical technology innovation and talent system construction.

As an important platform for cooperation, the "Smart Radiotherapy Joint Laboratory" is equipped with ten sets of high-end radiation therapy planning systems (TPS), establishing a high-level teaching and practice platform to support students in systematically mastering core radiotherapy skills such as target volume contouring and dose calculation, effectively bridging theoretical teaching and clinical practice. As the first implemented project under the "Qingyun Plan," this laboratory will gradually become a key training base for radiotherapy physicists in the Guangdong-Hong Kong-Macao Greater Bay Area and even nationwide, promoting the deepening of the university-enterprise collaborative education model and exploring new pathways for cultivating high-end interdisciplinary medical technology talents.

Furthermore, United Imaging Healthcare actively responds to global health governance needs, promoting its independently innovated high-end medical equipment and digital-intelligent diagnosis and treatment solutions to multiple countries and regions. Through various means such as financial support, platform sharing, and technology transfer, it continuously enhances the accessibility and professional level of local medical services, contributing Chinese medical technology strength to promoting more equitable development of global healthcare.

2. Specific details on consolidating and expanding the achievements in poverty alleviation, rural revitalization, and related work

√ Applicable□ Not applicable

Poverty Alleviation and Rural Revitalization Projects	Quantity/Content	Description
Total Investment (10,000 yuan)	2,352.06	During the reporting period, United Imaging Healthcare actively fulfilled its corporate social responsibility, continuously supported public welfare and charitable causes, and contributed to the development of public welfare through various forms such as emergency disaster relief, medical assistance, and educational and research support. On November 26, 2025, a severe fire

		accident occurred in Tai Po, Hong Kong. To support local emergency rescue and post-disaster recovery efforts, Shanghai United Imaging Healthcare Co., Ltd., together with its Hong Kong subsidiary, donated HKD 5 million to the disaster area for emergency rescue, humanitarian assistance, and post-disaster reconstruction. Simultaneously, United Imaging Healthcare continued to support the development of medical education and scientific research. During the reporting period, the company provided donations and research scholarships to institutions including the Xi'an Jiaotong University Education Foundation, Zhejiang University Education Foundation, and Dalian Medical University, supporting medical discipline construction, research development, and talent cultivation. Additionally, the company supported development projects of educational institutions such as the Second Clinical Medical College of Zhejiang University School of Medicine and Hangzhou Medical College, contributing to the construction of the medical education system and medical technology innovation. In terms of medical assistance and social welfare, the company also participated in supporting public welfare projects including the Beijing Wu Lien-teh Public Welfare Foundation, Nanjing First Hospital Medical Development and Medical Assistance Foundation, Dongrun Foundation, and Beijing Huatong Guokang Public Welfare Foundation, actively providing support for medical assistance, care for vulnerable groups, and public health initiatives.
Of which: Funds (10,000 yuan)	2,352.06	During the reporting period, United Imaging Healthcare actively fulfilled its corporate social responsibility, continuously supported public welfare and charitable causes, and contributed to the development of public welfare through various forms such as emergency disaster relief, medical assistance, and educational and research support. On November 26, 2025, a severe fire accident occurred in Tai Po, Hong Kong. To support local emergency rescue and post-disaster recovery efforts, Shanghai United Imaging Healthcare Co., Ltd., together with its Hong Kong subsidiary, donated HKD 5 million to the disaster area for emergency rescue, humanitarian assistance, and post-disaster reconstruction. Simultaneously, United Imaging Healthcare continued to support the development of medical education and scientific research. During the reporting period, the company provided donations and research scholarships to institutions including the Xi'an Jiaotong University Education Foundation, Zhejiang University Education Foundation, and Dalian Medical University, supporting

		medical discipline construction, research development, and talent cultivation. Additionally, the company supported development projects of educational institutions such as the Second Clinical Medical College of Zhejiang University School of Medicine and Hangzhou Medical College, contributing to the construction of the medical education system and medical technology innovation. In terms of medical assistance and social welfare, the company also participated in supporting public welfare projects including the Beijing Wu Lien-teh Public Welfare Foundation, Nanjing First Hospital Medical Development and Medical Assistance Foundation, Dongrun Foundation, and Beijing Huatong Guokang Public Welfare Foundation, actively providing support for medical assistance, care for vulnerable groups, and public health initiatives.
Value of Materials Donated (10,000 yuan)	/	On January 7, 2025, a magnitude 6.8 earthquake occurred in Dingri County, Shigatse City, Tibet Autonomous Region, causing severe casualties and property damage. Following the disaster, United Imaging Healthcare responded swiftly, donating one mobile DR device each to Dingri County People's Hospital and Lhaze County People's Hospital, with a total value exceeding 3 million yuan, to enhance the emergency diagnosis and treatment capabilities of local medical institutions and support medical relief efforts in the disaster area.
Number of Beneficiaries (persons)	/	
Forms of Assistance (e.g., industrial poverty alleviation, employment poverty alleviation, educational poverty alleviation)	Industrial poverty alleviation, educational poverty alleviation	

Specific Description
□ Applicable√ Not applicable

(vi) Protection of Shareholder and Creditor Rights

United Imaging Healthcare considers the expectations and demands of various stakeholders as an important basis for formulating the Group's sustainable development strategy. We utilize multiple communication channels such as telephone, email, investor relations interactive platforms, the 'Investor Relations' section of the official website, media interviews, and earnings briefings to strengthen communication and exchange with stakeholders including shareholders and investors, customers, suppliers and partners, employees, communities, and the media. This is achieved through various methods like issuing announcements, e-interaction Q&A sessions, conducting roadshows and non-deal roadshows, listening to key concerns from all parties, and providing active responses.

As a leading enterprise in the field of high-end medical imaging and radiotherapy equipment, United Imaging Healthcare is committed to continuously advancing medical device technology, improving healthcare service levels, while actively fulfilling social responsibilities. This further enhances corporate competitiveness and corporate image,

achieving win-win outcomes with stakeholders such as shareholders and investors, and making greater contributions to the global healthcare industry.

(vii) Employee Rights Protection

United Imaging Healthcare places high importance on the protection of employee rights, considering it a crucial foundation for the company's sustainable development. The company strictly complies with national labor laws and regulations as well as those in its operating locations, continuously improves employment management systems and internal governance mechanisms, and is dedicated to building a fair, standardized, and inclusive talent development environment to effectively safeguard employees' legitimate rights and interests in recruitment, employment, career development, and daily work.

In terms of employment management, the company adheres to the principles of fairness, justice, and transparency in employment, provides equal employment opportunities, resolutely prohibits any discrimination based on factors such as age, gender, nationality, race, ethnicity, or religion, and prevents child labor and illegal employment through strict identity verification mechanisms. The company respects employees' willingness to work, prohibits any form of forced labor, implements working hour management systems in accordance with the law, reasonably arranges working hours and rest periods, and effectively protects employees' legitimate labor rights.

In talent recruitment and development, the company continuously expands diversified recruitment channels, building an open and diverse talent reserve system through campus recruitment, social recruitment, internship programs, and global talent acquisition. The company deepens cooperation with domestic and international universities and research institutions, while leveraging digital recruitment platforms, employee referral mechanisms, and professional human resources agencies to attract high-potential talent and key technical personnel, providing continuous talent support for technological innovation and global development. During the reporting period, the company onboarded 1,336 new employees.

In employee development and diversity and inclusion, the company actively fosters an equal, diverse, and inclusive work environment, respects individual differences among employees, protects the legitimate rights and interests of female employees and employees from different cultural backgrounds, and opposes any form of unequal treatment. During the reporting period, female employees accounted for 27.4% of the company's workforce, with female employees in R&D positions accounting for 26.4%. Simultaneously, the company continuously enhances the work experience and career development environment by improving office facilities and supporting services, such as setting up multilingual office guidance systems, accessibility facilities, and care measures for pregnant employees.

Additionally, the company has established standardized employee communication and grievance mechanisms, handles employee complaints, disputes, and arbitration matters strictly in accordance with compliance requirements, actively safeguards employees' legitimate rights and interests, continuously improves employee satisfaction and organizational cohesion, and provides a solid talent foundation for the company's long-term stable development.

Employee Shareholding Status

Number of Employee Shareholders (persons)	1,604

Percentage of Employee Shareholders to Total Employees (%)	19.62
Number of Employee Shares (10,000 shares)	23,577.26
Percentage of Employee Shares to Total Share Capital (%)	28.61

Note: The above statistics are shareholding data for employees in service as of December 31, 2025, and do not include shares granted but not yet vested or shares bought/sold by individuals in the secondary market; as employee strategic placements are held indirectly, the converted shares are not whole numbers.

(viii) Supplier, Customer, and Consumer Rights Protection

United Imaging Healthcare places high importance on establishing long-term, stable, and mutually beneficial cooperative relationships with suppliers. By continuously optimizing supplier management mechanisms and communication and collaboration platforms, it promotes supply chain partners to jointly enhance management levels and sustainable development capabilities.

During the reporting period, the company strictly followed supplier management procedures and supplier audit procedures. All newly introduced Tier 1, Tier 2, and Tier 3 suppliers underwent rigorous evaluation, auditing, or qualification confirmation to ensure they met the entry criteria. As of December 30, 2025, 25 new suppliers were introduced, all of which passed evaluation and audit. Simultaneously, the company conducts regular assessments on Tier 1, Tier 2, and Tier 3 suppliers in daily management. The assessment criteria cover multiple key areas including technical support capability, business cooperation support, quality control, environmental hazardous material control, and employee occupational health. Among these, assessments are conducted annually for Tier 1 and Tier 2 suppliers, and biennially for Tier 3 suppliers. For suppliers that do not meet requirements, the company will push for corrective actions and, if necessary, phase them out.

In 2025, the company conducted annual assessments on 333 Tier 1, Tier 2, and Tier 3 suppliers, with a pass rate of 99.1%. The proportion of all suppliers obtaining third-party system certifications reached 97.3%, effectively ensuring the reliability of supply chain product quality.

In terms of cooperation mechanisms, the company actively encourages supplier participation in product R&D and technical optimization. Through collaborative design, process improvement, and supply chain efficiency optimization, it works with core suppliers to jointly enhance product quality and system performance. At the same time, the company continuously strengthens supply chain risk monitoring and information communication mechanisms to ensure the stability of key raw material and core component supplies, providing reliable support for the company's ongoing business development.

Regarding supplier audits, United Imaging Healthcare conducts comprehensive audit inspections for Tier 1 and Tier 2 suppliers every two years, including quality system audits, product audits, and environmental requirement audits, and urges suppliers to rectify issues identified during audits. For all Tier 3 suppliers, comprehensive qualification checks and archival reviews are conducted, auditing supplier agency qualifications, quality system certifications, and other certificates to ensure all certificates are valid. By the end of the reporting period, the company had audited 130 Tier 1 and Tier 2 suppliers, achieving a 100%

audit completion rate, and promoted the rectification of 81 non-conformities. Simultaneously, the inspection and updating of system or agency certificates for 115 Tier 3 suppliers were completed, achieving a 100% audit completion rate.

In the future, United Imaging Healthcare will continue to deepen strategic cooperative relationships with suppliers, further improve supply chain collaborative management mechanisms, promote continuous improvement among supply chain partners in areas such as quality management, green development, and compliant operations, and jointly build a safe, stable, green, and sustainable industrial chain ecosystem.

(ix) Product Safety Assurance

United Imaging Healthcare places high importance on product and service quality, building a quality management system that covers the entire product lifecycle, and continuously promotes digital and intelligent production technologies to comprehensively ensure the safety, effectiveness, and stability of products and services. The company adheres to a customer-centric approach, continuously optimizes the customer service management system, and is committed to providing customers with high-quality products and excellent service experiences. Simultaneously, the company practices responsible procurement concepts, establishes long-term and stable cooperative relationships with high-quality suppliers, and jointly builds a safe, reliable, and sustainable supply chain system.

United Imaging Healthcare has established a full lifecycle quality management system covering product R&D, production manufacturing, supplier quality, and after-sales service. Relying on digital and intelligent quality control platforms, it implements precise monitoring and continuous optimization of each link to ensure product service quality and safety. The company has established a comprehensive product safety and quality management architecture system, conducting strict supervision and control over various stages such as product R&D, production, procurement, and installation services to fully ensure product safety. The company strictly complies with relevant laws and regulations such as the 'Product Quality Law of the People's Republic of China', 'Regulations on the Supervision and Administration of Medical Devices', 'Measures for the Supervision and Administration of Medical Device Production', and 'Good Manufacturing Practice for Medical Devices'. It also adheres to international regulatory requirements including US 21 CFR 820 regulations, Japan's MHLW Ministerial Ordinance No. 169, EU Directive 93/42/EEC (MDD), and EU Medical Device Regulation (MDR) 2017/745, ensuring the safety and effectiveness of marketed products in the global market. Based on global medical device regulatory requirements, the company has established a Quality Manual applicable to all products and services that meet the definition of medical devices, covering all business units and related departments. It has also formulated key internal management documents such as the Quality Management System, Product Development Process, Production Control Process, and Labeling Control Procedure to standardize product production quality and ensure the entire process is controllable, compliant, and traceable. This year, the company continued to improve its quality management system, updating a total of 168 quality and safety-related management documents to comprehensively respond to changes in global regulations such as the EU MDR, US QMSR, and Korea's Digital Medical Device Act, and to align with business development needs.

United Imaging Healthcare has formulated and implemented a 'Zero Defect' quality management strategy, deeply integrating it into the corporate strategic management system,

committed to building a world-class medical equipment brand and providing safe and reliable products for global customers. The core strategies are 'Proactive Compliance, Precise Design, and Intelligent Manufacturing Empowerment,' which involve closely tracking global medical device regulatory trends to plan compliance strategies in advance; fully implementing Quality by Design and reliability engineering to maximize the elimination of potential risks through full lifecycle risk management; and building smart factories through informatization management to improve quality stability and traceability. The company proactively obtains various domestic and international system certifications and undergoes internal and external audits. As of the end of the reporting period, quality management system certification has achieved 100% coverage of all factories, realizing standardized production bases. All product lines on the market, including MR, PET/MR, CT, PET/CT, RT, DR, DSA, and medical image post-processing software, have obtained ISO 9001:2015, ISO 13485:2016, and MDSAP certifications. The MDSAP covers five countries: the United States, Canada, Japan, Brazil, and Australia, demonstrating the company's excellent quality management capabilities and laying the foundation for enhancing global market competitiveness. During the reporting period, the company underwent 32 audits by domestic regulatory authorities and third-party certification bodies, with a 100% pass rate, covering registration inspections, ISO 13485/9001 audits, MDSAP, EU MDD/MDR audits, INMETRO, NRTL, and CTF factory inspections.

In terms of quality and safety testing, the company strictly incorporates product testing into management processes, conducting design and clinical evaluation tests, product reliability tests, and environmental and product environmental regulation tests in accordance with product quality and safety management specifications, continuously optimizing production testing and quality control processes. The company strictly controls the testing process, following hundreds of product design and testing guidelines such as Product Risk Management, Reliability Testing Specification Guide, HALT Test Specification, Environmental Climate Test Specification, and EMC Test Specification, to ensure test results are true, accurate, complete, and traceable, and is equipped with professional testing equipment and teams. As of the end of the reporting period, all product lines possess comprehensive testing capabilities. The company's professional laboratories can perform various tests including environmental, vibration, impact, and durability tests. The laboratory qualifications have passed annual audits by TÜV SÜD, TÜV Rheinland, and SGS, covering IEC safety and electromagnetic compatibility standards.

United Imaging Healthcare conducts design validation and clinical evaluation tests for its products, assessing product interactivity, image quality, and workflow through clinical medical experts to ensure functional specialization, refinement, and intelligence, meeting clinical needs. During product development and prior to market launch, the company also requires external customer evaluations, covering the entire system, software, and functional applications. For products using new technologies, the company selects qualified medical institutions for trial use or validation in accordance with the Quality Management Norms for Clinical Trials of Medical Devices to assess safety and effectiveness. In 2025, the company cumulatively performed over 14.14 million core tests. The test matrix covered more than 440 key components and over 290 complete machine systems, with test case coverage consistently maintained at 100%. Third-party test reports were obtained for all product lines to meet domestic and international registration and safety access requirements.
In product reliability management, the company embeds reliability management throughout the entire product lifecycle, conducting planning, indicator decomposition, design analysis, test planning, and execution according to the Reliability Activity Guide, and outputting

complete technical reports. In 2025, the company cumulatively conducted over 5.92 million reliability tests, covering 449 key components and 23,000 test cases, with a test coverage rate of 100%. These tests covered the entire product lines of MR, PET/CT, CT, RT, XR and key components, including ceiling-mounted DSA, mobile C-arm X-ray machines, large-bore slide-guide CT, SPECT CT, 3T PET MR, CT tubes, PET detectors, radiotherapy electron guns, and high-voltage modules. Additionally, the company completed simulated 160,000-kilometer vibration durability tests and domestic road driving tests for vehicle-mounted imaging equipment, covering standard and harsh road conditions. The verification results provided an effective basis for product design iterations, enhancing the reliability of core components and complete systems under complex working conditions.

The company strictly implements environmental and product environmental regulations, covering all stages from product initiation, R&D, incoming materials, production, to market launch. Based on EU RAPEX alerts, the company tested 34,748 homogeneous materials to ensure compliance with environmental regulations. During the production process, the company has established a complete quality management system. Through core processes such as the Design Transfer Process, Production Control Procedure, and Incoming Inspection Control Procedure, it achieves full-process quality control from raw material management, process development, production manufacturing, to finished product inspection. A risk assessment system is implemented for raw materials, FMEA analysis is conducted for process development, and full-process management is applied to key processes. Combined with the 5M1E management framework, multi-dimensional monitoring of personnel, environment, equipment, and product sampling is performed to ensure stable and controllable production.

In the final product testing and inspection phase, the company strictly adheres to medical device regulations, performing 100% testing and inspection on all products, covering over 19,300 indicators including protective earth resistance, withstand voltage, noise, system functions, and images, with 100% test coverage. A long-term data storage and traceability mechanism is established, with records kept for 30 years. In 2025, a cumulative total of 14.14 million tests were performed, involving 83,250 test cases, covering over 447 components and nearly 290 systems. The company also collaborates with authoritative institutions such as TÜV Rheinland, TÜV SÜD, DEKRA, Bureau Veritas, SGS, and CTI to ensure products comply with market standards and safety requirements.

United Imaging Healthcare places high importance on building a quality and safety culture, integrating quality management advocacy into daily work. Through training on regulations and standards, processes and control procedures, product knowledge and technology, operational practices, and environmental and occupational health and safety, it comprehensively enhances employees' quality awareness and skill levels. In 2025, the company provided training to all employees (including interns and outsourced personnel), achieving 100% coverage, with a total training duration of 221,847.18 hours and 369,089 employee participations. The company organized 'Quality Month' activities, using diverse methods such as management sharing, immersive quizzes, scenario simulations, and case studies to strengthen overall quality awareness and solidify quality behavior habits.

In terms of impact, risk, and opportunity management, the company relies on the ISO 14971 standard and internal risk management procedures, combined with domestic and international medical device adverse events, recalls, and warning letters, to identify potential hazards throughout the product lifecycle. Through design protection, provision of safety

information, and user training, it reduces the overall residual risk to an acceptable level. In 2025, based on IEC 62366 and FDA human factors engineering guidelines, the company further strengthened usability-related risk control and acceptance activities, enhancing risk management during user operation.

United Imaging Healthcare has established clear, measurable quality management objectives, including maintaining industry-leading product customer satisfaction, achieving a 100% outgoing pass rate, and sustaining high reliability of post-market products. These are ensured through a quality performance system to effectively implement the strategy. Simultaneously, the company continuously strengthens production safety management, ensuring safe production operations through objective management, production inspections, employee training, and emergency drills.

(x) Intellectual Property Protection Status

United Imaging Healthcare consistently adheres to the principle of balancing innovation and compliance, building a systematic intellectual property management system. By optimizing patent layout, strengthening trademark strategy, and enhancing employee training, it continuously improves the efficiency of intellectual property management, providing solid support for sustained innovation and enhanced market competitiveness.

The company complies with relevant laws and regulations such as the Patent Law of the People's Republic of China and the Trademark Law of the People's Republic of China. Based on the Intellectual Property Management Work Manual and existing types of intellectual property, it has formulated institutional norms such as the Basic System for Intellectual Property Management, Trademark Management Measures, and Software Copyright Registration Work Guidelines, firmly protecting United Imaging Healthcare's intellectual property and innovation achievements. The company has established a comprehensive intellectual property protection management architecture, with collaborative efforts from institutions such as the Intellectual Property Management Committee, Innovation Achievement Evaluation Committee, Intellectual Property Department, and the Emergency Working Group for Major Intellectual Property Disputes, ensuring the orderly execution of intellectual property management and achieving closed-loop management of various types of intellectual property.

The company promotes the implementation of patent layout strategies, closely aligning with United Imaging Healthcare's technology development path, cutting-edge industry technologies, and market expansion directions to build patent barriers. The company's patent mining mechanism covers the entire process of technology research and development, ensuring that patent applications encompass all product lines. Simultaneously, the company plans and protects technologies that may be implemented in the future during the R&D process, seizing market opportunities to obtain more fundamental patents. In terms of trademarks, United Imaging Healthcare synchronized its layout with product launch plans from the early stages, leveraging the advantages of the Madrid trademark system to support overseas market expansion. By the end of 2025, United Imaging Healthcare had accumulated over 10,000 patent applications, with invention patent applications accounting for 82% of the total.

Based on its development strategy, the company has built a comprehensive and systematic intellectual property management system covering all aspects of intellectual property

acquisition, maintenance, utilization, and monitoring. In risk control, the company proactively identifies risks related to intellectual property and effectively handles potential legal disputes; in document regulations, the company establishes control procedures including intellectual property documents and legal regulations; in information security, the company implements strict confidentiality measures for intellectual property-related information resources to prevent information leakage. Additionally, the company has built a comprehensive database and intellectual property management platform, achieving systematic management of the entire lifecycle of intellectual property such as patents, trademarks, copyrights, and technical secrets, safeguarding core technologies and brand value.

The company continuously strengthens intellectual property control, requiring every employee to sign a 'Confidentiality and Non-Competition Agreement' to avoid intellectual property management loopholes caused by commercial information leakage. Simultaneously, the company provides systematic intellectual property-related training for new employees, intellectual property department personnel, R&D staff, and marketing personnel, continuously enhancing all employees' awareness and capability of intellectual property protection.

(xi) Other aspects of social responsibility

√Applicable□Not applicable

United Imaging Healthcare actively practices responsible marketing, adhering to the basic requirements of compliance and integrity, improving the systematic marketing control system, ensuring truthful and transparent product information, maintaining corporate credibility, and fostering a healthy and orderly market ecosystem. The company follows policies such as the 'Advertising Law of the People's Republic of China,' 'Consumer Rights Protection Law of the People's Republic of China,' and 'Basic Standards for Enterprise Internal Control,' and in combination with specific market supervision requirements and business ethics, formulates and issues the 'Responsible Marketing System,' building a marketing activity management system covering headquarters, subsidiaries, and branches. The 'Responsible Marketing System' clearly requires all personnel representing the company in business activities and participating in group marketing work, including directors, senior managers, full-time employees, labor dispatch, part-time, temporary employees, and consultants, as well as third-party partners, to strictly comply with relevant norms. The system also stipulates that marketing activities should follow the principles of legality, fairness, honesty, and truthfulness, uphold fair competition, adhere to business ethics, value customer trust, and protect patient rights. The company adheres to high ethical standards, resolutely opposes improper behaviors such as corruption and bribery, ensures comprehensive compliance of marketing activities, achieves traceable and truthful marketing content, and highly prioritizes data and information security, fully protecting the information privacy of partners and customers.

The company has established a Marketing Compliance Committee and an Ethics Committee composed of senior management, responsible for supervising and reviewing the compliance and ethics of marketing activities, while also setting up a marketing system compliance team to conduct regular compliance audits and special inspections, ensuring full compliance of marketing activities. The company continuously optimizes the promotion and publicity process, ensuring that the functions, quality, and uses of products and services are clear, accurate, objective, and truthful, and consistent with the latest scientific research,

experimental data, and clinical practices. The company formulates the 'Market Promotion Document Control Process,' requiring that promotional documents must accurately correspond with product registration or filing materials, and promotional information such as scientific research results, statistical data, and survey findings must be cited truthfully and completely, indicating sources and validity periods, strictly prohibiting exaggeration of product functions or fabrication of performance indicators. For products and functions that have not obtained marketing authorization or registration, the company will not promote their safety and effectiveness and will clearly indicate their status in promotional materials. In the production of promotional materials, business departments must conduct self-inspections using the 'United Imaging Promotion Compliance Self-Check Form,' identifying and resolving potential risks in advance, and obtain verification and confirmation from relevant departments before release to ensure compliance with all norms. For advertising and promotion requiring mandatory approval under local regulations, the company strictly follows the complete approval process to ensure full legality and compliance.

The company implements continuous and systematic responsible marketing audit and control procedures, conducting annual marketing compliance audits covering all operating entities of the group, focusing on key areas such as risk assessment of marketing activities, implementation of laws and regulations and internal systems, and the truthfulness of information disclosure, ensuring that the market behaviors of the group and its agents strictly adhere to responsible marketing principles and eliminate misleading or false advertising. The company issues the 'Internal Audit Practice Guide - Responsible Marketing Audit,' delineating clear responsibility boundaries for various functional departments and providing explicit action guidelines, establishing a compliance baseline for the group's market promotion, advertising, and various marketing activities at the system level. To effectively ensure policy implementation, the company implements a full-process review and closed-loop rectification mechanism, using diversified measures such as annual risk assessments and sampling checks to accurately assess the implementation of responsible marketing policies by business personnel and third-party representatives, achieving comprehensive and gap-free supervision and control throughout the policy implementation process. In 2025, the company revised the 'Internal Audit System,' providing standardized operational guidelines for the marketing department's execution of market activities, and newly formulated the 'Market Activity Control and Spot Check System,' specifying spot checks and post-audits for market activities. The Audit Department independently verifies whether related activities comply with business ethics and responsible marketing requirements and promotes the closed-loop rectification of identified issues, ensuring control measures are effectively implemented.

In 2025, the company conducted responsible marketing audits, comprehensively covering key areas such as promotional behaviors of various operating institutions, dealer behavior norms, implementation of employee compliance training, and privacy protection controls. For issues identified during audits that require rectification, the company promptly provides feedback to the corresponding business departments, issues special audit reports and rectification requirements, and requires relevant responsible units to develop rectification plans and measures. The Audit Department continuously tracks the progress of rectification to ensure closed-loop management of issues. The company continuously improves the responsible marketing training system and optimizes training mechanisms, focusing on enhancing the compliance literacy and professional practical abilities of all employees. Through marketing system and practical training, and introducing external visits to educational institutions, the company promotes a multi-level, three-dimensional, and

systematic marketing empowerment plan covering all employees, comprehensively strengthening their understanding and execution of responsible marketing. In 2025, the company continued to advance the 'Marketing Professional Competence' training program, using training methods such as online courses, regional rotation training, and external exchanges to create a systematic specialized development plan for marketing talents. The course content covers key topics including strategy and tactics, practical experience, and team management, taught by senior company executives and external experts, attracting over 1,500 marketing personnel to participate. Simultaneously, the company organized and implemented the 'Theater Commander' project, targeting nearly a hundred core marketing managers such as regional business directors and regional general managers. The training content includes role recognition, management skills, and customer relationship management, comprehensively enhancing their practical management capabilities.

20. Other corporate governance matters

(i) Investor relations and protection

Type	Frequency	Relevant details
Holding performance briefings	3	On May 19, 2025, the company held the 2024 Annual and 2025 First Quarter and Cash Dividend Briefing; on October 13, 2025, the company held the 2025 Semi-Annual Performance Briefing; on November 11, 2025, the company held the 2025 Third Quarter Performance Briefing, with a question response rate of 100%.
Conducting investor relations management activities through new media	2	The company released 'A Visual Guide to United Imaging Healthcare's 2024 Performance Report & 2025 Q1 Performance Report' and 'United Imaging Healthcare 2025 Interim Report Overview' via its official WeChat public account.
Setting up an investor relations section on the official website	√Yes□No	The company's official website https://www.united-imaging.com has an investor relations section, which includes company stock information, announcements, etc.

Specific details of investor relations management and protection
√Applicable□Not applicable
The company has established a dedicated investor relations email and hotline, and set up an 'Investor Relations' section on its official website. To improve the quality of the company's information disclosure, ensure the authenticity, accuracy, timeliness, and completeness of external information disclosure, and effectively protect the legitimate rights and interests of the company and its investors, the company has formulated relevant systems such as the 'Information Disclosure Management System' and 'Investor Relations Management System' to strengthen the protection of minority investors' rights.

Description of other methods for communicating with investors
√Applicable□Not applicable
The company conducts offline exchanges with investors periodically and compiles and releases the 'Investor Relations Activity Record Form' based on actual circumstances.

(ii) Transparency of information disclosure

√Applicable□Not applicable
In accordance with the 'Measures for the Administration of Information Disclosure by Listed Companies' and the company's 'Information Disclosure Management System,' the company ensures that information is disclosed to all investors in a true, accurate, timely, and complete manner.

The company continuously improves investor relations management, actively receives visits and research from shareholders, and communicates with investors through phone calls, emails, the company website, the SSE E-Interaction platform, and performance briefings to address investor concerns.

(iii) Participation of institutional investors in corporate governance

√Applicable□Not applicable
During the reporting period, the company continued to strengthen investor relations management by introducing the company's operations, development strategies, market expansion, and other commonly concerned issues to investors through various means such as on-site research, roadshows and reverse roadshows, online performance briefings, and investor collective reception days, while also listening to investors' suggestions on the company's operations.

The company has dedicated investor hotlines, email channels, and promptly responds to investor inquiries on the SSE E-Interaction platform, ensuring open and effective communication channels, fair, open, and impartial information disclosure, and fully respecting and safeguarding the legitimate rights and interests of stakeholders.

(iv) Operation of anti-commercial bribery and anti-corruption mechanisms

√Applicable□Not applicable
United Imaging Healthcare is committed to building a robust and orderly business ethics compliance system. The business ethics compliance management system covers key areas such as anti-bribery and anti-corruption, conflict of interest management, business conduct standards, anti-monopoly, anti-unfair competition, export controls, and economic sanctions, and is directly managed by the Board of Directors. Under the Board of Directors, the Strategy and Social Responsibility Committee and the Audit Committee ensure the effective implementation of high standards in business ethics. The Legal Compliance Department, Financial Control Department, Internal Audit, and various specialized committees are responsible for the specific execution and implementation of this system. This year, the Audit Committee reviewed the financial information in the company's financial reports and periodic reports, with a focus on the execution of business ethics audits, tracked key issues, and reported progress to the Board of Directors in a timely manner. The Strategy and Social Responsibility Committee regularly reviews anti-corruption and anti-fraud efforts, systematically assesses business ethics risks, and has reviewed and approved key policy documents such as the 'Anti-Bribery and Anti-Corruption Policy,' 'Whistleblower Protection System,' and 'Responsible Marketing System.'

United Imaging Healthcare continuously improves its internal compliance regulations. Based on compliance with laws and regulations such as the 'Anti-Unfair Competition Law of the People's Republic of China,' the 'Anti-Monopoly Law of the People's Republic of China,' the

U.S. Foreign Corrupt Practices Act (FCPA), and the U.K. Bribery Act (UKBA), the company has formulated compliance policies including the 'Anti-Bribery and Anti-Corruption Policy,' 'Business Conduct Standards,' 'Conflict of Interest Policy,' 'Internal Investigation System,' 'Whistleblower Protection System,' 'Responsible Marketing System,' and 'Trade Secret Management System.' During the reporting period, the company revised the 'Conflict of Interest Policy' and reviewed systems such as the 'Business Conduct Standards' and 'Anti-Bribery and Anti-Corruption Policy' to ensure they consistently meet the best requirements for the company's operations and business ethics regulations. The compliance policies apply to all employees of Shanghai United Imaging Healthcare Co., Ltd. and its subsidiaries. At the same time, the company encourages all business partners, including customers, suppliers, and distributors, to uphold high business ethics and adhere to relevant compliance codes of conduct. During the reporting period, United Imaging Healthcare did not experience any commercial bribery or corruption incidents, nor were there any lawsuits or significant administrative penalties due to unfair competition practices.

United Imaging Healthcare formulates and implements a business ethics governance strategy of 'dare not, cannot, and do not want to engage in corruption,' resolutely combats unethical behavior, continuously fosters an honest, transparent, and compliant operating environment, maintains fair and just market order, and strives to build a clean and upright business culture. The company requires all new employees to sign an 'Integrity Statement' upon joining and specifies employee conduct standards and disciplinary measures in the 'Employee Handbook' to ensure every employee develops business ethics and anti-corruption awareness. For employees in key and management positions, compliance performance is included in performance evaluations to further reinforce integrity requirements. Additionally, the company requires all suppliers and distributors to sign the 'Supplier Code of Conduct' and 'Distributor Code of Conduct,' clearly defining the business ethics and anti-corruption standards they must adhere to in business activities. The company continuously strengthens due diligence measures, focusing on the business ethics and integrity of partners to ensure transactions are legal and compliant.

United Imaging Healthcare continuously optimizes its whistleblowing management system, encouraging all employees to actively participate in monitoring and reporting misconduct, creating an open and transparent compliance oversight environment. The company provides multiple reporting channels, all of which are normally open and support anonymous and real-name reporting. The company takes all reported clues seriously, commits to initiating investigation procedures as quickly as possible, and ensures that final decisions on violations and related personnel are made transparently, fairly, and reasonably by the Disciplinary Committee in accordance with regulations. At the same time, the company issued the 'Whistleblower Protection System,' explicitly stating that no department, employee, or partner may obstruct or retaliate against whistleblowers in any way. If a whistleblower's rights are infringed, United Imaging Healthcare will initiate an investigation and take action against the responsible parties. Reporting channels include the reporting email: UIH_Compliance@united-imaging.com, reporting phone: 021-67076619, and the Feishu Workbench platform.

In terms of compliance culture building, United Imaging Healthcare continuously deepens education and training related to business ethics. In accordance with policies such as the 'Anti-Bribery and Anti-Corruption Policy' and 'Business Conduct Standards,' the company has established a multi-channel, diversified, and multi-level comprehensive training system. It regularly provides business ethics compliance training annually for all employees,

including full-time employees, interns, part-time employees, outsourced employees, and dispatched workers. The training covers key areas such as business conduct standards, bribery and corruption, internal fraud, and conflicts of interest, enhancing employees' awareness of business ethics compliance. The company has established a rigorous assessment mechanism to evaluate and provide feedback on employees' learning outcomes, consolidating training effectiveness and promoting better implementation of compliance requirements in practical work.

The company provides systematic business ethics and compliance training for all employees annually, covering relevant documents such as the Anti-Bribery and Anti-Corruption Policy, Whistleblower Protection System, Code of Business Conduct, and Conflict of Interest Policy. The training includes topics such as business conduct standards, promotion and responsible marketing, anti-bribery and anti-corruption, anti-fraud, conflict of interest, trade secret protection, internal investigations, and whistleblower protection, ensuring employees fully understand and adhere to business ethics standards. During the reporting period, United Imaging Healthcare has released this year's business ethics compliance training course to all employees, providing Chinese and English video courseware on the internal learning platform. The training coverage reached 100%, with over 16,000 participants. The course remains open for new employees to continue participating. The company provides specialized targeted training for key positions such as sales, marketing, and procurement, guiding employees to conduct business interactions, engage with healthcare professionals, and organize market activities in accordance with compliance policies, strengthening their understanding and application of business ethics, anti-corruption, anti-unfair competition, and conflict of interest. During the reporting period, the training coverage for key personnel reached 100%, with a total of over 3,400 participants in key position training. The company organizes specialized compliance training for directors and management annually, clarifying key compliance requirements such as business ethics, anti-bribery and anti-corruption, anti-unfair competition, responsible marketing, conflict of interest, and trade secrets, enhancing senior management's awareness of compliance importance and ensuring they play a leading role in compliant operations. The company stipulates that regional distributors must participate in at least one compliance training organized by United Imaging Healthcare each year, covering topics such as business ethics standards, anti-corruption policies, and preventing unfair competition practices, promoting a compliance culture throughout the supply chain.

United Imaging Healthcare continuously strengthens internal supervision, establishing a business ethics audit system covering operational and financial activities under the leadership of the board of directors, effectively auditing and supervising business ethics conduct standards. During the audit preparation phase, the company performs risk assessment procedures, collecting laws and regulations, system processes, operational data, and historical audit records to preliminarily assess business compliance and risk levels, and develops a detailed audit plan covering the global operational network. During the audit execution phase, the audit department focuses on high-risk areas such as anti-bribery, anti-fraud, and conflict of interest based on risk assessment results, reviewing relevant documents, financial records, contracts, and transaction processes to ensure operational compliance. In the preliminary results verification phase, the audit department communicates and confirms issues with the audited departments, ensuring problems are fully explained and resolved through on-site interviews and document checks. After issuing the audit report, the audited departments are required to develop corrective action plans, and the audit department continuously tracks progress to ensure issues are effectively resolved. The audit committee

regularly reviews reports on the audit department's work results and future plans, ensuring the independence and effectiveness of the internal audit system and compliance with the board's expectations.

United Imaging Healthcare has established a "three-year coverage" audit plan for the business ethics area. The audit department develops a detailed annual audit plan and implements a rotation arrangement: the first year focuses on headquarters, the second on domestic subsidiaries, and the third on overseas subsidiaries, ensuring coverage of all operational entities within three years. High-risk areas are subject to more frequent reviews to address market changes and new compliance challenges. The 2025 internal audit plan includes key audits for emerging markets and high-risk areas. During the reporting period, the company conducted systematic audits of domestic operational entities and branches in Australia, New Zealand, and Southeast Asia based on the annual audit plan and business ethics regulations. It completed specialized business ethics audits for Shanghai United Imaging headquarters, domestic subsidiaries, and six overseas branches, focusing on high-risk areas such as compliance in business cooperation with healthcare professionals, distributor management compliance, supplier qualification and management, anti-corruption and anti-bribery, anti-fraud and integrity control, conflict of interest, and data lifecycle compliance. Surprise spot checks were also conducted on market meeting activities to ensure compliance with regulations and company policies, effectively preventing corruption risks. Identified items requiring correction were communicated to relevant business departments, which were required to develop corrective action plans with clear responsibilities and deadlines. The audit department continuously tracks progress and includes correction results in subsequent audit evaluations.

United Imaging Healthcare actively improves the management of risks and opportunities related to business ethics and compliant operations. For more details, please refer to the "ESG Risk and Opportunity Management" section of the report. In terms of implementation, the company has established a three-lines-of-defense control procedure to strengthen internal management and risk prevention, ensuring legal and compliant business operations and safeguarding the interests of the company and stakeholders. The first line of defense consists of business departments, including Sales and Marketing, Procurement, Supply Chain Management, R&D, and Customer Service, responsible for identifying and controlling compliance risks in daily operations, establishing operational procedures and internal control mechanisms, conducting regular self-assessments, and taking preventive measures. The second line of defense comprises the Legal and Compliance Department and the Financial Control Department. The Legal and Compliance Department is responsible for developing and updating compliance policies, providing guidance and supervision, and conducting employee training, while the Financial Control Department oversees financial processes and supports business departments' compliance. Additionally, the company has specialized business compliance committees such as the Marketing Compliance Committee, Information Security and Privacy Protection Committee, Quality and Compliance Management Committee, and Anti-Corruption and Data Compliance Team, which supervise and guide compliance work in their respective areas. The third line of defense is the Audit Department, responsible for independently evaluating the effectiveness of the compliance management system, reviewing the compliance status of business activities and external partners, reporting audit results to the board of directors, and providing decision-making support to management.

United Imaging Healthcare has established business ethics-related indicators and targets to strengthen risk identification and monitoring in key business areas, ensuring continuous optimization and improvement of the internal control system. In terms of target setting, the company resolutely combats violations of business ethics, maintains a "zero tolerance" policy towards corruption and bribery, and builds a long-term management mechanism of "dare not, cannot, and do not want to be corrupt," with the long-term goal of zero major compliance incidents. The company vigorously advocates and cultivates a corporate culture of dedication, integrity, honesty, and progress, and encourages partners to uphold high business ethics, jointly creating an honest and compliant business environment.

(v) Other Corporate Governance Information

√ Applicable□ Not Applicable

United Imaging Healthcare consistently adheres to improving the corporate governance system, strengthening shareholder rights protection, and promoting fairness, transparency, and efficiency in governance structure. Shareholder voting mechanisms are a core component of corporate governance, directly impacting shareholders' decision-making rights on major company matters. To safeguard the interests of all shareholders, especially minority shareholders, the company continuously optimizes the board election and remuneration voting systems by improving cumulative voting, separate vote counting mechanisms, online voting methods, and proxy solicitation mechanisms, enhancing governance standards.

According to Article 87 of the Company's Articles of Association approved at United Imaging Healthcare's 2024 Annual Shareholders' Meeting, "When a single shareholder and its concerted parties hold more than 30% of the shares, cumulative voting shall be implemented for the election of two or more directors at the shareholders' meeting. Cumulative voting shall be implemented for the election of two or more independent directors at the shareholders' meeting. Cumulative voting as mentioned in the preceding paragraph means that at the shareholders' meeting for electing directors, each share carries the same number of votes as the number of directors to be elected, and shareholders may concentrate their votes. When directors are elected by cumulative voting, the voting for independent directors and non-independent directors shall be conducted separately." The implementation of cumulative voting helps enhance the voting influence of minority shareholders and further optimizes the corporate governance structure. Compared to the traditional simple majority voting system (where shareholders vote separately for each director based on their shareholding), cumulative voting provides shareholders with greater flexibility, allowing them to allocate votes according to their interests, effectively reducing the disadvantage of minority shareholders in board elections. To ensure the fairness and transparency of board elections, the company strictly adheres to the Company Law and relevant regulations. The board must fully disclose the resumes and basic information of candidates to all shareholders, ensuring informed voting decisions. Additionally, the company strictly implements cumulative voting and separate vote counting mechanisms. For major matters involving minority shareholders' interests (such as director remuneration proposals), the voting results of minority shareholders are disclosed separately to enhance their decision-making influence and ensure fairness in the election process.

United Imaging Healthcare places high importance on the reasonableness and transparency of director compensation, and submits relevant compensation plans for review at the annual shareholders' meeting each year to ensure that the compensation policy aligns with shareholders' interests. Article 83 of the Company's Articles of Association stipulates, 'When

the shareholders' meeting deliberates on major matters affecting the interests of minority investors, the votes of minority investors shall be counted separately.' The results of the separate vote counting shall be publicly disclosed in a timely manner. This provision enhances the decision-making influence of minority shareholders, ensuring their rights and interests are fully protected. In June 2025, the company held the 2024 Annual Shareholders' Meeting, where the 'Proposal on Director Compensation for 2025' was reviewed and approved. This proposal included separate vote counting for minority investors, reflecting the company's respect and protection of minority shareholders' rights.

The company is committed to enhancing shareholder participation and decision-making transparency, continuously optimizing the shareholder voting mechanism to ensure the fairness and efficiency of the governance structure. In the future, the company will further improve shareholder voting procedures, strengthen the fairness of board elections, and continuously optimize the compensation governance system to align with international advanced governance standards, thereby enhancing corporate governance levels and market recognition.

Regarding board independence and diversity, as of the end of the reporting period, United Imaging Healthcare's second board of directors consisted of 9 directors, including 3 executive directors, 1 employee director, and 5 non-executive directors, of which 3 were independent directors. During the reporting period, the company held 9 board meetings and 2 shareholders' meetings. All directors of the second board attended all board and shareholders' meetings, actively fulfilling their duties and promoting the stable operation of corporate governance, with no absences or proxy attendance. At the same time, all directors conducted comprehensive investigations and understanding of the matters under review, fully utilizing their professional knowledge and experience to provide reasonable suggestions to the company, exercising their rights as independent directors objectively and independently, actively promoting the objectivity and standardization of board decisions, and effectively safeguarding the legitimate interests of the company and all shareholders.

To further improve the corporate governance structure and strengthen the role of independent directors in the governance system, the company strictly adheres to the relevant provisions of the Company Law and the Company's Articles of Association, and refers to regulatory requirements such as the 'Measures for the Administration of Independent Directors of Listed Companies' and the 'Shanghai Stock Exchange Sci-Tech Innovation Board Listed Companies Self-Regulatory Guidelines No. 1—Standard Operation,' establishing under the board the Audit Committee, Nomination Committee, Compensation and Evaluation Committee, and Strategy and Social Responsibility Committee. Each committee is responsible for supervision and review in specific areas and performs decision-making duties within its authorized scope. Among them, the Audit Committee and the Compensation and Evaluation Committee are composed of 3 independent directors to ensure the independence, fairness, and professionalism of supervision and decision-making. During the reporting period, the Board's Compensation and Evaluation Committee held 4 meetings, the Audit Committee held 3 meetings, the Strategy and Social Responsibility Committee held 1 meeting, and the Nomination Committee held 1 meeting.

At the same time, United Imaging Healthcare places high importance on director independence, striving to enhance decision-making quality and supervisory effectiveness. The board includes 3 independent directors, accounting for one-third of the total number of directors. The company continuously improves the working mechanism for independent

directors, establishing the role of Lead Independent Director to fully leverage the positive role of independent directors in corporate governance. In 2025, the company formulated the 'Management System for the Departure of Directors and Senior Management' and the 'Public Opinion Management System,' and revised multiple systems including the 'Company's Articles of Association,' 'Rules of Procedure for Shareholders' Meetings,' 'Rules of Procedure for Board Meetings,' 'Working System for Independent Directors,' 'Working Rules for the Board's Strategy and Social Responsibility Committee,' and 'Working Rules for the Board's Audit Committee,' clarifying the establishment and responsibilities of the Lead Independent Director. On August 29, 2024, the company's second board of directors held its 11th meeting, reviewed and approved the relevant revisions, and elected Mr. Wang Shaofei as the Lead Independent Director of the second board. According to the system, the Lead Independent Director is responsible for convening and presiding over special meetings of independent directors, collecting suggestions from independent directors and communicating with senior management, proposing agendas for committee meetings, organizing research on relevant systems for independent directors and proposing revisions, effectively regulating the behavior of independent directors, safeguarding the overall interests of the listed company, and protecting the legitimate rights and interests of shareholders. This system optimization further strengthens the independence and supervisory functions of independent directors, ensuring the fairness and scientific nature of board decisions, effectively safeguarding the overall interests of the listed company, and protecting the legitimate rights and interests of shareholders. For more details, please refer to the 'Independent Director System' disclosed by the company on the Shanghai Stock Exchange website (www.sse.com.cn). During the reporting period, all independent directors of the company strictly adhered to the requirements of laws and regulations, faithfully and diligently fulfilled their duties as independent directors, participated in the decision-making of major company matters, expressed opinions independently and impartially, and exercised their voting rights, fully leveraging the supervisory role and independence of independent directors, and making due efforts to safeguard the overall interests of the company and the rights and interests of all shareholders.

United Imaging Healthcare deeply recognizes that board diversity and professionalism are crucial for the sustainable development and good governance of the enterprise, continuously promoting the construction of a diverse and inclusive board in terms of gender, age, cultural background, and professional experience, leveraging their multi-dimensional perspectives and rich experience to facilitate comprehensive complex decision-making and strategic formulation. The board members of United Imaging Healthcare have diverse nationalities and cultural backgrounds, with expertise covering multiple disciplines such as biomedical engineering, physics, law, and financial management, and possess professional experience from globally leading enterprises and academic institutions. This diverse and professional background enables the board to ensure that the group's policies align with international standards and best practices, while more effectively supervising and guiding management, enhancing the quality and transparency of governance. The company also values promoting gender diversity, with several female executives already in management positions, fully practicing gender-diverse management.

The company also places high importance on the professional composition and independence of the Audit Committee to ensure its effective performance in financial supervision, compliance management, and risk control. The company's second Audit Committee consists of 2 independent directors and 1 non-executive director. The three members have backgrounds as financial experts, industry experts, and legal experts, respectively, all

possessing professional knowledge and experience in financial management, audit supervision, legal compliance, and the pharmaceutical and biotechnology industry, forming multi-dimensional professional support to ensure the stable operation of the Audit Committee in core functions such as financial reporting quality, internal control, legal compliance, and risk management.

Among them, Mr. Wang Shaofei, a financial and risk management expert and Lead Independent Director, serves as the Chairman of the Audit Committee. Mr. Wang Shaofei has a solid professional background in accounting and financial management, with profound theoretical knowledge and practical experience in financial supervision, accounting standards, corporate financial management, and capital market operations. He studied Statistics at Shanghai University of Finance and Economics from 1995 to 1999, earning a bachelor's degree; from 2000 to 2003, he obtained a master's degree in Statistics from Shanghai University of Finance and Economics; and from 2003 to 2007, he earned a Ph.D. in Statistics from Shanghai University of Finance and Economics. He previously worked at Shanghai Donghu (Group) Co., Ltd., and from 2007 to 2013, he engaged in postdoctoral research at the School of Accounting, Shanghai University of Finance and Economics, and served as a teacher in the Business School. Since 2020, he has served as an independent director of United Imaging Healthcare.

Additionally, industry expert Mr. Shen Siyu, as a member of the Audit Committee, has over ten years of experience in the pharmaceutical and biotechnology industry management and investment fields, with deep accumulation in these areas. He is familiar with the investment and financing operations, financial governance, and capital market regulatory requirements of the healthcare industry, and can provide professional support for the company's financial supervision, internal control, and risk management based on industry characteristics, enhancing the industry adaptability of audit supervision. He studied Plant Science at Shanghai Jiao Tong University from 2000 to 2004, earning a bachelor's degree; from 2006 to 2012, he studied Molecular Biology and Biochemistry at Fudan University, earning a Ph.D. From 2012 to 2021, he served as an analyst, investment associate manager, senior investment manager, and deputy general manager of Investment Department III at Shanghai Alliance Investment Co., Ltd., and currently serves as the General Manager of Investment Department III at Shanghai Alliance Investment. Since 2020, he has served as a director of United Imaging Healthcare. Leveraging his profound industry background, Mr. Shen Siyu can provide forward-looking support for the company's financial supervision, internal control, and risk management based on the characteristics of the pharmaceutical and biotechnology field, further enhancing the professional relevance and effectiveness of the Audit Committee in industry regulation and financial compliance.

Legal and risk management expert Mr. Sheng Leiming also serves as a member of the Audit Committee, possessing a deep legal professional background and long-term focus on corporate governance, securities law compliance, and risk management, enabling him to provide professional support to the Audit Committee in areas such as corporate governance structure optimization, compliant operations, and legal risk control. He studied law at East China University of Political Science and Law from 1989 to 1993, obtaining a bachelor's degree; from 2005 to 2008, he studied economic law at East China University of Political Science and Law, obtaining a master's degree; from 2014 to 2020, he studied procedural law at East China University of Political Science and Law, obtaining a doctoral degree. He has previously worked at Shanghai Foreign Trade and Commerce Law Firm, East China University of Political Science and Law, and Shanghai Zhongmao Law Firm; since 2016, he

has been a lawyer at Guantao Zhongmao (Shanghai) Law Firm; since 2020, he has served as an independent director of United Imaging Healthcare. Mr. Sheng Leiming's legal expertise provides legal review and compliance risk control support for the company in areas such as securities compliance, financial supervision, and corporate governance, ensuring the legality and compliance of the company's internal control system.

The company also places great importance on the development of diverse capabilities among directors, actively encouraging board members to participate in various professional skill enhancement and compliance training programs, covering national policies, securities market laws and regulations, operational mechanisms, corporate systems, as well as environmental and social responsibility issues (such as climate change). Through these training sessions, the compliance awareness and performance capabilities of the board members have been effectively enhanced. In 2025, the company's board members participated in two annual training sessions, one of which focused on business ethics compliance, emphasizing the latest anti-corruption and anti-bribery regulations and compliance requirements. The other training session centered on United Imaging Healthcare's carbon reduction projects, delving into the company's carbon reduction targets, carbon neutrality pathways, and zero-carbon management practices, covering core issues such as climate change response, carbon emission management, and product responsibility, further enhancing the board members' professional capabilities in sustainable governance.

Section V Share Changes and Shareholder Information

1. Changes in Share Capital

(i) Share Change Table

(1). Share Change Table

Unit: shares

	Before This Change		Changes in This Period (+, -)					After This Change	
	Quantity	Proportion (%)	New Share Issuance	Bonus Shares	Capital Reserve Conversion	Others	Subtotal	Quantity	Proportion (%)
I. Shares with Sales Restrictions	230,859,012	28.01				-230,859,012	-230,859,012	-	-
1. State-owned Shares								-	-
2. State-owned Legal Person Shares	-	-							
3. Other Domestic Shares	230,859,012	28.01				-230,859,012	-230,859,012	-	-
Including: Domestic Non-State-Owned Legal Person Shares	230,859,012	28.01				-230,859,012	-230,859,012	-	-
Domestic Natural Person Shares									

4. Foreign-owned Shares									
Including: Overseas Legal Person Shares									
Overseas Natural Person Shares									
II. Non-Restricted Circulating Shares	593,298,976	71.99				230,859,012	230,859,012	824,157,988	100
1. RMB Ordinary Shares	593,298,976	71.99				230,859,012	230,859,012	824,157,988	100
2. Domestic Listed Foreign Shares									
3. Overseas Listed Foreign Shares									
4. Others									
III. Total Shares	824,157,988	100				-	-	824,157,988	100

(2). Explanation of Share Changes

√ Applicable□ Not Applicable

On August 22, 2025, 230,859,012 shares from the initial public offering became tradable. For details, refer to the 'United Imaging Healthcare Announcement on the Lifting of Sales Restrictions for Part of the Initial Public Offering Shares' (Announcement No.: 2025-031) published on the Shanghai Stock Exchange website (www.sse.com.cn) on August 16, 2025.

(3). Impact of Share Changes on Key Financial Indicators Such as Earnings Per Share and Net Assets Per Share for the Most Recent Year and Period (if any)

□ Applicable√ Not Applicable

(4). Other Content Deemed Necessary by the Company or Required by Securities Regulatory Authorities

□ Applicable√ Not Applicable

(ii) Changes in Restricted Shares

√ Applicable□ Not Applicable

Unit: shares

Shareholder Name	Restricted Shares at Beginning of Year	Shares Released from Restrictions This Year	Shares Added to Restrictions This Year	Restricted Shares at End of Year	Restricted Reason	Lift Restriction Date
United Imaging Healthcare Technology Group Co., Ltd.	167,550,968	167,550,968	-	-	Initial Restricted Shares	2025.8.22
Shanghai Yingsheng Investment Partnership (Limited Partnership)	60,204,628	60,204,628	-	-	Initial Restricted Shares	2025.8.22
Shanghai Yingzhi Investment Partnership (Limited Partnership)	3,103,416	3,103,416	-	-	Initial Restricted Shares	2025.8.22
Total	230,859,012	230,859,012	-	-	/	/

2. Securities Issuance and Listing Status

(i) Securities Issuance Status During the Reporting Period

□ Applicable√ Not Applicable

Explanation of Securities Issuance Status During the Reporting Period (For bonds with different interest rates during their term, please explain separately):

□ Applicable√ Not Applicable

(ii) Changes in Total Company Shares and Shareholder Structure, and Changes in Company Assets and Liabilities Structure

□ Applicable√ Not Applicable

3. Shareholders and Actual Controller Information

(i) Total Number of Shareholders

Total Number of Ordinary Shareholders at the End of the Reporting Period (Households)	29,558
Total Number of Ordinary Shareholders at the End of the Month Preceding the Annual Report Disclosure Date (Households)	36,273
Total Number of Preferred Shareholders with Voting Rights Restored at the End of the Reporting Period (Households)	/
Total Number of Preferred Shareholders with Voting Rights Restored at the End of the Month Preceding the Annual Report Disclosure Date (Households)	/
Total Number of Shareholders Holding Special Voting Rights Shares at the End of the Reporting Period (Households)	/
Total Number of Shareholders Holding Special Voting Rights Shares at the End of the Month Preceding the Annual Report Disclosure Date (Households)	/

Number of Depositary Receipt Holders

□ Applicable√ Not Applicable

(ii) Table of Shareholdings of Top Ten Shareholders and Top Ten Circulating Shareholders (or Shareholders with No Sales Restrictions) at the End of the Reporting Period

Unit: Share

Shareholdings of Top Ten Shareholders (Excluding Shares Lent Through Securities Lending)							
Shareholder Name (Full Name)	Change During Reporting Period	Number of Shares Held at Period End	Percentage (%)	Number of Shares with Sales Restrictions	Pledge, Tag or Freeze Status		Shareholder Nature
					Shares Status	Quantity	

United Imaging Healthcare Technology Group Co., Ltd.	-	167,550,968	20.33	-	None	-	Domestic Non-State-Owned Legal Person
Shanghai United Investment Co., Ltd.	-	134,959,614	16.38	-	None	-	State-Owned Legal Person
Shanghai Yingsheng Investment Partnership (Limited Partnership)	-	60,204,628	7.30	-	None	-	Other
Shanghai Yiduan Investment Co., Ltd.	-1,402,518	24,991,168	3.03	-	None	-	Domestic Non-State-Owned Legal Person
Shanghai Zhongke Daofu Investment Partnership (Limited Partnership)	-17,157,000	24,306,858	2.95	-	None	-	Others
Yan Quanliang	-1,313,515	19,371,789	2.35	-	None	-	Domestic Individual
China Merchants Bank Co., Ltd. - Huaxia SSE STAR 50 Index ETF	-6,749,078	19,316,799	2.34	-	None	-	Unknown
Industrial and Commercial Bank of China Limited - E Fund SSE STAR 50 Index ETF	786,467	18,031,317	2.19	-	None	-	Unknown

Hong Kong Securities Clearing Company Limited	3,205,375	17,551,960	2.13	-	None	-	Unknown
Shanghai Beiyuan Investment Partnership (Limited Partnership)	-11,929,400	16,900,961	2.05	-	None	-	Others

Shareholding of Top 10 Shareholders with Unrestricted Shares (Excluding Shares Lent through Securities Lending)			
Shareholder Name	Number of Unrestricted Shares Held	Type and Quantity of Shares	
		Type	Quantity
United Imaging Healthcare Technology Group Co., Ltd.	167,550,968	RMB Ordinary Shares	167,550,968
Shanghai United Investment Co., Ltd.	134,959,614	RMB Ordinary Shares	134,959,614
Shanghai Yingsheng Investment Partnership (Limited Partnership)	60,204,628	RMB Ordinary Shares	60,204,628
Shanghai Yiduan Investment Co., Ltd.	24,991,168	RMB Ordinary Shares	24,991,168
Shanghai Zhongke Daofu Investment Partnership (Limited Partnership)	24,306,858	RMB Ordinary Shares	24,306,858
Yan Quanliang	19,371,789	RMB Ordinary Shares	19,371,789
China Merchants Bank Co., Ltd. - Huaxia SSE STAR 50 Index ETF	19,316,799	RMB Ordinary Shares	19,316,799
Industrial and Commercial Bank of China Limited - E Fund SSE STAR 50 Index ETF	18,031,317	RMB Ordinary Shares	18,031,317
Hong Kong Securities Clearing Company Limited	17,551,960	RMB Ordinary Shares	17,551,960
Shanghai Beiyuan Investment Partnership (Limited Partnership)	16,900,961	RMB Ordinary Shares	16,900,961
Explanation of the Special Repurchase Account among the Top 10 Shareholders	Not Applicable		

Explanation of Voting Rights Entrusted, Delegated, or Waived by the Above Shareholders	Not Applicable
Explanation of Related Party Relationships or Acting in Concert among the Above Shareholders	1. United Imaging Group and Shanghai Yingsheng are enterprises controlled by Xue Min, the actual controller of the company. 2. Zhongke Daofu and Shanghai Beiyuan are both private investment funds managed by Shanghai Daofu Yuantong Equity Investment Management Co., Ltd. as the private fund manager. 3. Apart from the above, the company has not received any statements from other shareholders regarding related party relationships or acting in concert agreements, and it is unknown whether there are any related party relationships or acting in concert relationships among other shareholders.
Explanation of Preferred Shareholders with Restored Voting Rights and Their Shareholding Quantity	Not Applicable

Participation of Shareholders Holding Over 5%, Top 10 Shareholders, and Top 10 Unrestricted Shareholders in Securities Lending Business
□ Applicable√ Not Applicable

Changes in Top 10 Shareholders and Top 10 Unrestricted Shareholders Due to Securities Lending/Return Compared to the Previous Period
□ Applicable√ Not Applicable

Top 10 shareholders with restricted shares and their restrictions
□ Applicable√ Not applicable

List of top 10 domestic depositary receipt holders as of the end of the reporting period
□ Applicable√ Not applicable

Share lending through securities lending business by depositary receipt holders with over 5% stake, top 10 depositary receipt holders, and top 10 unrestricted depositary receipt holders
□ Applicable√ Not applicable

Changes in top 10 depositary receipt holders and top 10 unrestricted depositary receipt holders due to securities lending/return activities compared to the previous period
□ Applicable√ Not applicable

Top 10 depositary receipt holders with restricted shares and their restrictions
□ Applicable√ Not applicable

(iii) List of top 10 shareholders by voting rights as of the end of the reporting period

□ Applicable√ Not applicable

(iv) Strategic investors or corporate entities becoming top 10 shareholders through new share/depositary receipt placements

□ Applicable√ Not applicable

(v) Strategic placement in the initial public offering

(1). Holdings of senior management and core employees through special asset management plans participating in the IPO strategic placement

√ Applicable□ Not applicable

Unit: shares

Shareholder/Holder Name	Allotted Shares/Depositary Receipts	Tradable Date	Change in Quantity During Reporting Period	End-of-Period Holdings Including Securities Lending
CITIC Securities United Imaging Healthcare Employee Participation in Sci-Tech Innovation Board Strategic Placement No. 1 Collective Asset Management Plan	4,493,640	2023.8.22	-1,155,175	800,111
CITIC Securities United Imaging Healthcare Employee Participation in Sci-Tech Innovation Board Strategic Placement No. 2 Collective Asset Management Plan	3,695,573	2023.8.22	-246,859	837,566

CITIC Securities United Imaging Healthcare Employee Participation in Sci-Tech Innovation Board Strategic Placement No. 3 Collective Asset Management Plan	842,529	2023.8.22	-110,161	160,310
CITIC Securities United Imaging Healthcare Employee Participation in Sci-Tech Innovation Board Strategic Placement No. 4 Collective Asset Management Plan	816,449	2023.8.22	-112,087	114,658

(2). Holdings of underwriting-related subsidiaries participating in the IPO strategic placement

√ Applicable□ Not applicable

Unit: shares

Shareholder Name	Relationship with Underwriter	Allotted Shares/Depositary Receipts	Tradable Date	Change in Quantity During Reporting Period	End-of-Period Holdings Including Securities Lending
CITIC Securities Investment Co., Ltd.	Subsidiary	2,000,000	2024.8.22	-1,599,995	-
China Zhongjin Wealth Securities Co., Ltd.	Subsidiary	2,000,000	2024.8.22	-	-

4. Controlling Shareholder and Actual Controller Information

(i) Controlling Shareholder Information

(1). Legal Entity

√ Applicable□ Not applicable

Name	United Imaging Group
Principal or Legal Representative	Gan Shaojun
Date of Establishment	March 10, 2011
Main Business Activities	Engaged in technology development, transfer, consultation, and services in the medical technology field (excluding medical diagnosis and treatment activities); technology transfer, development, consultation, and services in the information technology field; investment

	consulting (excluding finance and securities), investment management, business management consulting, business consulting, conference services, exhibition services.
Equity holdings in other domestic and overseas listed companies controlled or participated in during the reporting period	None
Other Information	None

(2). Natural Person

□ Applicable√ Not applicable

(3). Special explanation for the absence of a controlling shareholder

□ Applicable√ Not applicable

(4). Explanation of changes in controlling shareholder during the reporting period

□ Applicable√ Not applicable

(5). Block diagram of property rights and control relationship between the company and the controlling shareholder

√ Applicable□ Not applicable



(ii) Information on the actual controller

(1). Legal person

□ Applicable√ Not applicable

(2). Natural person

√ Applicable□ Not applicable

Name	Xue Min
Nationality	China
Whether the right of residence in other countries or regions has been obtained	No
Main occupation and position	Chairman of United Imaging Group
Information on domestic and overseas listed companies controlled in the past 10 years	None

(3). Special explanation on the absence of an actual controller in the company

□ Applicable√ Not applicable

(4). Explanation of changes in company control during the reporting period

□ Applicable√ Not applicable

(5). Block diagram of property rights and control relationship between the company and the actual controller

√ Applicable□ Not applicable

Diagram of Ownership and Control Relationship Between United Imaging Healthcare and the Actual Controller (To date)



Note: Macheng Yingyuan subscribed to a capital contribution of RMB 748,793,803.08 in Botike, representing a contribution ratio of 98.3264%. According to the "Botike Partnership Agreement," Macheng Yingyuan's equity distribution ratio in United Imaging Healthcare through Botike and United Imaging Group is 95.2543%.

(6). Actual controller controls the company through trust or other asset management methods

□ Applicable√ Not applicable

(iii) Introduction to other circumstances of the controlling shareholder and actual controller

□ Applicable√ Not applicable

5. The cumulative number of pledged shares by the company's controlling shareholder or largest shareholder and their concerted parties accounts for more than 80% of their total shares in the company

□ Applicable√ Not applicable

6. Other legal person shareholders holding more than 10% of shares

√ Applicable□ Not applicable

Unit: RMB 10,000 Currency: RMB

Name of legal person shareholder	Unit head or legal representative	Date of establishment	Organization Code	Registered capital	Main business activities or management activities, etc.
Shanghai Alliance Investment Co., Ltd.	Ye Jun	1994.9.26	9131000013223401XX	1,000,000.00	Equity investment
Explanation of circumstances	None				

7. Explanation of restrictions on share/depository receipt reductions

□ Applicable√ Not applicable

8. Specific implementation of share repurchase during the reporting period

√ Applicable□ Not applicable

Unit: RMB Currency: RMB

Name of share repurchase plan	United Imaging Healthcare's Plan for Repurchasing Company Shares through Centralized Bidding Transactions
Disclosure time of share repurchase plan	August 23, 2023
Proposed number of shares to be repurchased and percentage of total share capital (%)	0.35-0.69
Proposed repurchase amount	400 million - 800 million

Proposed repurchase period	August 22, 2023 ~ August 21, 2024
Repurpose	Employee stock ownership plan or equity incentive
Number of shares repurchased (shares)	5,205,476
Percentage of repurchased shares to the target shares involved in the equity incentive plan (%) (if any)	100
Progress of the company's reduction of repurchased shares through centralized bidding transactions	Not applicable

Note: The number of shares repurchased is the cumulative repurchase amount as of the end of the reporting period. The balance of repurchased shares at the end of the reporting period was 4,134,116 shares.

Section VI Financial Statements

Consolidated Balance Sheet

December 31, 2025

Prepared by: Shanghai United Imaging Healthcare Co., Ltd.

Unit: Yuan Currency: RMB

Item	Note	December 31, 2025	December 31, 2024
Current assets:			
Cash and cash equivalents	VII (1)	5,502,937,108.96	8,399,997,063.38
Settlement reserve			
Funds lent			
Financial assets at fair value through profit or loss	VII (2)	4,926,542,409.75	1,705,986,636.59
Derivative financial assets	VII (3)	-	489,944.97
Notes receivable	VII (4)	91,603,965.94	1,056,048.00
Accounts receivable	VII (5)	5,590,248,672.01	4,358,808,221.15
Financing receivables			
Prepayments	7(8)	264,137,851.08	195,777,640.89
Premiums receivable			
Reinsurance receivables			
Reinsurance contract reserves receivable			
Other receivables	7(9)	160,381,814.73	137,492,774.23
Including: Interest receivable			
Dividends receivable			
Financial assets purchased under resale agreements			
Inventories	7(10)	5,728,954,000.61	5,528,382,408.16
Including: Data resources			
Contract assets	7(6)	39,544,383.52	50,253,819.13

Assets held for sale			
Non-current assets due within one year	7(12)	325,604,781.54	290,564,565.05
Other current assets	7(13)	243,037,673.10	225,032,196.91
Total current assets		22,872,992,661.24	20,893,841,318.46
Non-current assets:			
Loans and advances			
Debt investments			
Other debt investments			
Long-term receivables	7(16)	175,204,564.76	114,605,452.67
Long-term equity investments	7(17)	189,899,425.70	187,799,803.53
Other equity instrument investments			
Other non-current financial assets	7(19)	130,880,900.00	82,366,375.73
Investment properties			
Fixed assets	7(21)	3,228,066,733.05	2,944,033,041.66
Construction in progress	7(22)	2,868,572,615.90	1,770,074,723.58
Productive biological assets			
Oil and gas assets			
Right-of-use assets	7(25)	265,003,292.18	82,847,128.12
Intangible assets	7(26)	1,512,812,075.51	1,004,333,811.10
Including: Data resources			
Development costs		429,588,646.46	329,169,118.87
Including: Data resources			
Goodwill	7(27)	22,104,603.13	22,104,603.13
Long-term prepaid expenses	7(28)	58,610,076.19	67,946,154.27
Deferred tax assets	7(29)	474,663,559.66	439,339,625.67
Other non-current assets	7(30)	556,180,212.23	97,227,715.69
Total non-current assets		9,911,586,704.77	7,141,847,554.02
Total assets		32,784,579,366.01	28,035,688,872.48
Current liabilities:			

Short-term borrowings	7(32)	944,721,233.21	557,489,368.89
Borrowings from central bank			
Funds borrowed			
Trading financial liabilities			
Derivative financial liabilities			
Notes payable	Note 7(35)	420,141,402.99	520,013,867.50
Accounts payable	Note 7(36)	2,349,170,643.63	2,087,816,659.14
Advances from customers			
Contract liabilities	Note 7(38)	2,975,154,056.73	2,139,304,950.07
Funds from securities sold under repurchase agreements			
Deposits and placements from banks and other financial institutions			
Funds for brokerage trading of securities			
Funds for securities underwriting			
Employee benefits payable	Note 7(39)	806,276,577.83	578,225,593.32
Taxes payable	Note 7(40)	639,996,649.60	326,702,443.76
Other payables	Note 7(41)	898,235,871.92	677,339,798.99
Including: Interest payable			
Dividends payable			
Fees and commissions payable			
Reinsurance accounts payable			
Liabilities held for sale			
Non-current liabilities due within one year	Note 7(43)	58,753,856.21	54,499,168.71
Other current liabilities	Note 7(44)	187,384,320.84	134,355,301.68
Total current liabilities		9,279,834,612.96	7,075,747,152.06
Non-current liabilities:			
Insurance contract reserves			

Long-term borrowings			
Bonds payable			
Including: Preferred shares			
Perpetual bonds			
Lease liabilities	Note 7(47)	252,568,441.01	83,997,441.38
Long-term payables		-	-
Long-term employee benefits payable	Note 7(49)	-	5,642,483.55
Provisions	Note 7(50)	2,721,872.01	-
Deferred income	Note 7(51)	475,087,466.20	461,427,326.26
Deferred tax liabilities	Note 7(29)	10,358,896.33	12,179,906.91
Other non-current liabilities	Note 7(52)	1,202,627,471.57	490,453,489.65
Total non-current liabilities		1,943,364,147.12	1,053,700,647.75
Total liabilities		11,223,198,760.08	8,129,447,799.81
Owners' equity (or shareholders' equity):			
Paid-in capital (or share capital)	Note 7(53)	824,157,988.00	824,157,988.00
Other equity instruments		-	-
Including: Preferred shares		-	-
Perpetual bonds		-	-
Capital reserve	Note 7(55)	13,957,021,962.83	13,947,476,239.79
Less: Treasury shares	Note 7(56)	449,839,312.68	449,839,312.68
Other Comprehensive Income	VII (57)	-52,269,467.74	-14,329,564.58
Special Reserve		-	-
Surplus Reserve	VII (59)	412,078,994.00	412,078,994.00
General Risk Provision		-	-
Undistributed Profit	VII (60)	6,880,716,865.53	5,183,621,073.00
Total Equity Attributable to Owners of the Parent Company		21,571,867,029.94	19,903,165,417.53
Minority Interests		-10,486,424.01	3,075,655.14
Total Owners' Equity		21,561,380,605.93	19,906,241,072.67

Total Liabilities and Owners' Equity		32,784,579,366.01	28,035,688,872.48

Company Representative: Zhang Qiang Chief Accounting Officer: Wang Jianbao Head of Accounting Department: Zhang Hui

Consolidated Income Statement

January–December 2025

Unit: Yuan Currency: RMB

Item	Note	2025	2024
I. Total operating revenue		13,800,251,663.95	10,300,104,386.97
Including: Operating revenue	VII (61)	13,800,251,663.95	10,300,104,386.97
Interest income			
Earned premiums			
Fee and commission income			
II. Total operating costs		12,083,533,906.88	9,385,271,546.62
Including: Operating costs	VII (61)	7,312,582,446.96	5,300,161,724.44
Interest expense			
Fee and commission expense			
Surrender value			
Net claims incurred			
Net change in insurance contract liabilities			
Policyholder dividends			
Reinsurance expenses			
Taxes and surcharges	VII (62)	71,322,317.07	56,781,176.03
Selling expenses	VII (63)	2,261,407,623.18	1,823,187,055.28
Administrative expenses	VII (64)	626,904,263.90	555,965,099.19
Research and development expenses	VII (65)	1,841,943,294.35	1,761,466,670.35
Financial expenses	VII (66)	-30,626,038.58	-112,290,178.67
Including: Interest expense		18,769,868.00	9,073,217.24
Interest income		-85,727,321.21	-116,273,030.76

Add: Other income	VII (67)	433,981,526.27	444,193,498.96
Investment income (loss is indicated by "-")	VII (68)	80,512,625.69	98,073,989.14
Including: Investment income from associates and joint ventures		2,099,622.17	-5,623,417.56
Gain on derecognition of financial assets measured at amortized cost			
Exchange gain (loss is indicated by "-")			
Net exposure hedging gain (loss is indicated by "-")			
Fair value change gain (loss is indicated by "-")	VII (70)	-37,113,946.49	37,000,082.01
Credit impairment loss (loss is indicated by "-")	VII (71)	-194,450,990.75	-140,717,437.52
Asset impairment loss (loss is indicated by "-")	VII (72)	1,303,061.74	13,842,775.25
Gain on disposal of assets (loss is indicated by "-")	VII (73)	-641,405.91	-869,838.94
III. Operating profit (loss is indicated by "-")		2,000,308,627.62	1,366,355,909.25
Add: Non-operating income	VII (74)	6,189,198.45	5,546,317.51
Less: Non-operating expenses	VII (75)	25,102,821.54	20,194,712.78
IV. Total profit (total loss is indicated by "-")		1,981,395,004.53	1,351,707,513.98
Less: Income tax expense	VII (76)	137,347,560.82	109,783,513.52
V. Net profit (net loss is indicated by "-")		1,844,047,443.71	1,241,924,000.46
(I) Classified by business continuity			
1. Net profit from continuing operations (net loss is indicated by "-")		1,844,047,443.71	1,241,924,000.46
2. Net profit from discontinued operations (net loss is indicated by "-")			
(II) Classified by ownership			

1. Net profit attributable to shareholders of the parent company (net loss is indicated by "-")		1,869,300,805.65	1,261,869,451.27
2. Non-controlling interests (net loss is indicated by "-")		-25,253,361.94	-19,945,450.81
VI. Net amount of other comprehensive income after tax		-37,939,903.16	6,068,286.44
(I) Net amount of other comprehensive income attributable to owners of the parent company after tax		-37,939,903.16	6,068,286.44
1. Other comprehensive income that cannot be reclassified to profit or loss			
(1) Remeasurement of defined benefit plans			
(2) Other comprehensive income under equity method that cannot be transferred to profit or loss			
(3) Fair value changes of other equity instrument investments			
(4) Fair value changes due to entity's own credit risk			
2. Other comprehensive income that will be reclassified to profit or loss		-37,939,903.16	6,068,286.44
(1) Other comprehensive income under equity method that can be transferred to profit or loss			
(2) Fair value changes of other debt investments			
(3) Amount reclassified to other comprehensive income for financial assets			
(4) Credit impairment provision for other debt investments			
(5) Cash flow hedging reserve			
(6) Foreign currency translation difference		-37,939,903.16	6,068,286.44

(7) Others			
(II) After-tax net amount of other comprehensive income attributable to non-controlling interests			
VII. Total comprehensive income		1,806,107,540.55	1,247,992,286.90
(I) Total comprehensive income attributable to owners of the parent company		1,831,360,902.49	1,267,937,737.71
(II) Total comprehensive income attributable to non-controlling interests		-25,253,361.94	-19,945,450.81
VIII. Earnings per share:			
(I) Basic earnings per share (RMB/share)		2.28	1.54
(II) Diluted earnings per share (RMB/share)		2.28	1.54

For business combinations under common control occurring in the current period, the net profit realized by the merged party before the merger was: RMB 0, and the net profit realized by the merged party in the prior period was: RMB 0.

Company Responsible Person: Zhang Qiang Chief Accounting Officer: Wang Jianbao Head of Accounting Department: Zhang Hui

Consolidated Cash Flow Statement
January - December 2025

Unit: RMB Currency: RMB

Item	Note	2025	2024
I. Cash flows from operating activities:			
Cash received from sales of goods and rendering of services		15,364,921,917.28	10,536,648,225.07
Net increase in customer deposits and interbank deposits		-	-
Net increase in borrowings from central bank		-	-

Net increase in funds borrowed from other financial institutions		-	-
Cash received from original insurance contract premiums		-	-
Net cash received from reinsurance business		-	-
Net increase in policyholder deposits and investment funds		-	-
Cash received from interest, fees, and commissions		-	-
Net increase in funds borrowed		-	-
Net increase in funds from repurchase business		-	-
Net cash received from securities trading agency		-	-
Refund of taxes and fees		546,048,902.13	482,871,590.22
Cash received from other operating activities	VII (78)	272,389,039.47	270,305,930.58
Subtotal of cash inflows from operating activities		16,183,359,858.88	11,289,825,745.87
Cash paid for goods and services		7,989,420,173.80	6,887,356,311.03
Net increase in customer loans and advances		-	-
Net increase in deposits with central bank and other banks		-	-
Cash paid for claims under original insurance contracts		-	-
Net increase in funds lent		-	-
Cash paid for interest, fees, and commissions		-	-
Cash paid for policy dividends		-	-
Cash paid to and on behalf of employees		3,144,650,410.00	2,910,054,810.44
Payments of various taxes and fees		924,286,097.52	865,609,137.23

Cash paid relating to other operating activities	VII (78)	1,445,984,328.07	1,245,829,740.42
Subtotal of cash outflows from operating activities		13,504,341,009.39	11,908,849,999.12
Net cash flows from operating activities		2,679,018,849.49	-619,024,253.25
II. Cash flows from investing activities:			
Cash received from disposal of investments		34,799,167,283.24	26,853,066,600.00
Cash received from returns on investments		89,618,383.80	109,478,383.47
Net cash received from disposal of fixed assets, intangible assets, and other long-term assets		77,500.00	86,075.00
Net cash received from disposal of subsidiaries and other business units		-	-
Cash received relating to other investing activities	VII (78)	-	-
Subtotal of cash inflows from investing activities		34,888,863,167.04	26,962,631,058.47
Cash paid for acquisition of fixed assets, intangible assets, and other long-term assets		2,093,181,965.21	1,945,732,817.30
Cash paid for investments		36,153,137,997.23	26,250,851,509.72
Net increase in pledged loans		-	-
Net cash paid for acquisition of subsidiaries and other business units		-	10,354,444.15
Cash paid relating to other investing activities	VII (78)	-	-
Subtotal of cash outflows from investing activities		38,246,319,962.44	28,206,938,771.17
Net cash flows from investing activities		-3,357,456,795.40	-1,244,307,712.70
III. Cash flows from financing activities:			
Cash received from capital contributions		12,310,000.00	93,529,676.80

Including: Cash received from minority shareholders' investments in subsidiaries		11,700,000.00	7,800,000.00
Cash received from borrowings		1,056,617,791.72	554,982,982.06
Cash received relating to other financing activities		-	-
Subtotal of cash inflows from financing activities		1,068,927,791.72	648,512,658.86
Cash paid for debt repayment		671,484,320.94	9,455,172.40
Cash paid for dividends, profit distribution, or interest payments		176,081,824.06	303,596,850.17
Including: Dividends or profits paid to minority shareholders by subsidiaries		-	-
Cash paid relating to other financing activities	VII (78)	68,442,310.29	136,487,812.98
Subtotal of cash outflows from financing activities		916,008,455.29	449,539,835.55
Net cash flows from financing activities		152,919,336.43	198,972,823.31
IV. Effect of foreign exchange rate changes on cash and cash equivalents		-32,037,399.47	1,581,829.58
V. Net increase in cash and cash equivalents		-557,556,008.95	-1,662,777,313.06
Add: Cash and cash equivalents at beginning of period		5,867,855,094.11	7,530,632,407.17
VI. Ending balance of cash and cash equivalents		5,310,299,085.16	5,867,855,094.11

Company Representative: Zhang Qiang Chief Accounting Officer: Wang Jianbao Head of Accounting Department: Zhang Hui